

UNIVERSITAS CAROLINA PRAGENSIS

FOLIA PHARMACEUTICA UNIVERSITATIS CAROLINAE

LI



Folia Pharmaceutica Universitatis Carolinae

LI

Arranged by Assoc. Prof. RNDr. Veronika Opletalová, Ph.D.
Technical assistance by Tomáš Vojtíšek

Lectured:

Assoc. Prof. RNDr. Věra Klimešová, CSc.,
Assoc. Prof. PharmDr. Jakub Chlebek, Ph.D.

Editorial Advisory Board: Assoc. Prof. RNDr. Pavel Doležal, CSc.,
Prof. PharmDr. Martin Doležal, Ph.D., Prof. MUDr. Jaroslav Dršata, CSc.,
Prof. MUDr. Radomír Hrdina, CSc., Prof. RNDr. Lubomír Opletal, CSc.,
Assoc. Prof. RNDr. Veronika Opletalová, Ph.D.,
Assoc. Prof. RNDr. Miroslav Polášek, CSc., Prof. RNDr. Jiří Vlček, CSc.,
Assoc. Prof. RNDr. Pavla Žáčková, CSc.,
Assoc. prof. RNDr. Veronika Opletalová, Ph.D. (editor)

Published by Charles University
Karolinum Press
Prague 2024
Typeset by Karolinum Press

© Charles University, 2024
ISSN 1210-9495
ISBN 978-80-246-5628-1
ISBN 978-80-246-5666-3 (pdf)
<https://doi.org/10.14712/9788024656663>



Charles University
Karolinum Press

www.karolinum.cz
ebooks@karolinum.cz

CONTENTS

Abstracts

10th Postgraduate and Postdoc Conference of the Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, 22–23 January 2020	7
Bioorganic and Pharmaceutical Chemistry Section	7
Pharmacognosy and Toxicology of Natural Products Section	23
Pharmaceutical Technology Section	39
Pharmaceutical Analysis and Bioanalytical Chemistry Section	47
Biochemistry, Pharmacology and Toxicology Section	67
Clinical and Social Pharmacy Section	91

Bibliography

Publications of the Faculty of Pharmacy in Hradec Králové, Charles University in the Year 2017	103
Original Papers and Reviews	103
Articles in Journals without Impact Factor and Proceedings	113
Monographies and Textbooks	114
Degrees	114
Publications of the Faculty of Pharmacy in Hradec Králové, Charles University in the Year 2018	121
Original Papers and Reviews	121
Articles in Journals without Impact Factor and Proceedings	129
Monographies and Textbooks	130
Certified Methodology	131
Degrees	131
Publications of the Faculty of Pharmacy in Hradec Králové, Charles University in the Year 2019	138
Original Papers and Reviews	138
Articles in Journals without Impact Factor and Proceedings	147
Monographies and Textbooks	148
Utility Model and Certified Methodology	148
Degrees	148

Publications of the Faculty of Pharmacy in Hradec Králové, Charles University in the Year 2020	160
Original Papers And Reviews	160
Articles in Journals without Impact Factor and Proceedings	168
Monographies and Textbooks	169
Degrees	170
Social Happenings	
50th Anniversary of the Faculty of Pharmacy in Hradec Králové.....	179
Instructions for Authors	183

ABSTRACTS

10th POSTGRADUATE AND POSTDOC CONFERENCE OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ, CHARLES UNIVERSITY, HRADEC KRÁLOVÉ, 22–23 JANUARY 2020

BIOORGANIC AND PHARMACEUTICAL CHEMISTRY SECTION

HOW TO NOT KILL MOSQUITO: CYSTEINE-TARGETED INSECTICIDES

GÓRECKI, L.,¹ ANDRÝS, R.,² SCHMIDT, M.,^{1,2} KUČERA, T.,³ PSOTKA, M.,^{1,2}
SVOBODOVÁ, B.,^{1,3} HRABCOVÁ, V.,^{2,3} HEPNAROVÁ, V.,^{1,3} BZONEK, P.,^{2,3} JUN, D.,^{1,3}
KUČA, K.,² KORÁBEČNÝ, J.,^{1,3} MUSÍLEK, K.^{1,2}

¹ Biomedical Research Centre, University Hospital in Hradec Králové, Czech Republic

² Department of Chemistry, Faculty of Science, University of Hradec Králové, Czech Republic

³ Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences,
University of Defence, Hradec Králové, Czech Republic

e-mail: lukasgorecki@seznam.cz

Acetylcholinesterase cysteine-targeted insecticides against malaria vector *Anopheles gambiae* and other mosquitos have already been introduced. We have applied the olefin metathesis for the preparation of cysteine-targeted insecticides in high yields. The prepared compounds with either a succinimide or maleimide moiety were evaluated on *Anopheles gambiae* and human acetylcholinesterase with relatively high irreversible inhibition of both enzymes but poor selectivity. The concept of cysteine binding was not proved by several methods, and poor stability was observed with the chosen most potent/selective compounds in a water/buffer environment. Thus, our findings do not support the proposed concept of cysteine-targeted selective insecticides for the prepared series of succinimide or maleimide compounds.

The study was supported by Ministry of Health of the Czech Republic (Project No. NV16-34390A), University of Hradec Králové (Projects No. SV2115-2018, No. VT2019-2021 and postdoctoral job positions at UHK), and University of Defence (Faculty of Military Health Sciences, Long-term development plan and SV/FVZ2019/01).


CYCLIZATION REACTIONS MEDIATED BY TRANSITION METALS

MATOUŠ, P., KADANÍK, M., MAŘÍKOVÁ, J., TIMORACKÝ, M.,
KUNEŠ, J., POUR, M.

Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: matousp1@faf.cuni.cz

Synthesis of various types of heterocycles is possible from enyne precursors using cationic gold(I) species as catalysts. Our previous research on the cyclisation of propargyl vinyl ethers to dihydropyrans **II**¹ as well as chemoselective cyclizations of β -propargylamino acrylic esters to dihydropyridines **IV**² was extended to include nucleophile-assisted reactions.

The optimized synthetic protocol was applied to the preparation of a library of substituted tetrahydropyridines **V**. Their further transformations via *e.g.* cycloadditions gave highly substituted isoquinoline derivatives **VI**.



Scheme 1. Gold(I)-Catalyzed Synthesis of Piperidine Aminals

The study was supported by the Grant Agency of Charles University (Project No. 1590119), from the project of Specific Academic Research (SVV 260 401/2019) and by the Czech Science Foundation (Project No. 18-17868S).

References


1. MATOUŠOVÁ, E., RŮŽIČKA, A., KUNEŠ, J. *et al.*: Chem. Commun., 47, 2011, 6164–6199.
2. MIKUŠEK, J., MATOUŠ, P., MATOUŠOVÁ, E. *et al.*: Adv. Synth. Catal., 358, 2016, 2912–2922.
3. SAITO, A., KONISHI, T., HANZAWA, Y.: Org. Lett., 12, 2010, 372–374.

SYNTHESIS AND REACTIVITY OF ELECTRONICALLY TUNED [3]DENDRALENES


ANTAL, R., BRŮŽA, Z., KRATOCHVÍL, O., POUR, M.

Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: antalr@faf.cuni.cz

Dendralenes are acyclic cross-conjugated polyenes with an interesting, as yet unexamined reactivity and high potential for further synthesis.¹ We have focused on the synthesis of variously substituted electron poor [3]dendralenes containing electron withdrawing groups (*e.g.* carboxylic group), or a combination of electron withdrawing and donating groups. Synthesis is based on readily available *Z*-metallodienes **1**, which are subjected to Migita-Stille coupling² yielding the intended final products **3** (Scheme 1). Syntheses and possible applications of new compounds in domino Diels-Alder sequences (Scheme 2) will be discussed.



Scheme 1. Migita-Stille coupling



Scheme 2. Diels-Alder reactions

The study was supported from the project of Specific Academic Research (SVV 260 401/2019), by the Grant Agency of Charles University (Project. No. 1348119) and by the Czech Science Foundation (Project No. 18-17868S).

References

1. HENNING, H., SHERBURN, M.: *Angew. Chem. Int. Ed.*, 51, 2012, 2298–2338.
2. KRATOCHVÍL, J., NOVÁK, Z., GHAVRE, M. *et al.*: *Org. Lett.*, 17, 2015, 520–523.

UNUSUAL 1,3-IZOMERIZATION: PREPARATION OF POLYSUBSTITUTED PYRAN-2-ONES

BRŮŽA, Z.,¹ KRATOCHVÍL, J.,¹ HARVEY, J. N.,² RULÍŠEK, L.,³ NOVÁKOVÁ, L.,¹
KUNEŠ, J.,¹ KOČOVSKÝ, P.,^{1,3,4} POUR, M.¹

¹ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Chemistry, Katholieke Universiteit Leuven, B-3001 Leuven, Belgium


³ Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic

⁴ Faculty of Natural Sciences, Charles University, Prague, Czech Republic
e-mail: bruzazb@faf.cuni.cz

Originally discovered as minor by-products of our previous studies to the synthesis of disubstituted pyranones (Scheme 1)¹, we developed preparation of isomeric trisubstituted derivatives into proper synthetic protocol.

Having optimized the reaction conditions, we were able to prepare a broad library of compounds in high yields using mild conditions. In addition, our synthetic protocol showed high tolerance of functional groups. Screening of chiral ligands was also performed to probe the possibility of enantiocontrol over the newly introduced chiral centre.

We also performed quantum chemistry calculations in order to gain more insight into the mechanism of this transformation, which is seemingly unfavourable.



Scheme 1. General structures

The study was supported by the Grant Agency of Charles University (Project No. 1054216), by the Czech Science Foundation (Project No. 18-17868S) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. KRATOCHVÍL, J., NOVÁK, Z., GHAVRE, M. *et al.*: *Org. Lett.* 17, 2015, 520–523.
2. BRŮŽA, Z., KRATOCHVÍL, J., HARVEY, J. N. *et al.*: *Chem. Eur. J.* 2019, 25, 8053.

PREPARATION, HPLC PURIFICATION, AND EVALUATION OF MODIFIED OLIGODEOXYNUCLEOTIDE PROBES

KOSTELANSKÝ, F., HAVLÍNOVÁ, Z., MILETÍN, M., ZIMČÍK, P.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: kostelaf@faf.cuni.cz

Melting temperature difference between complementary and mismatched duplex has crucial role for discrimination of point mutations. Several oligodeoxynucleotide probes (ODNs) conjugated with melting temperature modifiers (acridine derivatives, modified Hoechst 33258) were prepared using copper-free click chemistry.¹ 13 and 18 bases long ODNs, containing one or two aza-dibenzocyclooctyne, were used. Modified ODNs were purified by zeta-dex gel filtration columns and HPLC. For HPLC purification PhenylHexyl column, triethylammonium acetate buffer (TEAA), and ACN in various ratios were used.² All samples were analysed using isocratic elution. Minor changes in ratio of TEAA and ACN were needed for optimization of elution times and resolution. Isocratic elution was used also for semipreparative HPLC. Two peaks were observed on all chromatograms (Fig. 1). They were identified as constitutional isomers and were taken together as one fraction.




Fig. 1. Chromatogram of probe modified by FK-27

HPLC purified ODNs were tested for ability to increase melting temperature (Fig. 2).




Fig. 2. Scheme of hybridization study

The study was supported by the Technology Agency of the Czech Republic (Project No. 060/860681), by the Grant Agency of Charles University (Project No. 994218) and from the project of Specific Academic Research (SVV 260 401/2019).

References


1. KIM, E., KOO, H.: Chem. Sci., 10, 2019, 7835–7851.
2. GILAR, M.: Anal. Biochem., 298, 2001, 196–206.

SYNTHESIS OF 1-AMINOADAMANTANE SUBSTITUTED PHTHALOCYANINES AND STUDYING THEIR SUPRAMOLECULAR COMPLEXES WITH CUCURBITURIL

KOČIŠČÁKOVÁ, L., ZIMČÍK, P.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: kociscal@faf.cuni.cz

Phthalocyanines (Pc) are macrocyclic compounds with central metal cation. They can be used for example as dyes, pigments, catalysts or as photosensitizers in photodynamic therapy in cancer treatment. One big limitation of Pc is their poor solubility and aggregation in water. Cucurbiturils (CB) are pumpkin shape macromolecules composed of various number of glycoluril monomers.¹ They can bind guest molecules into their cavities. We used one of the strongest reported interaction between CB[7] and 1-aminoadamantane.² By creating a supramolecular complex of Pc and CB we should be able to improve solubility and aggregation of Pc in water. Three phthalonitrile precursors were prepared and after cyclotetramerization reactions two Pcs **LK3-Zn** and **LK14-Zn** with four peripherally 1-aminoadamantane substituents were synthesized. Photophysical properties of **LK3-Zn** were measured and were compared to its cucurbituril complex. Biological tests on HeLa cells showed ten times higher photodynamic activity of Pc-CB complex compared to Pc without CB.



The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Grant Agency of Charles University (Project. No. 1606119).

References

1. WIEMANN, M., JONKHEIJM, P.: *Isr. J. Chem.*, 58, 2018, 314–325.
2. LIU, S., RUSPIC, C., MUKHOPADHYAY, P. *et al.*: *J. Am. Chem. Soc.*, 127, 2005, 15959–15967.


ANIONIC AND CATIONIC PHTHALOCYANINES FOR PHOTODYNAMIC THERAPY AND THEIR INTERACTION WITH BOVINE SERUM ALBUMIN

KOLLÁR, J.,¹ HALAŠKOVÁ, M.,² MACHÁČEK, M.,² ZIMČÍK P.¹

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: kollarj@faf.cuni.cz

Phthalocyanines (Pcs) and their aza-analogues are macrocyclic compounds with interesting photophysical properties (strong absorption in area over 600 nm and strong singlet oxygen production) highly suitable for the use in photodynamic therapy of cancer. The aim of this work was synthesis and study of interaction of symmetrical and unsymmetrical anionic and cationic Pcs with bovine serum albumin and effect of this interaction on their photodynamic activity. Symmetrical Pcs were obtained by cyclotetramerization reaction



(initiator magnesium butoxide) of one precursor while unsymmetrical Pcs were prepared by statistical condensation of phthalonitrile with 4,5-disubstituted phthalonitrile. Magnesium complexes were converted to metal-free ligands and then to zinc complexes. Basic hydrolysis of ester bonds was the last step of the synthesis of anionic Pcs. Quaternization of basic nitrogens was the last step of the synthesis of cationic Pcs. Pcs were tested on photodynamic activity *in vitro* on HeLa cells with different results in serum-free medium (SFM) and serum-containing medium (SCM). Effect of binding to serum proteins was studied as change in absorption and fluorescence spectra of Pcs after addition of bovine serum albumin. Obtained results corresponded well with change in photodynamic activity of these compounds in SFM and SCM.

The work was supported by the Czech Science Foundation (Project No. 19-14758Y) and from the project of Specific Academic Research (SVV 260 401/2019).

SYNTHETIC AND BIOLOGICAL STUDY ON RHODANINE DERIVATIVES AND THEIR OXYGEN ISOSTERES

KUČEROVÁ-CHLUPÁČOVÁ, M.,¹ KONEČNÁ, K.,² NOVOTNÁ, S.,² DIEPOLTOVÁ, A.,²
DUŠKOVÁ, A.,¹ JANĎOUREK, O.,² KUNEŠ, J.,³ DOLEŽAL, M.¹

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic

² Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

³ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: kucerom@faf.cuni.cz

Rhodanine derivatives have shown interesting biological activities. In the series of (*Z*)-5-arylmethylidenerhodanines, inhibition of *Staphylococcus* spp. was detected in the past.¹ Recently, selected compounds were re-tested on collection strains and evaluated in advanced studies, *e.g.* bacteriocidal/bacteriostatic effect, and checkerboard with some standard antibiotics.

Despite the rhodanine scaffold (2-thioxothiazolidin-4-one) being included in the PAINS filter (pan assay interference compounds),² it can serve in drug design for scaffold hopping approach.^{3,4} Oxygen isosteres of some (*Z*)-5-arylmethylidenerhodanines were prepared, tested on antimicrobial, including antimycobacterial, activity and compared with rhodanines.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. DOLEŽEL, J.: Deriváty thiazolu jako potenciální léčiva (Derivatives of thiazole as potential drugs). Dissertation thesis, Faculty of Pharmacy in Hradec Králové, Charles University, 2013.

2. BAELL, J. B., HOLLOWAY, G. A.: J. Med. Chem., 53, 2010, 2719–2740.
3. TOMAŠIČ, T., MAŠIČ, L. P.: Curr. Med. Chem., 16, 2009, 1596–1629.
4. MENDGEN, T., STEUER, C., KLEIN, D.: J. Med. Chem., 55, 2012, 743–753.

THE WAY FROM THE SYNTHESIS TO POTENTIAL CLINICAL TRIALS – FOCUSED ON CANDIDATE ANTIBACTERIAL DRUGS, CHALCONES

KONEČNÁ, K.,¹ KUČEROVÁ-CHLUPÁČOVÁ, M.,² DIEPOLTOVÁ, A.,¹ TREJTNAR, F.,³ JANDŮUREK, O.,¹ VOXOVÁ, B.,¹ DOLEŽAL, M.,²

¹ Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

³ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: konecna@faf.cuni.cz

Chalcones and their derivatives represent a group of compounds with a wide range of biological activities.¹ According to this fact, these compounds can be rightfully included in the group of a privileged structures in medicinal chemistry and they represent promising starting points for new drug design.

In our study, we have focused on the investigation of the antimicrobial activity of newly designed and synthesized chalcone derivatives. The total number of twelve compounds has been subjected to evaluation of antimicrobial potential. Based on the results from the basic methodical approach for the antimicrobial activity testing, two of these compounds were selected for advanced preclinical study.

In the advanced study, the antibacterial activity was confirmed by using bacterial strains, clinical isolates that fully represent the epidemiological situation in medical practice. Further, the investigation of *in vitro* (HepG2 cell line) and *in vivo* toxicity (acute and subacute toxicity testing, the invertebrate model *Galleria mellonella*)² was done. In view of previous satisfactory results, the *in vitro* interactions (checkerboard studies)³ of candidate tested compounds with selected antibiotics commonly used in medical practice were further investigated in order to identify a “partner drug” for synergic interaction.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. KAR MAHAPATRA, D., ASATI, V., BHARTI, S. K.: Expert Opin. Ther. Pat., 29, 2019, 385–406.
2. IGNASIAK, K., MAXWELL, A.: BMC Res. Notes, 10, 2017, art. 428.
3. HAMOUD, R., ZIMMERMANN, S., REICHLING, J. *et al.*: Phytomedicine, 21, 2014, 443–447.

DESIGN AND SYNTHESIS OF CASEIN KINASE II (CK2)/ HISTONE DEACETYLASES (HDAC) DUAL INHIBITORS

BOUZ, G.,¹ ORTIN REMON, I.,² De PASCUAL-TERESA, B.,² RAMOS, A.²

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain.
e-mail: bouzg@faf.cuni.cz

The aim of this study is to design and synthesize dual inhibitors combining the pharmacophores of the protein kinase CK2 and histone deacetylase (HDAC), see Fig. 1 below. CK2 is a ubiquitous serine/threonine protein kinase, whose upregulation is linked to tumor progression.¹ On the other hand, HDACs are a class of epigenetic enzymes responsible for gene silencing. Altered expression and mutations of genes that encode HDACs is linked to tumor development.² Synthetic procedures to obtain final compounds will be discussed in detail during the presentation.




Fig. 1. Rational design of title compounds

The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. KHAN, D. H., HE, S., YU, J. *et al.*: J. Biol. Chem., 288, 2013, 16518–16528.
2. WITT, O., DEUBZER, H. E., MILDE, T. *et al.*: Cancer Lett., 277, 2009, 8–21.

DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF POSITIONAL DERIVATIVES OF A SERIES OF *N*-(PYRAZIN-2-YL)CARBOXAMIDES

NAWROT, D., BOUZ, G., ZITKO, J., DOLEŽAL, M.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: nawrotd@faf.cuni.cz

Among infectious diseases, tuberculosis caused by *Mycobacterium tuberculosis*, is a leading cause of death worldwide¹ and major threat to public health. Tuberculosis can effectively be treated with first-line anti-TB drugs, however due to rising antimicrobial resistance new approaches to eradicate the disease are needed. A series of new *N*-(pyrazin-2-yl)carboxamides as potential antimycobacterial and antibacterial agent is presented. Derivatives to be presented are compounds based on positional isomers of picolinic acid linked to pyrazine derivatives (pyrazin-2-amine, 6-chloropyrazin-2-amine, propyl 5-aminopyrazine-2-carboxylate), 4-amino-2-hydroxybenzoic acid or 4-aminobenzoic acid by amidic bond. Compounds were tested for biological activity against selected strains of *Mycobacterium* (*M. tuberculosis* H37Rv, *M. tuberculosis* H37Ra, *M. kansasii*, *M. avium*, *M. smegmatis*, *M. aurum*). The minimum inhibitory concentration (MIC) for tested mycobacterial strains was determined for all tested compounds beside isoniazid, ciprofloxacin and rifampicin as a reference standard drug. Results of the biological testing and structure activity relationships are discussed in the presentation.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Grant Agency of Charles University (Project No. C-C3/1572317).

References

1. World Health Organization: Global Tuberculosis Report 2019. <https://www.who.int/publications/item/9789241565714>.

SYNTHESIS OF FREE OMEGA-HYDROXY CERAMIDES AND THEIR BEHAVIOUR IN THE STRATUM CORNEUM MODEL LIPID MEMBRANES

SOMMEROVÁ, V., OPÁLKA, L., SVATOŠOVÁ, L., VÁVROVÁ, K.

Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: sommerov@faf.cuni.cz

Omega hydroxy ceramides (O-Cer) belong to a subclass of Cer with ultralong ω -hydroxylated *N*-acyl chains. In extracellular spaces of human *stratum corneum* (SC), they are present in the free form or linked to the surface of corneocytes via their free hydroxy group and form the corneocyte lipid envelope (CLE). The main aim of this project

was to prepare 3 subclasses of O-Cer (Cer OS, OP and OdS) using an improved synthetic strategy and study their behaviour after their addition into model lipid membranes.

Complete synthesis of O-Cer has not yet been reported. We modified previously published procedure, where we focused on possible improvements of the synthesis of 32-hydroxydotriacontanoic acid, the backbone of O-Cer. The previously used Wittig reaction was changed for other olefinations, e.g. Julia and Julia-Kocienski reactions, which led to a significant improvement in the reaction yield.

Synthesized O-Cer were added into model lipid membranes consisting of a mixture of Cer, free fatty acids, cholesterol and cholesteryl sulfate mimicking the composition of SC. Membrane organization showed that the addition of O-Cer does not change the arrangement in the long periodicity phase (~12.3 nm), essential for the proper barrier function. Complete replacement of acylCer with O-Cer led to a formation of a new phase with shorter repeat distance (~10.7 nm). Permeability of the model membranes did not change significantly after the addition of O-Cer, however the complete replacement of acylCer with O-Cer increased permeability. In conclusion, the addition of O-Cer to the membrane did not improve the barrier properties and after a complete replacement of acylCer with O-Cer, the barrier was even more perturbed.


The study was supported by the Czech Science Foundation (Project No. 19-09135J), by the Grant Agency of Charles University (Project No. 1194119), and from the project of Specific Academic Research (SVV 260 401/2019).

SYNTHESIS OF NOVEL 2,3-DISUBSTITUTED PYRAZINES AS POTENTIAL ANTIMICROBIALS

PALLABOTHULA, V. S. K., ZITKO, J.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: pallabov@faf.cuni.cz

This research project is focused on synthesis of novel 3-substituted derivatives of pyrazinamide. The synthesis involves acylation of amino group of 3-aminopyrazine-2-carboxylate with acyl chlorides (benzoyl chlorides or phenylacetyl chlorides), followed by ammonolysis by ammonia in dry ethanol (Scheme 1).



Scheme 1. Synthesis of final compounds

The compounds will be assessed for *in vitro* antimicrobial activity against several mycobacterial strains (*Mycobacterium tuberculosis* H37Ra and H37Rv, *M. avium*, *M. kansasii*, *M. smegmatis*, *M. aurum*) and bacterial and fungal strains of clinical importance.

As an off-spin to this project, the compounds will also be studied as potential inhibitors of (human) prolyl-tRNA synthetase. This is rationalized by their structural similarity to confirmed inhibitors reported in literature.¹

The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by CELSA, Project title: Structure-based design of new antitubercular medicines, KU Leuven (Arthur Van Aerschoot) – Charles University in Prague (Martin Doležal).

References

1. ADACHI, R., OKADA, K., SKENE, R. *et al.*: Biochem. Biophys. Res. Commun., 488, 2017, 393–399.

N-PYRAZINOYL SUBSTITUTED AMINO ACIDS AS POTENTIAL ANTIMYCOBACTERIAL AGENTS – SYNTHESIS AND BIOLOGICAL EVALUATION OF ENANTIOMERS

JUHÁS, M., KUČEROVÁ, L., DOLEŽAL, M.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: juhasm@faf.cuni.cz

Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis* (Mtb), causing millions of deaths each year. We present synthesis and biological evaluation of new potential antimycobacterial compounds containing fragment of the first-line antitubercular drug pyrazinamide (PZA), coupled with methyl or ethyl esters of selected amino acids (Fig. 1). The antimicrobial activity was evaluated on a variety of mycobacterial strains including *Mycobacterium tuberculosis* (Mtb) H37Ra and bacterial and fungal strains of clinical importance *e.g.* *Staphylococcus aureus* or *Aspergillus flavus*. Emphasis was made on comparison of activities of individual enantiomers.




Fig. 1. General structure of the synthesized compounds

Overall, high activity against Mtb was seen in derivatives containing more lipophilic L-amino acids. The most potent derivative contained phenylglycine moiety (MIC < 1.98 µg ml⁻¹, < 7.3 µM). Compounds possessed low cytotoxicity in HepG2 cell line

($IC_{50} > 500 \mu M$) and good selectivity towards Mtb ($SI > 40$). No significant activity was detected against tested bacterial and fungal strains. To our best knowledge, this is the first study comparing the activities of D and L-amino acid derivatives of pyrazinamide as potential antimycobacterial compounds.


The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

SYNTHESIS OF SILICON COMPLEXES OF TETRAPYRAZINOPORPHYRAZINES

KOLÁŘOVÁ, M., MILETÍN, M.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: kolarova.michaela@faf.cuni.cz

Azaphthalocyanines such as tetrapyrazinoporphyrazines are widely examined compounds. Due to their large system of conjugated double bonds, they exhibit interesting photophysical and photochemical properties. They find use in many medicinal fields as photodynamic therapy, monitoring RT-PCR or diagnostic imaging. As their structure is planar, strong π - π interactions between macrocycles cause aggregation of molecules.¹ This is an undesirable property of all azaphthalocyanine derivatives because they lose their photoactivity in this state. One approach to suppress aggregation consist in the introduction of suitable metal cation into the macrocyclic core. Silicon cation has been used for this purpose mainly in phthalocyanine chemistry.² Its binding capacity exceeds coordinating bonds in the macrocycle core and provides spear axial bonds, which can bear bulky substituents creating sufficient inhibition of the aggregation process. In this project we focus on different ways of silicon tetrapyrazinoporphyrazine synthesis.



The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. MILETÍN, M., ZIMČÍK, P., NOVÁKOVÁ, V.: Photochem. Photobiol. Sci, 17, 2018, 1749–1766.
2. MAREE, M. D., KUZNETSOVA, N., NYOKONG, T.: J. Photochem. Photobiol. A: Chemistry, 140, 2001, 117–125.

(E)-2-(2-ISONICOTINOYLHYDRAZINYLIDENE)PROPANOIC ACID DERIVATIVES AS PROMISING ANTIMYCOBACTERIAL SUBSTANCES

PFLÉGR, V.,¹ KRÁTKÝ, M.,¹ STOLAŘÍKOVÁ, J.,² VINŠOVÁ, J.¹

¹ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Laboratory for Mycobacterial Diagnostics and Tuberculosis, Institute for Public Health in Ostrava, Czech Republic
e-mail: PflégrV@faf.cuni.cz

(E)-2-(2-Isonicotinoylhydrazinylidene)propanoic acid has been presented and tested as an antimycobacterial agent by Kryukova *et al.*¹ in the Soviet Union in the 1970s. A basic set of antibacterial tests has been described. Since then, derivatives of this compound have been presented only randomly. We are introducing a new comprehensive series in which we have been working on adjusting this structural motif (Fig. 1).

We are focused primarily on modifications of free carboxyl group by various amines or phenols to yield functional derivatives (amides and esters) *via* EDC coupling catalysed by 1-hydroxybenzotriazole or 4-(dimethylamino)pyridine.

The prepared compounds were tested against *Mycobacterium tuberculosis* and some atypical strains of mycobacteria (*M. avium*, *M. kansasii*) with significantly lower MIC values (sometimes up to 64 times lower) compared to the parent drug isoniazid (INH) used as a synthetic precursor. The derivatives don't show cytotoxicity to mammalian cells (assays were performed on HepG2 and MonoMac6 cells) and exhibit much greater ability to inhibit growth of the mycobacterial cells in comparison to the INH.




Fig. 1. (E)-2-(2-Isonicotinoylhydrazinylidene)propanoic acid

The study was supported by the Czech Science Foundation (Project No. 17-27514Y) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. KRYUKOVA, L. M., ZELENIN, K. N., ÉRTEVTSIAN, L. N. *et al.*: Pharm. Chem. J., 11, 1977, 26–29.

N-METHYLHYDRAZINE-1-CARBOXAMIDES AS POTENTIAL CHOLINESTERASES INHIBITORS

HOUNGBEDJI, N.-H.,¹ ŠTĚPÁNKOVÁ, Š.,² KRÁTKÝ, M.,¹ VINŠOVÁ, J.¹

¹ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Czech Republic
e-mail: hougben@faf.cuni.cz

Due to the increasing number of cases, Alzheimer's disease is a neurodegenerative disease that represents a serious threat to mankind. The impairment that this disease causes to one's health, urge for the research of new potential drugs for the treatment of this illness. Nowadays, the therapy of Alzheimer's disease is focused primarily on the use of acetylcholinesterase (AChE) inhibitors and dual AChE-butrylcholinesterase (BuChE) inhibitors.¹ Based on this fact, derivatives of *N*-methyl-hydrazine-1-carboxamide (Fig. 1) have been designed within this goal. The ability of the different derivatives to inhibit both AChE and BuChE was evaluated using modified Ellman's method.² AChE was inhibited with IC₅₀ values within the range of 44–73 μM, whereas BuChE was inhibited with IC₅₀ within the range of 170–514 μM. The most potent compound for AChE inhibition was 2-(4-chlorobenzoyl)-*N*-methylhydrazine-1-carboxamide (IC₅₀ = 44.08 μM). More derivatives will be tested in order to determine the structure-activity relationship.




Fig. 1 Structures of the studied compounds

The study was supported by the Czech Science Foundation (Projects No. 17-27514Y and 2019638Y) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. KRÁTKÝ, M., ŠTĚPÁNKOVÁ, Š., VORČÁKOVÁ, K. *et al.*: *Molecules*, 21, 2016, art. 191.
2. KOVÁŘOVÁ, M., KOMERS, K., ŠTĚPÁNKOVÁ, Š. *et al.*: *Z. Naturforsch. C – J. Biosci.* 68, 2013, 133–138.

PHARMACOGNOSY AND TOXICOLOGY OF NATURAL PRODUCTS SECTION

ANALYSIS OF COPPER-CHELATING ACTIVITY OF ISORHAMNETIN AND TAMARIXETIN

LOMOZOVÁ, Z.,¹ MACÁKOVÁ, K.,¹ KARLÍČKOVÁ, J.,¹ CATAPANO, M. C.,² MLADĚNKA, P.²

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: lomozovz@faf.cuni.cz

Isorhamnetin and tamarixetin are the main *O*-methylated metabolites of the flavonoid quercetin. Flavonoids represent a large group of polyphenolic compounds which belong to plant secondary metabolites and have been suggested to have a positive impact on human health. They are a common component of the human diet. Chelation of transient metal ions is one of their proposed mechanisms of action. Copper is an essential trace element necessary for many physiological processes. However, free copper ions can cause damage to various biomolecules and lead to tissue impairment.¹ Disorder of copper homeostasis can be treated with copper chelators. Due to the limited array of the currently used copper chelators, research of such compounds continues to be of clinical interest.² In this *in vitro* study, tamarixetin and isorhamnetin were tested for their interactions with copper at four (patho) physiologically relevant pH conditions ranging from 4.5 to 7.5 by competitive and non-competitive methods. Competitive studies showed that both compounds were active copper chelators and non-competitive studies showed that the preferred stoichiometries were mainly 3:2 and 2:1 (flavonoid:metal). Analysis of cupric ion reduction has also been performed. In conclusion, both compounds showed good ability to chelate and reduce copper ions.

The study was supported by the Grant Agency of Charles University (Project No. 1080217 C) and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. ŘÍHA, M., KARLÍČKOVÁ, J., FILIPSKÝ, T. *et al.*: RSC Advances, 4, 2014, 32628–32638.
2. CATAPANO, M. C., KARLÍČKOVÁ, J., TVRDÝ, V. *et al.*: J. Trace Elem. Med. Biol., 46, 2017, 88–95.

SCREENING OF ANTIPLATELET ACTIVITY OF ISOQUINOLINE ALKALOIDS

PARVIN, M. S.,¹ MACÁKOVÁ, K.²

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: parvins@faf.cuni.cz

Alkaloids are nitrogen containing secondary metabolites mostly found in plants and other organisms. They have been used for the treatment of many ailments such as cancer, malaria, diabetes and cardiovascular diseases (CVDs).¹ Platelet cells perform a significant role in haemostasis and uncontrolled regulation of platelets can lead to CVDs progression. However, antiplatelet therapy has its limits, so current research seeks to find active substances with different mechanisms of action. In this study, we have measured antiplatelet activity of selected 14 isoquinoline alkaloids isolated from plants. Multiple Electrode Aggregometry has been used where multiple measurement is possible in one time. The screening was performed with the use of whole human blood. Arachidonic acid was used as aggregation inducer and acetylsalicylic acid (ASA) as the standard drug. Percentage of aggregation has been measured from correlation of base line and linear portion of the aggregation curve. The most potent compounds were papaverine, scoulerine and bulbocapnine. The first two substances exhibited similar inhibitory activity as ASA at the concentration of 40 μ M while were significantly less potent at lower concentrations. Initial screening revealed the most potent substances that would need a series of experiments to determine the mechanism of their action. The compounds have already been tested for antagonism at thromboxane receptors using the stable thromboxane analogue U46619.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. AIN, Q. U., KHAN, H., MUBARAK, M. S. *et.al.*: Front. Pharmacol., 7, 2016, art. 292.

PHYTOCHEMICAL ANALYSIS AND BIOLOGICAL ACTIVITY OF *AZORELLA COMPACTA*

ŠTŮSKOVÁ, M., TŮMOVÁ, L.

Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: stuskovm@faf.cuni.cz

Azorella compacta Phil. (syn. *yareta*, Apiaceae) is a compact evergreen cushion shrub growing at altitudes between 3000 and 5000 metres in the South American Andes. The plant is frequently used in traditional medicine in the form of infusions and decoctions to treat various diseases (cold, pain, asthma, diabetes *etc.*) and relieve altitude sickness.¹ The major secondary metabolites that have been described in *azorella* plant are diterpenoids. A few of the potential medical effects were observed, such as antihyperglycemic effect and *in vivo* inhibition of *Plasmodium berghei* growth in mice.² An antimicrobial activity and an anti-*Trypanosoma cruzi* activity were further confirmed.³ Polyphenols are other metabolites found in the *azorella* plant. Previous experiments with aqueous extracts proved their antioxidant and immunomodulatory activity, however, it is not known which particular substances are responsible for the effects. The main aim of the study is to prove selected biological activities of aqueous and ethanolic extracts of the whole plant *Azorella*

compacta. Isolation and finding the specific substances responsible for biological effect is another goal of the study. Due to the current problems of widespread diseases and the lack or insufficient clarification of some findings on the effects of azorella plant, anti-aggregation, anti-tyrosinase, anti-allergic and anti-parasitic activities were selected for testing.

On account of the early stage of research, this study has not provided any valid data yet. The presentation will be focused on the introduction of the plant and planned methods.

The study was supported from the project of Specific Academic Research (SVV 260 416/2019).

References

1. WICKENS, G. E.: *Econ. Bot.*, 49, 1995, 207–212.
2. FUENTES, N. L., SAGUA, H., MORALES G. *et al*: *Phytother. Res.*, 19, 2005, 713–716.
3. NÚÑEZ, S., SAN-MARTÍN, A., CORSINI, G.: *J. Chil. Chem. Soc.*, 63, 2018, 4200–4204.

CYTOTOXIC EVALUATION OF ASTAXANTHIN MONOESTERS FROM MICROALGAE *HAEMATOCOCCUS PLUVIALIS*

FÁBRYOVÁ, T.,^{1,2} Da SILVA, D. C.,³ ANDRADE, P. B.,³ VALENTÃO, P.,³
PEREIRA, D. M.,³ KOPECKÝ, J.,² CHEEL, J.,² TŮMOVÁ, L.¹

¹ Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Laboratory of Algal Biotechnology-Centre ALGATECH, Institute of Microbiology,
Czech Academy of Sciences, Prague, Czech Republic

³ REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química,
Faculdade de Farmácia, Universidade do Porto, Portugal
e-mail: fabryovt@faf.cuni.cz

Reddish ketocarotenoid astaxanthin (AXT) has more powerful antioxidant capacity than β -carotene, vitamin E, zeaxanthin, lutein or canthaxanthin.¹ The ability of this compound to cope with various diseases and protect human body has been also examined. Nowadays, this pigment attracts more and more interest from various industries, such as nutraceutical and cosmetic, due to its different bio-functional properties that can have a huge impact on human health or its nutrition. The major natural source of AXT is the freshwater microalgae *Haematococcus pluvialis*, in which this compound is present mainly in the esterified form. AXT is esterified with different fatty acids that are well-known for having various biological properties. It is believed that they may bestow these properties to AXT esters. From *H. pluvialis* biomass, five AXT monoesters have been isolated in our laboratory by high performance countercurrent chromatography (HPLCCC) and their identity was confirmed using the high-performance liquid chromatography–atmospheric pressure chemical ionization–high resolution tandem mass spectrometry (HPLC–APCI–HRMS/MS). The fraction of astaxanthin monoesters showed a cytotoxic activity against the human gastric cancer cells (AGS cell line) using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay. Later, the cytotoxic effect of AXT esterified with linolenic acid (**1**), linoleic acid (**2**), palmitic acid (**3**), oleic acid (**4**) and stea-

ric acid (**5**) has been examined in these cells, showing that only the compound **4** exhibits a cytotoxic activity against this cell line.

The study was supported from the project of Specific Academic Research (SVV 260 416/2019) and by the Grant Agency of Charles University (Project No. 1134217).

References

1. MIKI, W.: Pure Appl. Chem., 63, 1991, 141–146.

ISOLATION OF ALKALOIDS FROM *VINCA MINOR* L. AND THEIR INHIBITORY ACTIVITY ON HUMAN CHOLINESTERASES

VRABEC, R.,¹ OPLETAL, L.,² LOČÁREK, M.,² MAŘÍKOVÁ, J.,³ JENČO, J.,²
HULCOVÁ, D.,¹ ŠAFRATOVÁ, M.,¹ JANOUŠEK, J.¹

¹ Department of Pharmacognosy, ADINACO Research Group, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmaceutical Botany, ADINACO Research Group, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

³ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: vrabecr@faf.cuni.cz

Vinca minor L. (Apocynaceae) is an evergreen trailing subshrub common in western and southern Europe, mostly as a groundcover in temperate gardens. It contains over 50 indole alkaloids. It has been discovered that the alkaloidal extract from overground parts exhibits selective inhibitory activity against human butyrylcholinesterase (BuChE) (IC_{50} $13.60 \pm 0.83 \mu\text{g ml}^{-1}$), contrary to acetylcholinesterase (AChE) (IC_{50} $191.58 \pm 38.03 \mu\text{g ml}^{-1}$). BuChE is responsible for cleavage of acetylcholine, especially at the advanced stage of Alzheimer's disease, and also for its aggregation of β -amyloid that increases its neurotoxicity. Thus, BuChE represents an interesting target for new drug development, and alkaloids from *V. minor* seem to be a promising source of effective structures. Seven alkaloids have been isolated from the original fractions no. 147–214, which had been obtained from the alkaloidal extract using column chromatography on aluminium oxide. The alkaloids have been separated by TLC techniques on silica-gel, and identification of their structures was performed by HPLC/DAD/MS-ESI, GC/MS-EI, and NMR instruments. Four of these alkaloids have been isolated for the first time from *V. minor* – (+)-aspidofractinine, (+)-raucubaine, (–)-demethoxycarbonyltetrahydrosecodine and (–)-demethoxyalstonamide), whereas (–)-minovincine, minoriceine and strictamine had already been isolated in previous research. All of the isolated alkaloids have been tested on the inhibitory activity of human AChE and BuChE. The most potent alkaloids against BuChE were (–)-demethoxycarbonyltetrahydrosecodine (IC_{50} $0.65 \pm 0.17 \mu\text{M}$) and (–)-demethoxyalstonamide (IC_{50} $56.38 \pm 2.58 \mu\text{M}$). Other isolated alkaloids did not show a substantial effect on the inhibition of BuChE. None of the alkaloids exhibited significant activity against AChE.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 412/2019).

NMR ELUCIDATION OF ACETYLCARANINE

MAŘÍKOVÁ, J.,¹ HOŠŤÁLKOVÁ, A.,² KUNEŠ, J.¹

¹ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: marikoj2@faf.cuni.cz

The presented alkaloid was isolated from *Nerine bowdenii* (Amarylidaceae) at the Department of Pharmaceutical Botany. The Amarylidaceae family is very rich in alkaloids containing isoquinoline scaffold.

The isolated substance was characterized by ¹H and ¹³C NMR experiments as well as Heteronuclear Single Quantum Correlation (HSQC), Heteronuclear Multiple Bond Correlation (HMBC) and Correlation Spectroscopy (COSY) experiments. Other spectroscopic methods such as HRMS and optical rotation were also used.

The determination of this structure will be discussed.




Fig. 1. The identified structure of acetylcaranine¹

The study was supported by the Czech Science Foundation (Project No. 18-17868S) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. CHO, N., DU, N., VALENCIANO, A. L. *et al.*: Bioorg. Med. Chem. Lett., 28, 2018, 40–42.

BROUSSONETIA PAPYRIFERA AS A RICH SOURCE OF VARIOUS SECONDARY METABOLITES

MALANÍK, M., PAULÍKOVÁ, M., POMYKALOVÁ, K., ŠAFÁŘOVÁ, H.,
POSPÍŠILOVÁ, T., ŠMEJKAL, K.

Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary
and Pharmaceutical Sciences Brno, Czech Republic
e-mail: malanikm@vfu.cz

Broussonetia papyrifera (L.) L'Hér. ex Vent. (Moraceae), known as paper mulberry, is a deciduous tree naturally occurring in Southeast Asia. This plant is used in traditional Chinese medicine for various medicinal purposes. Extracts of *B. papyrifera* exhibit antioxidant, antiinflammatory, antidiabetic and antimicrobial properties.¹ Several isolated compounds have huge potential to be used in medicine as they exert significant biological activities.

In the present work, chromatographic separation of chloroform part of ethanolic extract of the branches and twigs of *B. papyrifera* led to the isolation of 29 compounds belonging to the group of flavonoids, coumarins, lignans, stilbenoids, and fatty acid derivatives. The structures of the substances were determined by HRMS, and by 1D and 2D NMR. Broussonetone C and (*R*)-8-methoxymarmesin have been introduced as new compounds and 10 other compounds have been isolated from *B. papyrifera* for the first time. The effect on insulin signalling cascade and NF-κB inhibitory activity of selected phenolic substances have been evaluated in *in vitro* assays.

The study was supported by IGA VFU Brno (Project No. 303/2019/FaF).

References

1. WANG, G. W., HUANG, B. K., QIN, L. P.: *Phytother. Res.*, 26, 2012, 1–10.


ISOLATION AND IDENTIFICATION OF ACTIVE CONSTITUENTS FROM *PAULOWNIA TOMENTOSA* STEUD. FRUIT

MOLČANOVÁ, L.,¹ DALL'ACQUA, S.,² ŠMEJKAL, K.¹

¹ Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

² Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
e-mail: lenka.molcanova1993@gmail.com

Paulownia tomentosa Steud. (Paulowniaceae), a traditional Chinese medicinal plant, is a rich source of multifarious secondary metabolites, mainly of phenolic character. Flavonoids, lignans, phenolic glycosides, phenolic acids, terpenoids, quinones, glycerides, and miscellaneous other compounds have been isolated from different parts of this plant. Recent interest in *P. tomentosa* has focused on isolation and identification of prenylated or



geranylated flavonoids, which exhibit interesting biological activities, such as antioxidant, antimicrobial, anti-inflammatory, cytotoxic, and others.¹ More than sixty compounds with a prenyl or a geranyl side chain attached to the flavonoid skeleton at position C-6 have been isolated from leaves, flowers, and fruit of *P. tomentosa* till today.

Chromatographic separation of fractions obtained from *P. tomentosa* fruit led to the isolation of 14 flavonoid derivatives. The structures were determined by evaluation of the UV, MS, and NMR data. Eight of these compounds were isolated from a natural source for the first time.

The study was supported by IGA VFU Brno (Project No. 311/2019/FaF) and IMA VFU Brno 2019-FaF-04.

References

1. SCHNEIDEROVÁ, K., ŠMEJKAL, K.: *Phytochem. Rev.*, 14, 2015, 799–833.

IDENTIFICATION OF PLANT PHENOLICS AS NOVEL PPAR γ AGONISTS

TREML, J.,¹ DIRSCH, V.,² VÁCLAVÍK, J.,³ ŠMEJKAL, K.³

¹ Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

² Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Austria

³ Department of Natural Products, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

e-mail: tremlj@vfu.cz

Peroxisome proliferator activated receptor γ (PPAR γ) is a nuclear receptor protein playing an essential role in lipid and glucose homeostasis. It is recognized as the receptor of the thiazolidinediones – a class of drugs used to manage hyperglycaemia.¹

Aim of this project was to determine PPAR γ agonist activity of plant phenolics isolated from *Paulownia tomentosa* (Thunb.) Steud. (Paulowniaceae) and *Morus alba* L. (Moraceae). Potential agonists among the compounds isolated at the Department of Natural

Drugs were preselected using virtual screening based on binding to PPAR γ (AutoDock Vina; PDB ID: 1FM6). Only the compounds binding to binding site with satisfactory binding affinity were chosen.

The selected compounds were then tested for agonist activity using PPAR γ luciferase reporter gene transactivation assay. HEK293 cell culture was transiently transfected with PPAR γ expression plasmid, reporter plasmid (tk-PPREx3-luc), and pEGFP-N1 as internal control.

After 18h of incubation luminescence and fluorescence was measured and expressed as ratio. The two most potent compounds were geranylated flavanones from *P. tomentosa* – diplacone and mimulone. Both compounds exhibited dose-dependent activation of PPAR γ with its peak at 3 μ M: 2.6-fold and 3.6-fold, resp. ($p \leq 0.0001$). Whereas rosiglitazone (positive control) showed 7.4-fold activation. Both compounds therefore have an antidiabetic potential.

The research stay in Vienna was supported by AKTION semester scholarship. Special thanks to prof. V. Dirsch and her research group for hosting me.

References

1. WANG, L., WALTENBERGER, B., PFERSCHY-WENZIG, E.-M. *et al.*: Biochem. Pharmacol., 92, 2014, 73–89.

ISOLATION AND IDENTIFICATION OF *SCELETIUM TORTUOSUM* CONSTITUENTS

RJAŠKOVÁ, V.,¹ ČIČEK, S.,² ZIDORN, C.,² ŠMEJKAL, K.¹

¹ Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

² Department of Pharmaceutical Biology, Institute of Pharmacy, Faculty of Mathematics and Natural Sciences, Christian-Albrecht University of Kiel, Germany
e-mail: v.rjaskova@gmail.com

Sceletium tortuosum (L.) N.E.Br. (Aizoaceae), also known as kanna, is a succulent plant from South Africa. It is known to contain several types of alkaloids, from these the mesembrine alkaloids are the most abundant. Structure of the mesembrine alkaloids is based on 3a-aryl-*cis*-octahydroindole ring. Main alkaloids from this group are mesembrine, mesembrenol, mesembrenon, mesembranole. Studies of biological activities have shown that mesembrine alkaloids act primarily as monoamine releasing agents and secondarily as serotonin reuptake inhibitors. These compounds have also displayed inhibitory activity on phosphodiesterase 4.^{1,2}

In this work we present isolation of eight compounds from *S. tortuosum* plant. Dried plant collected in South Africa was extracted with methanol. The methanolic extract was subjected to liquid-liquid extraction with hexane and chloroform. Hexane and chloroform extracts were separated by several column chromatography procedures. We used semi-preparative HPLC with UV and ELSD detection for isolation of pure compounds. Five

compounds were isolated from the hexane part of methanolic extract and three from the chloroform part.

The study was supported by IGA VFU Brno (Projects 320/2016/FaF and 307/2017/FaF) and IMA VFU Brno 2019-FaF-02.

References

1. GERICKE, N., VILJOEN, A.: J. Ethnopharmacol., 119, 2008, 653–663.
2. KRSTENANSKY, J. L.: J. Ethnopharmacol., 195, 2017, 10–19.

ANTIMICROBIAL PROPERTIES OF CANNABINOIDS FROM *CANNABIS INDICA*

HELCMAN, M., TREML, J., ŠMEJKAL, K., BURCLOVÁ, Z.

Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary
and Pharmaceutical Sciences Brno, Czech Republic
e-mail: martin.helcman@gmail.com

Tested compounds were isolated from *C. indica* with the use of chromatographic methods (column chromatography, analytical TLC, analytical and semi-preparative HPLC). Six compounds obtained in the pure form were identified as major cannabinoids (CBG, CBGA, THCA, δ 9-THC, CBDA, CBN). These compounds, plus the standard of CBD, were then used for the research of their antimicrobial properties against gram-positive and gram-negative bacteria. Firstly, minimum inhibition concentrations were measured. As an example of gram-positive bacteria we chose *Staphylococcus epidermidis*, because of its ability to form biofilm. Activity of the subinhibition concentrations of cannabinoids against biofilm formation was also the subject of this research. Mutant strain of *Chromobacterium violaceum* was selected as an example of gram-negative bacteria. We also used this strain to study the effect of the subinhibition concentrations of the cannabinoids against the quorum sensing, the type of cell-cell communication, which plays the key role in the regulation of bacterial behaviour. As a result of this research, we observed strong bacteriostatic activity of the cannabinoids (excluding CBGA) against gram-positive bacteria, but almost no effect on gram-negative bacteria, which is in line with the previous experiments.¹ Specific anti-biofilm activity was observed for the CBGA. Quorum-quenching activity will be the subject of further research.

The study was supported by IGA VFU Brno (Project No. 310/2019/FaF).

References

1. KREJČÍ, Z., ŠANTAVÝ, F.: Acta Univ. Palacki. Olomuc. 6, 1955, 59–66.

ISOLATION OF AMARYLLIDACEAE ALKALOIDS FROM *HIPPEASTRUM* CULTIVAR FERRARI AND EVALUATION FOR THEIR BIOLOGICAL ACTIVITIES

ALSHAMMARI, L.,¹ KUNEŠ, J.,² HAVELEK, R.,³ CAHLÍKOVÁ, L.¹

¹ ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

³ Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové,
Charles University, Czech Republic
e-mail: alshamml@faf.cuni.cz

Hippeastrum is a well-known ornamental Amaryllidaceae genus native to South America and comprises approximately 60 species, about 30 of which are found in Brazil; the majority are endemic and poorly studied.¹ This genus has been traditionally used to cure piles, tumors and various inflammatory disorders such as asthma. Physiological activities reported for plants of this genus include psychopharmacological effects, inhibitory activity against *Trichomonas vaginalis* and cytotoxicity.²

The summary ethanolic extract was prepared from fresh bulbs of *Hippeastrum* cv. Ferrari and divided by column chromatography. More than three hundred fractions were collected and pooled together based on TLC into fifteen subfractions. So far, fourteen alkaloids belonging to different structural types have been isolated in pure form. The isolated compounds were identified by comparison of obtained analytical data (MS, NMR, optical rotatory) with the literature data. All isolated alkaloids were assayed for their biological activities, e.g. inhibition of HuAChE and HuBuChE, POP (prolyloligopeptidase), GSK-3 β (glycogen synthase kinase-3 β), anticancer potential (cytotoxicity against panel of cancerous and noncancerous cell lines) and others. Within isolated alkaloids montanine displayed strong cytotoxicity against all tested cancer cells with IC₅₀ values between 1.04–1.99 μ M.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. DEEPA, C. P., KURIAKOSE, B. B.: Int. J. Pharmacogn. Phytochem. Res. 6, 2014, 399–404.
2. SILVA, A. F. S., De ANDRADE, J. P., MACHADO, K. R. B. *et al.*: Phytomedicine, 15, 2008, 882–885.

ALIPHATIC AND AROMATIC DERIVATIVES OF MONTANINE-TYPE ALKALOIDS AND THEIR CYTOTOXIC ACTIVITY

MAAFI, N.,¹ CAHLÍKOVÁ, L.,¹ KUNEŠ, J.²

¹ ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: negarm@faf.cuni.cz

The Amaryllidaceae plant family is known as a fruitful source of particular alkaloids which possess different range of bioactivities, such as antitumor, antimalarial, antibacterial and cytotoxic ones. Among these compounds, montanine-type alkaloids are characterized by 5,11-methanomorphanthridine ring system and known for their potential cytotoxic activity. Montaine and coccinine isolated from *Haemanthus humilis* Jacq., have been shown to have *in vitro* IC₅₀ value between 1.9 and 23.3 μM against 6 different cancerous cell lines.¹ In another study manthine and 3-*O*-methylpancracine were synthesized through rearrangement of haemantamine and showed growth inhibitory GI₅₀ values between 3 to 31 μM on 6 cancerous cell lines.² These facts introduce montanine-type structure as a potential cytotoxic framework to be investigated.

This project is focused on different chemical group replacement on montanine type alkaloids in order to improve the cytotoxic activity and also to figure out the possible SAR of these compounds. Since these alkaloids are rare in natural sources, based on previous publications, they were synthesized using haemantamine intermolecular nucleophilic rearrangement², and various chemical groups were tried in position 3. In this presentation we will report the procedure of preparation of about 20 aliphatic and aromatic esters and ethers and results from their cytotoxic activity.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. MASI, M., GUNAWARDANA, S., Van RENSBURG, M. J. *et al.*: *S. Afr. J. Bot.*, 126, 2019, 277–281.
2. GOVINDARAJU, K., INGELS, A., HASAN, M. N. *et al.*: *Bioorg. Med. Chem.*, 28, 2018, 589–593.

DERIVATIVES OF AMARYLLIDACEAE ALKALOID AMBELLINE AS POTENTIAL DRUGS

RITOMSKÁ, A.,² HULCOVÁ, D.,² MAŘÍKOVÁ, J.,¹ CAHLÍKOVÁ, L.²

¹ Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: ritomska@faf.cuni.cz

Twenty-one derivatives of crinane-type alkaloid ambelline were developed. All of them were inspected for their potential inhibitory activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Esters of ambelline seem to be promising selective inhibitors of BuChE, which plays a significant role in later stages of AD when levels of BuChE rapidly increase. The benefits of BuChE inhibition are predicted based on its symptomatic-relief mode of action, but also on suggestion an involvement of this enzyme in regulating disease progression. Seven aromatic derivatives with different substitutions on the attached aromatic ring were endowed with remarkable inhibitory potency against *h*BuChE (IC₅₀ < 5 μM), highlighting three top-ranked compounds as follows: 11-*O*-(1-naphthoyl)ambel-

line, 11-*O*-(2-methylbenzoyl)ambelline, and 11-*O*-(2-methoxybenzoyl)ambelline with IC₅₀ values of 0.10 ± 0.01 μM, 0.28 ± 0.02 μM, and 0.43 ± 0.04 μM. Notably, four derivatives displayed selective *h*BuChE inhibition profile with selectivity index higher 100. *In vitro* investigation was supported by computational studies predicting compound's plausible binding modes in the active sites of *h*BuChE. To predict CNS availability logBB was calculated and the data correlated well with those obtained from PAMPA assay. Based on the obtained data all compounds should be able to permeate blood-brain barrier.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. GREIG, N. H., UTSUKI, T., YU, Q. *et al.*: *Curr. Med. Res. Opin.*, 17, 2001, 159–165.

ALKALOIDS AS POTENTIAL DRUGS IN THE TREATMENT OF ALZHEIMER'S DISEASE

HULCOVÁ, D.,¹ ŠAFRATOVÁ, M.,¹ HOŠŤÁLKOVÁ, A.,² CHLEBEK, J.,²
OPLETAL, L.,² CAHLÍKOVÁ, L.²

¹ Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: hulcovd@faf.cuni.cz

Alkaloids are very important group of secondary metabolites with a number of interesting biological effects (anticancer, analgesic, anticholinesterase, antimalarial, ...). Among the best known and most important substances are for example ergot alkaloids used in the therapy of diseases of the circulatory system, Vinca alkaloids such as vincristine and vinblastine with anticancer activity or Amaryllidaceae alkaloid galanthamine which is used in the therapy of Alzheimer's disease (AD).¹

AD is one of the most frequent causes of dementia in the world. AD consists of many cognitive and neuropsychiatric manifestations as is damage of memory, speech, orientation and others. During AD multiple pathological changes occur in the brain and some enzyme systems are damaged that results in loss of neurotransmitter acetylcholine (ACh) and formation of amyloid plaques and neurofibrillary tangles (NFTs). NFTs consist of paired helical filaments, with the main component being hyperphosphorylated τ -protein. Phosphorylation of τ -proteins is primarily dependent on glycogen synthase kinase-3 β (GSK-3 β) and cyclin-dependent kinase 5.² Alkaloids of different structural types have been screened for their potency to inhibit GSK-3 β at the concentration of 50 μM. Promising results have been demonstrated by two alkaloids 5/205 from *Vinca minor* (IC₅₀ = 4.08 ± 0.14 μM) and GV 8-3b from *Geissospermum vellosii* Alemao (IC₅₀ = 7.18 ± 1.12 μM).

The study was supported by project EFSA CDN, reg. č. CZ.02.1.01/0.0/0.0/16_019/000 0841 and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. CAHLÍKOVÁ, L., MACÁKOVÁ, K., BENEŠOVÁ, N. *et al.*: Natural Compounds (Small Molecules) as Potential and Real Drugs of Alzheimer's Disease: A Critical Review. In: Studies in Natural Products Chemistry, vol 42., Atta-ur Rahman (ed.), Oxford/Amsterdam, Elsevier, 2014, pp. 153–194.
2. HULCOVÁ, D., BREITEROVÁ, K., SIATKA T. *et al.*: *Molecules*, 23, 2018, art. 719.

ALKALOIDS OF AMARYLLIDACEAE FAMILY AS POTENTIAL DRUGS IN THERAPY OF DISEASES OF AFFLUENCE

BREITEROVÁ, K.,¹ MAŘÍKOVÁ, J.,² KOUTOVÁ, D.,³ CAHLÍKOVÁ, L.¹

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

³ Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University,
Hradec Králové, Czech Republic
e-mail: breiterk@faf.cuni.cz

51% of all drugs and 65% of small-molecule drugs approved between 1981–2014 are in certain connection with natural compounds.¹ This proves that natural compounds and their derivatives are still an important source where new potential drugs can be sought. One of interesting groups of bioactive compounds are alkaloids. Amaryllidaceae family belongs among the twenty most important alkaloidal families with almost 600 of various Amaryllidaceae alkaloids isolated and structurally described so far.

34.3 kg of fresh bulbs of *Narcissus* cv. Professor Einstein were processed to obtain 31.7 g of summary alkaloidal extract. This extract was subjected to separation by different chromatographic methods. At the end, twenty-five alkaloids were isolated and identified by GCMS, ESI-MS, NMR, X-ray, optical rotation and literature. One compound was identified as a new unpublished alkaloid of lycorine structure type – 7-oxonorpluviine. All compounds isolated in sufficient amount have undergone series of bioassays associated with Alzheimer's disease, cytotoxicity and activity against the liver stage malaria *in vitro*. The most promising was cytotoxic activity of pancracine – hence it went through study of the cell cycle and apoptosis induction interference.

The study was supported by Pre-application research into innovative medicines and medical technologies INOMED (Project No. CZ.02.1.01/0.0/0.0/18_069/001/0046) and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. NEWMAN, D. J., CRAGG, G. M.: *J. Nat. Prod.*, 79, 2016, 629–661.

SEMISYNTHETIC DERIVATIVES OF AMARYLLIDACEAE ALKALOID HAEMANTHAMINE AS POTENTIAL DRUGS IN THE TREATMENT OF ALZHEIMER'S DISEASE

PEŘINOVÁ, R.,¹ KOHELOVÁ, E.,¹ ŠPULÁK, M.,² MAŘÍKOVÁ, J.,² HULCOVÁ, D.,¹ CAHLÍKOVÁ, L.¹

¹ ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Charles University,
Hradec Králové, Czech Republic
e-mail: perinovr@faf.cuni.cz

Plants of Amaryllidaceae family include approximately 85 genera and 1100 species which have a wide distribution through both tropical and sub-tropical regions worldwide. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide with complex etiology and multifaceted pathophysiology and data indicate an exponential rise in the number of cases of this disease. The well-known Amaryllidaceae alkaloid (AA) galanthamine is a marketed drug for AD therapy under the commercial name Reminyl[®] (galanthamine hydrobromide).¹

Studies also pointed out various pharmacological properties of semisynthetic derivatives of some AA. One of the most interesting AA alkaloids is alkaloid haemanthamine (HMT), which is widely distributed through Amaryllidaceae plants. Based on our previous results,^{1,2} where we reported promising activity of pilot series of HMT derivatives, we decided to continue in preparation of further semisynthetic derivatives.

Several new aromatic and aliphatic esters and pilot ethers have been synthesized for structure-activity relationship (SAR). New compounds were identified by 1D and 2D NMR, GC/MS and ESI-MS methods. All newly developed compounds were screened for different biological activities connected with potential treatment of AD. Active compounds are studied in more detail (*e.g.* type of inhibition, docking studies, logBB *etc.*).

This project was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. KOHELOVÁ, E., PEŘINOVÁ, R., MAAFI, N. *et al.*: *Molecules*, 24, 2019, art. 1307.
2. HULCOVÁ, D., BREITEROVÁ, K., SIATKA, T. *et al.*: *Molecules*, 23, 2018, art. 719.

SEPARATION OF STEREOISOMERS OF HAEMANTHIDINE FROM *ZEPHYRANTHES CITRINA*

KOHELOVÁ E.,¹ JENČO J.,¹ CAHLÍKOVÁ, L.,¹ MAŘÍKOVÁ, J.²

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: kohelove@faf.cuni.cz

Zephyranthes is a genus of bulbous perennial plants belonging to Amaryllidaceae family that consists of about 90 various species. Phytochemical screening of their biologically active constituents revealed diverse group of compounds, especially Amaryllidaceae alkaloids having various pharmacological activities including anticancer, anticholinesterase, antiviral, antifungal and anti-inflammatory activity. To date, ten alkaloids of various structural types have been reported in *Zephyranthes citrina*.¹

So far, 26 alkaloids from 30 kg fresh bulbs of *Zephyranthes citrina* have been isolated by liquid-liquid extraction and commonly used chromatographic methods. All compounds were identified by MS and NMR techniques. Several alkaloids were obtained in the mixture of isomers. Haemanthidine, an alkaloid of β -crinine structure type, has been isolated in our lab in the form of mixture of 4 isomers. Within previous studies this alkaloid showed promising cytotoxic activity against various cancer cell lines. The aim of this study was separation of individual isomers and study of their biological activity as the biological activity of individual isomers is unknown. Direct resolution of haemanthidine into its enantiomers was achieved by normal-phase TLC on silica gel plates impregnated with optically pure L-tartaric acid and L-histidine as chiral selectors. The mobile phase that enabled the best resolution was combination of cyclohexane-ethyl acetate-isopropanol-diethylamine (45 : 45 : 5 : 5), the spots were detected with Dragendorff's reagent and under UV light. The studies of biological activities of each isomer are underway.

The study was supported by the Charles University Grant Agency (Project No. 178518) and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. SINGH, B., KATOCH, D.: Med. Aromat. Plants, 4, 2015, art. 212.

BIOLOGICAL EVALUATION OF ALKALOIDS ISOLATED FROM *NARCISSUS* CV. CARLTON AND ANTIPROLIFERATIVE POTENTIAL OF THEIR SEMISYNTHETIC DERIVATIVES

AL MAMUN, A.,¹ CAHLÍKOVÁ, L.,¹ MAŘÍKOVÁ, J.²

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Charles University, Czech Republic
e-mail: almamuna@faf.cuni.cz

Plants of genus *Narcissus* L., the most common genus of Amaryllidaceae family, have been used in traditional medicine worldwide. Most of the species can hybridize and some hybrid cultivars have been reported as potential sources of galanthamine and other Amaryllidaceae alkaloids (AA).¹ *Narcissus pseudonarcissus* cv. Carlton is an abundant species of *Narcissus* L. genus, often used for commercial extraction of galanthamine which is the most active AA used in the clinical management of mild to moderate stages of Alzheimer's disease (AD). So far, thirteen known AA have been isolated from *Narcissus pseudonarcissus* cv. Carlton. One undescribed isomer of hippeastrine and three new compounds

belonging to belladine structure types have been isolated. Compounds isolated in sufficient amounts were screened for acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), prolyl oligopeptidase (POP), glycogen synthase kinase-3 beta (GSK-3 β) and beta-secretase 1 (BACE1) inhibition activity. Hippéastrine isomer and new compounds named carltonine A, carltonine B, and carltonine C demonstrate BuChE inhibition activity in μM and nM concentrations (10.07 μM , 91 nM, 3 nM and 14.84 μM , respectively).² The next part of the current study was the preparation of semisynthetic derivatives of galanthamine and screening their biological activities connected with AD and oncological diseases.

The project was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. JIN, Z.: Nat. Prod. Rep., 33, 2016, 1318–1343.
2. AL MAMUN, A., MAŘÍKOVÁ, J., HULCOVÁ, D. *et. al.*: Biomolecules 10, 2020, art. 800.

NEUROPROTECTIVE ACTIVITY OF *NUPHAR LUTEA* L. ALKALOID

WIJAYA, V.,¹ OPLETAL, L.,¹ HULCOVÁ, D.,¹ KUNEŠ, J.,²
MAŘÍKOVÁ, J.,² CHLEBEK, J.¹

¹ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: wijayav@faf.cuni.cz

During the screening of potential plant inhibitors against human acetylcholinesterase (*hAChE*) and butyrylcholinesterase (*hBChE*) at our department, a *Nuphar lutea* alkaloidal extract demonstrated potent and selective *hBChE* inhibitory activity (IC_{50} value of $11.73 \pm 1.05 \mu\text{g ml}^{-1}$); against *hAChE* it was inactive (IC_{50} value $> 100 \mu\text{g ml}^{-1}$). From a dried plant material of *N. lutea* (12.25 kg; leaves and rhizomes) a summary ethanol extract (37.7 g) was prepared. It was subsequently fractionated with diethyl ether ($\text{Et}_2\text{O-A}$; 1.7 g and $\text{Et}_2\text{O-B}$; 34.4 g), chloroform ($\text{CHCl}_3\text{-B}$; 0.34 g), and ethyl acetate (EtOAc-B ; 0.95 g) by liquid-liquid extraction. The $\text{Et}_2\text{O-B}$ was separated by column chromatography on neutral alumina with step elution using petroleum ether, chloroform, and ethanol to collect 266 fractions that were monitored by TLC and 22 joined fractions were obtained. Subsequently, 5 fractions were separated by using different chromatographic techniques (flash chromatography and preparative TLC) to isolate five pure alkaloids (thiobinupharidine, neothiobinupharidine, two unpublished diastereomers of thiobinupharidine, and one unpublished diastereomer of deoxynupharidine). Their structures were elucidated by mass spectrometry (EI, ESI), NMR, and optical rotation. *hAChE* and *hBChE* inhibitory activity of pure alkaloids was determined using a modified Ellman's method.¹ The diastereomer of deoxynupharidine showed moderate activity against *hBChE* with the IC_{50} value $69.30 \pm 5.00 \mu\text{M}$, other compounds were considered inactive (IC_{50} values $> 100 \mu\text{M}$).

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. ELLMAN, G. L., COURTNEY, K. D., ANDRES, V. *et al.*: *Biochem. Pharmacol.* 7, 1961, 88–95.

PHARMACEUTICAL TECHNOLOGY SECTION

IMPROVING THE DISSOLUTION RATE OF POORLY SOLUBLE MELOXICAM BY CO-MILLING

BROKEŠOVÁ, J.,¹ TRPĚLKOVÁ, Ž.,¹ KOKTAN, J.,² ŠKLUBALOVÁ, Z.¹

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Research and Development, Zentiva, k. s., Czech Republic
e-mail: brokesoj@faf.cuni.cz

The aim of this work was to study the possibility of increasing the dissolution rate of the model drug meloxicam (MLX, BCS class II, solubility in water is $4.4 \mu\text{g ml}^{-1}$ at $25 \text{ }^\circ\text{C}$)¹ using solventless co-milling with a hydrophilic drug carrier chitosan (CHIT) of 85% deacetylation degree. Firstly, the properties of both substances were estimated. MLX particles are very fine with a mean particle size $x_{50} = 3.7 \mu\text{m}$ and a relatively narrow distribution (span = 1.94). On the other hand, CHIT has platelet particles with a mean size $x_{50} = 59.3 \mu\text{m}$ and a wider distribution (span = 2.30). The melting point $T_m = 262.4 \text{ }^\circ\text{C}$ was detected for MLX (crystalline substance). CHIT shows glass transition temperature T_g at $122.5 \text{ }^\circ\text{C}$ (amorphous substance). Subsequently, the binary powder mixtures were prepared at 1 : 1 and 1 : 8 ratios in a planetary ball mill. The effects of ball size, rpm and milling time on properties of co-milled mixtures were investigated. The changes in the particle size and particle size distribution were monitored by laser diffraction using a dry cell. Flow-through cell type of dissolution (USP 4, phosphate buffer pH 6.8) with open loop was used to evaluate the dissolution rate of the drug in the co-milled powder mixtures. The detected dissolution rate r ($\text{mg dm}^{-3} \text{ s}^{-1}$) of MLX in the MLX:CHIT mixture co-milled in 1 : 8 ratio for 15 minutes was approximately four times higher than the dissolution rate of MLX within the first ten minutes. The reason is presumably an increase in specific surface area of the micronized drug particles together with deagglomeration during the co-milling/mixing with the hydrophilic carrier with larger particles.

The study was supported by the Grant Agency of Charles University (Project No. 1286218/2018, from the project of Specific Academic Research (SVV 260 401/2019) and Zentiva, k. s.

References

1. AMBRUS, R., KOCBEK, P., KRISTL, J. *et al.*: *Int. J. Pharm.*, 381, 2009, 153–159.

AVALANCHE TESTING AND ITS RELATIONSHIP TO COHESION OF POWDERS

TRPĚLKOVÁ, Ž., ŠKLUBALOVÁ, Z.

Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: trpelkoz@faf.cuni.cz

Powders and granular materials are two-phase systems where individual solid particles touch each other and are diffused in gaseous surroundings; the interparticle contacts influence the behaviour of the powder bed. Powder properties depend on many parameters such as particle size, shape, density, cohesive forces as well as on the air humidity and temperature.¹ More cohesive materials can cause flow difficulties during pharmaceutical processes. Therefore, shear testing and new methods of avalanche measurements studying dynamic powder behaviour are used to describe these materials.

It has been observed previously that some portion of powder microcrystalline cellulose (MCC) in mixtures with pellets made of microcrystalline cellulose (C100) improved compressibility of mixtures into tablets. In this work, the influence of MCC on the interparticle cohesion and flow properties were studied using the automated shear cell (ShearScan) and dynamic flow measurements (Revolution Powder Analyser). The more MCC in the mixture the higher cohesion was observed with worsening in avalanche behaviour from slumping (C100 and M90) through cascading (M80–M60) to cataracting when 50% or more of MCC was added. The relationship between the cohesion and avalanche angle was described with the linear regression with the coefficient of regression $R = 0.9242$. The results show the importance of careful choice of mixture composition to achieve the optimum composition for both good compression and flowability.

The study was supported by the Grant Agency of Charles University (Project. No. 1286218/2018) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. PRESCOTT, J. K., BARNUM, R. A.: Pharm. Technol., 24, 2000, 60–84.

CHARACTERIZATION OF RHEOLOGICAL PROPERTIES OF POLYMERS FOR FORMULATION OF LIQUISOLID SYSTEMS TARGETED TO THE COLON

OGADAH, C., VRANÍKOVÁ, B., ŠKLUBALOVÁ, Z.

Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: ogadahc@faf.cuni.cz

Targeting drugs directly to the colon is beneficial for the local treatment of inflammatory bowel diseases and other colonic pathologies. Drug delivery systems which can control or sustain drug release in the colon are needed in order to achieve satisfactory drug levels for a longer duration, thereby minimizing dosing frequency and adverse effects.

A possible approach to control drug release is by the formulation of liquid systems by incorporating hydrophilic polymers as matrices. Such polymers become hydrated in aqueous medium to form a gel layer which controls the drug release. The ability of the polymer to control drug release is partly influenced by viscosity of the hydrated gel layer. Therefore, this study aims to characterize a range of polymer candidates (guar gum, sodium alginate, sodium carboxymethyl cellulose and various grades of hydroxypropyl methylcellulose) by rheological measurements. Biorelevant media Fasted State Simulated Gastric Fluid (FaSSGF) and Fasted State Intestinal Fluid (FaSSIF) of pH 1.6 and 6.5, resp., were used to prepare polymer dispersions simulating the gel layer formed at the surface of hydrated matrices in the gastrointestinal tract. Flow rheology measurements were carried out on a rheometer. Flow curves were obtained, using a shear rate ramp at shear rate 0.01–100 s⁻¹. Ostwald-de Waele (power law) model was applied to describe the rheological flow behaviour. The apparent viscosities of the polymers at shear rates of practical importance were reported. Although other formulation parameters will influence the drug release, viscosity data from the rheological studies will serve as a useful basis for further studies with regards to the formulation of liquid systems for colon-targeted drug delivery.

The study was supported by the Grant Agency of Charles University (Project No. 70119/2019) and from the project of Specific Academic Research (SVV 260 401/2019).

IN VITRO MODELS OF SKIN LIPID BARRIER

SAGRAFENA, I.,¹ PARASKEVOPOULOS, G.,¹ VÁVROVÁ, K.²

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: sagrafei@faf.cuni.cz

First-line protection of the human body is carried out by the outermost skin layer, the stratum corneum (SC), which is composed of corneocytes embedded in a lipid matrix of ceramides, cholesterol and fatty acids.¹ Skin diseases are associated with modified skin barrier functions which result from alterations in the skin barrier composition. In this regard, the use of model lipid membranes is a very useful tool to mimic healthy or diseased skin states.²

The aim of this study is to create model lipid membranes and investigate the polymorphic nature of the lipids at different annealing conditions. Initially, skin isolated lipids were annealed at different temperatures (from room temperature to 90 °C) in the presence or absence of water. Preliminary results did not show major differences for the lengths of long periodicity phase or cholesterol phase between the different annealing conditions, while short periodicity phase starts to be visible when annealing temperature is 70 °C in presence of water. Moreover, even if annealing of lipids was considered an essential step for the creation of model lipid membranes, our results indicate that lipids are also able to spontaneously arrange.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Czech Science Foundation (Project No. 19-09135J)

References

1. JACKSON, S. M., WILLIAMS, M. L., FEINGOLD, K. R. *et al.*: West. J. Med., 158, 1993, 279–285.
2. ČUŘÍKOVÁ, B. A., PROCHÁZKOVÁ, K., FILKOVÁ, B. *et al.*: Int. J. Pharm., 534, 2017, 287–296.

DELIVERY OF SKIN BARRIER LIPIDS TO RECONSTRUCTED HUMAN EPIDERMIS

NOVÁČKOVÁ, A.,¹ OPÁLKA, L.,² VÁVROVÁ, K.,² JONCA, N.³

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

³ Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, Inserm – Université Toulouse 3, France
e-mail: novacka1@faf.cuni.cz

Skin barrier is found in the outermost part of the skin called *stratum corneum* (SC), which consists of flattened dead cells (corneocytes) embedded in a lipid matrix. A lipid species specific for epidermis, ω -*O*-acylceramides (ω -*O*-acylcer), are essential for the organization of the two SC lipid structures: the highly organized intercellular lipid lamellae and the monolayer of lipids covalently bound to the surface of corneocytes. Both are essential for our survival on dry land.¹ One of the key enzyme in the synthesis of ω -*O*-acylcer is PNPLA1, which was found deficient in a subset of patients suffering from Autosomal Recessive Congenital Ichthyoses.² The available treatment is only symptomatic, thus, we attempted to restore skin barrier by delivering ω -*O*-acylcer to the SC. In this study, delivery systems for ω -*O*-acylcer were tested for their ability to deliver ω -*O*-acylcer to reconstructed human epidermis (RHE) deficient in PNPLA1. Effect of treatment on permeability (Lucifer yellow assay), ultrastructure of the SC (electron microscopy) and lipid content (LC/MS) was evaluated. Furthermore, two different models of RHE were compared for their ability to mimic diseased epidermis and protocol for application of delivery systems on RHE was developed.

The study was supported by the Czech Science Foundation (Project No. 19-09135J) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. ELIAS, P. M., GRUBER, R., CRUMRINE, D. *et al.*: Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids, 1841, 2014, 314–331.
2. PICHERY, M., HUCHENQ, A., SANDHOFF, R. *et al.*: Hum. Mol. Genet., 26, 2017, 1787–1800.

SNEDDS FOR TARGETED OLIGONUCLEOTIDE DELIVERY TO INFLAMED INTESTINAL TISSUE

KUBAČKOVÁ, J.,¹ HOLAS, O.,¹ ZBYTOVSKÁ, J.,¹ PÁVEK, P.,² MÜLLERTZ, A.³

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

³ Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark
e-mail: kubaackja@faf.cuni.cz

Self-nanoemulsifying drug delivery systems (SNEDDS) have potential to locally deliver an anti-inflammatory acting oligonucleotide (OND) to inflamed intestinal tissue. A non-specific OND was complexed with a cationic lipid to increase its lipophilicity.¹ This allowed to load the complex (OND-CL) into SNEDDS containing medium-chain fatty acids that enhance tight junction (TJ) opening.² Caco-2 cells were pre-treated with Compound 48/80 (C48/80), an inhibitor of TJ opening, and subsequently incubated with OND-CL loaded in SNEDDS, blank SNEDDS (bSN) and the cationic lipid dissolved in SNEDDS both dispersed in a solution of OND, and a solution of OND. Size of dispersed nanodroplets between 180 and 215 nm together with zeta potential ~ -8 mV are properties enabling passive targeting to the inflamed area. All treatments containing SNEDDS showed permeation of OND unlike in the case of the OND solution. The highest amount of OND permeated after treatment with OND-CL in SNEDDS. C48/80 lowered and delayed the transport of OND-CL, however, there was no significant difference in the case of bSN in presence and absence of the inhibitor. When treated with SNEDDS, TEER dropped to $\sim 50\%$ of initial values. The inhibitor C48/80 modulates opening of TJs and suggests their role in transport of OND through Caco-2 monolayer.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Czech Science Foundation (Project No .GA17-06841S).

References

1. LOBOVKINA, T., JACOBSON, G., GONZALEZ-GONZALEZ, E. *et al.*: ACS Nano, 12, 2011, 9977–9983.
2. HAYASHI, M., SAKAI, T., HASEGAWA, Y. *et al.*: J. Control. Release, 62, 1999, 141–148.

POLYMERIC PARTICLES: A TOOL FOR TARGETED INFLAMMATION MANAGEMENT

BOLTAROVÁ, B.,¹ KUBAČKOVÁ, J.,¹ HOLAS, O.,¹ PÁVEK, P.²

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: boltnarb@faf.cuni.cz

The aim of this work is to prepare biodegradable polymeric nanoparticles with encapsulated anti-inflammatory substance. Polymeric particles are actively scavenged from systemic circulation by phagocytic cells of the reticuloendothelial system. Macrophages such as Kupffer cells play an important modulatory role in the development of inflammation. Therefore, such particles could be suitable for liver targeting.¹ The encapsulation of the active substance into nanoparticles has undeniable advantages, such as reduced side effects, site specific action or reduced active substance dose.² A number of different variants of poly(lactic-co-glycolic) acid (PLGA) (several linear variants and a branched with polyacrylic acid) were tested for preparation of nanoparticles. These co-polymers are sufficiently stable, biodegradable and do not induce stimulation of the immune system.³ PLGA nanoparticles of desired size (80–300 nm) with low polydispersity were prepared and assayed *in vitro*. Particles with size under 100 nm were prepared by emulsification solvent evaporation method. Nanoprecipitation yielded nanoparticles ranging between 150 and 200 nm. Formulations of such parameters are attractive to target cells, non-toxic and also with high cell entry demonstrated *in vitro* (more than 50%).

The study was supported from the project of Specific Academic Research (SVV 260 401/2019), by the Grant Agency of Charles University (Project No. 158611) and by the Czech Science Foundation (Project No. 19-14497S).

References

1. TAMMAM, S. N., AZZAZY, H. M., LAMPRECHT, A.: J. Biomed. Nanotech., 11, 2015, 555–577.
2. WANG, M. T., JIN, Y., YANG, Y. X. *et al.*: Int. J. Nanomed., 5, 2010, 487–497.
3. BARTNECK, M., PETERS F. M., WARZECHA K. T. *et al.* Nanomedicine, 10, 2014, 1209–1220.

IMIQUIMOD CONTAINING LIPOSOMES FOR DERMAL DELIVERY

PANOUSOPOULOU, E.,¹ PARASKEVOPOULOS, G.,¹ SAGRAFENA, I.,¹
NOVÁČKOVÁ, A.,¹ VÁVROVÁ, K.,² ZBYTOVSKÁ, J.¹

¹ Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: panoutse@faf.cuni.cz

Over the past years, (trans)dermal delivery has gained extensive popularity due to its advantages over other routes of administration.¹ Dermal delivery has been improved by different methods and vehicles, of which, liposomes seem to be the most studied.² Imiquimod (IMQ) is a topically applied imidazoquinolon, used for the treatment of several skin diseases, like actinic keratosis and basal cell carcinoma.³ Traditional formulations restrict IMQ's efficiency for dermal delivery because of the drug's poor solubility and low cutaneous permeability.³ The aim of the present study is to prepare IMQ loaded liposomes and evaluate their ability to deliver the active substance to the desired skin layers. Different liposomal formulations with IMQ were prepared by using the thin film method. The physicochemical properties of the prepared formulations were determined in terms of particle

size, polydispersity index, zeta potential, and entrapment efficiency. *Ex vivo* experiments on human tissue showed that liposomes have a potential as carriers of IMQ for dermal application

The study was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Czech Science Foundation (Project No. 19-09600S).

References

1. PRAUSNITZ, M., LANGER, R.: *Nat. Biotechnol.*, 26, 2008, 1261–1268.
2. NOUNOU, M. I., EL-KHORDAGUI, L. K., KHALAFALLAH, N. A. *et al.*: *Recent Pat. Drug Deliv. Formul.*, 2, 2008, 9–18.
3. MA, M., WANG, J., GUO, F. *et al.*: *J. Mater. Sci.: Mater. Med.*, 26, 2015, art. 192.

OPTIMIZATION OF RIFAMPICIN-LOADED NANOPARTICLES PREPARATION

COSTA, P.,¹ ŠNEJDROVÁ, E.,² MARTIŠKA, J.,² DITTRICH, M.²

¹ Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal

² Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: paulinha_xana@hotmail.com

In past two decades, poly lactic-co-glycolic acid (PLGA) has been among the most attractive polymeric candidates used to fabricate devices for drug delivery and tissue engineering applications.¹ Using different branching agents, direct melt polycondensation without addition of catalyst led to group of PLGA with diverse architecture.² These polymers were used for the preparation of rifampicin-loaded nanoparticles by the nanoprecipitation method. The aim of this work was to optimize this method by selecting a suitable polymeric carrier and its concentration, the ratio of organic phase to aqueous phase, the total amount of rifampicin added, and the concentration of the previously verified stabilizer didodecyldimethylammonium bromide (DDAB). Prepared formulations were evaluated and compared by testing of their parameters such as stability, particles size, polydispersity, zeta potential, and encapsulation efficiency. Two suitable PLGA derivatives were found, star-shaped PLGA branched on tripentaerythritol appeared to be the most appropriate. The effect of the amount of stabilizer on the encapsulation efficiency was significant. Encapsulation efficiency increased with decreasing amount of stabilizer to maximum at 0.02%, but further decrease in concentration led to the encapsulation efficiency drop, even in the case of stable formulations with low polydispersity. Dissolution tests were performed in phosphate buffer pH 7.4 and showed sustained release of rifampicin.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. MAKADIA, H., SIEGEL, S.: *Polymers*, 3, 2011, 1377–1397.
2. ŠNEJDROVÁ, E., PODZIMEK, Š., MARTIŠKA, J. *et al.*: *Acta Pharm.*, 70, 2020, 63–75.

A STUDY OF COMPRESSIBILITY AND COMPACTABILITY OF TABLETING MATERIALS WITH CHITOSAN

DOUBKOVÁ, B., MUŽÍKOVÁ, J.

Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: doubkovba@faf.cuni.cz

Natural polysaccharides find use as excipients for the formulation of oral controlled drug release systems. Some of these systems can target drug release to the distal part of the gastrointestinal tract. One of these polysaccharides is cationic chitosan, which is safe, non-toxic and biodegradable. Its very important property is the ability to adhere to mucosa. In the presence of an anionic polysaccharide (sodium alginate) it forms a polyelectrolyte complex.

The aim of this work was to study the compressibility, compactibility and lubricant sensitivity of directly compressible tableting materials containing chitosan, sodium alginate and two viscous types of hypromellose. Tableting materials containing silicified microcrystalline cellulose Prosolv SMCC 90 and chitosan in proportion 1:3, were tested as well. Compressibility was evaluated by energy profile of compression, compactibility by tensile strength of the tablets, lubricant sensitivity by values of lubricant sensitivity ratio (LSR).

The mixture of chitosan and Prosolv SMCC 90 in the ratio 3:1 showed the highest total energy of compression values. Prosolv SMCC 90 increased the values of total energy of compression in all formulations, except for the mixtures with HPMC K 100M. The adding of retarding components decreased them, most significantly in the case of alginate sodium.

Tensile strength of tablets was increased by Prosolv SMCC 90 in all formulations. Alginate sodium and magnesium stearate decreased strength values. Formulations with HPMC K 100M exhibited the highest strength values. The mixture of chitosan and Prosolv SMCC 90 had the lowest LSR value, whilst the highest LSR value were observed for this mixture with 50% sodium alginate.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. BADWAN, A. A., RASHID, I., MAHMOUD, M. H. *et al.*: Mar. Drugs, 13, 2015, 1519–1547.
2. LI, L., WANG, L., SHAO, Y. *et al.*: Int. J. Pharm., 450, 2013, 197–207.

INTRODUCTION INTO THE MAIN IDEAS OF PCA WITH ILLUSTRATIONS FROM PHARMACEUTICAL TECHNOLOGY AND PHARMACOLOGY

MARUSHKA, J.,¹ DUINTJER TEBBENS, J.,^{1,2} KARAHODA, R.,³ ŠTAUD, F.³

¹ Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Institute of Computer Science, Czech Academy of Sciences, Prague, Czech Republic

Principal component analysis (PCA) is a mathematical algorithm that helps to reduce the dimensionality of the data while retaining most of the variation in the data set. It accomplishes this reduction by identifying directions, called principal components, along which the variation in the data is maximal.¹ In the context of drug design PCA is used to identify the two principal components and to indicate by visual assessment of the plotted point the influence of the factor on a principal component or on a subset of outcomes. In this presentation we would like to demonstrate the main ideas of PCA on the example of its use in pharmaceutical technology and pharmacology.

The first example illustrates the application of PCA in tablet formulation in order to find the influential process formulation parameters and describe their optimal settings.² The second example related to pharmacology demonstrates gene expression depending on the clinical/pathological conditions of the placenta. The study was conducted on 177 placenta tissues (39 healthy and 138 pathological divided into subgroups). The parameter of interest is the expression of 16 genes directly involved in placental homeostasis of tryptophan and serotonin. The main aim of the study is to indicate a difference in gene expression between the pathological vs healthy placentas, taking the main patient characteristics such as markers of inflammation, fetal sex, fetal weight, BMI *etc.* into account.

The study was supported from the projects of Specific Academic Research (SVV 260 401/2019 and SVV 260 414/2019).

References

1. RINGNÉR, M.: Nat. Biotechnol., 26, 2008, 303–304.
2. KURHAJEC, S., FRANC, A., DOLEŽEL, P. *et al.*: Pharm. Dev. Technol., 22, 2017, 881–888.

PHARMACEUTICAL ANALYSIS AND BIOANALYTICAL CHEMISTRY SECTION

DETERMINATION OF URINARY RETINOL AS A NEW POTENTIAL BIOMARKER

KUČEROVÁ, K.,^{1,2} KUJOVSKÁ KRČMOVÁ, L.,^{1,2} MATYSOVÁ, L.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Clinical Biochemistry and Diagnostics, University Hospital
in Hradec Králové, Czech Republic
e-mail: kucerok1@faf.cuni.cz

Renal proximal tubule cells are very important for the metabolism and homeostasis of vitamins, especially vitamin A. Some studies show that urinary retinol might be used

as an early stage biomarker for detection of kidney failure but no clinically useful chromatographic method for simultaneous determination of urinary retinol and creatinine as a urine dilution factor is currently available.¹ Therefore, we developed new UHPLC-UV-MS/MS method using column packed with fluorinated core-shell stationary phase, and acetonitrile with ammonium formate buffer solution as the mobile phase for separation of these two analytes that differ significantly in their physicochemical properties. The method involves very fast and simple sample preparation requiring small amount of sample matrix and solvents. Deuterium labeled internal standard was used for the more precise quantification.² The method was tested with real-life samples using urine collected from patients suffering from colorectal or peritoneal cancer, and malignant neoplasm of kidney.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019), by Ministry of Health of the Czech Republic – conceptual development of research organization (UHHK, 00179906), by Ministry of Health of the Czech Republic (Project. No. NV18-03-00130) and from the project STARSS (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF.

References

1. KUČEROVÁ, K., KUJOVSKÁ KRČMOVÁ, L., MATYSOVÁ, L. *et al.*: Trends Anal. Chem., 95, 2017, 57–61.
2. KUČEROVÁ, K., KUJOVSKÁ KRČMOVÁ, L., MIKANOVÁ, Z. *et al.*: J. Chromatogr. A, 1607, 2019, art. 460390.

MITOCHONDRIAL ANALYSIS OF HUMAN PLATELETS: COMPARISON OF DIFFERENTIAL CENTRIFUGATION AND CONTINUOUS FLOW APHERESIS

VERNEROVÁ, A.,^{1,2} GARCIA-SOUZA, L. F.,³ GNAIGER, E.,³
KUJOVSKÁ KRČMOVÁ, L.,^{1,2} SOBOTKA, O.^{4,5}

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Clinical Biochemistry and Diagnostics, University Hospital
in Hradec Králové, Czech Republic

³ Medical University of Innsbruck, Innsbruck, Austria and Oroboros Instruments, Innsbruck, Austria

⁴ 3rd Department of Internal Medicine, University Hospital in Hradec Králové, Czech Republic

⁵ Department of Physiology, Faculty of Medicine in Hradec Králové,
Charles University, Czech Republic
e-mail: verneran@faf.cuni.cz

Using modern high-resolution respirometers (HRR) the analysis of mitochondrial functions and the metabolic profile of platelets (PLT) from a small sample of human blood was made accessible. A standardized isolation procedure for human PLT was developed in the frame of international COST action MitoEAGLE and PLT prepared by this differential centrifugation (DC) secured a high inter-laboratory reproducibility of respirometry results.¹ Continuous flow apheresis (CFA) is a clinical method for PLT isolation aiming at

the treatment of bleeding diathesis in severe thrombocytopenia with years of good clinical outcomes.

The aim of this project was to introduce a new method of HRR at University Hospital Hradec Králové and compare mitochondrial respiration of PLT obtained by two different techniques: DC and CFA. HRR was assessed by Oroboros Oxygraph-2k FluoRespirometer (Oroboros Instruments, Austria). According to our preliminary results, the isolation method did not affect maximal respiratory capacity of PLT in this study. PLT isolated by CFA had 30% decrease in succinate oxidation in comparison to DC. Moreover, CFA affected PLT viability. These differences were reversed after washing the PLT by phosphate buffer saline, suggesting possible influence of isolation medium on our results.

We conclude that HRR is a highly sensitive and suitable method to describe the metabolic profile of human PLT. The application of HRR is promising in PLT research in patients with thrombocytopenia, sepsis and metabolic disorders as well as in diagnostics.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019), by Ministry of Health of the Czech Republic – conceptual development of research organization (UHHK, 00179906) and from European Union Framework Programme Horizon 2020 COST Action CA15203 MitoEAGLE. The loan of oxygraphs was kindly provided by Oroboros Instruments.

References

1. SUMBALOVA, Z., DROESCHER, S., HILLER, E. *et al.*: Mitochondr. Physiol. Network 21.17 (03), 2018, 1–16.

THE METHOD DEVELOPMENT FOR THE DETERMINATION OF CISPLATIN IN HUMAN PLASMA

TUROŇOVÁ, D.,^{1,2} KUJOVSKÁ KRČMOVÁ, L.^{1,2}

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Clinical Biochemistry and Diagnostics, University Hospital in Hradec Králové, Czech Republic
e-mail: turonovd@faf.cuni.cz

Cisplatin is well known for its antitumor activity but it is also associated with side effects, relevancy of which depends on its exposure. Extended exposition can cause nephrotoxicity and other health problems.^{1,2} Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy is a procedure combining maximal surgical removal of the tumor with intra-operative administration of a chemotherapeutic drug that is heated up. The aim of the whole process is to increase the anticancer effect and minimize the systemic side effects of the chemotherapy in comparison with systemic chemotherapy.³

For the purpose of clinical research, a HPLC method with diode-array detection for the determination of cisplatin in human plasma with simple sample pretreatment has been developed and current results will be discussed. The separation was carried out in 8 minutes

using C18 core-shell column with mobile phase consisting of methanol, acetonitrile, and water. As internal standard palladium chloride was used.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019), by Ministry of Health of the Czech Republic – conceptual development of research organization (UHHK, 00179906) and by Ministry of Health of Czech Republic (Project No. NV18-03-00130).

References

1. SHAIK, A. N., ALTOMARE, D. A., LESKO, L. J. *et al.*: J. Chromatogr. B., 1046, 2017, 243–249.
2. Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations. Li, W., Zhang, J., Tse, F. L. S. (eds.), Hoboken, Wiley, 2013.
3. WITKAMP, A. J., De BREE, E., Van GOETHEM, A. R. *et al.*: Cancer Treat. Rev., 27, 2001, 365–374.

DEVELOPMENT AND VALIDATION OF UHPLC METHOD FOR THE MONITORING OF TARGET ACTIVE SUBSTANCES AND THEIR RELEASING FROM SOLID DISPERSIONS

ARNOLTOVÁ, K.,^{1,2} KUJOVSKÁ KRČMOVÁ, L.,^{1,2} MATYSOVÁ, L.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Clinical Biochemistry and Diagnostics, University Hospital in Hradec Králové, Czech Republic
e-mail: arnoltok@faf.cuni.cz

This work is part of a project, that is focused on the development, optimization, and validation of UHPLC methods and their subsequent application on the evaluation of new modern drug forms based on solid dispersions. The research is based on the development of modern drug forms, which use branched polymers as a carrier of active substances with the effort to influence the release of the target drugs and increase their bioavailability. The determination of drug-releasing from the new carrier is crucial for the research. Newly developed chromatographic methods will serve as the main tool for testing various materials used as a carrier of active substances, for the determination of drug content and detection of possible impurities.

In the presented UHPLC method, miconazole, econazole and their main impurities were chosen as the target analytes. An UHPLC method, using diode-array detection, has been created. A Kinetex™ C18 column, 1.7 µm particle size, 50 × 2.1 mm was used for the separation in combination with the acetate buffer, methanol, and acetonitrile as the mobile phase. Butylparaben was chosen as the internal standard. All substances were detected at the wavelength of 225 nm. The total analysis time was 9 minutes. The new method will be validated and used for testing various branched polymers as suitable carriers.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. ŠNEJDROVÁ, E., DITTRICH, M., DRASTÍK, M.: *Int. J. Pharm.*, 458, 2013, 282–286.

IDENTIFICATIONS OF ARTIFICIAL MODIFICATIONS INDUCED IN THE COURSE OF LC-MS ANALYSES OF PEPTIDES

LENČO, J.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: lenco@faf.cuni.cz

Column temperature is one of the key parameters that remarkably increases efficiency in bottom-up LC-MS proteomic analyses. We noticed, however, that at some point the benefit of elevated temperature to the peak shape is redeemed by lower number of identified peptides. We hypothesized that an on-column peptide degradation might occur when the peptides are separated at an elevated temperature using acidic mobile phases. To this end, we scrutinized the effect of temperature on the stability of model proteins trapped in a reversed phase column. We confirmed that temperature as high as 45 °C in combination with 0.1% formic acid may already induce on-column peptide bonds cleavage. We subsequently carried out data-dependent LC-MS analyses of tryptic peptides at various column temperatures. We found out that besides on-column peptide bonds cleavage, peptides trapped in a stationary reversed phase may undergo various artificial chemical modifications in the presence of 0.1% formic acid in mobile phases. Additionally, the risk of artificial peptides formylation due to inappropriate sample handling was discovered within the study.

The study was supported by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 412/2019).

AUTOMATION OF ON-LINE SAMPLE PREPARATION FOR THE PEPTIDE MAPPING ANALYSIS OF BIOPHARMACEUTICALS

KHALIKOVA, M., LENČO, J., FAISTAUEOVÁ, K., ŠVEC, F.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: khalikom@faf.cuni.cz

Peptide mapping is critical methodology in routine biopharmaceutical analysis used to confirm identity, characterize primary structure, monitor degradative events, and meet quality assurance.¹ Peptide mapping is the gold standard method for the in-depth study of post-translational modifications (PTMs) of monoclonal antibodies (mAb). PTMs are critical quality attributes defining therapeutic efficacy and safety.² Both PTMs and chemical

modifications may arise during production, processing, and storage of proteins.¹ Thus, the identification and quantification of PTMs is essential in development and analysis of therapeutic biomolecules.

Sample preparation for peptide mapping requires enzymatic digestion of protein that is typically a time-consuming and labor intensive process. It includes several steps prone to operator error that can induce an increase in artificial modifications such as asparagine deamidation.³

The multidimensional LC system was used for automation of the digestion procedure of trastuzumab to optimize the sample preparation of this mAb prior to peptide mapping. We will describe ongoing project focused on the setup of automated digestion process as a part of multiattribute analysis of mAb. Our study concerns effects of method conditions on the quality of digests of trastuzumab including type and pH of digestion buffer, incubation time, and temperature.

This work was supported by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. MOUCHAHOIR, T., SCHIEL, J. E.: *Anal. Bioanal. Chem.*, 410, 2018, 2111–2126.
2. JENKINS, N., MURPHY, L., TYTHER, R.: *Mol. Biotechnol.* 39, 2008, 113–118.
3. HAO, P., REN, Y., DATTA, A. *et al.*: *J. Proteome Res.*, 14, 2015, 1308–1314.

ELECTROCHEMICAL STUDY OF OLIGONUCLEOTIDE PROBES LABELED BY QUANTUM DOTS FOR THE DETECTION OF BACTERIAL AND VIRAL PATHOGENS

BANÁŠ, D.,^{1,2,6} AKSU, D. A.,^{1,3,4} NOGUERA, M. V.,^{1,3,5} PAY, M.,^{1,3,4} HOSNEĐLOVÁ, B.,⁶ KIZEK, R.,^{1,3,6}

¹ Department of Research and Development, Prevention Medicals s. r. o.,
Studénka-Butovice Czech Republic

² Department of Biochemistry, Faculty of Science, Masaryk University, Brno, Czech Republic

³ Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

⁴ Bezmialem Foundation University, Istanbul, Turkey

⁵ Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain

⁶ Veterinary Research Institute, Brno, Czech Republic

e-mail: dominik.banass@gmail.com

African swine fever virus (ASFV) is a virus with high morbidity and mortality, which is infectious for domestic and wild pigs and causes serious socioeconomic impact.¹ Because of the non-existence of a suitable vaccine, it is necessary to determine the presence of the virus directly in the focus of infection. Thus, the cornerstone of design of a biosensor for rapid analysis of ASFV was suggested. This work is focused on the electrochemical study of oligonucleotides (ODNs) KING R and KING F which are specifically complementary to ASFV DNA, and quantum dots (CdTe QDs) as a label for these ODNs. The adsorptive

transfer technique was used for the accumulation of ODNs to a working electrode. In the first phase, the dependences of the current on concentration and time of accumulation of ODNs were measured. The calibration ranges from 0.4 to 1.7 $\mu\text{g mL}^{-1}$ for KING F and 0.1 to 0.6 $\mu\text{g mL}^{-1}$ for KING R were measured and the LODs, LOQs and CVs were calculated. CdTe QDs interacted with ODNs. CA (cytosine and adenine) signals of ODNs were 33.9 ± 8.7 nA and 22.0 ± 3.3 nA for KING F and KING R, respectively. For interaction CA signals were detected as follows: KING F/QDs 15.8 ± 8.6 nA, KING R/QDs 16.1 ± 5.1 nA and cadmium signals were detected as follows: KING F/QDs 61.8 ± 15.7 nA and KING R/QDs 89.3 ± 18.2 nA. This study brought pilot results for the creation of biosensor for detecting bacterial and viral pathogens, which can be useful for the suggestion of suitable pharmaceutical therapy.

The study was supported by the EU programme for education, training, youth and sport ERASMUS+ and project AMOR QK1920113.

References

1. GALINDO, I., ALONSO, C.: *Viruses*, 9, 2017, art. 103.

LC-MS/MS STUDY OF THE FIRST PHASE OF *IN VITRO* BIOTRANSFORMATION OF NEW PROMISING TACRINE DERIVATIVES

NOVÁK, M.,^{1,2} KUČERA, R.,¹ DOLEŽAL, R.,² PRCHAL, L.²

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Biomedical Research Center, University Hospital in Hradec Králové, Czech Republic
e-mail: novakm61@faf.cuni.cz

Alzheimer's disease is a neurodegenerative disorder causing decline in cognitive functions, gradual loss of self-control, development of disorientation, and afterwards motoric failure. Current symptomatic pharmacotherapy is primarily focused on acetylcholinesterase inhibitors and NMDA (*N*-methyl-D-aspartate) receptor blocking.¹ Tacrine molecule, which is one of the acetylcholinesterase inhibitors, was withdrawn from the market due to the hepatotoxicity of its metabolite 7-hydroxytacrine in 2013. The substitution of tacrine molecule may potentially block the formation of toxic metabolites. The introduction of methoxy group to position of 7 of 1,2,3,4-tetrahydroacridine led to 7-methoxytacrine.²

The aim of our work was to determine the metabolites of tacrine and 7-methoxytacrine and to evaluate the effects of biotransformation in a *in vitro* study. Human liver microsomes (HLM) were used as first phase *in vitro* biotransformation model and HPLC coupled with Q Exactive Plus mass spectrometer was used for the characterization of metabolites.

The new HPLC-MS method for the separation and identification of tacrine and 7-methoxytacrine metabolites was created and structures of metabolites were experimentally designed from Full-MS and MS/MS spectra and confirmed by MassFrontier (MetWorks).

The results of the study show that the main way of biotransformation of both compounds is their monohydroxylation and dihydroxylation. Moreover, several novel *in vitro*

metabolites of tacrine and 7-methoxytacrine which have not been reported in the literature so far were found and the relative proportion of individual metabolites was calculated.

The work was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. JOUANNE, M., RAULT, S., VOISIN-CHIRET, A.-S.: Eur. J. Med. Chem., 139, 2017, 153–167.
2. PATOČKA, J., JUN, D., KUČA, K.: Curr. Drug Metab., 9, 2008, 332–335.

ANALYSIS OF ECCRINE SWEAT

PRCHAL, L.

Biomedical Research Centre, University Hospital in Hradec Králové, Czech Republic
e-mail: lukas.prchal@fnhk.cz

Sweating is usually found unpleasant and annoying. It is, however, very important mechanism that provides our bodies with effective temperature control in different situations. Also its composition can be influenced by various substances or state of health. There are two main types of human sweat. Apocrine sweat consists predominantly of lipophilic substances while eccrine sweat, which could be described as hydrophilic, consists mainly from water and various ions and small amount of other substances.¹ Our research focuses on eccrine sweat and these substances. Sweat is collected by patches worn for one week. Then the patch is collected and extracted and extracts are lyophilised. The samples are then analysed by HPLC coupled with mass spectrometry. As the majority of metabolites are hydrophilic, HILIC column was used to separate them at least partially. The analysis was performed in both positive and negative modes. In this initial state we have processed only a small amount of patches, which are considered healthy controls for future research.

The study was supported by Ministry of Health of the Czech Republic – conceptual development of research organization (UHHK, 00179906).

References

1. WILKE, K., MARTIN, A., TERSTEGEN, L. *et al.*: Int. J. Cosmet. Sci., 29, 2007, 169–179.

ION MOBILITY SPECTROMETRY IN DOPING ANALYSIS

PLACHKÁ, K.,¹ PEZZATTI, J.,² NICOLI, R.,³ VEUTHEY, J.-L.,² GUILLARME, D.,² NOVÁKOVÁ, L.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² School of Pharmaceutical Sciences, Faculty of Science, University of Geneva, Switzerland

³ Swiss Laboratory for Doping Analysis, Centre Universitaire Romand de Médecine Légale, Switzerland
e-mail: plachkka@faf.cuni.cz

This project aimed at examining the effects of using ion mobility spectrometry-mass spectrometry in doping control analysis using 194 compounds from World Anti-Doping Agency prohibited list, including stimulants and narcotics (Class I) and anabolic steroids, glucocorticoids, and hormones (Class II). MSe data independent acquisition scan type with high-resolution mass spectrometry was used for the experiments. The analyses were carried out using q-TOF (quadrupole-time of flight) with and without activation of the ion mobility spectrometry dimension. The ultra-high-performance liquid chromatography-mass spectrometry method was developed using standard mixtures to tune the settings of mass spectrometer and to optimize the data processing method. Subsequently, the method was used with urine samples prepared by dilute and shoot approach for Class I and by supported liquid-liquid extraction (SLE) for Class II. Prior to the analysis, SLE procedure was optimized to ensure sufficient sensitivity with final pre-concentration by factor of 10. Finally, the analyses of standard doping agents and urine samples were compared with and without ion mobility function, including the comparison of collision cross section (CCS) values, fragmentation, and quality of spectra. The robustness of the method was proved by intraday, interday, and interweek repeatability of retention times and CCS values, providing RSD values always lower than 2%. The effect of matrix on CCS values was examined as well as matrix effects and fulfillment of minimum required performance limits. The effect of ion mobility on the quality of spectra, elimination of interferences, and method sensitivity was evaluated with the aim to improve screening capabilities, especially to prevent false positive and false negative results.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019) and by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF.

STUDY OF INCREASING SENSITIVITY IN ESI⁻ BY ANION ATTACHMENT

LHOTSKÁ, I., KOČOVÁ VLČKOVÁ, H., NOVÁKOVÁ, L.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: lhotski@faf.cuni.cz

Increasing detection sensitivity is crucial task in LC-MS method development. Apart from the instrument limits, ionization efficiency is the key to good sensitivity. In case of poorly ionized analytes, alternative LC-MS mobile phase additive can be considered. Besides conventional volatile acids and buffers enhancing deprotonation of analytes in ESI⁻ and increasing conductivity, the ionization can be achieved by adduct formation or through gas phase proton-transfer reactions.

For this study, ammonium fluoride was selected as anion attachment additive for its strong gas-phase proton affinity. Generally, signal improvement of less polar molecules can be provided by an anion attaching to electropositive region of analyte molecule forming an adduct. Fluoride anion, due to higher gas-phase basicity than most of other anions and

deprotonated molecules, is able to abstract the shared proton from the analyte and separate as HF. Finally, ionization efficiency is enhanced by production of $[M-H]^-$ in gas phase.¹

Mobile phase containing ammonium fluoride (0.1–1.0 mM) was compared to conventional additive 0.1% formic acid and its positive effect on signal intensity was assessed for broad spectrum of compounds varying in molecular weight, polarity, lipophilicity, and structures. Fluoride anion attachment potential as a solution for increasing sensitivity in ESI⁻ will be discussed.

The study was supported by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 412/2019).

References

1. WANG, G., COLE, R. B.: *Anal. Chem.*, 81, 2009, 8826–8838.

MODIFICATION OF CAPILLARY WALL BY GRAPHENE FOR SEPARATION IN CAPILLARY ELECTROPHORESIS

LOCHMAN, L.,¹ FELIX, O.,² DECHER, G.,² KUČERA, R.¹

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Institute Charles Sadron, National Centre for Scientific Research (CNRS), Strasbourg, France
e-mail: lochmanl@faf.cuni.cz

Graphene (G) is two-dimensional sp² single-atom-thick carbon sheet with hexagonal structure. High specific area (theoretical value 2630 m² g⁻¹) together with the affinity to carbon ring structures via π - π stacking interactions make G and graphene oxide (GO) promising candidates for application in analytical chemistry.^{1,2}

Our work aims at the modification of inner surface of bare silica capillary by Layer-by-Layer method (LbL).³ LbL is very simple self-assembly procedure which controls through electrostatic interactions adsorption of negatively charged GO onto wall covered by positively charged polyelectrolyte. Modification of capillary wall by GO is believed to substantially improve the separation properties for analysis of charged/neutral analytes due to the combination of the high CE efficiency and additional interactions with the modified surface. As it is difficult to characterize and optimize a nanoscale coating, the deposition was firstly done on the flat surface (silicon wafer or quartz slide) and different techniques (ellipsometry, UV-VIS spectroscopy, AFM) were employed. Different combinations of polyelectrolyte/GO were tested. Based on these results, the coating process was transferred into the capillary and the separation of the model analyte mixture was compared with unmodified capillary.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 401/2019).

References

1. Graphene: Synthesis, Properties, and Phenomena. Rao, C. N. R., Sood, A. K. (eds.), Weinheim, Wiley-VCH, 2012.
2. WANG, X., LIU, B., LU, Q. *et al.*: J. Chrom. A, 1362, 2014, 1–15.
3. DECHER, G.: Nature, 277, 1997, 1232–1237.

ANALYTICAL STUDY OF THE INFLUENCE OF EXPERIMENTAL CONDITIONS ON THE CHIRAL SEPARATION OF BORON CLUSTER COMPOUNDS

HORÁČEK, O., KUČERA, R.

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic
e-mail: horaceko@faf.cuni.cz

Boron clusters are artificial compounds which create 3D-cage structure and exhibit unique physicochemical properties. Carboranes are prepared by substituting BH units for CH units. They are studied as stereoselective catalysts, monomers for thermostable polymers and in medicine as compounds which enhance the effectivity of boron neutron capture therapy. Steric similarity with rotating phenyl ring enables extensive research of carboranes as new pharmacophores.¹

Chirality of boron clusters is caused by introducing endo-/exoskeletal substituents, which impair the symmetry of the cage. Due to the chiral character of these compounds, it is vital to evaluate the influence of experimental conditions on chiral separations with respect to their potential use.

Even though zwitterionic carboranes were successfully separated on native beta-cyclodextrin based chromatographic columns, attempts to separate anionic carboranes were unsuccessful.² On the other hand, native beta-cyclodextrins were able to resolve some anionic carboranes in capillary zone electrophoresis.³ To clarify this contradiction, chromatographic behavior of anionic carboranes was tested on the native beta-cyclodextrin column (ChiraDex, Merck).

Our work aims to elucidate the discrepancy between chiral separations of anionic carboranes by high performance liquid chromatography and capillary zone electrophoresis.

The study was supported from the project of Specific Academic Research (SVV 260 401/2019).

References

1. ISSA, F., KASSIOU, M., RENDINA, L. M.: Chem. Rev., 111, 2011, 5701–5722.
2. HORÁKOVÁ, H., GRUNER, B., VESPALEC, R.: Chirality, 23, 2011, 307–319.
3. HORÁKOVÁ, H., VESPALEC, R.: J. Chromatogr. A, 1143, 2007, 143–152.

LC-MS/MS INVESTIGATION OF CARDIOPROTECTIVE DRUGS

VÁŇOVÁ, N.,¹ BAVLOVIČ-PISKÁČKOVÁ, H.,¹ BRÁZDOVÁ, P.,² ŠTĚRBA, M.,²
ŠTĚRBOVÁ-KOVAŘÍKOVÁ, P.¹

¹ Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy
in Hradec Králové, Charles University, Czech Republic

² Department of Pharmacology, Faculty of Medicine in Hradec Králové,
Charles University, Czech Republic
e-mail: vanovan@faf.cuni.cz

Current anticancer therapy with anthracyclines is, despite its efficiency, limited due to the high risk of cardiotoxic effects. Up-to-date, the only clinically approved cardioprotective agent is dexrazoxane (DEX). Its novel analogue, JAS-2 – [4,4'-(butane-2,3-diyl)bis(piperazine-2,6-dione)], exerts greater efficiency *in vitro* (neonatal rat cardiomyocytes model) when compared with DEX. Previously, UHPLC-MS/MS method for determination of JAS-2, its metabolite JAS-2met and its pro-drug with a code name GK-667 was employed in our laboratory using UHPLC system (Nexera, Shimadzu) coupled with a triple quadrupole mass spectrometer (LCMS-8030, Shimadzu). Although this method was successfully applied on *in vitro* stability study of GK-667 and JAS-2 in plasma and DMEM medium, its use in pilot *in vivo* pharmacokinetic study was limited in terms of low sensitivity to GK-667 and JAS-2met. Besides the attempts to enhance the recovery of these analytes by modification of the sample preparation step (*i.e.* precipitation with methanol), new LC-MS/MS method for determination of JAS-2 and its metabolite in plasma carried on LC system (1290 Infinity II, Agilent) coupled with a triple quadrupole mass spectrometer (Triple Quad LC/MS 6400 series, Agilent) was developed. Chromatographic separation of JAS-2 and JAS-2met was performed on Luna Omega Polar column (100 × 3.0 mm, 2.5 μm, Phenomenex) using gradient elution system consisting of 1mM ammonium formate and methanol. The presented method led to achievement of the LLOQ at the level of 0.01 μM for both analytes, which is 20 times lower than the former procedure. Increased sensitivity enabled determination of JAS-2 and JAS-2met in plasma of rabbits administered with GK-667 (5 mg kg⁻¹, *i. v.*, n = 8).

The study was supported by Research programme Development and Study of Drugs (Progres Q42), by the Czech Science Foundation (Project No. 18-08169S) and from the project of Specific Academic Research (SVV 260 401/2019).

MONITORING INFLUENCE OF PESTICIDE SPRAY ON ANTIOXIDANTS IN APRICOTS

HOLLÁ, M., KHOLOVÁ, A., SKLENÁŘOVÁ, H., ŠATÍNSKÝ, D.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: hollama@faf.cuni.cz

Pesticides are substances used in agriculture to control pests and weeds. Their use is controlled, and the highest toxicologically acceptable amount of each pesticide is determined by maximum residue level. Apricots are valuable source of phytonutrients and substances with antioxidant properties in human diet. Amount of these substances is influenced by cultivar type, harvest time, storage, processing, *etc.* For the presented study, 'Betyнка' apricot cultivar grown in orchards of Research and Breeding Institute of Pomology in Holovousy, was used.

This study focuses on influence of pesticide spray type applied in permitted level on nutritional properties of apricots regarding phenolics content and potential antioxidant properties. Effect of pesticide spray type was studied in fresh fruits and fruits stored for 10, 20, and 30 days after harvest in ultra-low oxygen warehouse. HPLC separation with diode array detection (DAD) was used to monitor content of 17 selected phenolic substances typically present in apricots. Moreover, HPLC with 8-channel electrochemical coulometric detector (CA) was used for evaluation of overall content of reducing agents, and Trolox equivalent antioxidant capacity assay (TEAC) for evaluation of radical scavenging activity of methanolic apricot extracts.

Results of phenolics determination and antioxidation activity in fresh and stored fruits with individual pesticide spray type obtained by HPLC-DAD, HPLC-CA, and TEAC methods were compared with control sample, without pesticide spray application. For statistical evaluation of the effect of applied pesticide spray on nutritional properties of fresh and stored apricots, ANOVA with repeated measures was applied on results obtained by HPLC-DAD. Based on the comparison, samples of tested spray types and control sample significantly differ from each other, considering the spray type and storage period.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019), by the Grant Agency of Charles University (Project No. 1466119) and by the Technology Agency of the Czech Republic (Project No. TJ02000196).

COMPARATIVE STUDY OF VARIOUS SORBENTS FOR DETERMINATION OF OCHRATOXIN A AND OCHRATOXIN B IN ARCHIVE TOKAJ WINES USING ON-LINE SPE-HPLC

KHOLOVÁ, A.,¹ LHOTSKÁ, I.,¹ ŠPÁNIK, I.,² MACHYŇÁKOVÁ, A.,² ŠATÍNSKÝ, D.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Institute of Analytical Chemistry, Faculty of Chemical and Food Technology,
Slovak University of Technology in Bratislava, Slovakia
e-mail: kholovaa@faf.cuni.cz

Various sorbents for on-line extraction and determination of ochratoxin A (OTA) and ochratoxin B (OTB) in archive Tokaj wine have been compared. Tokaj wine is a special type of sweet wine from grapes infected with mould *Botrytis cinerea* produced in Hungarian Tokaj wine region and in Slovakia. Our method involved on-line extraction using precolumn coupled to liquid chromatography with fluorescence detection and enabled fast

and sensitive control of mycotoxin contamination. Four types of fibrous sorbents, including polyethylene microfibers, polypropylene microfibers, polycaprolactone microfibers/nanofibers composite, and polycaprolactone microfibers/polyvinylidene difluoride nanofibers composite, typical fused-core C18 sorbent, and commercial molecularly imprinted polymers were compared while varying extraction approaches. The polymer fibers filled in a cartridge were directly connected to HPLC system and the clean-up efficiency and the subsequent chromatography separation optimized. Typically, 50 μL wine was directly loaded and preconcentrated in extraction column. The separation was then carried out using analytical column Kinetex Phenyl-Hexyl (100×4.6 mm, particle size 2.6 μm) followed by fluorescence detection (Ex 335 nm, Em 463 nm). Solvents suitable for extraction and separation were methanol or acetonitrile and 0.5% aqueous acetic acid. The separations were carried out in the gradient elution mode at a flow rate of 1.0 mL min^{-1} . These conditions provided reliable validation results with a limit of detection of 0.03–0.06 $\mu\text{g L}^{-1}$ and recoveries exceeding 90% were determined for both OTA and OTB in archive Tokaj wines. The maximum tolerable limit for OTA in wines authorized by the European Union is 2 $\mu\text{g L}^{-1}$. Among the tested nanofibers, polyethylene enabled the best results while other nanofibrous materials are unsuitable for the analysis of ochratoxins. Comparable results were obtained using molecularly imprinted polymers, fused-core C18, and polyethylene microfibers. However, the last sorbent excels in affordability. A more detailed comparison of sorbents will be presented.

This work was supported from the project of Specific Academic Research (SVV 260 412/2019), by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by the ERDF, and by the Grant Agency of Charles University (Project No. 1134119).

PEAR TREES MATERIAL AS A RICH SOURCE OF IMPORTANT PHENOLIC COMPOUNDS

ADAMCOVÁ, A., ŠÍROVÁ, K., ŠATÍNSKÝ, D.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: adamcoal@faf.cuni.cz

The aim of the study was to determine the spectrum of phenolic compounds and their content in pear trees – leaves, bark, buds, stems, floral ovaries, blossom, and also in fruit and seeds. The methanol extracts were obtained from raw material of different pear tree cultivars. Extracted phenolic compounds – arbutin, chlorogenic acid and its derivatives (1,5- and 3,5-dicaffeoylquinic acid) and rutin were analyzed by high performance liquid chromatography. Finally, ASCENTIS Express RP-Amide (150×4.6 mm, particle size 2.7 μm) analytical column was used for analysis due to ability to separate both derivatives of chlorogenic acid. Column temperature was 30 $^{\circ}\text{C}$ and injection volume was 1 μL . The separation was performed with gradient elution at flow rate 1 ml/min and analysis time 10.50 min. The mobile phase consisted of acetonitrile and 0.1% phosphoric acid. The detection was carried out at wavelengths 220, 327 and 354 nm. The method was validated before the

quantification of phenolic compounds in the leave extracts with following parameters: the linearity ($R^2 = 0.997-0.999$), repeatability ($RSD = 0.49\% - 3.09\%$), recovery ($88.66\% - 114.26\%$) and precision ($RSD = 0.77\% - 2.87\%$). The following concentration range of total content expressed in mg g^{-1} of dry mass in defined extracts were obtained: leave extracts ($22.62-54.80 \text{ mg g}^{-1}$), bark extracts ($17.44-55.18 \text{ mg g}^{-1}$), bud extracts ($14.24-31.93 \text{ mg g}^{-1}$), stem extracts ($55.00-74.04 \text{ mg g}^{-1}$), ovary extracts ($50.26-87.60 \text{ mg g}^{-1}$) and blossom extracts ($38.04-62.83 \text{ mg g}^{-1}$). The concentration of evaluated phenolic compounds occurring in fruit and seeds extracts was significantly lower. Arbutin and chlorogenic acid were found as major components. This research revealed that pear trees material is a rich source of phenolic compounds and could be potentially used for further utilization.

The study was supported by the Technology Agency of the Czech Republic (Project No. TJ02000196) and from the project of Specific Academic Research (SVV 260 412/2019).

POLYMER INCLUSION MEMBRANE (PIM)-COATED MAGNETIC STIRRER BAR FOR THE PRECONCENTRATION OF SULFAMETHOXAZOLE

ZATROCHOVÁ, S.,¹ ALMEIDA, M. I. G. S.,² KOLEV, S. D.,² ŠATÍNSKÝ, D.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² School of Chemistry, Faculty of Science, The University of Melbourne, Australia
e-mail: zatrochs@faf.cuni.cz

Sulfamethoxazole (SMX) belongs to the group of emerging organic contaminants, which may accumulate in natural waters causing environmental concern.¹ Its monitoring is thus very important. However, the levels of SMX present in natural waters is often very low (ng L^{-1} to $\mu\text{g L}^{-1}$) and for that reason its analysis presents a challenge. The aim of this study is the using of magnetic stirrer bars coated with polymer inclusion membranes (PIMs) for the separation and preconcentration of SMX from natural waters. Initially the analyte is selectively retained within the PIM via ion-exchange by stirring the coated magnetic bar in the natural water sample. Following step is dipping the loaded PIM-coated stirrer bar in a smaller volume of a stripping solution to remove the SMX back to an aqueous solution for further analysis. Different types of base polymers, namely cellulose triacetate (CTA), polyvinyl chloride (PVC) or poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP) were tested for the fabrication of the PIM coating, while Aliquat 336 was used as the extractant. 1-Tetradecanol and 2-nitrophenyloctyl ether (NPOE) were used as the modifier or plasticizer, respectively.

This study involves important PIM optimizations, particularly testing of different concentrations of casting solutions and the number of dips into the casting solution required to prepare a sufficient layer of PIM on the stirrer bar surface. Preliminary experiments revealed that the optimum PIM thickness that facilitates the fastest extraction rates is $20 \mu\text{m}$, which corresponds to a variable number of dips depending on the PIM composition.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

References

1. GARCIA-RODRÍGUES, A., MATAMOROS, V., KOLEV, S. D. *et al.*: J. Membrane. Sci., 492, 2015, 32–39.

CARBON DIOXIDE EXPANDED LIQUID AS A SOLVENT FOR THE EXTRACTION OF QUERCETIN FROM PLANT MATERIAL

PILAŘOVÁ, V.,¹ KUDA, L.,¹ NOVÁKOVÁ, L.,¹ Van STADEN, J.,² DOLEŽAL, K.³

¹ Department of Analytical, Chemistry Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Research Centre for Plant Growth and Development, School of Life Sciences, University of KwaZulu-Natal,
Pietermaritzburg, South Africa

³ Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological
and Agricultural Research, Faculty of Science, Palacký University, Olomouc, Czech Republic
e-mail: pilarovv@faf.cuni.cz

Supercritical fluid extraction (SFE) using non-polar CO₂ as an extraction solvent is commonly used approach to extract bioactive compounds from natural sources such as dried leaves, herbs, fruits, and flowers. Neat CO₂ is an optimal choice to extract non-polar compounds. Thus, an organic solvent is often added to CO₂ to achieve extraction of more polar compounds. Methanol, ethanol (EtOH), 2-propanol, and small water proportion are usually added to change polarity, mass transfer, extraction yield, and analytes solubility. Depending on the amount of added organic solvent, we recognize SFE, SFE with modifier, CO₂ expanded liquid extraction, and pressurized liquid extraction. Other parameters including temperature, pressure, and type of extraction can also improve the extraction yield. In our study, we optimized method for the extraction of quercetin from quince fruit (*Cydonia oblonga*). Plackett-Burman model was used to determine the effect of addition of 0% – 20% water in EtOH as a green organic solvent added to CO₂ in ratio 10% – 90%. We used temperatures in a range of 30–80 °C and a pressure of 100–300 bar. After its evaluation, the water amount in ethanol was set up on 20% due to low effect of this parameter. The tested ranges were consequently narrowed for other parameters using design of experiment. Then, 4 different flow rates in a range of 1–4 mL min⁻¹ were explored to find the final extraction conditions. Optimized method used CO₂/EtOH + 20% H₂O (10/90, V/V) at 66 °C, pressure of 223 bar, and flow rate of 4 mL min⁻¹. These conditions enabled extraction of quercetin in 30 min with recoveries of 120 ng (22% RSD, n = 9, 3 different days) from 0.5 g sample.

The study was supported by the project STARSS (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 412/2019).

3D-PRINTED MAGNETIC STIRRING CAGES FOR THE EXTRACTION OF BISPHENOLS FROM WATER USING MICRO- AND NANOFIBERS

ŠRÁMKOVÁ, I. H.,¹ HORSTKOTTE, B.,¹ ERBEN, J.,² CHVOJKA, J.,² ŠVEC, F.,¹ SOLICH, P.,¹ ŠATÍNSKÝ, D.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Nonwovens and Nanofibrous Materials, Faculty of Textile Engineering, Technical University of Liberec, Liberec, Czech Republic
e-mail: sramkovai@faf.cuni.cz

Electrospun nanofibers are currently in the focus of analytical chemists for their great potential as a sorbent in solid phase extraction techniques.¹ Apart from that, 3D printing nowadays holds a stable position in many areas of human activities, including analytical chemistry, due to the possibility of fast prototyping.²

Using the 3D printing technology “Fused Deposition Modelling”, we designed a cage-like holder with integrated magnetic stirring bar. The cage allowed accommodating up to 60 mg nano-polycaprolactone/micro-polycaprolactone fibers as a loose package for sorbent extraction. The device was immersed into 100 mL sample and was allowed to stir for 50 min for the extraction of eight bisphenols from natural waters. The analytes were then stripped using 5 mL methanol during 35 min. The limits of detection and quantitation were between 0.1–2.1 $\mu\text{g L}^{-1}$ and 0.4–7.0 $\mu\text{g L}^{-1}$, respectively. The average analyte recovery at 50 ppb spike level was 99.0% \pm 7.0%.

This work was supported from the project of Specific Academic Research (SVV 260 412/2019), by the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF and the Czech Science Foundation (Project No. 20-19297S).

References

1. HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., SOLICH, P. *et al.*: Trends Anal. Chem., 110, 2019, 81–96.
2. COCOVI-SOLBERG, D. J., WORSFOLD, P. J., MIRÓ, M.: Trends Anal. Chem. 2018, 108, 13–22.

BIOMIMETIC CRYSTALLIZATION OF METAL ORGANIC FRAMEWORK FOR THE PREPARATION OF HYBRID MONOLITH IN CAPILLARY FORMAT FOR THE SELECTIVE EXTRACTION OF DRUGS

FIKAROVÁ, K.,^{1,2} MAYA, F.,² HORSTKOTTE, B.,¹ SKLENÁŘOVÁ, H.,¹ ŠVEC, F.¹

¹ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Australian Centre for Research on Separation Science, School of Natural Sciences (Chemistry), University of Tasmania, Australia
e-mail: fikaroka@faf.cuni.cz

Organic polymer monoliths are excellent supports for the chromatographic separation of large molecules. Monolithic columns feature high permeability and low back pressure. However, they suffer from a rather small surface area needed for the separation of small molecules. On the other hand, porous metal-organic framework (MOF) crystals are highly porous with widely tunable properties. Unfortunately, their packing in separation columns is challenging due to their small particle size and non-spherical shape. Therefore, we designed a new generation of separation media combining advantages of organic polymer monoliths and MOF while reducing their drawbacks. We prepared polydivinylbenzene monolith containing ZnO nanoparticles as the MOF metallic precursor. ZnO nanoparticles were then converted to zeolitic imidazolate framework ZIF-8 via biomimetic crystallization using 2-methylimidazole as the organic linker with addition of a bioactive molecule – an amino acid – that enabled further modulation of MOF size and increased its selectivity. L-histidine, L-valine, phenylalanine, and glutamic acid were selected for our experiment and their effects on crystal morphology and adsorption selectivity were demonstrated. *In situ* polymerization time and MOF crystals growth were optimized to create open tubular capillary columns for enantioselective solid phase microextraction. Chiral selectivity and extraction capacity of the material were studied with batch extraction of propranolol enantiomers.

The project was supported from the project of Specific Academic Research (SVV 260 412/2019), the STARSS project (Reg. No. CZ.02.1.01/0.0/0.0/15_003/0000465) co-funded by ERDF, CASSS Frantisek Svec Fellowship 2019, and The Mobility Fund of Charles University.

COMBINING LAB-IN-SYRINGE WITH BEAD-INJECTION FOR PRECONCENTRATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN SURFACE WATERS COUPLED ONLINE TO HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

GEMUH, C., HORSTKOTTE, B., SOLICH, P.

Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: gemuhc@faf.cuni.cz

The modern flow techniques Lab-In-Syringe (LIS) and Lab-On-Valve (LOV) were combined and hyphenated to high-performance liquid chromatography for online micro-solid phase extraction of 5 nonsteroidal anti-inflammatory drugs (NSAIDs), namely ketoprofen, naproxen, flurbiprofen, diclofenac, and ibuprofen. The combined system ensured adequate mixing of large volume of sample with buffer inside the syringe enabling higher enrichment than typically achieved by simple LOV. SPE on a micro-SPE, packed automatically and in-system following the Bead Injection principle, was carried out in the LOV conduit using 4.4 mg of Oasis HLB® sorbent of particle size 30 µm for each sample analysis. Parameters such as injection volume, volume of sorbent suspension, ionic strength of buffer and the elution and loading flow rates were optimized. After washing the

micro-SPE column with water to remove any unretained matrix components, the retained analytes were eluted with acetonitrile/water (50 : 50, V/V) and 350 μL of the eluate loaded into the HPLC injection loop. Separation of 5 NSAID was done on Symmetry C18 column (4.6×150 mm, 5 μm) and C18 OPTI-GUARD® 1 mm guard column using a mobile phase of 30% (V/V) acetonitrile and 30% (V/V) methanol in 25 mmol L^{-1} ammonium formate buffer, pH 3.5, in isocratic regime. The method developed was reproducible with RSD values of 1% to 7% on 20 $\mu\text{g L}^{-1}$ level with linear range of 10 $\mu\text{g L}^{-1}$ to 200 $\mu\text{g L}^{-1}$ and LOD less than 5 $\mu\text{g L}^{-1}$. Recovery factors between 91 to 109 were obtained for surface water samples at 20 $\mu\text{g L}^{-1}$ level.

The study was supported from the project of Specific Academic Research (SVV 260 412/2019).

POLYSULFONE MEMBRANE ENRICHED IN BIOACTIVE COMPOUNDS TO REDUCE OXIDATIVE STRESS AND INFLAMMATION IN DIALYSIS PATIENTS

KOHLOVÁ, M.,^{1,3} ROCHA, S.,^{2,3} AMORIM, C. G.,³ SANTOS-SILVA, A.,²
SOLICH, P.,¹ MONTENEGRO, C.³

¹ Department. of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² UCIBIO\REQUIMTE Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Portugal

³ LAQV\REQUIMTE Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Portugal
e-mail: kohlm5aa@faf.cuni.cz

Oxidative stress (OS) and chronic inflammation are commonly present in dialysis patients, due to frequent contact of patients' blood with artificial membrane. To reduce oxidative stress, vitamin E-coated membranes are used to scavenge the reactive oxygen species formed during the hemodialysis. Although the use of this type of membrane showed diminishment in some inflammatory and OS markers,¹ the overall beneficial effect on mortality is still uncertain.

The aim of our work was to evaluate, if the enriched polysulfone (PSf) membranes with other bioactive substances, such as antioxidant lipoic acid or synthetic inhibitors of neutrophil elastase, could have preferable impact on OS and/or inflammation than vitamin E. Lipoic acid was incorporated in PSf membranes alone or together with vitamin E, while synthetic elastase inhibitors were immobilized on the membranes surface through adsorption. The biological activity and biocompatibility of the modified membranes were studied *in vitro*. Both types of bioactive compounds immobilized on PSf membrane showed promising effect on diminishment of OS/inflammation and therefore could be considered for future treatment.

The study was supported by the Charles University Grant Agency (Project No. 860216), from the project of Specific Academic Research (SVV 260 412/2019), by EFSA-CDN (CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF, by the North Portugal Region-

al Operational Programme NORTE 2020 (Project. No. 01/0145/FEDER/000024), and from the project Dial4Life co-financed by FCT/MCTES (PTDC/MEC-CAR/31322/2017) and FEDER/COMPETE 2020 (POCI/01/0145/FEDER/031322).

References

1. D'ARRIGO, G., BAGGETTA, R., TRIPEPI G. *et al.*: *Blood Purif.*, 43, 2017, 101–122.

LIQUID-PHASE MICROEXTRACTION OF ORGANOPHOSPHORUS PESTICIDES USING SUPRAMOLECULAR SOLVENT AS A CARRIER FOR FERROFLUID

HASHEMI, B.,¹ ZOHRABI, P.,² SHAMSIPUR, M.,¹ HASHEMI, M.^{1,2}

¹ Department of Analytical Chemistry, Faculty of Chemistry, Razi University, Kermanshah, Iran

² Department of Analytical Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, Iran
e-mail: hashemib@faf.cuni.cz

Supramolecular solvents (SUPRASs) are water immiscible nano-structured solvents composed of 3D amphiphilic aggregates, which have been used in microextraction procedures. The most important feature of supramolecular solvents is their high solvation potential for a wide range of target analytes (both polar and non-polar ones). As collecting of extracting solvent is of great importance in the liquid-phase microextraction, ferrofluids – suspended magnetic nanoparticles in a carrier liquid – can overcome the drawbacks such as centrifugation and refrigeration. In this study, we used supramolecular solvent as a carrier for ferrofluid and extracted three organophosphorus pesticides (OPPs) in water and fruit juice samples. To this end, oleic acid coated magnetic nanoparticles were prepared to omit the centrifugation step and they were used in combination with SUPRAS in the extraction process. The influence of main variables on the extraction efficiency was investigated using response surface methodology (RSM) based on central composite design (CCD). Under the optimum experimental conditions, the resulting calibration curves were linear in the concentration range of 0.5–400 $\mu\text{g L}^{-1}$. The intra-day and inter-day precisions were evaluated to be in the range of 2.0%–5.3% and 2.6%–5.7%, respectively. The obtained limits of detection (LODs) also ranged from 0.1 to 0.35 $\mu\text{g L}^{-1}$.

The study was supported by the Research Council of Razi University, (Faculty of Chemistry, Razi University, Kermanshah, Iran).

BIOCHEMISTRY, PHARMACOLOGY AND TOXICOLOGY SECTION

IN VITRO SCREENING OF STRUCTURALLY DIFFERENT TOPOISOMERASE II INHIBITORS FOR PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY

KUBEŠ, J.,¹ JANSOVÁ, H.,¹ KARABANOVICH, G.,² MELNIKOVÁ, I.,² JIRKOVSKÁ, A.,¹
SKALICKÁ, V.,¹ JIRKOVSKÝ, E.,¹ ROH, J.,² ŠIMŮNEK, T.¹

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: kubesjal@faf.cuni.cz

Anthracyclines (ANTs) retain the prominent role in many cancer treatments due to their high efficacy. However, the use of all of the ANTs is associated with a risk of severe cardiotoxicity. To date, dexrazoxane (DEX) has been the only cardioprotective agent approved for clinical use; therefore, it represents the main lead in the search for effective cardioprotection. The focus regarding its cardioprotective mechanism has recently shifted from metal chelation to its effect on topoisomerase II (TOP2).

This inspired us to examine various structural types of compounds described as TOP2 inhibitors for potential cardioprotective effect. In the first stage, we screened a series of commercially available compounds reported to inhibit TOP2 for their protective properties on primary cultures of neonatal rat cardiomyocytes. We also examined the effects of studied compounds on proliferation of HL-60, cell line derived from acute promyelocytic leukemia, and their effect on antiproliferative activity of daunorubicin. Because mitigation of adverse effect loses meaning if it diminishes the main effect.

From the series of inhibitors evaluated so far, three compounds show promising cardioprotection. Therefore, in the next stage, effect of the selected compounds on activity and depletion of TOP2 will be ascertained, to gain better mechanistical insight; and also, analogues of the perspective compounds are being prepared and studied.

This study was supported from the project of Specific Academic Research (SVV 246 216/2019) and by InoMed (Project No. CZ.02.1.01/0.0/0.0/18_069/0010046) co-funded by the European Union.

EVALUATION OF DAUNORUBICIN ANTIPROLIFERATIVE EFFECT ON TOPOISOMERASE 2B DEPLETED HL-60 GENERATED WITH CRISPR-CAS9

SKALICKÁ, V.,¹ KHAZEEM, M. M.,² JAŠČEVSKÁ, N.,¹ AUSTIN, C. A.,² JIRKOVSKÁ, A.¹

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Centre for Haemato-Oncology, Faculty of Medical Sciences, Newcastle University, United Kingdom
e-mail: skaliev1@faf.cuni.cz

Topoisomerase II β (TOP2B) inhibition was identified as one of possible mechanisms of dexrazoxane protection of cardiomyocytes from anthracycline (ANT) cardiotoxicity. In 2012, Zhang *et al.* outlined, that mice with heart specific depletion of TOP2B were prevented from ANT-induced cardiac damage.¹ Unlike heart cells, human leukemic cell line HL-60 contain both TOP2A and TOP2B isoforms. TOP2A enables cell division while the precise function of TOP2B has not been fully understood yet. Dexrazoxane (DEX) as the only approved cardioprotective agent acts as catalytic inhibitor of both TOP2 isoforms, and due to its TOP2 inhibition effect it is suspected of compromising the cytotoxicity effect of anthracyclines in cancer cells. The TOP2B was also implicated in the resistance of tumor cells and the increase of secondary malignances. We aimed at depleting TOP2B with CRISPR-Cas9 technology and evaluate the effects of daunorubicin (DAU) on these mutants regarding their sensitivity to DAU. HL-60 were transfected with specific CRISPR-Cas9 plasmid targeting TOP2B. Forty-eight hours after transfection the cells were sorted with GFP as a selection marker to 96-well plates. After approximately 6 weeks of cell growth individual clones were tested for TOP2B occurrence by immunofluorescence and western blotting. TOP2B deficient clones were spotted and genotyped to characterize individual clonal mutations. Based on these acquired data several homozygous and heterozygous TOP2B deficient mutants were identified. Antiproliferative effect of DAU was evaluated in both homozygous and heterozygous mutants using MTT.

The study was supported from the project of Specific Academic Research (SVV 260 416/2019).

References

1. ZHANG, S., LIU, X., BAWA-KHALFE, T. *et al*: Nat. Med. 18, 2012, 1639–1642.

TYROSINE KINASE INHIBITORS AS MULTITASKING SOLDIERS AGAINST CANCER DRUG RESISTANCE: THE EXEMPLARY CASE OF MIDOSTAURIN

MORELL, A., NOVOTNÁ, E., WSÓL, V.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: morellga@faf.cuni.cz

Tyrosine kinase inhibitors (TKIs) are proven active antileukemic agents that suppress aberrant tyrosine kinase signaling involved in cell proliferation. TKIs have shown additional targeting of proteins involved in cancer multidrug resistance, like membrane transporters and detoxifying enzymes. Midostaurin is a selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) approved for the treatment of acute myeloid leukemia (AML), in combination with anthracycline daunorubicin (DAU). Midostaurin-based combination chemotherapy has demonstrated significant clinical benefits and safety, but the molecular mechanisms involved are still poorly understood. It has been reported how carbonyl reducing enzymes (CREs) expressed in leukemic cells contribute to resistance towards

daunorubicin. In this context, we evaluated the effect of midostaurin on DAU reduction by several recombinant CREs, observing a tight-binding inhibition of Aldo-keto reductase 1C3 (AKR1C3). Likewise, midostaurin decreased DAU metabolism in an HCT116 cell model overexpressing AKR1C3. Furthermore, acute myeloid leukemia cell line KG1a naturally expresses CREs that correlates to its inherent resistance to anthracyclines. Midostaurin performs a dual effect on KG1a cells, by inducing DAU accumulation but significantly reducing DAU metabolism. Confocal microscopy and flow cytometry showed that the combination with midostaurin increases the nuclear localization of daunorubicin in KG1a cells, probably due to the higher availability of the non-reduced form of DAU. Our findings revealed that midostaurin improves DAU cytotoxicity by the simultaneous inhibition of different proteins that are critical in cancer multidrug resistance.

The study was supported by EFSA-CDN (CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 416/2019).

EMD1214063 REVERSES MULTIDRUG RESISTANCE BY INHIBITING THE EFFLUX FUNCTION OF ABCB1 AND ABCG2 TRANSPORTERS

VAGIANNIS, D.,¹ ZHANG, Y.,¹ BUDAGAGA, Y.,¹ SKARKA, A.,² ŠTAUD, F.,¹ HOFMAN, J.¹

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Chemistry, Faculty of Science, University of Hradec Králové, Czech Republic
e-mail: vagiannnd@faf.cuni.cz

ABC (ATP-binding cassette) drug efflux transporters play an important role in pharmacokinetic drug-drug interactions as well as in the phenomenon of multidrug resistance (MDR) in cancer cells. EMD1214063 (EMD) is a novel c-MET tyrosine kinase inhibitor that has been developed for several types of cancer, including non-small cell lung cancer. In this study, we aimed at evaluating the inhibitory activity of EMD towards human ABC transporters and its role in the MDR. In accumulation studies in MDCKII cell lines overexpressing particular ABC transporters we showed that EMD is an inhibitor of ABCB1 and ABCG2. Furthermore, we demonstrated that EMD1214063 significantly reverses ABCB1- and ABCG2-mediated daunorubicin and mitoxantrone MDR, respectively. For reversal experiments, MTT proliferation assay in MDCKII, A431 and HL60 cells overexpressing ABCB1 and ABCG2 transporters, was used. Additionally, EMD was found to be a substrate of ABCB1 but not of ABCG2 or ABCC1, in MDCKII monolayer transport assays followed by UHPLC/MS analysis. No significant induction effects of EMD on ABCB1, ABCG2 or ABCC1 mRNA levels were found in physiological cells as well as non-small cell lung cancer cellular models using qRT-PCR analysis. Overall, we conclude that EMD could participate in the pharmacokinetic drug-drug interactions and overcome the pharmacokinetic MDR phenomenon in cancer cells. Future *in vivo* confirmation of our results might potentially open the way for the establishment of safe and effective combination pharmacotherapy for many oncological patients.

The study was supported by the Czech Science Foundation (Project No. 20-20414Y), Grant Agency of Charles University (Project No. 1568218/C) and from the project of Specific Academic Research (SVV 260 414/2019).

MIDOSTAURIN AS A NOVEL MODULATOR OF ABC TRANSPORTERS IN ACUTE MYELOID LEUKEMIA

SUCHÁ, S.,¹ ŠORF, A.,¹ VÍŠEK, B.,² ČEČKOVÁ, M.¹

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² 4th Department of Internal Medicine – Hematology, University Hospital in Hradec Králové,
Czech Republic
e-mail: suchas@faf.cuni.cz

Midostaurin is a multi-kinase inhibitor recently approved for the treatment of patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome, who carry the FMS-like tyrosine kinase 3 (FLT3) mutation accountable for a poor prognosis. One of the most common mechanisms responsible for a failure of anticancer therapy is multidrug resistance (MDR) with ABC efflux transporters being one of important causative factors. Specifically ABCB1 and ABCG2 are confirmed to be related to resistant CD34⁺ leukemic blast cells. In this study we aimed to evaluate interaction of midostaurin with ABC transporters using resistant HL60 cell lines and *ex vivo* isolated peripheral blood monocyte cells (PBMC) from patients *de novo* diagnosed with AML. Gene expression of ABC transporters was established in AML patients' PBMC employing droplet digital PCR. Our results showed that *ABCB1* and *ABCG2* were highly expressed in CD34⁺ cells while differences between FLT3⁺ and FLT3⁻ patients fell short of statistical significance. Accumulation assays in resistant HL60-ABCB1 and HL60-ABCG2 cells revealed midostaurin as inhibitor of both transporters. When applied to PBMC of CD34⁺ patients, midostaurin significantly increased the intracellular levels of mitoxantrone, a conventional anticancer drug that is recognized as a substrate of ABC transporters. Since a noticeable correlation of *ABCB1* and *ABCG2* expression with the effect of midostaurin on accumulation of mitoxantrone in PBMC was found, we can assume that the expression of ABC transporters might affect therapeutic outcomes of combination therapy in AML. In conclusion, we show here the potential of midostaurin to contribute to overcoming the pharmacokinetic MDR in AML patients and thereby prevent the pharmacotherapy failure.

The study was supported from the project of Specific Academic Research (SVV 260 414/2019) and PRIMUS 20/MED/010.

OVERCOMING DAUNORUBICIN RESISTANCE MEDIATED BY ALDO-KETO REDUCTASE 1B10

BUKUM, N., MORELL, A., NOVOTNÁ, E., WSÓL, V.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: bukumn@faf.cuni.cz

Tyrosine kinase inhibitors (TKi) have been found to have effective antitumor activity and have been approved or are under clinical trials.¹ Recent studies show that some TKis are able to enhance the cytotoxicity of anthracyclines.²

Dasatinib is an orally administered, small-molecule inhibitor of multiple tyrosine kinases that blocks the function of the Bcr-Abl protein that signals cancer cells to multiply. Targeted therapy of dasatinib is used to treat most cases of chronic myeloid leukemia and acute lymphoblastic leukemia in patients.³ AKR1B10 has recently been found to be over-expressed in certain types of cancers, including hepatocellular carcinoma and lung cancer associated with tobacco smoking.⁴

Our combination strategy of the daunorubicin together with dasatinib may, therefore, minimize the adverse effects of each individual drug, enhance the effectiveness of the treatment and allow its prolonged continuity. Dasatinib exhibited a significant inhibitory effect on recombinant AKR1B10, with a half-maximal inhibitory concentration of 0.8 μM . Its inhibition constant K_i was found to be 0.4 μM , and the inhibition data best fitted a mixed-type mode with $\alpha = 1.7$. In conclusion, based on our results, dasatinib may affect the therapeutic efficacy of anthracyclines by preventing anthracycline resistance and reducing their adverse effects.

The study was supported by the Grant Agency of Charles University (Project No. 1006218) and from the project of Specific Academic Research (SVV 260 416/2019).

References

1. ARORA, A., SCHOLAR, E. M.: J. Pharmacol. Exp. Ther., 315, 2015, 971–979.
2. ZHAI, B., SUN, X.: World J. Hepatol., 5, 2013, 345–352.
3. CONCHON, M., FREITAS, C., REGO, M. *et al.*: Rev. Bras. Hematol. Hemoter., 33, 2011, 131–139.
4. LIU, J., WEN, G., CAO, D.: Recent Pat. Anticancer Drug Discov., 4, 2016, 246–253.

INHIBITION OF HUMAN ALDO KETO REDUCTASE (AKR1C3) BY OLAPARIB – A POSSIBLE REMEDY FOR DAUNORUBICIN RESISTANCE

TAVARES, T. S.,¹ HOFMAN, J.,² MORELL, A. G.,¹ WSÓL, V.¹

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: silvatat@faf.cuni.cz

The chemotherapeutic application of daunorubicin has significant drawbacks due to drug resistance and related cardiotoxicity. Several members of aldo-keto reductase and short-chain dehydrogenases/reductases superfamilies are responsible for reductive metabolism of parent drug to its less potent metabolite daunorubicinol and belong thus to the most important daunorubicin resistance drivers. Olaparib is a poly (ADP-ribose) polymerase inhibitor used in the treatment of patients with ovarian cancer. In this work, we have aimed at describing possible interactions of olaparib with selected daunorubicin reductases and evaluate their possible utilization for overcoming daunorubicin resistance. Results of incubation experiments with recombinant carbonyl reductases (AKR1C3, AKR1B10, AKR1B1, AKR1A1, and CBR1) showed significant inhibition of AKR1C3, the most potent anthracycline reductase. High inhibitory potency ($IC_{50} = 5.913 \mu\text{M}$) was subsequently confirmed in intact HCT116 cells overexpressing AKR1C3. Using proliferation XTT assay in the same cellular model we demonstrated the ability of olaparib to reverse enzyme-mediated daunorubicin resistance in a synergistic fashion. Currently, additional experiments focusing on the description of olaparib's effect on expression of *AKR1C3* gene in leukemic KG1 α and hepatic HepG2 cells are being conducted. In conclusion, our results present olaparib as a potent AKR1C3 inhibitor able to effectively attenuate daunorubicin resistance at clinically relevant concentrations. Future *in vivo* studies would be helpful to support the rationality of our conclusions and possibly offer new therapeutic option for oncological patients.

The study was supported by InoMed (Project No. CZ.02.1.01/0.0/0.0/18_069/001/0046) co-funded by the European Union and from the project of Specific Academic Research (SVV 246 216/2019).

NOVEL PHOTODYNAMICALLY ACTIVE HYDROPHILIC AND AMPHIPHILIC ANIONIC (AZA)PHTHALOCYANINE DERIVATIVES FOR TREATMENT OF TUMOROUS DISEASES

HALAŠKOVÁ, M.,¹ KOLLÁR, J.,² ZIMČÍK, P.,² MACHÁČEK, M.¹

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: halaskma@faf.cuni.cz

Photodynamic therapy is a clinically approved non-invasive treatment and subject of intense research for the eradication of solid tumors. Phthalocyanines (Pcs) proved to be very promising photosensitizers (PS). Aim of this work is to evaluate the photodynamic activity of newly synthesized anionic water-soluble zinc(II) Pcs with sulfonyl or carboxyl substituents in *in vitro* conditions. Cytotoxicity experiments were performed mainly on human cervix carcinoma cell line HeLa using neutral red uptake assay. Localization of the compounds within the cell, uptake profiles of PSs to the cells and morphological changes after irradiation were also studied. The results of individual experiments have shown

high photodynamic activity after irradiation (phototoxicity; EC_{50}) and exceptionally low inherent toxicity (toxicity in the absence of activating light; TC_{50}) of all studied compounds. Phototoxicity was further evaluated on two other human tumor cell lines: MCF-7 (breast carcinoma) and HCT116 (colorectal carcinoma). The most suitable properties were achieved with P44 ($EC_{50} = 0.33 \mu\text{M}$, $TC_{50} > 1000 \mu\text{M}$) in the serum-containing medium. For all studied compounds, photodynamic effect resulted in significant morphological changes indicating ongoing cell death. It is worth noting that photodynamic activity of all studied compounds is negatively affected by the presence of serum (serum-free conditions resulted in up to 95-time increase in phototoxicity). Based on obtained results, selected compounds will be included in subsequent studies on 3D spheroid cultures as well as in the *in vivo* evaluation of their photodynamic efficiency on mouse tumor model.

The study was supported by the Grant Agency of Charles University (Project No. 1620219), by the Czech Science Foundation (Project No. 19-14758Y) and from the project of Specific Academic Research (SVV 260 416/2019).

PRECISION-CUT INTESTINAL SLICES FROM HUMAN TISSUE AS AN *EX VIVO* MODEL FOR ABCB1 TRANSPORTER INDUCTION

MARTINEC, O.,¹ BIEL, C.,² ČERVENÝ, L.,¹ VOKŘÁL, I.,¹ De GRAAF, I. A. M.,³ OLINGA, P.²

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy,
University of Groningen, Groningen, The Netherlands

³ Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy
University of Groningen, Groningen, The Netherlands
e-mail: martinon@faf.cuni.cz

P-glycoprotein (ABCB1), an ATP-binding-cassette efflux transporter, limits intestinal absorption of its substrates and is a common site of drug-drug interactions (DDIs). The drugs causing DDIs on this transporter can act as substrates, inhibitors and/or inducers. Therefore, the absorption of the compounds may be changed and can lead to inappropriate drug plasma levels. Current options for investigating the induction process are limited. For this purpose, we decided to evaluate and optimize human precision-cut intestinal slices (PCIS) to be suitable for long term induction studies. Three types of media were evaluated: 1) Williams' Medium E (WME) as a standard medium used for PCIS; 2) two different organoid media (ORG and Vacy) with cooperation of Applied University of Utrecht. Incubations were performed with and without rifampicin, known inducer of the ABCB1, to validate the model for induction studies.

During the evaluation, we collected samples after 24, 48, 72 hours. ATP/protein measurement was used as a viability marker, RT-PCR and immunohistochemical methods were used to study ABCB1 levels. Rhodamine 123 accumulation assay was used as a functional control of ABCB1 expression. In WME after 24 h rifampicin induced the efflux activity of the ABCB1 and increased level of the *ABCB1* mRNA. With increasing incubation time,

we saw a similar effect, but also with the increasing deviation. On the other hand, Vacy and ORG medium have a better effect on the ATP/protein level, proliferation and the stability of the activity of ABCB1, but we didn't observe any effect on the induction with added rifampicin.

Finally, we could summarize that human PCIS can be used as an *ex vivo* induction model of the ABCB1 in the WME medium. The effect is observed on the activity and mRNA level.

This work was supported from the project of Specific Academic Research (SVV 260 414/2019), by the Czech Science Foundation (Project No. 18-07281Y) and the Grant Agency of Charles University (Project No. 1600317).

IN VITRO AND EX VIVO EVALUATION OF ANTI-HIV AND ANTI-HCV DRUGS EFFECTS ON DIGOXIN INTESTINAL ABSORPTION

HULIČIAK, M., MARTINEC, O., ŠTAUD, F., VOKŘÁL, I., ČERVENÝ, L.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: hulicim@faf.cuni.cz

Efflux transporter P-glycoprotein (ABCB1) is known to limit intestinal absorption of its substrates and represents a site of drug-drug interactions (DDIs). Competition on specific ABCB1 binding sites (for rhodamine 123, Hoechst 33342, and digoxin) may result in increased drug bioavailability. Using *in vitro* bi-directional transport studies across Caco2 cells and *ex vivo* method of accumulation in rat- and human-derived precision-cut intestinal slices (PCIS) we showed in previous study that numerous anti-HIV and anti-HCV drugs reveal ability to increase absorption of model ABCB1 substrate, rhodamine 123. In this follow-up project, we aimed to investigate the potency of anti-HIV and anti-HCV drugs to decrease intestinal ABCB1-controlled efflux of digoxin and thus to bring direct evidence about the molecular mechanism of interactions between antivirals and digoxin in the intestinal barrier. We found that lopinavir (50 μ M), ritonavir (100 μ M), atazanavir (50 μ M), darunavir (50 μ M, 100 μ M), daclatasvir (20 μ M), grazoprevir (20 μ M, 50 μ M) and asunaprevir (20 μ M, 50 μ M) inhibit the efflux of digoxin in Caco-2 cells and human-derived PCIS, while possible interindividual variability was observed in the inhibition of intestinal ABCB1 by rilpivirine (20 μ M), abacavir (100 μ M), elbasvir (5 μ M) and velpatasvir (5 μ M). Abacavir (100 μ M), dolutegravir (10 μ M), elbasvir (5 μ M), velpatasvir (5 μ M) and sofosbuvir (100 μ M) revealed no inhibition of intestinal ABCB1 in Caco-2 cells. In conclusion, we have demonstrated that tested antivirals have potency for DDIs on intestinal ABCB1 with drugs with affinity to digoxin binding site. Our data contribute to explaining the molecular mechanism of reported increased bioavailability of drugs interacting with digoxin binding site when administered together with antivirals.

The study was supported by the Czech Science Foundation (Project No. 18-07281Y) and from the project of Specific Academic Research (SVV 260 414/2019).

EFFECT OF ANTIDEPRESSANTS ON PLACENTAL HANDLING OF SEROTONIN

HORÁČKOVÁ, H., KARAHODA, R., VÁCHALOVÁ, V., ČERVENÝ, L., ABAD, C., ŠTAUD, F.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: horackha@faf.cuni.cz

Serotonin (5-HT) is a crucial monoamine for proper fetal development/programming and, therefore, tight regulation of 5-HT homeostasis in the fetoplacental unit is required throughout gestation. It is suggested that early in pregnancy the placenta supplies 5-HT to the embryo/fetus. However, at later stages of gestation, the fetus can produce its own 5-HT from maternally-derived tryptophan. Recently, we have discovered a new pathway of placental serotonin handling: placental extraction of excess 5-HT from fetal circulation through organic cation transporter 3 (OCT3). This transporter is known to be inhibited by many endogenous compounds and pharmacological agents including antidepressant drugs. Up to 25% of pregnant women suffer from depression and approximately 10% are using antidepressants (ADs), typically serotonin-reuptake inhibitors. Safety of this treatment is still discussed since many adverse effects have been reported. We hypothesize, that ADs can affect serotonin handling in placenta via inhibition of SERT and/or OCT3. This inhibition could lead to accumulation of 5HT in placental circulation. Experiments were performed using *in situ* dually perfused rat term placenta and *ex vivo* membrane vesicles isolated from human term placenta. Six ADs were tested (paroxetine, citalopram, fluoxetine, fluvoxamine, sertraline, venlafaxine) to affect 5-HT uptake by placenta. We observed significant inhibitory effect by all ADs in both human and rat placenta. We suggest that AD use in pregnancy may affect placental homeostasis of 5-HT and, therefore, placental and/or fetal development.

This project was funded by the Grant Agency of Charles University (Project No. 1464119/C/2019), by the Czech Science Foundation (Project No. 17-16169S) and from the project of Specific Academic Research (SVV 260 414/2019).

EFFECT OF GESTATION AGE ON EXPRESSION AND FUNCTION OF ENZYMES INVOLVED IN TRYPTOPHAN METABOLISM IN HUMAN AND RAT PLACENTA

ABAD, C.,¹ KARAHODA, R.,¹ HORÁČKOVÁ, H.,¹ KASTNER, P.,² KUČERA, R.,² ŠTAUD, F.¹

¹ Department of Pharmacology and Toxicology, Charles University, Faculty of Pharmacy
in Hradec Králové, Czech Republic

² Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Charles University,
Faculty of Pharmacy in Hradec Králové, Czech Republic
e-mail: abadmarc@faf.cuni.cz

Tryptophan (TRP) is an essential amino acid that, besides being utilized for protein synthesis, is a precursor of key physiological biomolecules, such as kynurenine (immuno-

suppressive), quinolinic acid (neuroactive), serotonin and melatonin. In the placenta, TRP is metabolized via the serotonin (5-HT) and kynurenine (KYN) pathways and the relative flux of substances through these pathways changes depending on the physiological state. We hypothesize that embryo and fetal needs of TRP and its metabolites change over the course of gestation. Therefore, in our study we investigated gestational age-dependent changes (expression/function) of key enzymes and transporters in tryptophan metabolism by KYN and 5-HT pathways in both human and rat placenta. In detail, we analyzed gene and protein expression of 5-HT transporters (SERT and OCT3) and gene/protein expression and function of TRP metabolizing enzymes (TPH1,2, MAO-A, IDO1,2) in first and third trimester human placenta and in rat placenta of gestation ages 15, 18 and 21. In both human and rat placenta, we detected significant effect of gestation age on expression and/or function of investigated proteins. We suggest these regulatory pathways control levels of TRP and 5-HT in fetoplacental unit to ensure proper embryo and fetal development throughout pregnancy.

This project was funded by EFSA-CDN (No. CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 414/2019).

THE CONTRIBUTIVE ROLE OF THE PLACENTAL ABCC1 IN MATERNAL AND FETAL PROTECTION. THE CASE OF MARAVIROC

TUPOVÁ, L.,¹ HIRSCHMUGL, B.,² PILAŘOVÁ, V.,³ SZÉKELY, V.,⁴ BAKOS, É.,⁴ SUCHÁ, S.,¹ NOVÁKOVÁ, L.,³ ŠTAUD, F.,¹ LACZKA, C.,⁴ WADSACK, C.,² ČEČKOVÁ, M.¹

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Obstetrics and Gynaecology, Medical University of Graz, Austria

³ Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

⁴ Membrane Protein Research Group, Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary
e-mail: tupoval@faf.cuni.cz

The protection of the developing fetus against potentially toxic xenobiotics is traditionally discussed in the context of efflux activity of ATP-dependent (ABC) drug transporters, especially ABCB1 and ABCG2, which are located in the apical membrane of the maternal blood facing trophoblast layer. CCR5 antagonist maraviroc shows low cord blood-maternal blood ratio (0.33), indicating limited transfer across placenta. Based on our previous study this could be attributed to the maraviroc substrate affinity toward ABCB1. Nevertheless, only negligible contribution of ABCB1 was recorded in closed-circuit dual perfusion of maraviroc across human placental cotyledon. Surprisingly, we observed decline of maraviroc concentration from circulating perfusates in both, materno-fetal and feto-maternal directions, suggesting retention of maraviroc in placental tissue. Subsequent *in vitro* studies revealed transport of maraviroc with ABCC1 transporter. Localization and function of placental ABCC1 is an object of many discussions, nevertheless, it is obviously placed in basal membrane of trophoblast layer. Besides the trophoblast, we show also high ex-

pression of *ABCC1* mRNA in the fetal endothelial cells. Considering placental structure, *ABCC1* localization indicates possible transport of its substrates from both maternal and fetal circulations and their accumulation in placental interstitium, which corresponds to the situation observed during perfusion of maraviroc. Since placenta is a temporary organ leaving the body after delivery, we hypothesize *ABCC1* might contribute to accumulation of xenobiotics in the placental tissue, as a possible mechanism of a complex strategy ensuring protection of mother and fetus during pregnancy.

This study was supported from the project of Specific Academic Research (SVV 260 414/2019).

PRIMARY HUMAN HEPATOCYTE SPHEROIDS AS *IN VITRO* PLATFORM FOR PRECLINICAL DRUG DEVELOPMENT

SMUTNÝ, T., PÁVEK, P.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: smutt6aa@faf.cuni.cz

Primary human hepatocytes are considered the golden standard of *in vitro* models for evaluating hepatic metabolism and toxicity during drug development. However, a culture of primary human hepatocytes is known to lose hepatic phenotype resulting in a significant widespread alteration of metabolic capacity.

Hepatocyte dedifferentiation occurs due to loss of a structural architecture as hepatocytes are disrupted from their organized microenvironment and seeded in a monolayer culture. In this line, the growing effort has been put to develop more relevant *in vitro* models closely mimicking physiological cell environment and phenotype.

Recently, 3D spheroids of primary human hepatocytes have been developed using low adherent plates and well-defined culture conditions. This model showed similar molecular phenotype as that present in adult human liver and maintained hepatocyte functions over the long term.

In my talk, I will focus on the application of 3D hepatocytes in assessing preclinical pharmacokinetic and toxicological properties of drug candidates.

The study was supported by EFSA-CDN (CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF and from the project of Specific Academic Research (SVV 260 414/2019).

CHARACTERIZATION OF TRANSCRIPTOME IN HUMANIZED CAR MICE REGULATED BY MODEL MURINE LIGAND TCPOBOP

ŠKODA, J., DUŠEK, J., PÁVEK, P.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: skodajo@faf.cuni.cz

Nuclear receptor CAR (constitutive androstane receptor; Nr1h3) is a hepatic regulator of xenobiotic and endobiotic metabolism.¹ In mice, CAR activation normalizes glucose and triglyceride serum levels and decreases body weight during high fat diet and nutritional stress.² Murine CAR agonist, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) is connected with hepatomegaly and hepatic proliferation.³ We studied the effect of TCPOBOP in the wild type mice as well as in mice with humanized CAR, which is not activated by TCPOBOP. We found that TCPOBOP increases liver weights in genetic backgrounds independently on CAR activation. Gene expression study shows similar trends on proliferation genes after TCPOBOP treatment, when metabolism is strictly regulated in CAR-dependent manner. Our data shows that TCPOBOP may be a non-specific ligand promoting hepatocyte proliferation independently of human CAR activation.

The study was supported by the Grant Agency of Charles University (Project No. 170-050/75006) and from the project of Specific Academic Research (SVV 260 414/2019).

References

1. HONKAKOSKI, P., ZELKO, I., SUEYOSKI, T. *et al.*: Mol. Cell. Biol., 18, 1998, 5652–5658.
2. DONG, B., SAHA, P., HUANG, W. *et al.*: PNAS, 106, 2009, 18831–18836.
3. COSTA, R., KALINCHENKO, V., TAN, Y. *et al.*: Hepatology, 42, 2005, 1004–1008.

DISCOVERY OF POTENT GPBAR1 AGONISTS/FXR ANTAGONISTS

HORVÁTOVÁ, A.,¹ KAŠPAR, M.,² DRASTÍK, M.,³ PÁVEK, P.,¹ KUDOVÁ, E.²

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Institute of Organic Chemistry and Biochemistry, Academy of Sciences, Prague, Czech Republic

³ Department of Physical Chemistry and Biophysics, Charles University, Hradec Králové, Czech Republic
e-mail: horvatal@faf.cuni.cz

Bile acid receptors, GPBAR1 and farnesoid X (FXR), emerge as important regulators of glucose, lipid and steroids metabolism in the intestine and liver. Recent animal experiments showed that compounds with combined GPBAR1 agonistic activity in the intestine and FXR antagonistic activity in the liver may be promising candidates for the treatment of glucose metabolic diseases. In the study, we have discovered first-in-class GPBAR1 agonist/FXR antagonists based on testing a set of steroid molecules derived from obeticholic acid (OCA), the prototype FXR agonist. Several derivatives demonstrated potent activation of TGR5, among them compound 2 appeared as highly potent GPBAR1 agonist with EC₅₀ being 12 nM in cellular reporter assays. At the same time, compound 2 as well as compound 8 inhibited FXR activation in various FXR reporter gene assays and suppressed OCA- and GW4064-mediated regulation of FXR target genes in differentiated HepaRG cells and primary human hepatocytes. In conclusion, we discovered novel class of dual GPBAR1 agonists/FXR antagonists.

The study was supported by the Grant Agency of Charles University (Project. No. 170/50/85006) and from the project of Specific Academic Research (SVV 260 414/2019).

References

1. PATHAK, P., LIU, H., BOEHME, S. *et al.*: J. Biol. Chem., 292, 2017, 11055–11069.
2. PERINO, A., SCHOONJANS, K.: Trends Pharmacol. Sci., 36, 2015, 847–857.
3. FIORUCCI, S., DISTRUTTI, E., RICCI, P. *et al.*: Expert Opin. Ther. Targets, 18, 2014, 1449–1459.

MATHEMATICAL MODELLING OF THE SIGNALLING PATHWAYS OF NUCLEAR RECEPTORS

MATTHIOS, A.,¹ DUINTJER TEBBENS, E. J.,¹ PÁVEK, P.²

¹ Department of Biophysics and Physical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: matthioa@faf.cuni.cz

The presentation is focused on the mathematical modelling of the signalling pathways of obeticholic acid activated farnesoid X receptor (FXR). Nuclear receptors like FXR are a family of ligand-regulated transcription factors that are activated by lipid-soluble substances. These substances cross the plasma membrane and interact directly with the nuclear receptors inside the cell.¹ Ordinary differential equations (ODEs) will be used to describe the gene transcription products changes over time. The final model will be used for predictions and extrapolations.

FXR does not directly bind to the CYP7A1 promoter. Rather, FXR induces expression of small heterodimer partner (SHP), which then functions to inhibit transcription of the CYP7A1 gene.² This process is modelled as a continuous function of time: $dR/dt = K_{in} - (1 - (I_{max} \times C^n / (IC_{50}^n + C^n))) - K_{out} \times R$ where drug effect is mediated as inhibition of SHP. Graphical comparison of observations and simulated predictions depicted a good fit of our model to the dataset. Additional mathematical models that describe and link these pathways will be built.

This work was supported from the project of Specific Academic Research (SVV 260 401/2019) and by the Grant Agency of Charles University (Project No. 110/50/85003).

References

1. SEVER, R., GLASS, C. K.: Cold Spring Harb Perspect. Biol., 5, 2013, art. a016709.
2. GOODWIN, B., JONES, S. A., PRICE, R. R. *et al.*: Mol. Cell, 6, 2000, 517–526.

PROBING THE STRUCTURE AND FUNCTION OF THE CYTOSOLIC DOMAIN OF THE HUMAN ZINC TRANSPORTER ZNT8 WITH NICKEL(II) IONS

CATAPANO, M. C.,¹ MLADĚNKA, P.,¹ MARET, W.²

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

The human zinc transporter ZnT8 is important for assembly of insulin hexamers of β -cells with zinc and for its storage. Its structure and function were modelled on the basis of the 3D structure of the *E.coli* zinc exporter YiiP.¹ However, there are important differences in function as the YiiP protein exports an excess of zinc from cells, whereas ZnT8 exports zinc into subcellular vesicles when there is no apparent excess of zinc. There are two variants, one with tryptophan (W) and the other one with arginine (R) at position 325. These variants have generated considerable interest as the R-variant is associated with a higher risk of developing type 2 diabetes.² Since these mutations are at the apex of the C-terminal domain (CTD) towards the cytoplasm, it is not clear how they would affect zinc transport. We expressed the CTD of both variants of human ZnT8 and have begun structural and functional studies. In particular, we found that (i) the metal binding site of the human protein is different from that of *E.coli* protein, (ii) the human protein has a C-terminal extension with three cysteine residues that also bind zinc, (iii) there are small differences in stability between the two variants, and (iiii) nickel ions bind to the cytoplasmic domain of the zinc transporter ZnT8.

The study was supported by European Union ERASMUS+ Programme and the London Metallomics Facility (Project No. 202902/Z/16/Z) funded by Wellcome Trust and from the project of Specific Academic Research (SVV 260 414/2019).

References

1. LU, M., FU, D.: Science, 317, 2007, 1746–1748.
2. DAVIDSON, H. W., WENZLAU, J. M., O'BRIEN, R. M.: Trends Endocrinol. Metab., 25, 2014, 415–424.

ISOLATED SILYMARIN FLAVONOLIGNANS AND THEIR ABILITY TO INTERACT WITH TRANSITION METALS AND PLATELETS

TVRDÝ, V.,¹ APPLOVÁ, L.,² KARLÍČKOVÁ, J.,³ MACÁKOVÁ, K.,⁴ HRUBŠA, M.,¹ VALENTOVÁ, K.,⁵ MLADĚNKA, P.¹

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

³ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

⁴ Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

⁵ Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
e-mail: tvrdyvac@faf.cuni.cz

Silymarin, a complex of flavonolignans extracted from fruits of *Silybum marianum* (L.) Gaertn., is approved in the EU as a drug. It is also frequently used as a food supplement. Flavonolignans have a polyhydroxylated structure and are poorly absorbed. In addition,

if absorbed, they are rapidly conjugated. For this reason, parent flavonolignans rather remain in the gastrointestinal tract while their conjugates are the dominant forms in the systemic circulation. This study was focused on testing 1) the ability of optically pure flavonolignans to interact with transition metals and 2) if their sulphates can block platelet aggregation. Only 2,3-dehydrosilybin (racemate as well as both enantiomers – A and B) has shown moderate ability to chelate iron and copper. Silybin A, silybin B and silychristin were less potent or inactive chelators. Silychristin was found to be the most potent iron and copper reductant. This study also discovered a low potential of sulphates of flavonolignans to block aggregation in whole human blood. Parent flavonolignans were tested for comparison, but their potential was low as well, since it was observed only at concentrations $\geq 120 \mu\text{M}$. Mechanistic study showed that their mild activity was likely mediated by antagonism at thromboxane receptors. Although some silymarin flavonolignans blocked recombinant cyclooxygenase 1, their effect on this platelet enzyme in whole human blood was negligible. In conclusion, it is highly improbable that this activity would be manifested *in vivo* due to relatively high concentrations needed to evoke this effect. On the contrary, oral administration of silymarin may influence the kinetics of copper and iron in the GIT.

The study was supported from the project of Specific Academic Research (SVV 260 414/2019) and by the Czech Science Foundation (Project No. 18-00121S).

PLATELET AGGREGATION IN HEALTHY POPULATION: PRELIMINARY DATA ON AGE-DEPENDENT DIFFERENCES

HRUBŠA, M.,¹ MACÁKOVÁ, K.,² KARLÍČKOVÁ, J.,³ CARAZO, A.,¹ PARVIN, S.,³ MLADĚNKA, P.¹

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Pharmacognosy, Faculty of Pharmacy in Hradec Králové, Charles University,
Czech Republic

³ Department of Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University,
Czech Republic
e-mail: hrubsam@faf.cuni.cz

Primary haemostasis is a process which contributes to preserving the integrity of the cardiovascular system. It is enabled by platelets, anucleate cells circulating in the bloodstream which aggregate in response to certain stimuli. Altered platelet aggregation can severely affect circulation and lead to many cardiovascular diseases. Dysregulation of this process can result in life-threatening events, such as stroke and acute myocardial infarction, which are the most prevalent causes of mortality in developed countries.¹ An important factor influencing platelet aggregation is the age. There is, however, little data concerning the significance of this factor in experiments using whole blood. Therefore, we have performed a screening of 11 healthy individuals aged 21–58 of both sexes using Multiplate analyzer which utilizes whole blood and allows examination of various aggregation inducers. A response to several aggregation inducers and standard drugs affecting these inducers were evaluated. We have observed a fairly high interindividual variance with all

inducers and used drugs. Preliminary data showed a decrease in response to adenosine diphosphate (ADP) with increasing age. Younger individuals also appeared to be more responsive to acetylsalicylic acid (ASA). Authors are aware that these are initial data and a higher sample size is required to reach more solid conclusion.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 414/2019).

References

1. ALBERS, G. W., AMARENCO, P., EASTON, J. D. *et al.*: Chest 133, 2008, 630S–669S.

SOLUBLE ENDOGLIN DOES NOT AFFECT CHOLESTEROL AND BILE ACIDS METABOLISM IN NASH MOUSE MODEL

IGREJA SÁ, I. C.,¹ PRAŠNICKÁ, A.,¹ LAŠTŮVKOVÁ, H.,² HROCH, M.,³ HYŠPLER, R.,⁴ DOLEŽELOVÁ, E.,¹ MIČUDA, S.,² NACHTIGAL, P.¹

¹ Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Czech Republic

³ Department of Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Czech Republic

⁴ Department of Research and Development, University Hospital in Hradec Králové, Czech Republic
e-mail: igrejasi@faf.cuni.cz

Plasma concentrations of soluble endoglin (sEng) are increased in cardiovascular and metabolic diseases associated with hypercholesterolemia, which affect liver functions. Previously, we showed that high sEng plasma levels affect cholesterol and bile acids (BA) homeostasis based on complex liver and intestinal effects. Therefore, the aim of the present study was to investigate effects of high levels of sEng on cholesterol and BA metabolism in liver upon induction of non-alcoholic steatohepatitis (NASH). Three-months-old wild-type and transgenic male mice overexpressing human sEng were fed for 6 months with high fat diet (HFD) enriched with cholesterol and fructose or chow diet and underwent *in vivo* study with plasma and bile collection. Plasma biochemical analysis, LC/MS of plasma BA and histology were performed. Expression of enzymes and transporters in liver were assessed by qRT-PCR and Western blot. HFD significantly increased body and liver weight, and analysis of liver tissue confirmed NASH by presence of steatosis, fibrosis, oxidative stress, increased activity of ALP and ALT, and hypercholesterolemia in both HFD groups. However, high sEng levels did not significantly modulate development of diet-induced NASH and associated changes in cholesterol and BA metabolism in mice.

The study was supported by the Ministry of Health of the Czech Republic (Project No. 150/52/75201), by the Grant Agency of Charles University (Project No. 1166119) and from the project of Specific Academic Research (SVV 260 414/2019).

ENDOGLIN MODULATES ADHESION AND TRANSMIGRATION OF MONOCYTES IN OXYSTEROL INDUCED ENDOTHELIAL DYSFUNCTION

VICEN, M.,¹ HAVELEK, R.,² MACHÁČEK, M.,³ TRIPSKÁ, K.,¹ VITVEROVÁ, B.,¹ NACHTIGAL, P.¹

¹ Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Czech Republic

³ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic
e-mail: vicenm@faf.cuni.cz

Endoglin (CD105, TGF- β RIII receptor) is essential for proper function of endothelium, but participates also in inflammatory infiltration of monocytes. We hypothesized that endoglin play crucial role in monocyte adhesion and transmigration via endothelial cells when exposed to oxysterol simulating oxidized LDL effects in atherogenesis. HAECs were exposed to 7K (5, 10 μ g/mL) for 12 hours. Gene expression (endoglin, KLF6, RELA (NF- κ B p65), NR1H3 (LXR), ICAM-1) was evaluated using qRT-PCR. Protein levels of endoglin, ICAM-1 and P/E-selectins were evaluated by flow cytometry analysis. Protein levels and localization of RELA, eNOS, p-eNOS was evaluated using confocal fluorescent microscopy. Gene expression and protein levels of endoglin, eNOS, p-eNOS and cell adhesion molecules (ICAM-1, E/P-selectin) as well as transcription genes regulating endoglin expression were significantly increased after premedication with 7K compared to non-treated cells. Inhibition of transcription factors (KLF6, RELA, NR1H3 resulted in inhibition of 7K induced increase of endoglin expression. 7K was able to increase adhesion and transmigration of THP-1 monocytes, through endothelial cells monolayer. Silencing of endoglin in HAECs inhibited adhesion and transmigration of THP-1 monocytes. In this study, we demonstrated that 7K is able to induce inflammation and increase endoglin expression in endothelial cells via activation of KLF6, RELA and NR1H3 transcription genes. Moreover, we showed that 7K induced adhesion and transmigration of monocytes through endothelial monolayer depends on the expression of endoglin suggesting that endoglin might play crucial role in cholesterol (oxysterol) induced endothelial dysfunction.

This study was supported by project EFSA-CDN (No. CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF, by the Grant agency of Charles University (Project No. 1216217), by the Czech health research council (Project No. 17-31754A), and from the project of Specific Academic Research (SVV 260 414/2019).

ENDOGLIN EXPRESSION, SIGNALIZATION AND FUNCTION IN INFLAMMATION INDUCED ENDOTHELIAL DYSFUNCTION

TRIPSKÁ, K.,¹ VICEN, M.,¹ HAVELEK, R.,² NACHTIGAL, P.¹

¹ Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

Endoglin (Eng) expression is linked to regulation of endothelial nitric oxide synthase (eNOS) in endothelial cells resulting in proper function of endothelium. On the other hand, it was proposed that Eng also participates in inflammatory infiltration of leukocytes through endothelium and thus plays negative role in endothelial dysfunction. We aimed at evaluating Eng expression, signalization and function related to endothelial dysfunction induced by proinflammatory tumour necrosis factor alpha (TNF- α) in human aortic endothelial cells (HAECs). HAECs were treated with 10 ng mL⁻¹ TNF- α for 12 h. The mRNA expression of Eng, eNOS, adhesion molecules (ICAM-1, VCAM-1) and transcription factors (KLF6, NF- κ B, p65 and LXR- α) was measured with qRT-PCR. Protein levels of membrane Eng, ICAM-1, VCAM1, P/E-selectin and MMP-14 were measured by flow cytometry and soluble endoglin (sEng) levels by ELISA. Transmigration assay was performed using Nunc cell culture inserts. TNF- α treatment decreased mRNA expression and protein levels of Eng and eNOS. The mRNA expression and protein levels of cell adhesion molecules and MMP-14 were significantly increased as well as sEng levels. Interestingly, meanwhile mRNA expression of KLF6 and NF- κ B were increased; mRNA expression of LXR- α was decreased. TNF- α induced inflammation led to increased adhesion but not transmigration of monocytes through endothelial cells. We demonstrated that inflammation decreases endoglin expression, increases adhesion but does not affect transmigration of monocytes through aortic endothelial cells. Reduced expression of Eng and increased levels of sEng (that inhibits effects of membrane endoglin) might be responsible for no change in transmigration of monocytes under inflammatory conditions. We propose that Eng participates on the regulation of endothelial dysfunction during inflammation, but to which extent must be further investigated.

The study was supported by EFSA-CDN (No. CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF, by the Grant Agency of Charles University (Project. No. 1216217) and from the project of Specific Academic Research (SVV 260 414/2019).

THE TOXICITY OF ALANTOLACTONE AND GERMACRONE TOWARDS DIFFERENTIATED HepaRG CELLS AND THEIR INFLUENCE ON CHOLESTEROL METABOLISM

ZÁRYBNICKÝ, T., MATOUŠKOVÁ, P., BOUŠOVÁ, I.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: zarybnto@faf.cuni.cz

Sesquiterpenes alantolactone (ALA) and germacrone (GER) are naturally occurring molecules that are studied as potential anti-cancer agents. ALA is one of the major sesquiterpene lactone compounds isolated from the roots of *Inula helenium* (Asteraceae). GER

is a main bioactive constituent found in *Zedoary* oil extracted from *Curcuma zedoaria* Roscoe (Zingiberaceae). Both of these plants were used in traditional medicine historically. Using the differentiated HepaRG (dHepaRG) cells, a human hepatocyte-like model, we wanted to compare the toxicity towards dHepaRG cells in comparison with results published on highly proliferative cancer cell lines after ALA and GER treatment. Furthermore, a bioinformatic tool BATMAN-TCM¹ was searched for new molecular targets of tested sesquiterpenes. Analysis of their common targets led us to studying their effects on cholesterol metabolism and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a major regulatory enzyme in mevalonate pathway. HMGCR protein and mRNA expression were studied at multiple time points, concentrations, as well as single and multiple dose. HMGCR protein expression has shown inhibition after ALA and GER treatment, but mostly at the highest concentrations tested, equal to respective half-maximal inhibitory concentration of cell viability. The mRNA changes were much more variable and time and concentration dependent. The cholesterol level in dHepaRG cells was measured by Amplex Red Cholesterol Assay Kit in a multiple dose experiment in comparison to the model inhibitor lovastatin.

The study was supported by the Czech Science Foundation (Project No. 18-09946S) and from the project of Specific Academic Research (SVV 260 416/2019).

References

1. Liu, Z., Guo, F., Wang, Y. *et al.*: Sci. Rep. 2016, 6, art. 21146.

THE UDP-GLYCOSYLTRANSFERASES IN *HAEMONCHUS CONTORTUS* AND THE METABOLISM OF ANTHELMINTICS

DIMUNOVÁ, D., RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: dimunovd@faf.cuni.cz

UDP-glycosyltransferases (UGTs) are important enzymes in the metabolism of xenobiotics and eobiotics. Glycosylation is often the most important conjugation reaction catalyzed by these enzymes in drug metabolism. This reaction results in enhanced elimination of the drug from the organism. Increased expression of UGTs can cause reduction of pharmacotherapy efficiency and development of resistance to drugs. Our model organism is *Haemonchus contortus*, a gastrointestinal parasite of small ruminants that have a great ability to develop resistance to anthelmintic drugs. Our previous metabolism study showed that albendazole, ricobendazole and flubendazole underwent several glycosylation steps. Differences of glycosides quantities between resistant and sensitive strains confirmed the connection between anthelmintics metabolism and resistance.¹ In addition, some enzymes from the UGT superfamily, *e.g.* UGT368B2, are significantly more expressed in adult *H. contortus* of resistant strains than sensitive strains.² For functional characterization, the UGT368B2 was expressed in baculovirus-infected insect cells. However, the preliminary

results show that UGT368B2 cannot metabolize benzimidazole anthelmintics but steroids. This particular UGT has different role in the organism than biotransformation of xenobiotics (e.g. benzimidazoles). Revealing the features of UGTs from *H. contortus* (e.g. affinity to hexose or to different substrate) could contribute to a more detailed understanding of the reaction's mechanism catalyzed by these enzymes and their role in helminths.

This study was supported by the Czech Science Foundation (Project No. 17-11954Y), by Charles University (PRIMUS/17/SCI/04) and from the project of Specific Academic Research (SVV 260 416/2019).

References

1. STUHLÍKOVÁ, L. R., MATOUŠKOVÁ, P., VOKŘÁL, I. *et al.*: Int. J. Parasitol. Drugs Drug Resist., 8, 2018, 50–58.
2. MATOUŠKOVÁ, P., LECOVÁ, L., LAING, R. *et al.*: Int. J. Parasitol. Drugs Drug Resist. 8, 2018, 420–429.

PROFILING MicroRNA EXPRESSION IN SUSCEPTIBLE AND RESISTANT STRAINS OF *HAEMONCHUS CONTORTUS* USING SMALL RNA SEQUENCING

NGUYEN, L. T., MATOUŠKOVÁ, P., SKÁLOVÁ, L.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: nguyenli@faf.cuni.cz

The widespread development of anthelmintic resistance (AR) in *Haemonchus contortus* compromises treatment of helminthosis caused by this economically important parasite of small ruminants. The molecular mechanisms of AR are not fully elucidated. In our study, we focus on microRNAs (miRNAs) which are a class of small non-coding RNAs. MiRNAs play important role in post-transcriptional regulation of gene expression and their dysregulation has been linked to a range of different pathologies. A comprehensive understanding of the functions of miRNAs in AR might help us to develop better strategies to the sustainable parasite control. For this reason, we undertook the small RNA sequencing of *H. contortus* isolates with various level of resistance to anthelmintics, namely the susceptible strain, the benzimidazole resistant strain and the multi-drug resistant strain. Differential expression analysis revealed significantly up- or down- regulated miRNAs in adults of resistant strains in comparison to sensitive ones. Since cytochromes P450, UDP-glycosyltransferases and P-glycoproteins were reported to play role in drug resistance,¹ we investigated them as the putative targets of differentially expressed miRNAs using RNAhybrid software. Moreover, from the sequencing data, 207 sequences were defined as potential novel miRNAs using miRDeep2 program.

The study was supported by Charles University (PRIMUS/17/SCI0/4) and from the project of Specific Academic Research (SVV 260 416/2019).

References

I. MATOUŠKOVÁ, P., VOKŘÁL, I., LAMKA, J. *et al.*: Trends Parasitol., 32, 2016, 481–491.

METABOLIC PATHWAYS OF NEW POTENTIAL ANTHELMINTICS IN *HAEMONCHUS CONTORTUS* AND ITS HOST

ZAJÍČKOVÁ, M.,¹ NAVRÁTILOVÁ, M.,¹ NGUYEN, L. T.,¹ PRCHAL, L.,²
STUHLÍKOVÁ, R. L.,¹ KELLEROVÁ, P.,¹ SKÁLOVÁ, L.¹

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Biomedical Research Centre, University Hospital in Hradec Králové, Czech Republic
e-mail: zajickm@faf.cuni.cz

Haemonchus contortus is one of the most important parasitic nematodes of small ruminants with worldwide distribution causing significant losses to many farmers. Anthelmintic drugs still represent the main strategy to control burdens of *H. contortus*. Unfortunately, widespread resistance to available anthelmintics makes treatment difficult. Therefore, there is a global need for new and effective anthelmintic drugs. Two newly synthesized compounds HBK4 and BLK127 as well as already registered antidepressant drug sertraline are promising candidates for new anthelmintics. It is known that drug resistance is associated with accelerated drug metabolism and for this reason we would like to compare biotransformation of HBK4, BLK127 and sertraline in drug-resistant and drug-sensitive strains of *H. contortus*. In addition, we will also monitor biotransformation and hepatotoxicity of these compounds in ovine liver.

The study was supported by the Charles University Grant Agency (Project No. 1568519) and from the project of Specific Academic Research (SVV 260 416/2019).

CIRCULATION OF ANTHELMINTICS IN THE ENVIRONMENT

NAVRÁTILOVÁ, M., STUHLÍKOVÁ, R. L., SKÁLOVÁ, L.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: navratimart@faf.cuni.cz

Several ways can cause drug resistance in sheep breeding. Our project monitors the intake of a residual amount of the albendazole (ABZ) and its transformation products (TPs) during grazing of sheep.

Our preceding studies showed the ability of plants to uptake and metabolize anthelmintics such as benzimidazole, macrocyclic lactones and amino-acetonitrile derivatives in six plant species. Plant derived metabolites can be considered as deactivation products, but some of them show even higher anthelmintic effectiveness than the parent compound. Moreover, a lot of anthelmintic metabolites (especially glycosides) can be converted back

to parent compound through enzymatic or acidic hydrolysis in the gastrointestinal tract of grazing animals. In the case of infected animals, nematodes thus might be exposed to very low doses of anthelmintics and this phenomenon could help to increase the anthelmintic resistance.

This project simulates such a situation and monitors the occurrence of residues of ABZ and TPs in biological samples collected from ten domestic sheep (*Ovis aries*). In the pilot study naive sheep (without nematodes) were used. Two species of meadow plants *Medicago sativa* and *Trifolium pratense*, common plants on pastures, were chosen. An experimental field area with these plants was fertilized by excrements from ABZ treated sheep (different flock of sheep) in spring 2019.

ABZ and TPs have been found in the fertilized plants and in related soil too, after two months from fertilization. Furthermore, these plants were administered to the sheep for ten days and during that time samples of abomasum content, faeces, and plasma were collected in different time intervals. ABZ and the main TPs, ABZ-sulfone, and ABZ-sulfoxide, were detected in all samples. UHPLC-MS/MS was used for qualitative and quantitative analyses.

The study was supported by the Czech Science Foundation (Project No. 18-07724S), and from the projects of Specific Academic Research (SVV 260 416/2019 and 260 412/2019).

EFFECT OF ANTHELMINTIC RESIDUES ON TRANSCRIPTION LEVEL OF BIOTRANSFORMATION ENZYMES

KELLEROVÁ, P., MATOUŠKOVÁ, P., NAVRÁTILOVÁ, M., ŠTĚRBOVÁ, K.,
STUHLÍKOVÁ RAISOVÁ, L., SKÁLOVÁ, L.

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: voborilp@faf.cuni.cz

Anthelmintics, the only effective treatment of devastating infection diseases of animals caused by parasitic helminths, have been widely and heavily distributed all over the world. In the agriculture, the most used classes of anthelmintics are benzimidazoles, macrocyclic lactones, imidazothiazoles and amino-acetonitrile derivatives. Parasitic helminths, especially nematodes, have developed resistance to all of them. In front of all parasites stands *Haemonchus contortus*, as the quickest nematode in resistance development. This hematophagous parasite living in sheep abomasum and causing enormous losses in animals' production, is well studied for mechanisms of resistance development. *H. contortus* prosper with very effective detoxification system via biotransformation enzymes and can relatively quickly react to constant usage of anthelmintic drugs. In our current studies we observed that even very low – sublethal concentrations of anthelmintics, that may be preserved in environment, can cause up and down regulation of biotransformation enzymes on transcription levels. Furthermore, the analysis of albendazole metabolites showed enhanced biotransformation after preincubation in sublethal concentrations of albendazole.

The study was supported by the Czech Science Foundation (Project No. 18-07724S), by Charles University projects (PRIMUS/17/SCI/04 and UNCE/18/SCI/012) and from the project of Specific Academic Research (SVV 260 416/2019).

PRELIMINARY RESULTS OF ANTI-INFLAMMATORY ACTIVITY IN SELECTED FERN SPECIES

PAVIČIČ, A.,^{1,2} SZOTÁKOVÁ, B.,¹ LANGHANSOVÁ, L.²

¹ Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Institute of Experimental Botany, Czech Academy of Sciences, Prague, Czech Republic
e-mail: pavicia@faf.cuni.cz

Ferns are a potential source of bioactive phytochemicals and based on our previous research, we tested selected species for the anti-inflammatory activity. The crude methanol extracts were screened at a concentration of 10 µg mL⁻¹ for inhibitory activity against pro-inflammatory enzymes cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX). The COX-1 inhibitors have been reported as effective in the prevention of neuroinflammatory or cardiovascular diseases¹ and several tumours.² COX-2 is considered as a key pro-inflammatory enzyme, over-expressed in most sites of inflammation and responsible for the characteristic inflammatory symptoms (redness, pain, edema, fever and loss of functions).² 5-LOX inhibitors have been reported to play a role in the prevention of tumours, allergic disorders and asthma.² Our results revealed that the most fern species have potential in selective COX-1 inhibitory activity. Significant inhibition of COX-1 was measured in *Dryopteris cambrensis* (92.46%) and *Athyrium distentifolium* (91.18%). Only a few fern species revealed moderate inhibition to COX-2 (*Dryopteris expansa* and *Dryopteris aemula*). Significant 5-LOX inhibitory activity was measured in *Onoclea sensibilis* (71.06%) and *Dryopteris caucasica* (68.32%). Our results reveal several European ferns as a potential source of anti-inflammatory compounds.

The study was supported from the project of Specific Academic Research (SVV 260 416/2019).

References

1. PERRONE, M. G., SCILIMATI, A., SIMONE, L. *et al.*: *Curr. Med. Chem.*, 17, 2010, 3769–3805.
2. CHARLIER, C., MICHAUX, C.: *Eur. J. Med. Chem.*, 38, 2003., 645–659.

DETERMINATION OF TOXICITY OF BRAF INHIBITORS *IN VITRO*

MAIXNEROVÁ, J., HYRŠOVÁ, L., TREJTNAR, F.

Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: maixj6a1@faf.cuni.cz

Malignant melanoma belongs to the most serious skin diseases nowadays. However, treatment of advanced melanoma is difficult and ineffective. A significant part of melanomas exhibits a mutation of the gen for oncogenic BRAF kinase, which is responsible for stimulation of proliferation and surviving of cancer cells. These melanomas can be treated using novel therapeutic approach encompassing specific BRAF inhibitors dabrafenib or vemurafenib.¹ Available clinical studies indicate that the toxic effect of the BRAF inhibitors is focused primarily on podocytes localized in the glomerular membrane. Our study is focused on evaluation of cytotoxic effect of BRAF inhibitors on selected model renal cells *in vitro* to confirm the renal target of toxicity. Main aim was to analyze whether renal toxic effect of BRAF inhibitors is specifically limited only to the podocytes or other renal cells may be damaged. The experiments were performed using human cell lines representing different types of kidney cells (HEK-293, PODO/TERT256, HK-2) and standard liver cell line HepG2 as a comparator. Amphotericin B and paracetamol were employed as comparative toxins. The IC₅₀ values determined by analysis of inhibition curves were used for comparison. The found experimental data showed comparable toxic effect of the tested BRAF inhibitors in each used kidney cell line. However, vemurafenib exhibited significantly higher toxicity compared to dabrafenib. The *in vitro* toxicity of vemurafenib in all renal cell lines was even stronger than that of known renal toxin amphotericin B. The results may suggest that the toxic damage of kidney caused by BRAF inhibitors encompasses not only podocytes but also other kinds of kidney cells including renal tubular cells.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 414/2019).

References

1. RAHMAN, M. A., SALAJEGHEH, A., SMITH, R. A. *et al.*: Crit. Rev. Oncol. Hematol., 90, 2014, 220–232.

THE EFFECTS OF THE CIGARETTE SMOKE ON HUMAN SKIN AND POSSIBILITIES OF ITS PROTECTION

ŠULCOVÁ, K.,^{1,2} JAKUBÍKOVÁ, K.,² MAZUROVÁ, M.,² DOLEČKOVÁ, I.,² VÁVROVÁ, K.¹

¹ Skin Barrier Research Group, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Contipro a.s., Dolní Dobrouč, Czech Republic
e-mail: sulcovk3@faf.cuni.cz

Cigarette smoke (CS) represents a significant source of air pollution with negative effects on human health. CS is strongly associated with the number of pulmonary and cardiovascular diseases, but it also induces significant damage of the skin which is often neglected. In the skin, one of the negative impacts of the long-term exposure to CS is the skin barrier impairment, premature skin aging and development of skin diseases such as atopic dermatitis, psoriasis, acne, even skin cancer.

In this study we investigated the effect of CS on the skin using porcine cadaver auricular skin explants that are very similar to human skin. After application of the CS on the surface

of the skin samples, we observed significant negative changes in both the epidermis and dermis such as the presence of large amount of reactive oxygen species (ROS), oxidation of proteins and lipids, DNA damage, inhibition of collagen gene expression, upregulation of matrix metalloproteinase 1 and filaggrin and overall decrease in the skin cell viability.

Furthermore, this model was used to evaluate the ability of the selected compounds commonly used in cosmetics and dermatology with various mechanisms of action to prevent CS-induced skin damage. We tested several polysaccharides and their derivatives such as sodium hyaluronate (HA) of various molecular weight (MW: 1.7 MDa, 500 kDa, 15 kDa, 5 kDa), carboxymethyl-glucan, schizophyllan, glucomannan; then sodium ascorbyl phosphate (vitamin C), niacinamide (vitamin B3) and D-panthenol (provitamin B5). After incubation of the skin explants with the tested compounds and subsequent exposure to CS, the level of ROS and peroxidation of the skin barrier lipids together with gene expression of the proinflammatory cytokine IL-6 were determined. All the tested substances significantly protected the skin against CS from which the most effective was vitamin C due to its strong antioxidant properties and 1.7 MDa HA with its ability to create a protective film on the skin surface. The film-forming properties of HA were MW-dependent and correlated with its protective effect which both decreased with lower MW.

The results show that the exposure of the skin to CS leads to the significant skin damage which can be effectively prevented using some conventional cosmetic and dermatological ingredients with various mechanisms of action.

In the second part of our research we investigated the differences between the epidermis of smokers and non-smokers. For this experiment we used samples of the epidermis obtained by suction-blister technique from volar forearm of smoking (history of smoking min 15 years, min 15 cigarettes/day) and non-smoking women. We performed cDNA microarray analysis for the determination of the gene expression profile of the epidermis of smokers and non-smokers. Significant differences were observed in the expression level of the number of genes with various functions. In the epidermis of smokers, we found significant upregulation of genes involved in the epidermal differentiation complex which was also confirmed using qRT-PCR and on the protein level.

The study was supported by the Grant Agency of Charles University (Project No. 332119) and from the project of Specific Academic Research (SVV 260 401/2019).

CLINICAL AND SOCIAL PHARMACY SECTION

ANALYSIS AND MANAGEMENT OF NURSES' MEDICATION ERRORS DURING DRUG ADMINISTRATION

MĚRKOVÁ, V., MALÁ-LÁDOVÁ, K., MALÝ, J., KUBĚNA, A., DOSEDĚL, M., VLČEK, J.

Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic
e-mail: merkovav@faf.cuni.cz

Improving safety is currently one of the priorities in the field of healthcare provision. Medication errors during drug administration (DAMES) are quite frequent abroad.¹ In the Czech Republic, data resulting from the reporting of adverse drug events are rather underestimated or missing. The aim of this study is to analyze the occurrence of nurses' DAMES, propose appropriate interventions to minimize DAMES and assess their effectiveness.

In a prospective interventional study, trained pharmacists observed nurses' DAMES on seven wards of an inpatient rehabilitation healthcare facility. During April 2018, baseline prevalence and types of DAMES were determined. Patient risk assessment was performed in order to identify serious DAMES. An intervention phase was conducted in February and March 2019, including repeated discussions with healthcare professionals and facility management, adjustment of internal guidelines, printed educational materials, and seminars. In May 2019, a postinterventional observation of nurses' DAMES took place to evaluate the effectiveness of interventions. Data were processed in Wolfram Mathematica using descriptive statistics and chi-square test.

During the baseline and postinterventional observations, 4661 and 4386 individual drug administrations were monitored, respectively. The total number of DAMES was significantly reduced from 918 (19.70%) to 148 (3.37%) ($p < 0.001$). The prevalence of serious DAMES (e.g., administration of the wrong drug) decreased from 0.45% to 0.20% of all individual drug administrations.

As a result of interventions, DAMES were decreased. The sustainability of the interventions will be monitored within one year.

The study was supported from the project of Specific Academic Research (SVV 260 417/2019).

References

1. KEERS, R. N., WILLIAMS, S. D., COOKE, J. *et al.*: *Ann. Pharmacother.*, 47, 2013, 237–256.

DRUG-RELATED HOSPITAL ADMISSIONS FOLLOWING EMERGENCY DEPARTMENT VISIT: A CROSS-SECTIONAL STUDY

OČOVSKÁ, Z.,¹ MAŘÍKOVÁ, M.,^{1,2} VLČEK, J.^{1,2}

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital in Hradec Králové, Czech Republic
e-mail: ocovskaz@faf.cuni.cz

Drug-related hospital admissions (DRA) have attracted much research attention worldwide. The aims of this study are to determine the prevalence and preventability of DRA, to identify the implicated medications in DRA and to examine the preventability aspects of DRA. The methodology of this cross-sectional observational study draws upon the drug-related admissions adjudication guide developed by Thevelin *et al.*¹ In the first step, relevant clinical data are abstracted into an Access database. The second step includes

screening for potential adverse drug events which are the main or contributory reason for hospital admissions. The third step is drug-related admission adjudication process, which consists of causality assessment and assessment of contribution to hospital admission. Hospital admissions to University Hospital Hradec Králové in 2018 following emergency department visit are included in this study. So far, 879 hospital admissions have been included, and 147 DRA have been identified (112 related to treatment safety, 35 related to treatment effectiveness). The prevalence of DRA was 16.7% (95% CI 14.3–19.2). Anti-thrombotic agents, psycholeptics, analgesics, antiinflammatory and antirheumatic products and corticosteroids for systemic use represented the most common medication classes involved in DRA related to treatment safety. Diuretics, antihypertensives, drugs used in diabetes, antithrombotic agents and antibacterials for systemic use represented the most common medication classes involved in DRA related to treatment effectiveness.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 417/2019).

References

1. THEVELIN, S., SPINEWINE, A., BEUSCART, J.-B. *et al.*: Br. J. Clin. Pharmacol., 84, 2018, 2600–2614.

MATERNAL NUTRITIONAL INTAKE IN RELATIONSHIP WITH PREGNANCY OUTCOMES IN CZECH PREGNANT WOMEN

NAJPAVEROVÁ, S.,¹ KOVAŘÍK, M.,¹ KAČEROVSKÝ, M.,² HRONEK, M.¹

¹ Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

² Department of Obstetrics and Gynaecology, University Hospital in Hradec Králové, Czech Republic
e-mail: najpaves@faf.cuni.cz

Optimal maternal nutrition contributes to the maintenance of homeostasis of pregnant organism and promotes proper fetal development. The aim of the study was to evaluate the nutritional intake of energy and macronutrients (PNEM) in relation to resting energy expenditure (REE) and birth parameters in Czech pregnant women throughout the pregnancy, which has not been well known. Sixty-five healthy Czech pregnant women with age of 29 years, height of 166.5 cm and weight 67.8 kg in average attended our study. REE measurements were recorded after 12 h fasting, by indirect calorimetry in three periods: G1 (17–27 gestational week), G2 (28–35 gw.) and G3 (36–38 gw.). PNEM was obtained in weekly records and nutritional analysis was performed by the computer program NutriDan. PNEM, expressed per kilogram of woman's weight, was significantly related to REE. Energy intake decreased with increasing of pregnancy state (2061 kcal per day, 1965 kcal per day, 1962 kcal per day). Decreasing trends were reported in the areas of protein (79.91 g, 75.63 g, 73.94 g), fat (76.66 g, 75.06 g, 72.4 g) and carbohydrates (239.6 g, 223.3 g, 225.2 g) intake. In all trimesters, PNEM significantly correlated with the birth weight of the newborn ($p < 0.001$). In the 2nd trimester, PNEM positively associated with the birth length ($p < 0.01$) and negatively (except for carbohydrates) with the duration of labour ($p < 0.01$).

Increased PNEM in the last trimester was significantly associated with a shortening of the pregnancy period ($p < 0.01$).

Intake of nutritional energy and macronutrients significantly affects energy expenditure and correlates with birth parameters in all trimesters of pregnancy.

The study was supported by the Grant Agency of Charles University (Project No. 1306218), by Research programme Development and Study of Drugs (Progres Q42), by Ministry of Health of the Czech Republic – conceptual development of research organization (UHHK, 00179906) and from the project of Specific Academic Research (SVV 260 417/2019).

DEVELOPMENT, IMPLEMENTATION AND TESTING OF MEDICATION ADHERENCE ENHANCING INTERVENTION IN KIDNEY TRANSPLANT OUTPATIENTS: EFFECTIVENESS–IMPLEMENTATION STUDY (TAKTIS)

VAŇKOVÁ, B.,¹ MALÁ-LÁDOVÁ, K.,² DUSILOVÁ-SULKOVÁ, S.,³ MALÝ, J.⁴

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Haemodialysis Centre, University Hospital in Hradec Králové, Czech Republic
e-mail: vankovb@faf.cuni.cz

Patients after kidney transplantation (KTx) are on long-term immunosuppression with an emphasis on strict medication adherence. Nonadherence to immunosuppression, which in KTx setting means mainly during implementation phase (*e.g.* dosing, timing), leads to poor clinical and economical outcomes. This sub-study is a part of a multiphase project TAKTIS (developing, implementing, and testing an integrated care model for adults after KTx). The ongoing project is single-centre, prospective and interventional. As a part of contextual analysis, this sub-study aimed at evaluating the prevalence of nonadherence and attitudes toward immunosuppression. All adults at least 4 weeks after KTx were included, who were on basal immunosuppression and signed a written consent with study participation. Data was collected using questionnaires, *e.g.* Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS-CZ[®]); specific subscale of Beliefs about Medicine Questionnaire (BMQ-CZ[®]) and a review of medical charts, *e.g.* immunosuppressives blood levels. Of 415 patients in regular follow up, 390 met inclusion criteria and 359 (92% of 390) patients fulfilled the questionnaires. Main measured immunosuppressives were tacrolimus, cyclosporine, sirolimus, and everolimus in 238, 79, 46, and 4 cases, respectively. According to BAASIS-CZ[®], 133 (37% of 359) patients were nonadherent with deviations in taking (45; 12.5%), timing (118; 32.9%), and dosing (3; 0.8%). One patient completely discontinued to take all immunosuppression. Mean necessity score was 4.3 ± 0.57 of 5.0 points (= maximal necessity) and mean concern score was 2.6 ± 0.71 of 5.0 (= maximal concerns). To conclude, prevalence of medication nonadherence in implementation phase was high among patients after KTx with the most frequent deviation in

timing of immunosuppression. This information is essential in contextual analysis needed for TAKTIS care model development.

The study was supported from the project of Specific Academic Research (SVV 260 417/2019).

ANALYSIS OF DRUG-RELATED PROBLEMS IN PATIENTS AFTER KIDNEY TRANSPLANTATION

VAŇKOVÁ, B.,¹ DVOŘÁČKOVÁ, S.,¹ MALÁ-LÁDOVÁ, K.,¹
DUSILOVÁ-SULKOVÁ, S.,² MALÝ, J.¹

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Haemodialysis Centre, University Hospital in Hradec Králové, Czech Republic
e-mail: dvoracsi@faf.cuni.cz

Patients after kidney transplantation (KTx) in care of nephrologist and other specialists are specific by polypharmacy, long-term immunosuppression and changed renal functions, so they may be at increased risk of drug-related problems (DRPs). The aim of this study was to analyze the prevalence of DRPs and to determine the riskiest areas of their pharmacotherapy. This cross-sectional study was conducted at the University Hospital in Hradec Králové in the Czech Republic. All outpatients aged ≥ 18 years, at least 3 weeks after KTx treated by maintenance immunosuppression were included. Data were collected during one-year period (2016–2017) from electronic medical records. Personal, family, occupational, allergic and drug related anamnestic data, selected physical as well as laboratory parameters were collected in a pre-created electronic database. The identified DRPs were classified according to the modified Pharmaceutical Care Network Europe classification V5.01 and their relevance was assessed by 2 pharmacists. The data was evaluated by descriptive statistics. Of the total of 412 outpatients at the clinic, 211 were enrolled (123 men; aged 55.8 ± 12.41). Patients were 6.6 ± 5.9 years after KTx and used in average 11.3 drugs/patient/day. The total of 668 DRPs were identified, which was equivalent to 3.17 DRPs/patient. Most frequent DRPs were missing of clearly indicated drugs in 27.4% (e.g. calcium or vitamin D), inappropriate dose timing in 16.0% and no clear indication for the drug in 12.6% of DRPs (e.g. aspirin or gastroprotection). The most relevant DRPs (5.2%) were e.g. contraindicated (CI) combination of cyclosporin and simvastatin, duplicity of betaxolol, CI nitrofurantoin in relation to decreased renal function, etc. DRPs were common in KTx outpatients, the most prone was the long-term pharmacotherapy. Medication review conducted by pharmacists can effectively minimize DRPs and thus enhance safety of pharmacotherapy.

The study was supported from the project of Specific Academic Research (SVV 260 417/2019).

POTENTIALLY INAPPROPRIATE PRESCRIBING IN OLDER ADULTS IN CENTRAL AND EASTERN EUROPE AND ASSOCIATED RISK FACTORS – PRELIMINARY RESULTS OF TWO SYSTEMATIC LITERATURE REVIEWS

BRKIĆ, J.,¹ KUMMER I.,¹ POULÍKOVÁ K.,¹ FIALOVÁ, D.^{1,2}

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Geriatrics and Gerontology, 1st Faculty of Medicine, Charles University, Czech Republic
e-mail: jovanabrkcic37@gmail.com

Potentially inappropriate prescribing (PIP) in older adults is highly prevalent in Europe and risk factors (RFs) of PIP have been described by several studies.^{1,2,3,4} The aim of our study was to conduct two systematic literature reviews determining 1) the prevalence of PIP in Central and Eastern European Countries (CEECs) participating in the Horizon 2020 EUROAGEISM FIP7 project (Albania, Bulgaria, Croatia (HR), Czech Republic (CZ), Estonia, Lithuania, Serbia and Slovakia) and 2) to document social, economic and health-care-provision related RFs of PIP.

We searched in SCOPUS and MEDLINE databases (papers published by 2019) and included only primary studies published in English as full-texts. Of 146 and 2740 studies in primary literature search, 14 and 69 were selected using pre-defined criteria, respectively.

The prevalence of PIP ranged from 15.7% (CZ) to 68.8% (HR). In total, 72 RFs were analyzed. Among economic and social RFs “patients’ low income” reached the highest odds ratio (OR = 2.48 (1.82–3.39), $p < 0.001$) and “not having a partner” (OR = 1.50 (1.10–2.10), $p < 0.05$). Among care-related RFs these were “residency in long-term care institutions” and “admission to acute care” (OR = 2.29 (2.25–2.33), $p < 0.001$) and (OR = 3.35 (2.43–4.62), $p < 0.05$), respectively), as well as “care provided by non-geriatricians” (OR = 5.54 (1.62–18.89), $p = 0.01$) or “by more prescribers” (OR = 1.40 (1.29–1.51), $p < 0.001$).

The results create an important base for the started EUROAGEISM Horizon 2020 FIP7 project, assessing PIP in older adults in 10 European and other countries. This project supports the development of geriatric clinical pharmacy in different settings of care.

The study was supported by the EUROAGEISM H2020 project, FIP7 program (ITN-MSCF No764632), INOMED (Project No. CZ.02.1.01/0.0/0.0/18069/0010046) and from the project of Specific Academic Research (SVV 260 417/2019) and Research programme Development and Study of Drugs (Progres Q42) at the Department of Social and Clinical Pharmacy, Charles University – Scientific group “Ageing and Changes in the Therapeutic Value of Drugs in the AgeD” chaired by Assoc. Prof. Daniela Fialová, PharmDr., Ph.D.

References

1. MORIN, L., LAROCHE, M., TEXIER, G. *et al.*: J. Am. Med. Dir. Assoc., 17, 2016, 862.e1–862.e9.
2. TOMMELEIN, E., MEHUY, E., PETROVIĆ, M. *et al.*: Eur. J. Clin. Pharmacol., 71, 2015, 1415–1427.
3. SANTOS, A., SILVA, D., ALVES-CONCEICAO, V. *et al.*: J. Clin. Pharm. Ther., 40, 2015, 167–176.
4. FIALOVÁ, D., LAFFON, B., MARINKOVIĆ, V. *et al.*: Eur. J. Clin. Pharmacol., 75, 2019, 451–466.

INITIAL EXPERIMENT WITH THE LEFT ATRIAL APPENDAGE OCCLUSION WITH THE AMPLATZER AMULET™

KOBLIŠKOVÁ, Z., HARAMIOVÁ, Z., TESAŘ, T.

Department of Organization and Management of Pharmacy, Faculty of Pharmacy in Bratislava, Comenius University, Slovak Republic
e-mail: kobliskova@fpharm.uniba.sk

Atrial fibrillation is the most common rhythm disorder in clinical practice. Stroke is one of the most severe thromboembolic disorders associated with atrial fibrillation.¹ The CHA₂DS₂VASc scoring system assess the risk of stroke in patients with atrial fibrillation.² Oral anticoagulation is recommended in atrial fibrillation patients at moderate to high risk of stroke and thromboembolism.³ The HAS-BLED scoring system evaluates the risk of bleeding in patients receiving anticoagulation therapy.⁴ Percutaneous left atrial appendage occlusion provides a treatment alternative for patients with atrial fibrillation at high risk of stroke in whom anticoagulation therapy is associated with high bleeding risk.⁵

Goals of our observational, retrospective, multi-centre, case-series study were: 1) describe the initial experience with the Amplatzer Amulet™ left atrium appendage occlusion in Slovakia; 2) evaluate the effectiveness and safety of the procedure in stroke prevention in patients with atrial fibrillation.

We analyzed 93 patients with atrial fibrillation at high risk of stroke undergoing left atrial appendage occlusion from June 2015 to October 2018. The mean patient age was 70.9 ± 8.6 years. The mean CHA₂DS₂VASc and HAS-BLED score was 4.4 ± 4.4 and 3.5 ± 0.9 , respectively. The left atrial appendage was successfully closed in 98.9% (92) of patients. The mean total procedural time was 110.4 ± 54.5 min. Periprocedural complications were observed in 5.4% (5) of patients. Three months after the procedure, small postprocedural leaks up to 3 mm were observed in 89.2% (83) of patients.

In this initial experience study, left atrial appendage occlusion was shown to be an effective and safe alternative to anticoagulation therapy in patients with atrial fibrillation at high risk of stroke for whom anticoagulation therapy is associated with high bleeding risk.

The study was supported by Faculty of Pharmacy, Comenius University, Bratislava.

References

1. KIRCHOF, P., BENUSSI, S., AHLSSON, A. *et al.*: Eur. Heart J., 37, 2013, 2893–2962.
2. OLESEN, J. B., LIP, G. Y. H., HANSEN, P. R. *et al.*: BMJ, 342, 2011, d124.
3. PISTERS, R., LANE, D. A., NIEUWLAAT, C. B. *et al.*: Chest., 138, 2010, 1193–1100.
4. APOSTOLAKIS, S., GUO, Y., BULLER, H. *et al.*: J. Am. Coll. Cardiology, 60, 2012, 861–870.
5. KIRCHOF, P., BENUSSI, S., AHLSSON, A. *et al.*: Eur. Heart J., 37, 2013, 2897–2899.

IMPACT OF A COMPUTERIZED PROTOCOL ON THROMBOPROPHYLAXIS USE IN GENERAL SURGERY: STUDY DESIGN

GAMBACORTA, J.,^{1,2} HORÁK, P.,^{3,4} VLČEK, J.^{1,5}

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² University Hospital in Motol, Prague, Czech Republic

³ First Faculty of Medicine, Prague, Charles University, Czech Republic

⁴ Hospital Na Bulovce, Prague, Czech Republic

⁵ University Hospital in Hradec Králové, Czech Republic

e-mail: gambacorta@faf.cuni.cz

A large proportion of hospitalized patients are at risk for venous thromboembolism (VTE), but there is a low rate of appropriate prophylaxis in clinical practice.¹ According to the American College of Chest Physicians (ACCP) guidelines, all hospitalized patients admitted in a surgical ward should be assessed for the risk of VTE.² Various strategies to improve the use of thromboprophylaxis have been recommended including the computerized systems.³ To our knowledge, there is no protocol standardization or any other active strategy leading to the appropriate thromboprophylaxis in surgical patients described in the Czech literature. In the past, there was also a lack of standardization in prescribing thromboprophylaxis to the surgical patients in our hospital. Therefore we decided to create and implement the VTE prophylaxis computerized protocol (VTEP-CP) as a decision support tool for physicians. After the protocol has been routinely used by physicians for several years, we decided to analyze the rate of compliance with the guidelines on VTE prophylaxis and to determine the incidence of VTE and major bleeding before and after implementation of VTEP-CP. The list of patients admitted in the surgical ward that underwent elective general surgery was provided through the hospital information system for a period of eleven months in 2012 (group A = before VTEP-CP implementation) and eleven months in 2014 (group B = before VTEP-CP implementation). We were able to obtain some of the required data of the patients in electronic form directly from the hospital information system and thus create a baseline database that we must now complete with the data from the patient medical records. Patients in group A are scored by the VTEP-CP using the data from the hospital admission form. For group B, the data from the VTEP-CP are used and also medical records are reviewed. The risk score, the dose and type of LMWH recommended by the VTEP-CP, the dose and type of LMWH administered to the patient and usage of mechanical prophylaxis is registered for both groups. We also review the documentation of patients for the diagnosis of VTE and signs or diagnosis of major bleeding.

In the presentation, we will discuss the study design, its limitations, and the possible benefit of the research in the field of clinical pharmacy.

The study was supported by Research programme Development and Study of Drugs (Progres Q42) and from the project of Specific Academic Research (SVV 260 417/2019)

References

1. COHEN, A. T., TAPSON, V. F., BERGMANN, J. F. *et al.*: Lancet, 371, 2008, 387–394.
2. GOULD, M. K., GARCIA, D. A., WREN, S. M. *et al.*: Chest, 141, 2012, e227S–e277S.
3. KUCHER, N., KOO, S., QUIROZ, R. *et al.*: N. Engl. J. Med., 74, 2005, 969–977.

NEUTROPHIL-TO-LYMPHOCYTE RATIO AND PROGNOSTIC INFLAMMATORY AND NUTRITIONAL INDEX AS THE PREDICTORS OF POSTOPERATIVE INFECTION AFTER KNEE OR HIP ARTHROPLASTY

DOMECKÝ, P.,¹ PÁTKOVÁ, A.,¹ KUČERA, T.,² PATEROVÁ, P.,³ ŠPONER, P.,² MALÝ, J.¹

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Orthopaedics, University Hospital in Hradec Králové, Czech Republic

³ Department of Clinical Microbiology, University Hospital in Hradec Králové, Czech Republic
e-mail: domeckyp@faf.cuni.cz

Surgical site infection (SSI) is a potential complication of all surgical procedures and also the second most common type of nosocomial infection. The very presence of SSI leads to an increase in mortality. In patients with developed infection who underwent a surgical procedure, there is double mortality compared to non-infected patients. SSI prevalence may be reduced by various preoperative and postoperative measures. One of the ways in which SSI is affected is antibiotic prophylaxis (AP). It is desirable to adjust AP length for arthroplasty, according to individual SSI risk estimated by appropriate processes. The aim of this study is to stratify patients based on the risk of postoperative infection and to verify the findings in clinical practice on the basis of examinations focusing mainly on laboratory tests, especially neutrophil-to-lymphocyte ratio (NLR) and prognostic inflammatory and nutritional index (PINI). NLR is an easily verifiable, easy, broadly robust, and appropriate laboratory test. Neutrophil levels in the blood are increased due to cytokines, while lymphocyte counts are reduced by surgical trauma. The increase occurs within 2 days after surgery and the return to physiological values takes place in a matter of days. It depends on the nutritional status of the patient, therefore its use in combination with PINI seems appropriate. These properties have been demonstrated in the diagnosis of cardiovascular diseases. In 2020, we plan to perform a prospective interventional study with an approximate number of 300 patients. In addition to the systematic literature review, we will collect patient and surgical procedure data before, during and after surgery. The usability of NLR and PINI will be evaluated with the postoperative complication analysis. Complications will be monitored 28–35 days after the surgery. Regarding these results, the interventions will be arranged to optimize and individualize the use of AP.

The study was supported from the project of Specific Academic Research (SVV 260 417/2019).

AVAILABILITY OF INFORMATION ON LOWER GERIATRIC DOSING
OF POTENTIALLY INAPPROPRIATE MEDICATIONS (PIM_S)
IN NATIONAL DRUG FORMULARIES AND SUMMARY
OF PRODUCT CHARACTERISTICS (SPC_S)

APOSTOLI, P.,¹ MANFREDI, R.,² GREŠÁKOVÁ, S.,¹ BRKIĆ, J.,¹ FIALOVÁ, D.^{1,3}

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Faculty of Pharmacy in Bologna, Alma Mater Studiorum University of Bologna, Italy

³ Department of Geriatrics and Gerontology, First Faculty of Medicine in Prague,
Charles University, Czech Republic
e-mail: apostolpr@faf.cuni.cz

One of the main public health concerns nowadays is the appropriate prescribing for older patients.¹ The concept of potentially inappropriate medications in the aged (so called PIMs –medications having higher risks than benefits in older adults or potentially ineffective in the aged) was defined to better ensure the medication safety in older adults.² The aim of our study was to clarify for how many PIMs (potentially inappropriate medications) geriatric dosing is stated in official drug information sources. Information on recommended single and daily geriatric dose for all PIMs (364) identified by expert panels in different explicit criteria was searched between March and May 2019 using AIFA website (Agenzia Italiana del Farmaco), BNF (British National Formulary) and US PDR (US Prescriber's Drug Reference). The same single dose for middle age and geriatric population was found in all SPCs for 234 (64.3%) PIMs, lower single dose for geriatric patients was clarified for 61 (16.8%) PIMs in all SPCs and for 19 (5.2%) in some SPCs. For daily geriatric dosing, 3 above stated results were 212 (58.2%), 69 (19.0%) and 33 (9.1%), respectively. For 50 (13.7%) PIMs no information was found about specific approaches in geriatrics and for 6.9% PIMs only “general warnings to be more cautious in older adults” were available. Recommendation of geriatric dosing was stated in less than 30% of SPCs of PIMs. In the majority of SPCs, the geriatric dose was not clarified. Therefore, new evidence on appropriate geriatric dosing from clinical and/or observational studies is needed to clarify specific aspects of the use of PIMs (indications, single and daily dosing) in order to better ensure higher safety of medications in geriatric patients.

The study was supported by INOMED (Project No. CZ.02.1.01/0.0/0.0/18069/0010046), EU COST Action IS1402, EUROAGEISM H2020 project (ITN-MSCFNo764632), from the project of Specific Academic Research (SVV 260 417) and Research programme Development and Study of Drugs (Progres Q42) at the Department of Social and Clinical Pharmacy, Charles University – Scientific group “Ageing and Changes in the Therapeutic Value of Drugs in the AgeD” chaired by Assoc. Prof. Daniela Fialová, PharmDr., Ph.D.

References

1. REMON-GUITERAS, A., MEYER, G., THÜRMAN, P. A.: Eur. J. Clin. Pharmacol., 71, 2015, 861–875.
2. FIALOVÁ, D., LAFFON, B., MARIANKOVIĆ, V. *et al.*: Eur. J. Clin. Pharmacol., 75, 2019, 451–466.

SPECIFICITY OF THE EU(7)-PIM LIST OF POTENTIALLY
INAPPROPRIATE MEDICATIONS FOR THE EVALUATION
OF RATIONALITY OF DRUG PRESCRIBING IN OLDER ADULTS
IN EUROPEAN COUNTRIES

GREŠÁKOVÁ, S.,¹ BRKIĆ, J.,¹ APOSTOLI, P.,¹ REISSIGOVÁ, J.,² FIALOVÁ, D.^{1,3}

¹ Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové,
Charles University, Czech Republic

² Department of Statistical Modelling, Czech Academy of Sciences, Prague, Czech Republic

³ Department of Geriatrics and Gerontology, First Faculty of Medicine in Prague,
Charles University, Czech Republic
e-mail: gresakova.silvia@faf.cuni.cz

The EU(7)-PIM (potentially inappropriate medication) list presents nowadays the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe.^{1,2} The aim of our study was to determine the specificity of EU(7)-PIM list in ten European countries.

Research teams from Czech Republic, Croatia, Estonia, Hungary, Poland, Serbia, Slovak Republic, Spain, Portugal, and Turkey participated in this study conducted by WG1b group of the EU COST Action IS1402 initiative. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug regulatory authorities in the period October 2015 – November 2018. The EU(7)PIM list was applied in this study as a research tool.

Approval rates for EU(7)-PIMs ranged from 39.0% in Estonia to 71.4% in Spain. Higher percentages of approved PIMs were documented in Spain (71.4%), Turkey (67.5%), Portugal (67.1%), and Poland (60.6%), lower in Hungary (55.5%), Czech Republic (51.1%), Slovak Republic (47.9%), Serbia (42.8%), Croatia (41.5%) and Estonia (39.0%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8–21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4–48.1%).

Applicability of the EU(7)-PIM list is limited in some countries. The EU project EURO-AGEISM H2020 (2017–2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.

The study was supported by the EU COST Action IS1402, EUROAGEISM H2020 project (ITN-MSCF No764632), INOMED (Project No. CZ.02.1.01/0.0/0.0/18069/0010046), from the project of Specific Academic Research (SVV 260 417/2019) and Research programme Development and Study of Drugs (Progres Q42) at the Department of Social and Clinical Pharmacy, Charles University – Scientific group “Ageing and Changes in the Therapeutic Value of Drugs in the AgeD” chaired by Assoc. Prof. Daniela Fialová, PharmDr., Ph.D.

References

1. RENOM-GUITERAS, A., MEYER, G., THÜRMAN, P. A.: Eur. J. Clin. Pharmacol., 71, 2015, 861–875.
2. FIALOVÁ, D., BRKIĆ, J., LAFFON, B. *et al.*: Ther. Adv. Drug Saf., 10, 2019, art. 2042098619854014.

BIBLIOGRAPHY

PUBLICATIONS OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ, CHARLES UNIVERSITY IN THE YEAR 2017

ORIGINAL PAPERS AND REVIEWS

- AFONSO-OLIVARES, C., ČADKOVÁ, T., SOSA-FERRERA, Z., SANTANA-RODRÍGUEZ, J. J., NOVÁKOVÁ, L.: Simplified solid-phase extraction procedure combined with liquid chromatography tandem-mass spectrometry for multiresidue assessment of pharmaceutical compounds in environmental liquid samples. *Journal of Chromatography A*, 1487, 2017, 54–63.
- ALEXOVIČ, M., HORSTKOTTE, B., ŠRÁMKOVÁ, I., SOLICH, P., SABO, J.: Automation of dispersive liquid-liquid microextraction and related techniques. Approaches based on flow, batch, flow-batch and in-syringe modes. *Trends in Analytical Chemistry*, 86, 2017, 39–55.
- ALI, B. H., CAHLÍKOVÁ, L., OPLETAL, L., KARACA, T., MANOJ, P., RAMKUMAR, A., AL SULEIMANI, Y. M., AL ZA'ABI, M., NEMMAR, A., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., LOČÁREK, M., SIATKA, T., BLUNDEN, G.: Effect of aqueous extract and anthocyanins of calyces of *Hibiscus sabdariffa* (Malvaceae) in rats with adenine-induced chronic kidney disease. *Journal of Pharmacy and Pharmacology*, 69 (9), 2017, 1219–1229.
- AMBROŽ, M., MATOUŠKOVÁ, P., SKARKA, A., ZAJDLOVÁ, M., ŽÁKOVÁ, K., SKÁLOVÁ, L.: The effects of selected sesquiterpenes from *Myrica rubra* essential oil on the efficacy of doxorubicin in sensitive and resistant cancer cell lines. *Molecules*, 22 (6), 2017, art. 1021.
- APPOVÁ, L., KARLÍČKOVÁ, J., ŘÍHA, M., FILIPSKÝ, T., MACÁKOVÁ, K., SPILKOVÁ, J., MLADĚNKA, P.: The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid. *Phytomedicine*, 35, 2017, 11–17.
- AUFARTOVÁ, J., BRABCOVÁ, I., TORRES-PADRÓN, M. E., SOLICH, P., SOSA-FERRERA, Z., SANTANA-RODRÍGUEZ, J. J.: Determination of fluoroquinolones in fishes using microwave-assisted extraction combined with ultra-high performance liquid chromatography and fluorescence detection. *Journal of Food Composition and Analysis*, 56, 2017, 140–146.
- AUFARTOVÁ, J., SÁNCHEZ-PANIAGUA LÓPEZ, M., MARTÍN-FERNÁNDEZ, B., LÓPEZ-RUIZ, B.: Key factors of ternary monolayers to improve DNA sensors performance. *Electroanalysis*, 29 (1), 2017, 131–139.
- BARANYAI, Z., KRÁTKÝ, M., VOSÁTKA, R., SZABÓ, E., SENONER, Z., DÁVID, S., STOLARÍKOVÁ, J., VINŠOVÁ, J., BŐSZE, S.: *In vitro* biological evaluation of new antimycobacterial salicylanilide-tuftsin conjugates. *European Journal of Medicinal Chemistry*, 133, 2017, 152–173.
- BÁRTA, P., JANOUŠEK, J., ŽILKOVÁ, K., TREJTNAR, F.: *In vitro* evaluation of concentration, labeling effectiveness and stability for I-131-labeled radioimmunoassay ligand using real-time detection technology. *Journal of Labelled Compounds and Radiopharmaceuticals*, 60 (1), 2017, 80–86.
- BÁRTÍKOVÁ, H., BOUŠOVÁ, I., MATOUŠKOVÁ, P., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: Effect of green tea extract-enriched diets on insulin and leptin levels, oxidative stress parameters and antioxidant enzymes activities in obese mice. *Polish Journal of Food and Nutrition Sciences*, 67 (3), 2017, 233–240.
- BÁRTOVÁ, E., KOBĚDOVÁ, K., LAMKA, J., KOTRBA, R., VODIČKA, R., SEDLÁK, K.: Seroprevalence of *Neospora caninum* and *Toxoplasma gondii* in exotic ruminants and camelids in the Czech Republic. *Parasitology Research*, 116 (7), 2017, 1925–1929.

- BEBOVÁ, M., BOŠTIKOVÁ, Z., MOSEROVÁ, M., PÁVEK, P., ANZENBACHEROVÁ, E., STIBOROVÁ, M., HODEK, P.: Modulation of xenobiotic conjugation enzymes by dihydromyricetin in rats. *Monatshefte für Chemie – Chemical Monthly*, 148 (11), 2017, 2003–2009.
- BEEGUM, S., MARY, Y., VARGHESE, H. T., PANICKER, C., ARMAKOVIĆ, S., ARMAKOVIĆ, S. J., ZITKO, J., DOLEŽAL, M., Van ALSENOY, C.: Vibrational spectroscopic analysis of cyanopyrazine-2-carboxamide derivatives and investigation of their reactive properties by DFT calculations and molecular dynamics simulations. *Journal of Molecular Structure*, 1131, 2017, 1–15.
- BELKINA, T., DUVANOVA, N., KARBOVSKAJA, J., DUINTJER TEBBENS, E. J., VLČEK, J.: Antibiotic use practices of pharmacy staff: A cross-sectional study in Saint Petersburg, the Russian Federation. *BMC Pharmacology & Toxicology*, 18, 2017, art. 11.
- BENEK, O., HROCH, L., AITKEN, L., DOLEŽAL, R., HUGHES, R., GUEST, P., BENKOVÁ, M., SOUKUP, O., MUSIL, K., KUČA, K., SMITH, T., GUNN-MOORE, F., MUSÍLEK, K.: 6-Benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17 β -HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and *in vitro* evaluation. *Medicinal Chemistry*, 13 (4), 2017, 345–358.
- BENEŠ, M.: Quality by Design – Plánované řízení kvality ve farmaceutickém průmyslu (Quality by Design – Planned quality management in pharmaceutical industry). *Chemické listy*, 111 (9), 2017, 559–566.
- BENEŠ, M., PEKÁREK, T., BERÁNEK, J., HAVLÍČEK, J., KREJČÍK, L., ŠIMEK, M., TKADLECOVÁ, M., DOLEŽAL, P.: Methods for the preparation of amorphous solid dispersions – A comparative study. *Journal of Drug Delivery Science and Technology*, 38, 2017, 125–134.
- BENEŠ, M., PEKÁREK, T., KREJČÍK, L., DOLEŽAL, P.: Application of spectroscopic imaging for characterizing API: Polymer systems as a screening tool for the development of potential amorphous solid dispersions. *Acta Poloniae Pharmaceutica*, 74 (6), 2017, 1851–1858.
- BERÁNEK, M., FIALA, Z., KREMLÁČEK, J., ANDRÝS, C., KREJSEK, J., HAMÁKOVÁ, K., CHMELAROVÁ, M., PALÍČKA, V., BORSKÁ, L.: Changes in circulating cell-free DNA and nucleosomes in patients with exacerbated psoriasis. *Archives of Dermatological Research*, 309 (10), 2017, 815–821.
- BEZROUK, A., FIALA, Z., KOTINGOVÁ, L., SELKE-KRULICHOVÁ, I., KOPEČNÁ, M., VÁVROVÁ, K.: SAMPA: A free software tool for skin and membrane permeation data analysis. *Toxicology in Vitro*, 44, 2017, 361–371.
- BOSQUILLON, C., MÁDLOVÁ, M., PATEL, N., CLEAR, N., FORBES, B.: A comparison of drug transport in pulmonary absorption models: Isolated perfused rat lungs, respiratory epithelial cell lines and primary cell culture. *Pharmaceutical Research*, 34 (12), 2017, 2532–2540.
- BOUŠOVÁ, I., KOŠŤÁKOVÁ, Š., MATOUŠKOVÁ, P., BARTÍKOVÁ, H., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: Monosodium glutamate-induced obesity changed the expression and activity of glutathione *S*-transferases in mouse heart and kidney. *Die Pharmazie*, 72 (5), 2017, 257–259.
- BOUZ, G., JUHÁS, M., NIKLOVÁ, P., JANDŮREK, O., PATEROVÁ, P., JANOUŠEK, J., TŮMOVÁ, L., KOVALÍKOVÁ, Z., KASTNER, P., DOLEŽAL, M., ZITKO, J.: Ureidopyrazine derivatives: Synthesis and biological evaluation as anti-infectives and abiotic elicitors. *Molecules*, 22 (10), 2017, art. 1797.
- BUREŠ, J., JIRKOVSKÁ, A., ŠESTÁK, V., JANSOVÁ, H., KARABANOVICH, G., ROH, J., ŠTĚRBA, M., ŠIMŮNEK, T., KOVÁŘIKOVÁ, P.: Investigation of novel dextrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. *Toxicology*, 392, 2017, 1–10.
- CARAZO FERNÁNDEZ, A. J., HYRŠOVÁ, L., DUŠEK, J., CHODOUNSKÁ, H., HORVÁTOVÁ, A., BERKA, K., BAZGIER, V., GAN-SCHREIER, H., CHAMULITRAT, W., KUDOVÁ, E., PÁVEK, P.: Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. *Toxicology Letters*, 265, 2017, 86–96.
- CATAPANO, M. C., TVRDÝ, V., KARLÍČKOVÁ, J., MIGKOS, T., VALENTOVÁ, K., KŘEN, V., MLADĚNKÁ, P.: The stoichiometry of isoquercitrin complex with iron or copper is highly dependent on experimental conditions. *Nutrients*, 9 (11), 2017, art. 1193.
- CIDLINA, A., MILETÍN, M., FATHI-RASEKH, M., NEMYKIN, V., ZIMČÍK, P., NOVÁKOVÁ, V.: OFF-ON-OFF red-emitting fluorescent indicators for a narrow pH window. *Chemistry – A European Journal*, 23 (8), 2017, 1795–1804.
- CYRUSOVÁ, T., PETROVÁ, Š., VANĚK, T., PODLIPNÁ, R.: Responses of wetland plant *Carex vulpina* to copper and iron nanoparticles. *Water, Air & Soil Pollution*, 228 (7), 2017, art. 258.

- ČERMÁK, P., OLŠOVSKÁ, J., MIKYŠKA, A., DUŠEK, M., KADLEČKOVÁ, Z., VANÍČEK, J., NYČ, O., SIGLER, K., BOŠTÍKOVÁ, V., BOŠTÍK, P.: Strong antimicrobial activity of xanthohumol and other derivatives from hops (*Humulus lupulus* L.) on gut anaerobic bacteria. *APMIS*, 125 (11), 2017, 1033–1038.
- ČERVINKOVÁ, B., KUJOVSKÁ KRČMOVÁ, L., KLABAČKOVÁ, S., SOLICHOVÁ, D., SOLICH, P.: Rapid determination of lipophilic vitamins in human serum by ultra-high performance liquid chromatography using a fluorinated column and high-throughput miniaturized liquid-liquid extraction. *Journal of Separation Science*, 40 (17), 2017, 3375–3382.
- ČERVINKOVÁ, B., KUJOVSKÁ KRČMOVÁ, L., ŠESTÁKOVÁ, V., SOLICHOVÁ, D., SOLICH, P.: A fully validated bioanalytical method using an UHPLC-MS/MS system for quantification of DNA and RNA oxidative stress biomarkers. *Analytical and Bioanalytical Chemistry*, 409 (14), 2017, 3611–3621.
- ČUŘÍKOVÁ, B. A., PROCHÁZKOVÁ, K., FILKOVÁ, B., DIBLÍKOVÁ, P., SVOBODA, J., KOVÁČIK, A., VÁVROVÁ, K., ZBYTOVSKÁ, J.: Simplified stratum corneum model membranes for studying the effects of permeation enhancers. *International Journal of Pharmaceutics*, 534 (1–2), 2017, 287–296.
- DAVLETBAEVA, P., CHOCHOLOUŠ, P., BULATOV, A., ŠATÍNSKÝ, D., SOLICH, P.: Sub-1 min separation in sequential injection chromatography for determination of synthetic water-soluble dyes in pharmaceutical formulation. *Journal of Pharmaceutical and Biomedical Analysis*, 143, 2017, 123–129.
- DOLEŽELOVÁ, E., PRAŠNICKÁ, A., CERMANOVÁ, J., CARAZO FERNÁNDEZ, A. J., HYRŠOVÁ, L., HROCH, M., MOKRÝ, J., ADAMCOVÁ, M., MRKVICOVÁ, A., PÁVEK, P., MIČUDA, S.: Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats. *World Journal of Gastroenterology*, 23 (43), 2017, 7678–7692.
- DOLEŽELOVÁ, E., STEIN, E., DEROSA, G., MAFFIOLI, P., NACHTIGAL, P., SAHEBKAR, A.: Effect of ezetimibe on plasma adipokines: A systematic review and meta-analysis. *British Journal of Clinical Pharmacology*, 83 (7), 2017, 1380–1396.
- DONG, L., KOVÁŘOVÁ, J., BAJZÍKOVÁ, M., BEZAWORK-GELETA, A., ŠVEC, D., ENDAYA, B., SACHAPHIBULKIJ, K., COELHO, A., ŠEBKOVÁ, N., RŮŽIČKOVÁ, A., TAN, A., KLUČKOVÁ, K., JUDASOVÁ, K., ZÁMEČNÍKOVÁ, K., RYCHTARČÍKOVÁ, Z., GOPALAN, V., ANDĚRA, L., SOBOL, M., YAN, B., PATNAIK, B., BHATRAJU, N., TRUKSA, J., STOPKA, P., HOZÁK, P., LAM, A., SEDLÁČEK, R., OLIVEIRA, P., KUBISTA, M., AGRAWAL, A., DVOŘÁKOVÁ-HORTOVÁ, K., ROHLENA, J., BERRIDGE, M. V., NEUŽIL, J.: Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. *eLife*, 6, 2017, art. e22187.
- DREIER, D., LATKOLIK, S., RYCEK, L., SCHNUERCH, M., DYMÁKOVÁ, A., ATANASOV, A., LADURNER, A., HEISS, E., STUPPNER, H., SCHUSTER, D., MIHOVILOVIC, M., DIRSCH, V.: Linked magnolol dimer as a selective PPAR gamma agonist – structure-based rational design, synthesis, and bioactivity evaluation. *Scientific Reports*, 7, 2017, art. 13002.
- DU, K., DUINTJER TEBBENS, E. J., MEURANT, G.: Any admissible harmonic Ritz value set is possible for GMRES. *Electronic Transactions on Numerical Analysis*, 47, 2017, 37–56.
- DUŠEK, J., CARAZO FERNÁNDEZ, A. J., TREJTAR, F., HYRŠOVÁ, L., HOLAS, O., SMUTNÝ, T., MIČUDA, S., PÁVEK, P.: Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation. *Food and Chemical Toxicology*, 109, 2017, 130–142.
- FERNÁNDEZ-RAMOS, C., BALLESTEROS, O., ZAFRA-GÓMEZ, A., ŠATÍNSKÝ, D., SOLICH, P., NAVALÓN, A., VERGE, C., De FERRER, J., PEREZ-PASCUAL, M., VÍLCHEZ, J. L.: Seasonal variations in the behavior of alcohol sulfates in agricultural soils: A field study. *Water, Air & Soil Pollution*, 228 (3), 2017, art. 104.
- FIBIGR, J., ŠATÍNSKÝ, D., SOLICH, P.: A new approach to the rapid separation of isomeric compounds in a *Silybum marianum* extract using UHPLC core-shell column with F5 stationary phase. *Journal of Pharmaceutical and Biomedical Analysis*, 134, 2017, 203–213.
- FIBIGR, J., ŠATÍNSKÝ, D., SOLICH, P.: A UHPLC method for the rapid separation and quantification of anthocyanins in acai berry and dry blueberry extracts. *Journal of Pharmaceutical and Biomedical Analysis*, 143, 2017, 204–213.
- FIBIGR, J., ŠATÍNSKÝ, D., SOLICH, P.: A UHPLC method for the rapid separation and quantification of phytoosterols using tandem UV/Charged aerosol detection – A comparison of both detection techniques. *Journal of Pharmaceutical and Biomedical Analysis*, 140, 2017, 274–280.

- FILIPSKÝ, T., ŘÍHA, M., HAŠKOVÁ, P., PILAŘOVÁ, V., NOVÁKOVÁ, L., SEMECKÝ, V., VÁVROVÁ, J., HOLEČKOVÁ, M., PALIČKA, V., ŠIMŮNEK, T., HRDINA, R., MLADĚNKA, P.: Intravenous rutin in rat exacerbates isoprenaline-induced cardiotoxicity likely due to intracellular oxidative stress. *Redox Report*, 22 (2), 2017, 78–90.
- FRÝDLOVÁ, J., RYCHTARČÍKOVÁ, Z., GURIEVA, I., VOKURKA, M., TRUKSA, J., KRIJT, J.: Effect of erythropoietin administration on proteins participating in iron homeostasis in *Tmprss6*-mutated mask mice. *PLoS One*, 12 (10), 2017, art. e0186844.
- GHAZAL, B., MACHÁČEK, M., ABBAS SHALABY, M., NOVÁKOVÁ, V., ZIMČÍK, P., MAKHSEED, S.: Phthalocyanines and tetrapyrrozinoporphyrazines with two cationic donuts: High photodynamic activity as a result of rigid spatial arrangement of peripheral substituents. *Journal of Medicinal Chemistry*, 60 (14), 2017, 6060–6076.
- HANUŠOVÁ, V., CALTOVÁ, K., SVOBODOVÁ, H., AMBROŽ, M., SKARKA, A., MURÍNOVÁ, N., KRÁLOVÁ, V., TOMŠÍK, P., SKÁLOVÁ, L.: The effects of β -caryophyllene oxide and *trans*-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice. *Biomedicine & Pharmacotherapy*, 95, 2017, 828–836.
- HAVELEK, R., MUTHNÁ, D., TOMŠÍK, P., KRÁLOVEC, K., SEIFRTOVÁ, M., CAHLÍKOVÁ, L., HOŠŤÁLKOVÁ, A., ŠAFRATOVÁ, M., PERWEIN, M. K. E., ČERMÁKOVÁ, E., ŘEZÁČOVÁ, M.: Anti-cancer potential of Amaryllidaceae alkaloids evaluated by screening with a panel of human cells, real-time cellular analysis and Ehrlich tumor-bearing mice. *Chemico-Biological Interactions*, 275, 2017, 121–132.
- HAVELEK, R., SEIFRTOVÁ, M., KRÁLOVEC, K., HABARTOVÁ, K., CAHLÍKOVÁ, L., ŘEZÁČOVÁ, M.: Chelidonine and homochelidonine induce cell death through cell cycle checkpoints and MAP kinase pathways. *Natural Product Communications*, 12 (9), 2017, 1419–1430.
- HLOCH, K., MLADĚNKA, P., DOSEDĚL, M., ADRIANI, W., ZORATTO, F.: The current clinical knowledge on the treatment of gambling disorder: A summary. *Synapse*, 71 (8), 2017, art. e21976.
- HOLAS, O., KORÁBEČNÝ, J., GAŽOVÁ, Z., ŠIPOŠOVÁ, K., MUSÍLEK, K., OPLETALOVÁ, V., GÓRECKI, L., NEPOVIMOVÁ, E., ŠPILOVSKÁ, K., MEZEIOVÁ, E., KUČA, K.: Alzheimer's disease drugs – *In vitro* comparison of cholinesterase inhibition and beta-amyloid modulation. *Letters in Drug Design & Discovery*, 14 (6), 2017, 743–750.
- HORSTKOTTE, B., FIKAROVÁ, K., COCOVI-SOLBERG, D. J., SKLENÁŘOVÁ, H., SOLICH, P., MIRÓ, M.: Online coupling of fully automatic in-syringe dispersive liquid-liquid microextraction with oxidative back-extraction to inductively coupled plasma spectrometry for sample clean-up in elemental analysis: A proof of concept. *Talanta*, 173, 2017, 79–87.
- HRABCOVÁ, V., KORÁBEČNÝ, J., MÁNYOVÁ, B., MATOUŠKOVÁ, L., KUČERA, T., DOLEŽAL, R., MUSÍLEK, K., GÓRECKI, L., NEPOVIMOVÁ, E., KUČA, K., JUN, D.: Bis-isoquinolinium and bis-pyridinium acetylcholinesterase inhibitors: *In vitro* screening of probes for novel selective insecticides. *RSC Advances*, 7 (62), 2017, 39279–39291.
- HROCH, L., GUEST, P., BENEK, O., SOUKUP, O., JANOČKOVÁ, J., DOLEŽAL, R., KUČA, K., AITKEN, L., SMITH, T., GUNN-MOORE, F., ZALA, D., RAMSAY, R., MUSÍLEK, K.: Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment. *Bioorganic & Medicinal Chemistry*, 25 (3), 2017, 1143–1152.
- HULCOVÁ, D., BREITEROVÁ, K., ZEMANOVÁ, L., SIATKA, T., ŠAFRATOVÁ, M., VANĚČKOVÁ, N., HOŠŤÁLKOVÁ, A., WSÓL, V., CAHLÍKOVÁ, L.: AKR1C3 inhibitory potency of naturally-occurring Amaryllidaceae alkaloids of different structural types. *Natural Product Communications*, 12 (2), 2017, 245–246.
- CHOCHOLOUŠ, P., DĚDKOVÁ, L., BOHÁČOVÁ, T., ŠATÍNSKÝ, D., SOLICH, P.: Fast separation of red colorants in beverages using cyano monolithic column in sequential injection chromatography. *Microchemical Journal*, 130, 2017, 384–389.
- CHOCHOLOUŠ, P., GIL, R., ACEBAL, C., KUBALA, V., ŠATÍNSKÝ, D., SOLICH, P.: Multilayered particle-packed column: Evaluation and comparison with monolithic and core-shell particle columns for the determination of red azo dyes in sequential injection chromatography. *Journal of Separation Science*, 40 (6), 2017, 1225–1233.
- CHOCHOLOUŠ, P., WIECZOREK, M., ŚWIT, P., KOZAK, J., SOLICH, P., KOŚCIELNIAK, P.: Novel approach to two-component analysis based on the generalized calibration strategy. *Analytical Letters*, 50 (4), 2017, 617–628.

- CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., URBANOVÁ, M., CHOCHOLOUŠ, P., SOLICH, P.: Novel dispersed sorbent sorptive extraction method for the chromatography profiling of active substances in ginger. *Food Analytical Methods*, 10 (4), 2017, 1016–1023.
- JANĎOUREK, O., TAUCHMAN, M., PATEROVÁ, P., KONEČNÁ, K., NAVRÁTILOVÁ, L., KUBÍČEK, V., HOLAS, O., ZITKO, J., DOLEŽAL, M.: Synthesis of novel pyrazinamide derivatives based on 3-chloropyrazine-2-carboxamide and their antimicrobial evaluation. *Molecules*, 22 (2), 2017, art. 223.
- JAVORSKÁ, L., KUJOVSKÁ KRČMOVÁ, L., SOLICH, P., KAŠKA, M.: Simple and rapid quantification of vancomycin in serum, urine and peritoneal/pleural effusion via UHPLC-MS/MS applicable to personalized antibiotic dosing. *Journal of Pharmaceutical and Biomedical Analysis*, 142, 2017, 59–65.
- JENČO, J., KUJOVSKÁ KRČMOVÁ, L., SOLICHOVÁ, D., SOLICH, P.: Recent trends in determination of thiamine and its derivatives in clinical practice. *Journal of Chromatography A*, 1510, 2017, 1–12.
- JERÁBEK, J., ULIASSI, E., GUIDOTTI, L., KORÁBEČNÝ, J., SOUKUP, O., ŠEPSOVÁ, V., HRABINOVÁ, M., KUČA, K., BARTOLINI, M., PENNA-ALTAMIRA, L., PETRALLA, S., MONTI, B., ROBERTI, M., BOLOGNESI, M.: Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. *European Journal of Medicinal Chemistry*, 127, 2017, 250–262.
- JOSEPH, T., VARGHESE, H. T., PANICKER, C. Y., VISWANATHAN, K., DOLEŽAL, M., VAN ALSENOY, C.: Spectroscopic (FT-IR, FT-Raman), first order hyperpolarizability, NBO analysis, HOMO and LUMO analysis of *N*-[(4-(trifluoromethyl)phenyl)pyrazine-2-carboxamide] by density functional methods. *Arabian Journal of Chemistry*, 10 (S2), 2017, S2281–S2294.
- JOŠT, P., FIKROVÁ, P., SVOBODOVÁ, H., PEJCHAL, J., ŠTĚTINA, R.: Protective potential of different compounds and their combinations with MESNA against sulfur mustard-induced cytotoxicity and genotoxicity. *Toxicology Letters*, 275, 2017, 92–100.
- KARABANOVICH, G., NĚMEČEK, J., VALÁŠKOVÁ, L., CARAZO FERNÁNDEZ, A., KONEČNÁ, K., STOLARÍKOVÁ, J., HRABÁLEK, A., PAVLIŠ, O., PÁVEK, P., VÁVROVÁ, K., ROH, J., KLIMEŠOVÁ, V.: *S*-substituted 3,5-dinitrophenyl-1,3,4-oxadiazole-2-thiols and tetrazole-5-thiols as highly efficient antitubercular agents. *European Journal of Medicinal Chemistry*, 126, 2017, 369–383.
- KARBANOVÁ, S., ČERVENÝ, L., ČEČKOVÁ, M., PTÁČKOVÁ, Z., JIRÁSKOVÁ, L., GREENWOOD, S., ŠTAUD, F.: Role of nucleoside transporters in transplacental pharmacokinetics of nucleoside reverse transcriptase inhibitors zidovudine and emtricitabine. *Placenta*, 60, 2017, 86–92.
- KASTNER, P., PILÁŘOVÁ, P., NEJEDLÝ, T., MACHÁČEK, M., KLIMEŠ, J.: Stability indicating method for determination of sodium picosulfate in pharmaceutical preparation – Comparison of HPLC, UHPLC and HTLC. *Current Pharmaceutical Analysis*, 13 (3), 2017, 250–255.
- KAŠPAROVÁ, M., MARTIN, J., TŮMOVÁ, L., SPILKOVÁ, J.: Production of podophyllotoxin by plant tissue cultures of *Juniperus virginiana*. *Natural Product Communications*, 12 (1), 2017, 101–103.
- KOPEČNÁ, M., MACHÁČEK, M., PRCHALOVÁ, E., ŠTĚPÁNEK, P., DRAŠAR, P., KOTORA, M., VÁVROVÁ, K.: Dodecyl amino glucoside enhances transdermal and topical drug delivery via reversible interaction with skin barrier lipids. *Pharmaceutical Research*, 34 (3), 2017, 640–653.
- KOPEČNÁ, M., MACHÁČEK, M., PRCHALOVÁ, E., ŠTĚPÁNEK, P., DRAŠAR, P., KOTORA, M., VÁVROVÁ, K.: Galactosyl pentadecene reversibly enhances transdermal and topical drug delivery. *Pharmaceutical Research*, 34 (10), 2017, 2097–2108.
- KOVÁČIK, A., ŠILAROVÁ, M., PULLMANNOVÁ, P., MAIXNER, J., VÁVROVÁ, K.: Effects of 6-hydroxyceramides on the thermotropic phase behavior and permeability of model skin lipid membranes. *Langmuir*, 33 (11), 2017, 2890–2899.
- KOVAŘÍK, M., JOSKOVÁ, V., PATKOVÁ, A., KOBLÍŽEK, V., ZADÁK, Z., HRONEK, M.: Hand grip endurance test relates to clinical state and prognosis in COPD patients better than 6-minute walk test distance. *International Journal of Chronic Obstructive Pulmonary Disease*, 12, 2017, 3429–3435.
- KRASULOVÁ, K., HOLAS, O., ANZENBACHER, P.: Influence of amlodipine enantiomers on human microsomal cytochromes P450: Stereoselective time-dependent inhibition of CYP3A enzyme activity. *Molecules*, 22 (11), 2017, art. 1879.
- KRÁTKÝ, M., BÖSZE, S., BARANYAI, Z., STOLARÍKOVÁ, J., VINŠOVÁ, J.: Synthesis and biological evolution of hydrazones derived from 4-(trifluoromethyl)benzohydrazide. *Bioorganic and Medicinal Chemistry Letters*, 27 (23), 2017, 5185–5189.
- KRÁTKÝ, M., DZURKOVÁ, M., JANOUŠEK, J., KONEČNÁ, K., TREJTNAR, F., STOLARÍKOVÁ, J., VINŠOVÁ, J.: Sulfadiazine salicylaldehyde-based Schiff bases: Synthesis, antimicrobial activity and cytotoxicity. *Molecules*, 22 (9), 2017, art. 1573.

- KRÁTKÝ, M., STOLAŘÍKOVÁ, J., VINŠOVÁ, J.: Novel sulfamethoxazole ureas and oxalamide as potential antimycobacterial agents. *Molecules*, 22 (4), 2017, art. 535.
- KRÁTKÝ, M., ŠTĚPÁNKOVÁ, Š., VORČÁKOVÁ, K., NAVRÁTILOVÁ, L., TREJTNAR, F., STOLAŘÍKOVÁ, J., VINŠOVÁ, J.: Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity. *Bioorganic Chemistry*, 71, 2017, 244–256.
- KRÁTKÝ, M., VINŠOVÁ, J., STOLAŘÍKOVÁ, J.: Antimicrobial activity of rhodanine-3-acetic acid derivatives. *Bioorganic & Medicinal Chemistry*, 25 (6), 2017, 1839–1845.
- KUČEROVÁ, K., KUJOVSKÁ KRČMOVÁ, L., MATYSOVÁ, L., SOLICH, P.: Could urinary retinol be used as a new biomarker of kidney damage? *Trends in Analytical Chemistry*, 95, 2017, 57–61.
- KUDLÁČEK, K., NESMĚRÁK, K., ŠTÍCHA, M., KOZLÍK, P., BABICA, J.: Historical injection solutions of quinine analyzed by HPLC/MS. *Monatshefte für Chemie – Chemical Monthly*, 148 (9), 2017, 1613–1618.
- KVĚTINA, J., TACHECÍ, I., NOBILIS, M., KOPÁČOVÁ, M., KUNEŠ, M., BUREŠ, J.: The importance of wireless capsule endoscopy for research into the intestine absorption window of 5-aminosalicylic acid in experimental pigs. *Current Pharmaceutical Design*, 23 (12), 2017, 1873–1876.
- LACZÓ, J., MARKOVÁ, H., LOBELLOVÁ, V., GAŽOVÁ, I., PAŘÍZKOVÁ, M., CERMAN, J., NEKOVÁŘOVÁ, T., VALEŠ, K., KLOVRZOVÁ, S., HARRISON, J., WINDISCH, M., VLČEK, K., SVOBODA, J., HORT, J., STUCHLÍK, A.: Scopolamine disrupts place navigation in rats and humans: A translational validation of the hidden goal task in the Morris water maze and a real maze for humans. *Psychopharmacology*, 234 (4), 2017, 535–547.
- LHOTSKÁ, I., HOLZNEROVÁ, A., SOLICH, P., ŠATÍNSKÝ, D.: Critical comparison of the on-line and off-line molecularly imprinted solid-phase extraction of patulin coupled with liquid chromatography. *Journal of Separation Science*, 40 (23), 2017, 4599–4609.
- LNĚNIČKOVÁ, K., DYMÁKOVÁ, A., SZOTÁKOVÁ, B., BOUŠOVÁ, I.: Sulforaphane alters beta-naphthoflavone-induced changes in activity and expression of drug-metabolizing enzymes in rat hepatocytes. *Molecules*, 22 (11), 2017, art. 1983.
- LOCHMAN, L., ZIMČÍK, P., KLIMANT, I., NOVÁKOVÁ, V., BORISOV, S.: Red-emitting CO₂ sensors with tunable dynamic range based on pH-sensitive azaphthalocyanine indicators. *Sensors and Actuators B: Chemical*, 246, 2017, 1100–1107.
- LOVERIDGE, E., HROCH, L., HUGHES, R., WILLIAMS, T., DAVIES, R., ANGELASTRO, A., LUK, L., MAGLIA, G., ALLEMANN, R.: Reduction of folate by dihydrofolate reductase from *Thermotoga maritima*. *Biochemistry*, 56 (13), 2017, 1879–1886.
- MACHYŇÁKOVÁ, A., LHOTSKÁ, I., HROBOŇOVÁ, K., ŠATÍNSKÝ, D.: On-line coupling of molecularly imprinted solid phase extraction with liquid chromatography for the fast determination of coumarins from complex samples. *Journal of Pharmaceutical and Biomedical Analysis*, 145, 2017, 144–150.
- MALÁTKOVÁ, P., SKARKA, A., MUSILOVÁ, K., WSÓL, V.: Reductive metabolism of tiaprofenic acid by the human liver and recombinant carbonyl reducing enzymes. *Chemico-Biological Interactions*, 276, 2017, 121–126.
- MEINCKE, R., POKLADNÍKOVÁ, J., STRÁŽNICKÁ, J., MEYBOOM, R. H., NIEDRIG, D., RUSSMANN, S., JAHODÁŘ, L.: Allergy-like immediate reactions with herbal medicines in children: A retrospective study using data from VigiBase®. *Pediatric Allergy and Immunology*, 28 (7), 2017, 668–674.
- MELICHAR, B., HRŮZOVÁ, K., KUJOVSKÁ KRČMOVÁ, L., JAVORSKÁ, L., PEŠKOVÁ, E., SOLICHOVÁ, D., HYŠPLER, R., MALÍŘOVÁ, E., VOŠMIK, M., BARTOUŠKOVÁ, M., KLOS, D., ŠTUDENTOVÁ, H.: Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab. *Pteridines*, 28 (3–4), 2017, 221–232.
- MELICHAR, B., VITÁSKOVÁ, D., BARTOUŠKOVÁ, M., JAVORSKÁ, L., KUJOVSKÁ KRČMOVÁ, L., PEŠKOVÁ, E., HYŠPLER, R., SOLICHOVÁ, D., HRŮZOVÁ, K., ŠTUDENTOVÁ, H.: Comparison of performance of composite biomarkers of inflammatory response in determining the prognosis of breast cancer patients. *Pteridines*, 28 (3–4), 2017, 213–220.
- MELNIKOVA, I., ROH, J., KUNEŠ, J., ARTAMONOVA, T., ZEVATSKII, Y., MYZNIKOV, L.: Non-catalyzed addition of heterocyclic thiols and 5-substituted-1*H*-tetrazoles to vinyl ethers. *Tetrahedron Letters*, 58 (40), 2017, 3842–3845.
- MERGANCOVÁ, J., JAVORSKÁ, L., ŠILLER, J., SÁKRA, L., MERGANCOVÁ, J., SOLICHOVÁ, D., KUJOVSKÁ KRČMOVÁ, L., MELICHAR, B., MOHELNÍKOVÁ-DUCHOŇOVÁ, B., ŠTUDENTOVÁ, H.,

- KLOS, D.: Concentrations of neopterin, kynurenine and tryptophan in wound secretions of patients with breast cancer and malignant melanoma: A pilot study. *Pteridines*, 28 (3–4), 2017, 205–211.
- MEZEIOVÁ, E., KORÁBEČNÝ, J., ŠEPSOVÁ, V., HRABINOVÁ, M., JOŠT, P., MŮČKOVÁ, L., KUČERA, T., DOLEŽAL, R., MISÍK, J., ŠPILOVSKÁ, K., PHAM, N. L., POKRIEVKOVÁ, L., ROH, J., JUN, D., SOUKUP, O., KAPING, D., KUČA, K.: Development of 2-methoxyhuprine as novel lead for Alzheimer's disease therapy. *Molecules*, 22 (8), 2017, art. 1265.
- MICHÁLKOVÁ NEČEDOVÁ, M., MARTINICKÁ, A., MAGDOLEN, P., NOVÁKOVÁ, V., ZAHRADNÍK, P.: Phthalocyanine-triphenylamine dyads: Synthesis, electrochemical, spectral and DFT study. *Dyes and Pigments*, 141, 2017, 448–456.
- MLČOCH, T., KLIMEŠ, J., FILA, L., VÁVROVÁ, V., SKALICKÁ, V., TURNOVEC, M., KRULIŠOVÁ, V., JIRČÍKOVÁ, J., ZEMKOVÁ, D., VILIMOVSKÁ DĚDEČKOVÁ, K., BÍLKOVÁ, A., FRŮHAUFOVÁ, V., HOMOLA, L., FRIEDMANNOVÁ, Z., DRNEK, R., DŘEVÍNEK, P., DOLEŽAL, T., MACEK, M.: Cost-of-illness analysis and regression modeling in cystic fibrosis: A retrospective prevalence-based study. *European Journal of Health Economics*, 18 (1), 2017, 73–82.
- MUČAJI, P., ATANASOV, A. G., BAK, A., KOZIK, V., SIEROŃ, K., OLSEN, M., PAN, W., LIU, Y., HU, S., LAN, J., HAIDER, N., MUSIOŁ, R., VANČO, J., DIEDERICH, M., JI, S., ZITKO, J., WANG, D., AGBAB, D., NIKOLIĆ, K., OLJAČIĆ, S., VUČIČEVIĆ, J., JEŽOVÁ, D., TSANTILI-KAKOULIDOU, A., TSOPELAS, F., GIAGINIS, C., KOWALSKA, T., SAJEWICZ, M., SILBERRING, J., MIELCZAREK, P., SMOLUCH, M., JENDRZEJEWSKA, I., POLAŃSKI, J., JAMPÍLEK, J.: The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot. *Molecules*, 22 (11), 2017, art. 1848.
- MUŽÍKOVÁ, J., SRBOVÁ, A., SVAČINOVÁ, P.: A study of a novel coprocessed dry binder composed of alpha-lactose monohydrate, microcrystalline cellulose and corn starch. *Pharmaceutical Development and Technology*, 22 (8), 2017, 964–971.
- NEJEDLÝ, T., KLIMEŠ, J.: A model of natural degradation of 17 α -ethinylestradiol in surface water and identification of degradation products by GC-MS. *Environmental Science and Pollution Research*, 24 (29), 2017, 23196–23206.
- NĚMEČEK, J., SYCHRA, P., MACHÁČEK, M., BENKOVÁ, M., KARABANOVICH, G., KONEČNÁ, K., KAVKOVÁ, V., STOLAŘÍKOVÁ, J., HRABÁLEK, A., VÁVROVÁ, K., SOUKUP, O., ROH, J., KLIMEŠOVÁ, V.: Structure-activity relationship studies on 3,5-dinitrophenyl tetrazoles as antitubercular agents. *European Journal of Medicinal Chemistry*, 130, 2017, 419–432.
- NESMĚRÁK, K., KUDLÁČEK, K., BABICA, J.: Analytical chemistry studying historical pharmaceuticals and health care formulations. *Monatshefte für Chemie – Chemical Monthly*, 148 (9), 2017, 1557–1568.
- NGUYEN, T. L., MYSLIVEČKOVÁ, Z., SZOTÁKOVÁ, B., ŠPIČÁKOVÁ, A., LNĚNIČKOVÁ, K., AMBROŽ, M., KUBÍČEK, V., KRASULOVÁ, K., ANZENBACHER, P., SKÁLOVÁ, L.: The inhibitory effects of β -caryophyllene, β -caryophyllene oxide and α -humulene on the activities of the main drug-metabolizing enzymes in rat and human liver *in vitro*. *Chemico-Biological Interactions*, 278 (4), 2017, 123–128.
- NOVÁKOVÁ, L., DOUŠA, M.: General screening and optimization strategy for fast chiral separations in modern supercritical fluid chromatography. *Analytica Chimica Acta*, 950, 2017, 199–210.
- NOVÁKOVÁ, V., MAŁACHWIEJ, B., ŠEBL, R., MILETÍN, M., ZIMČÍK, P.: Tetra(pyrazino[2,3-*b*]pyrazino)porphyrazines: Synthesis, absorption, photophysical and electrochemical properties of strongly electron-deficient macrocycles. *Journal of Porphyrins and Phthalocyanines*, 21 (4–6), 2017, 302–310.
- NOVOTNÁ, E., WAISSER, K., KUNEŠ, J., PALÁT, K., SKÁLOVÁ, L., SZOTÁKOVÁ, B., BUCHTA, V., STOLAŘÍKOVÁ, J., ULMANN, V., PÁVOVÁ, M., WEBER, J., KOMRSKOVÁ, J., HAŠKOVÁ, P., VOKŘÁL, I., WSÓL, V.: Design, synthesis, and biological evaluation of isothiosemicarbazones with antimycobacterial activity. *Archiv der Pharmazie*, 350 (8), 2017, art. e1700020.
- OPLETAL, L., CHOJDOUŠOVÁ HAVLÍKOVÁ, L., SIATKA, T., CAHLÍKOVÁ, L., LOČÁREK, M., ALI, B., MANOJ, P., RAMKUMAR, A., AL SULEIMANI, Y., AL ZA'ABI, M., KARACA, T., NEMMAR, A.: Preparation and validated analysis of anthocyanin concentrate from the calyces of *Hibiscus sabdariffa*. *Natural Product Communications*, 12 (1), 2017, 43–45.
- PAPASTERGIOU, J., KHEIR, N., LÁDOVÁ, K., RYDANT, S., De RANGO, F., ANTONIOU, S., VIOLA, R., MURILLO, M. D., STEURBAUT, S., ALVES da COSTA, F.: Pharmacists' confidence when providing pharmaceutical care on anticoagulants, a multinational survey. *International Journal of Clinical Pharmacy*, 39 (6), 2017, 1282–1290.

- PARASKEVOPOULOS, G., MONTEIRO, S., VOSÁTKA, R., KRÁTKÝ, M., NAVRÁTILOVÁ, L., TREJT-NAR, F., STOLARÍKOVÁ, J., VINŠOVÁ, J.: Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity. *Bioorganic & Medicinal Chemistry*, 25 (4), 2017, 1524–1532.
- PATKOVÁ, A., JOSKOVÁ, V., HAVEL, E., KOVAŘÍK, M., KUCHAROVÁ, M., ZADÁK, Z., HRONEK, M.: Energy, protein, carbohydrate, and lipid intakes and their effects on morbidity and mortality in critically ill adult patients: A systematic review. *Advances In Nutrition*, 8 (4), 2017, 624–634.
- PICHERY, M., HUCHENQ, A., SANDHOFF, R., SEVERINO-FREIRE, M., ZAAFOURI, S., OPÁLKA, L., LEVADE, T., SOLDAN, V., BERTRAND-MICHEL, J., LHUILLIER, E., SERRE, G., MARUANI, A., MAZEREEUW-HAUTIER, J., JONCA, N.: PNPLA1 defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain PNPLA1 irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. *Human Molecular Genetics*, 26 (10), 2017, 1787–1800.
- PILAŘOVÁ, V., SULTANI, M., SKOGLUND ASK, K., NOVÁKOVÁ, L., PEDERSEN-BJERGAARD, S., GJELSTAD, A.: One-step extraction of polar drugs from plasma by parallel artificial liquid membrane extraction. *Journal of Chromatography B*, 1043, 2017, 25–32.
- POSPÍŠILOVÁ, M., ZÁPOTOČKÝ, V., NEŠPOROVÁ, K., LÁZNIČEK, M., LÁZNIČKOVÁ, A., ŽÍDEK, O., ČEPA, M., VÁGNEROVÁ, H., VELEBNÝ, V.: Preparation and biodistribution of ⁵⁹Fe-radiolabelled iron oxide nanoparticles. *Journal of Nanoparticle Research*, 19 (2), 2017, art. 80.
- PRAŠNICKÁ, A., CERMANOVÁ, J., HROCH, M., DOLEŽELOVÁ, E., ROZKYDALOVÁ, L., SMUTNÝ, T., CARAZO FERNÁNDEZ, A. J., CHLÁDEK, J., LENÍČEK, M., NACHTIGAL, P., VÍTEK, L., PÁVEK, P., MIČUDA, S.: Iron depletion induces hepatic secretion of biliary lipids and glutathione in rats. *Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids*, 1862 (12), 2017, 1469–1480.
- PRYDDERCH, H., HAISS, A., ŠPULÁK, M., QUILTY, B., KUEMMERER, K., HEISE, A., GATHER-GOOD, N.: Mandelic acid derived ionic liquids: Synthesis, toxicity and biodegradability. *RSC Advances*, 7 (4), 2017, 2115–2126.
- PULLMANOVÁ, P., PAVLÍKOVÁ, L., KOVÁČIK, A., SOCHOROVÁ, M., ŠKOLOVÁ, B., SLEPIČKA, P., MAIXNER, J., ZBYTOVSKÁ, J., VÁVROVÁ, K.: Permeability and microstructure of model stratum corneum lipid membranes containing ceramides with long (C16) and very long (C24) acyl chains. *Biophysical Chemistry*, 224, 2017, 20–31.
- RAISOVÁ STUHLÍKOVÁ, L., PODLIPNÁ, R., SZOTÁKOVÁ, B., SYSLOVÁ, E., SKÁLOVÁ, L.: Evaluation of drug uptake and deactivation in plant: Fate of albendazole in ribwort plantain (*Plantago lanceolata*) cells and regenerants. *Ecotoxicology and Environmental Safety*, 141, 2017, 37–42.
- RANJITH, P., AL-ABDULLAH, E., AL-OMARY, F., EL-EMAM, A., ANTO, P., SHEENA, M., ARMAKOVIĆ, S., ARMAKOVIĆ, S. J., ZITKO, J., DOLEŽAL, M., Van ALSENOY, C.: FT-IR and FT-Raman characterization and investigation of reactive properties of *N*-(3-iodo-4-methylphenyl)pyrazine-2-carboxamide by molecular dynamics simulations and DFT calculations. *Journal of Molecular Structure*, 1136, 2017, 14–24.
- RATHOUSKÁ, J., FIKROVÁ, P., MRKVICOVÁ, A., BLAŽÍČKOVÁ, K., VAŘEJČKOVÁ, M., DOLEŽELOVÁ, E., NĚMEČKOVÁ, I., VITVEROVÁ, B., PEŠLOVÁ, L., GALLARDO-VARA, E., PERICACHO, M., NACHTIGAL, P.: High soluble endoglin levels do not induce changes in structural parameters of mouse heart. *Heart and Vessels*, 32 (8), 2017, 1013–1024.
- RODRIGUES, C., MENDES, A., SIMA, F., BAVLOVIČ, J., MACHADO, E., NOVAIS, A., PEIXE, L.: Long-term care facility (LTCF) residents colonized with multidrug-resistant (MDR) *Klebsiella pneumoniae* lineages frequently causing infections in Portuguese clinical institutions. *Infection Control & Hospital Epidemiology*, 38 (9), 2017, 1127–1130.
- ROH, J., KARABANOVICH, G., VLČKOVÁ, H., CARAZO FERNÁNDEZ, A., NĚMEČEK, J., SYCHRA, P., VALÁŠKOVÁ, L., PAVLIŠ, O., STOLARÍKOVÁ, J., KLIMEŠOVÁ, V., VÁVROVÁ, K., PÁVEK, P., HRABÁLEK, A.: Development of water-soluble 3,5-dinitrophenyl tetrazole and oxadiazole antitubercular agents. *Bioorganic & Medicinal Chemistry*, 25 (20), 2017, 5468–5476.
- RYCHTARČÍKOVÁ, Z., LETTLOVÁ, S., TOMKOVÁ, V., KORENKOVÁ, V., LANGEROVÁ, L., SIMONOVA, E., ZJABLOVSKAJA, P., ALBERICH-JORDA, M., NEUŽIL, J., TRUKSA, J.: Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. *Oncotarget*, 8 (4), 2017, 6376–6398.
- ŘEZNIČEK, J., ČEČKOVÁ, M., ČERVENÝ, L., MUELLER, F., ŠTAUD, F.: Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. *Xenobiotica*, 47 (1), 2017, 77–85.

- ŘEZŇÍČEK, J., ČEČKOVÁ, M., PTÁČKOVÁ, Z., MARTINEC, O., ŤUPOVÁ, L., ČERVENÝ, L., ŠTAUD, F.: MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption. *Antimicrobial Agents and Chemotherapy*, 61 (9), 2017, art. e00837-17.
- SAHEBKAR, A., FERRI, C., GIORGINI, P., BO, S., NACHTIGAL, P., GRASSI, D.: Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*, 115, 2017, 149–161.
- SÁNCHEZ, R., HORSTKOTTE, B., FIKAROVÁ, K., SKLENÁŘOVÁ, H., MAESTRE, S., MIRÓ, M., TODOLÍ, J.-L.: Fully automatic in-syringe magnetic stirring-assisted dispersive liquid liquid microextraction hyphenated to high-temperature torch integrated sample introduction system-inductively coupled plasma spectrometer with direct injection of the organic phase. *Analytical Chemistry*, 89 (6), 2017, 3787–3794.
- SEIFRTOVÁ, M., HAVELEK, R., CAHLÍKOVÁ, L., HULCOVÁ, D., MAZÁNKOVÁ, N., ŘEZÁČOVÁ, M.: Haemanthamine alters sodium butyrate-induced histone acetylation, p21(WAF1/Cip1) expression, Chk1 and Chk2 activation and leads to increased growth inhibition and death in A2780 ovarian cancer cells. *Phytomedicine*, 35, 2017, 1–10.
- SEMELKOVÁ, L., JANĎOUREK, O., KONEČNÁ, K., PATEROVÁ, P., NAVRÁTILOVÁ, L., TREJTNAR, F., KUBÍČEK, V., KUNEŠ, J., DOLEŽAL, M., ZITKO, J.: 3-Substituted *N*-benzylpyrazine-2-carboxamide derivatives: Synthesis, antimycobacterial and antibacterial evaluation. *Molecules*, 22 (3), 2017, art. 495.
- SEMELKOVÁ, L., JANOŠCOVÁ, P., FERNANDES, C., BOUZ, G., JANĎOUREK, O., KONEČNÁ, K., PATEROVÁ, P., NAVRÁTILOVÁ, L., KUNEŠ, J., DOLEŽAL, M., ZITKO, J.: Design, synthesis, antimycobacterial evaluation, and *in silico* studies of 3-(phenylcarbamoyl)pyrazine-2-carboxylic acids. *Molecules*, 22 (9), 2017, art. 1491.
- SCHROETER, A., STAHLBERG, S., ŠKOLOVÁ, B., SONNENBERGER, S., EICHNER, A., HUSTER, D., VÁVROVÁ, K., HAUSS, T., DOBNER, B., NEUBERT, R., VOGEL, A.: Phase separation in ceramide[NP] containing lipid model membranes: Neutron diffraction and solid-state NMR. *Soft Matter*, 13 (10), 2017, 2107–2119.
- SIATKA, T., ADAMCOVÁ, M., OPLETAL, L., CAHLÍKOVÁ, L., JUN, D., HRABINOVÁ, M., KUNEŠ, J., CHLEBEK, J.: Cholinesterase and prolyl oligopeptidase inhibitory activities of alkaloids from *Argemone platyceras* (Papaveraceae). *Molecules*, 22 (7), 2017, art. 1181.
- SIATKA, T., CHLEBEK, J., HOŠTÁLKOVÁ, A.: Copper(II) sulfate stimulates scopoletin production in cell suspension cultures of *Angelica archangelica*. *Natural Product Communications*, 12 (11), 2017, 1779–1780.
- SKLENÁŘOVÁ, H., VORÁČOVÁ, I., CHOCHOLOUŠ, P., POLÁŠEK, M.: Quantum dots as chemiluminescence enhancers tested by sequential injection technique: Comparison of flow and flow-batch conditions. *Journal of Luminescence*, 184, 2017, 235–241.
- SOCHOROVÁ, M., STAŇKOVÁ, K., PULLMANNOVÁ, P., KOVÁČIK, A., ZBYTOVSKÁ, J., VÁVROVÁ, K.: Permeability barrier and microstructure of skin lipid membrane models of impaired glucosylceramide processing. *Scientific Reports*, 7, 2017, art. 6470.
- SOUKUP, O., WINDER, M., KILLI, U. K., WSÓL, V., JUN, D., KUČA, K., TOBIN, G.: Acetylcholinesterase inhibitors and drugs acting on muscarinic receptors – Potential crosstalk of cholinergic mechanisms during pharmacological treatment. *Current Neuropharmacology*, 15 (4), 2017, 637–653.
- SOUKUP, T., DOSEDĚL, M., NEKVINDOVÁ, J., KUBĚNA, A., TACHECÍ, I., DUINTJER TEBBENS, E. J., VLČEK, J., BRADNA, P., BARVÍK, I., PÁVEK, P.: The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate. *Pharmacogenetics and Genomics*, 27 (2), 2017, 43–50.
- STAHLBERG, S., EICHNER, A., SONNENBERGER, S., KOVÁČIK, A., LANGE, S., SCHMITT, T., DEMÉ, B., HAUSS, T., DOBNER, B., NEUBERT, R. H. H., HUSTER, D.: Influence of a novel dimeric ceramide molecule on the nanostructure and thermotropic phase behavior of a stratum corneum model mixture. *Langmuir*, 33 (36), 2017, 9211–9221.
- STRÁŽNICKÁ, J., POKLADNÍKOVÁ, J., JAHODÁŘ, L.: Safety assessment of food additives in top-selling dietary supplements in the Czech Republic. *Acta Poloniae Pharmaceutica*, 74 (6), 2017, 1929–1935.
- SVOBODA, M., HLOBILOVÁ, M., MAREŠOVÁ, M., SOCHOROVÁ, M., KOVÁČIK, A., VÁVROVÁ, K., DOLEČKOVÁ, I.: Comparison of suction blistering and tape stripping for analysis of epidermal genes, proteins and lipids. *Archives of Dermatological Research*, 309 (9), 2017, 757–765.
- SVOBODA, P., SANDER, D., PLACHKÁ, K., NOVÁKOVÁ, L.: Development of matrix effect-free MISPE-UHPLC-MS/MS method for determination of lovastatin in Pu-erh tea, oyster mushroom, and red yeast rice. *Journal of Pharmaceutical and Biomedical Analysis*, 140, 2017, 367–376.

- ŠKOLOVÁ, B., KOVÁČIK, A., TESAR, O., OPÁLKA, L., VÁVROVÁ, K.: Phytosphingosine, sphingosine and dihydrosphingosine ceramides in model skin lipid membranes: Permeability and biophysics. *Biochimica et Biophysica Acta – Biomembranes*, 1859 (5), 2017, 824–834.
- ŠMÍDOVÁ, B., ŠATÍNSKÝ, D., DOSTÁLOVÁ, K., SOLICH, P.: The pentafluorophenyl stationary phase shows a unique separation efficiency for performing fast chromatography determination of highbush blueberry anthocyanins. *Talanta*, 166, 2017, 249–254.
- ŠPAČEK, J., KESTRÁNEK, J., JÍLEK, P., LEŠKO, D., PLUCNAROVÁ, S., BUCHTA, V.: Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. *Mycoses*, 60 (4), 2017, 260–265.
- ŠPIČÁKOVÁ, A., SZOTÁKOVÁ, B., DIMUNOVÁ, D., MYSLIVEČKOVÁ, Z., KUBÍČEK, V., AMBROŽ, M., LNĚNÍČKOVÁ, K., KRASULOVÁ, K., ANZENBACHER, P., SKÁLOVÁ, L.: Nerolidol and farnesol inhibit some cytochrome P450 activities but did not affect other xenobiotic-metabolizing enzymes in rat and human hepatic subcellular fractions. *Molecules*, 22 (4), 2017, art. 509.
- ŠPULÁK, M., GHAVRE, M., POUR, M.: Recent advances in the transition-metal catalyzed synthesis of multi-substituted pentenolides and related pyranones. *Tetrahedron Letters*, 58 (4), 2017, 263–270.
- ŠVEC, F.: Monolithic columns: A historical overview. *Electrophoresis*, 38 (22–23), 2017, 2810–2820.
- TSHEPELEVITSH, S., HERNITS, K., JENČO, J., HAWKINS, J. M., MUTEKI, K., SOLICH, P., LEITO, I.: Systematic optimization of liquid-liquid extraction for isolation of unidentified components. *ACS Omega*, 2 (11), 2017, 7772–7776.
- TŮMOVÁ, L., DOLEČKOVÁ, I., HENDRYCHOVÁ, H., KAŠPAROVÁ, M.: Arbutin content and tyrosinase activity of *Bergenia* extracts. *Natural Product Communications*, 12 (4), 2017, 549–552.
- TŮMOVÁ, L., DUČIAIOVÁ, Z., CHEEL, J., VOKŘÁL, I., SEPŮLVEDA, B., VOKURKOVÁ, D.: *Azorella compacta* infusion activates human immune cells and scavenges free radicals *in vitro*. *Pharmacognosy Magazine*, 13 (50), 2017, 260–264.
- VAREJČKOVÁ, M., GALLARDO-VARA, E., VICEN, M., VITVEROVÁ, B., FIKROVÁ, P., DOLEŽELOVÁ, E., RATHOUSKÁ, J., PRAŠNICKÁ, A., BLAŽIČKOVÁ, K., MIČUDA, S., BERNABÉU, C., NĚMEČKOVÁ, I., NACHTIGAL, P.: Soluble endoglin modulates the pro-inflammatory mediators NF-kappa B and IL-6 in cultured human endothelial cells. *Life Sciences*, 175, 2017, 52–60.
- VITÁSKOVÁ, D., MELICHAR, B., BARTOUŠKOVÁ, M., VLACHOVÁ, Z., VRÁNA, D., JANKOVÁ, J., ADAM, T., JURÁŇOVÁ, J., ZLÁMALOVÁ, N., KUJOVSKÁ KRČMOVÁ, L., JAVORSKÁ, L., KLOS, D., ŠTUDENTOVÁ, H.: Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: A case report and biomarker study. *Pteridines*, 28 (3–4), 2017, 233–241.
- VLČKOVÁ, H., PILAŘOVÁ, V., NOVÁK, O., SOLICH, P., NOVÁKOVÁ, L.: Micro-SPE in pipette tips as a tool for analysis of small-molecule drugs in serum. *Bioanalysis*, 9 (11), 2017, 887–901.
- VRANÍKOVÁ, B., PAVLOKOVÁ, S., GAJZDIK, J.: Experimental design for determination of effects of superdisintegrant combinations on liquisolid system properties. *Journal of Pharmaceutical Sciences*, 106 (3), 2017, 817–825.
- VYTRÍŠALOVÁ, M., TOUŠKOVÁ, T., FUKSA, L., KARASČÁK, R., PALÍČKA, V., BÝMA, S., ŠTĚPÁN, J.: How general practitioners and their patients adhere to osteoporosis management: A follow-up survey among Czech general practitioners. *Frontiers in Pharmacology*, 8, 2017, art. 258.
- WALLMEYER, L., DIETERT, K., SOCHOROVÁ, M., GRUBER, A., KLEUSER, B., VÁVROVÁ, K., HEDTRICH, S.: TSLP is a direct trigger for T cell migration in filaggrin-deficient skin equivalents. *Scientific Reports*, 7, 2017, art. 774.
- ZELENÁ, L., ŘEZNÍČEK, J., ČEČKOVÁ, M., SKLENÁŘOVÁ, H.: Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV. *Journal of Pharmaceutical and Biomedical Analysis*, 137, 2017, 70–77.
- ZEMANOVÁ, L., KIRUBAKARAN, P., HERNANDO PATO, I., ŠTAMBERGOVÁ, H., VONDRÁŠEK, J.: The identification of new substrates of human DHRS7 by molecular modeling and *in vitro* testing. *International Journal of Biological Macromolecules*, 105, 2017, 171–182.
- ZIMČÍK, P., MÁLKOVÁ, A., HRUBÁ, L., MILETÍN, M., NOVÁKOVÁ, V.: Bulky 2,6-diphenylphenylsulfanyl substituents efficiently inhibit aggregation in phthalocyanines and tetrapyrroloporphyrazines and control their photophysical and electrochemical properties. *Dyes and Pigments*, 136, 2017, 715–723.

ZIMČIKOVÁ, E., ŠIMKO, J., KAREŠOVÁ, I., KREMLÁČEK, J., MALÁKOVÁ, J.: Behavioral effects of antiepileptic drugs in rats: Are the effects on mood and behavior detectable in open-field test? *Seizure*, 52, 2017, 35–40.

ARTICLES IN JOURNALS WITHOUT IMPACT FACTOR AND PROCEEDINGS

- ARNDT, T., DOHNAL, F.: Osudy židovských farmaceutů z českých zemí během holocaustu (The fate of Jewish pharmacists from the Czech Lands during the holocaust). *Česká a slovenská farmacie*, 66 (1), 2017, 35–45.
- ARNDT, T., DOHNAL, F.: Příběh jednoho zmizelého světa. Lékárna U bílého jednorožce v Praze, její osud a osud jejich majitelů (nejen) ve dvacátém století (The story of a vanished world. The White Unicorn Pharmacy in Prague, its destiny and the destiny of its owners (not only) into the twentieth century). *Dvacáté století / The Twentieth Century*, 9 (1), 2017, 120–141.
- ARNDT, T., DOHNAL, F.: Významné osobnosti z řad židovských farmaceutů z českých zemí od 18. do 20. století (Significant persons from the Jewish pharmacists of the Czech Lands from 18th to 20th century). In: *Medicína, farmacie a veterinární lékařství: Kapitoly k dějinám a vybraným tématům*. Brno, Technické muzeum, 2017, 71–77. ISBN 978-80-87896-43-3.
- BABICA, J., VALÁŠKOVÁ, L., SVATOŠ, L.: České farmaceutické muzeum a jeho nová expozice Z apatyky do fabriky (Czech Pharmaceutical Museum and its new exhibition called From Pharmacy to Factory). In: *Medicína, farmacie a veterinární lékařství: Kapitoly k dějinám a vybraným tématům*. Brno, Technické muzeum, 2017, 7–17. ISBN 978-80-87896-43-3.
- DOHNAL, F.: Několik poznámek k historii oboru válečná chirurgie v českých zemích do roku 1939 (Several notes on the history of the branch of military surgery in the Czech lands until 1939). In: *Medicína, farmacie a veterinární lékařství: Kapitoly k dějinám a vybraným tématům*. Brno, Technické muzeum, 2017, 40–45. ISBN 978-80-87896-43-3.
- ČÁŇOVÁ, K., ROZKYDALOVÁ, L., RUDOLF, E.: Anthelmintic flubendazole and its potential use in anticancer therapy. *Acta Medica (Hradec Králové)*, 60 (1), 2017, 5–11.
- DVOŘÁČKOVÁ, S., LÁDOVÁ, K., MALÝ, J., KOLÁŘ, J., PENKA, M.: Adherence k léčbě non-vitamin K perorálními antikoagulancii u nevalvulární fibrilace síní: Přehled literatury (Medication adherence to non-vitamin K antagonist oral anticoagulants at non-valvular atrial fibrillation: The literature review). *Vnitřní lékařství*, 63 (10), 2017, 633–639.
- ENCARNACAO, J., BÁRTA, P., FORNSTEDT, T., ANDERSSON, K.: Impact of assay temperature on antibody binding characteristics in living cells: A case study. *Biomedical Reports*, 7 (5), 2017, 400–406.
- KESTŘÁNEK, J., LEŠKO, D., BUCHTA, V., JÍLEK, P., ŠPAČEK, J.: Aktuální pohled na možnosti diferenciální diagnostiky a léčby vulvovaginálního diskomfortu (Current view on diagnostics and treatment possibilities of vulvovaginal discomfort). *Gynekologie a porodnictví*, 1 (5), 2017, 310–318.
- LÁDOVÁ, K., MALÝ, J., VEGERBAUER, M., THOMSON, P.: Použití neregistrovaných léčiv na příkladech v pediatrii (Unlicensed drug use in examples from pediatric practice). *Pediatric pro praxi*, 18 (1), 2017, 22–26.
- LEŠKO, D., BUCHTA, V., SALAVEC, M., JÍLEK, P., KESTŘÁNEK, J., DRBOHLAVOVÁ, A., ŠPAČEK, J.: Současné využití technik v diagnostice recidivujícího vulvovaginálního diskomfortu (Current use of techniques in the diagnosis of recurrent vulvovaginal discomfort). *Česká gynekologie*, 82 (2), 2017, 152–157.
- MALÝ, J., MALÁ, K.: XIX. symposium klinické farmacie René Macha (XIX. Symposium on Clinical Pharmacy René Mach). Hradec Králové, Farmaceutická fakulta UK, 2017, 81 pp. ISBN 978-80-906644-1-8.
- MELICHAR, B., SPISAROVÁ, M., BARTOUŠKOVÁ, M., KUJOVSKÁ KRČMOVÁ, L., JAVORSKÁ, L., ŠTUDENTOVÁ, H.: Neopterin as a biomarker of immune response in cancer patients. *Annals of Translational Medicine*, 5 (13), 2017, art. 280.
- NACHTIGAL, P., ŠIMŮNEK, T., ATKINSON, J.: Pharmacy Practice and Education in the Czech Republic. *Pharmacy*, 5 (4), 2017, art. 54.
- PETRŽELOVÁ, M., HORÁK, P., HORDĚJČUKOVÁ, A., MATYSOVÁ, L.: Omeprazolová suspenze 2 mg/ml – Nová léková forma pro pediatrii (Omeprazole suspension 2 mg/ml – A new dosage form for pediatric use). *Praktické lékařství*, 13 (1), 2017, 18–20.
- VAŇKOVÁ, B., MALÝ, J., MALÁ, K., DUSILOVÁ SULKOVÁ, S.: Analýza lékových problémů u pacientů po transplantaci ledvin – kazuistiky (Analysis of drug-related problems in patients after kidney transplantation – Case reports). *Aktuality v nefrologii*, 23 (4), 2017, 191–201.

- VÁVROVÁ, K., KOVÁČIK, A., OPÁLKA, L.: Ceramides in the skin barrier. *European Pharmaceutical Journal*, 64 (2), 2017, 28–35.
- VOSÁTKA, J., DVOŘÁČKOVÁ, S., MALÝ, J., KOLÁŘ, J.: Revize farmakoterapie u polymorbidního geriatrického pacienta se zaměřením na rizika pádu a jejich řešení (The pharmacotherapy review in the polymorbid geriatric patient with focus on the risk of falls and its management). *Praktické lékařství*, 13 (2e), 2017, e16–e24.

MONOGRAPHS AND TEXTBOOKS

- KOLDA, J.: Kuskusbaad – uzdrawisko jako wyraz świadomości człowieka baroku (Kuskusbaad – Spa as a reflection of Baroque man's thinking). In *Elitarny model europejskiego uzdrawiska – ewolucja koncepcji i jej funkcjonowanie w praktyce*. Wrocław, Arboretum, 2017, 35–52. ISBN 978-83-62563-57-9.
- HAVLÍČKOVÁ, I., DOSTÁLOVÁ, Š., KATEROVÁ, Z.: *English for Pharmacy and Medical Bioanalytics*, 2nd ed., Prague, Karolinum Press, 2017. ISBN 978-80-246-2797-7.
- MATOUŠKOVÁ, P.: MicroRNAs and reference gene methodology. In *Handbook of Nutrition, Diet, and Epigenetics*. Cham, Springer, 2017, 1–17. ISBN 978-3-319-31143-2.
- NOVÁKOVÁ, L., PLACHKÁ, K.: Pharmaceutical applications. In *Supercritical Fluid Chromatography*. Amsterdam, Elsevier, 2017, 461–494. ISBN 978-0-12-809207-1.
- NOVÁKOVÁ, L., PLACHKÁ, K., JAKUBEC, P.: Ultra-high performance supercritical fluid chromatography-mass spectrometry. In *Handbook of Advanced Chromatography/Mass Spectrometry Techniques*. London, AOCS Press, 2017, 445–487. ISBN 978-0-12-811732-3.
- NOVÁKOVÁ, L., SVOBODA, P., PAVLÍK, J.: Ultra-high performance liquid chromatography. In *Liquid Chromatography: Fundamentals and Instrumentation*. Amsterdam, Elsevier, 2017, 719–769. ISBN 978-0-12-805393-5.
- SKÁLOVÁ, L., BOUŠOVÁ, I., MACHALA, M., MATOUŠKOVÁ, P., PÁVEK, P., PODLIPNÁ, R., SOUČEK, P., SVOBODOVÁ, H., SZOTÁKOVÁ, B., TREJTNAR, F., VONDRÁČEK, J., WSÓL, V.: *Metabolismus léčiv a jiných xenobiotik (Metabolism of drugs and other xenobiotics)*, 2nd modified and extended ed., Prague, Karolinum Press, 2017. ISBN 978-80-246-3733-4.

DEGREES

Lectures for the Professorship Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2017

doc. RNDr. PETER MIKUŠ, Ph.D.: Associate Professor, Head of the Department of Pharmaceutical Analysis and Nuclear Pharmacy, Comenius University, Faculty of Pharmacy, Bratislava (SK)

Discipline: Analytical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 6. 11. 2015

Continuation: 8. 12. 2015

Title of Lecture: Pokročilé metódy kapilárnej elektroforézy vo farmaceutickej a biomedicinskej analýze (Advanced methods of capillary electrophoresis in pharmaceutical and biomedical analysis), 8. 3. 2016

Appointment: 19. 6. 2017

doc. PharmDr. KATEŘINA VÁVROVÁ, Ph.D.: Associate Professor, Department of Inorganic and Organic Chemistry, Faculty of Pharmacy, Hradec Králové.

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 22. 9. 2016

Continuation: 11. 10. 2016

Title of Lecture: Role ceramidů ve zdravé i nemocné kožní bariéře (The role of ceramides in healthy and sick skin barrier), 13. 12. 2016

Appointment: 19. 6. 2017

doc. PharmDr. TOMÁŠ ŠIMŮNEK, Ph.D.: Associate Professor, Department of Biochemical Sciences, Dean of the Faculty, Faculty of Pharmacy, Hradec Králové.

Discipline: Biochemistry, MŠMT 24 295/2007-30/1

Inauguration: 21. 11. 2016

Continuation: 13. 12. 2016

Title of Lecture: Perspektivy výzkumu toxických a protektivních účinků léčiv na kardiovaskulární systém (Perspectives of the research of toxic and protective effects of drugs on cardiovascular system), 14. 3. 2017

Appointment: 13. 12. 2017

Habilitation Theses and Lectures for Associated Professor Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2017

RNDr. LENKA KUJOVSKÁ KRČMOVÁ, Ph.D.: Senior Lecturer, Department of Analytical Chemistry, Faculty of Pharmacy, Hradec Králové.

Discipline: Analytical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 6. 9. 2016

Continuation: 11. 10. 2016

Habilitation Thesis: Vývoj chromatografických metod pro klinický výzkum (Development of chromatographic methods for clinical research), defended 13. 12. 2016

Title of Lecture: Moderní trendy ve zpracování biologického materiálu v klinickém výzkumu (Modern trends in processing of biological material in clinical research), 13. 12. 2016

Appointment: 1. 2. 2017

Mgr. JARMILA ZBYTOVSKÁ, Dr. rer. nat.: Senior Lecturer, Department of Pharmaceutical Technology, Faculty of Pharmacy, Hradec Králové.

Discipline: Pharmaceutical Technology, MŠMT 29 593/2011-M3

Inauguration: 20. 2. 2017

Continuation: 14. 3. 2017

Habilitation Thesis: Kožní bariéra a možnosti jejího ovlivnění z farmaceutického pohledu (Skin barrier and possibilities of influencing it from the pharmaceutical point of view), defended 13. 6. 2017

Title of Lecture: Nanosložky pro dermální a transdermální podání léčiv (Nanocarriers for dermal and transdermal administration of drugs), 13. 6. 2017

Appointment: 1. 10. 2017

PharmDr. MARTINA ČEČKOVÁ, Ph.D.: Senior Lecturer, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hradec Králové.

Discipline: Human and Veterinary Pharmacology, MŠMT 24 295/2007-30/1

Inauguration: 18. 5. 2017

Continuation: 13. 6. 2017

Habilitation Thesis: Role membránových transportérů ve farmakokinetice a mnohočetné lékové rezistenci (Role of membrane transporters in multi-drug resistance), defended 10. 10. 2017

Title of Lecture: Farmakokinetické lékové interakce zprostředkované transportéry (Pharmacokinetic drug interactions mediated by transporters), 10. 10. 2017

Appointment: 1. 12. 2017

Doctoral Dissertation Theses to obtain the Ph.D. Degree, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2017

Mgr. AMBROŽ, MARTIN: Seskviterpeny v protinádorové terapii (Sesquiterpenes in cancer therapy), 30. 11. 2017, Ph.D.

PharmDr. ARNDT, TOMÁŠ: Československá a česká farmacie – projevy, dopady a důsledky genocidy Židů u dalších forem rasového pronásledování (Czechoslovak and Czech pharmacy – expressions, impacts and consequences of the genocide of Jews and other forms of racial persecution), 7. 12. 2017, Ph.D.

- MSc. BELKINA, TATIANA: Non-prescribed antibiotic use in some developing countries and its association with drug resistance, 2. 5. 2017, Ph.D.
- PharmDr. BENEŠ, MICHAL: Technologické aspekty formulování pevných roztoků (Technological aspects of solid solution formulations), 20. 6. 2017, Ph.D.
- Mgr. CARAZO FERNÁNDEZ, ALEJANDRO JOSÉ: Nuclear receptors – new ligands study and importance of the genetic variability, 29. 6. 2017, Ph.D.
- Mgr. CIDLINA, ANTONÍN: Vliv strukturních aspektů na fotofyzikální vlastnosti ftalocyaninů (Influence of structural aspects on photophysical properties of phthalocyanines), 14. 9. 2017, Ph.D.
- Mgr. ČERVINKOVÁ, BARBORA: Uplatnění moderních separačních technik v analýze biologického materiálu (Application of modern separation techniques in the analysis of biological material), 18. 9. 2017, Ph.D.
- Mgr. HROCH, LUKÁŠ: Inhibitors of mitochondrial enzymes as potential therapeutics for Alzheimer's disease, 14. 9. 2017, Ph.D.
- Mgr. KADOVÁ, ZUZANA: Vliv modulace zánětu na exkretční mechanismy během intrahepatální cholestázy (Influence of inflammation modulation on excretory mechanisms during intrahepatic cholestasis), 29. 6. 2017, Ph.D.
- Mgr. KASALOVÁ, EVA: Moderní separační techniky pro analýzu biologického materiálu v klinickém výzkumu (Modern separation techniques for the analysis of biological material in clinical research), 28. 11. 2017, Ph.D.
- PharmDr. KLOVRZOVÁ, SYLVA: Formulace tekutých pediatrických přípravků v podmínkách nemocniční lékárny (Formulation of extemporaneous paediatric liquid preparations in the hospital pharmacy), 15. 2. 2017, Ph.D.
- Mgr. KOVÁČIK, ANDREJ: Studium vlivu hydroxylace ceramidů na permeabilitu a mikrostrukturu modelových lipidových membrán (Study of effect of ceramide hydroxylation on permeability and microstructure of model lipid membranes), 8. 12. 2017, Ph.D.
- Mgr. LNĚNIČKOVÁ, KATEŘINA: Modulace biotransformačních a antioxidačních enzymů vybranými přírodními látkami (Modulation of biotransformation and antioxidant enzymes by selected natural compounds), 30. 11. 2017, Ph.D.
- Mgr. NAJMANOVÁ, IVETA: Vliv polyfenolických látek na hladký cévní sval (The effect of polyphenolic substances on vascular smooth muscle), 24. 3. 2017, Ph.D.
- Mgr. PILÁŘOVÁ, VERONIKA: Vývoj a optimalizace kroku úpravy vzorku pro rychlé chromatografické analýzy (Development and optimization of sample preparation step for fast chromatographic analysis), 28. 2. 2017, Ph.D.
- Mgr. PRCHAL, LUKÁŠ: Anthelmintic and other xenobiotic biotransformation in helminths and its contribution to resistance development, 30. 11. 2017, Ph.D.
- Mgr. SEMELKOVÁ, LUCIA: Příprava derivátů pyrazinu jako potenciálních antituberkulotik: Studium vztahů mezi chemickou strukturou a biologickou aktivitou (Preparation of pyrazinamide derivatives as potential antituberculars: Study of structure activity relationships), 14. 9. 2017, Ph.D.
- Mgr. SMUTNÝ, TOMÁŠ: Novel approaches for development of *in vitro* liver cell models, 24. 3. 2017, Ph.D.
- Mgr. SVOBODA, PAVEL: Matricové efekty v LC-MS analýze: vznik, hodnocení a jejich odstranění (Matrix effects in LC-MS analysis: occurrence, evaluation, and their elimination), 25. 9. 2017, Ph.D.
- Mgr. ŠESTÁK, VÍT: Analytické a bioanalytické hodnocení nových protinádorových léčiv (Analytical and bio-analytical assessment of novel anticancer drugs), 18. 9. 2017, Ph.D.
- Mgr. TOUŠKOVÁ, TEREZA: Kvalitativní a kvantitativní aspekty adherence v léčbě osteoporózy (Qualitative and quantitative aspects of adherence to osteoporosis treatment), 3. 11. 2017, Ph.D.
- Mgr. VÁCHOVÁ, LENKA: Syntéza a studium fotofyzikálních a fotochemických vlastností ftalocyaninů a azaftalocyaninů (Synthesis and study of photophysical and photochemical properties of phthalocyanines and azaphthalocyanines), 14. 9. 2017, Ph.D.
- Mgr. VAŘEJČKOVÁ, MICHALA: Sledování vlivu statinů a solubilního endoglinu na markery endotelové dysfunkce u vybraných buněčných linií a kultur (Monitoring the effect of statins and soluble endoglin on markers of endothelial dysfunction in selected cell line and culture), 21. 9. 2017, Ph.D.
- Mgr. ZAHÁLKA, LUKÁŠ: Stability studies of oral liquid preparations using HPLC, 25. 9. 2017, Ph.D.

Rigorous Theses to obtain the degree PharmDr. (Doctor of Pharmacy, graduates of the study programme Pharmacy) or RNDr. (Doctor of Natural Sciences, graduates of study programme Bioanalytical Laboratory Diagnostics in Medicine), Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2017

- Mgr. ADAMCOVÁ, MARKÉTA: Studium biologické aktivity alkaloidů izolovaných z *Argemone grandiflora* (Papaveraceae) I. (Study of biological activity of isolated alkaloids from *Argemone grandiflora* (Papaveraceae) I.), 21. 9. 2017, PharmDr.
- Mgr. ANDRÝS, RUDOLF, Ph.D.: Vývoj a aplikace afinitního nosiče pro izolaci lidských karbonyl-redukujících enzymů (Development and applications of affinity carrier for isolation of human carbonyl-reducing enzymes), 10. 2. 2017, PharmDr.
- Mgr. BARVÍNKOVÁ, ZUZANA: Stanovení fluoridů ve vzorcích zubních past pomocí SIA systému (Determination of fluoride in toothpaste using SIA system), 24. 2. 2017, PharmDr.
- Mgr. BAVLOVIČ, JAN: Charakterizace multirezistentních izolátů *Klebsiella pneumoniae* a *Enterococcus faecium* spektroskopickými a genotypickými metodami (Characterisation of multidrug resistant *Klebsiella pneumoniae* and *Enterococcus faecium* isolates by spectroscopic and genotypic method), 17. 2. 2017, PharmDr.
- Mgr. BENEK, ONDŘEJ, Ph.D.: Preparation and evaluation of potential drugs inhibiting mitochondrial enzymes, 06. 3. 2017, PharmDr.
- Mgr. BORKOVCOVÁ, RENÁTA: Vliv rychlosti lisování na parametry testu stresové relaxace (The influence of the tableting speed on the parameters of the stress relaxation test), 19. 12. 2017, PharmDr.
- Mgr. BURGETOVÁ, LENKA: Přípravek s terbinafinem aplikovatelný na mykózy (The application of terbinafine in the treatment of mycosis), 3. 5. 2017, PharmDr.
- Mgr. CIDLINA, ANTONÍN: Syntéza kationických ftalocyaninů (Synthesis of cationic phthalocyanines), 09. 11. 2017, PharmDr.
- Mgr. ČERVINKOVÁ, BARBORA, Ph.D.: Uplatnění moderních separačních technik v analýze biologického materiálu (Application of modern separation techniques in the analysis of biological material), 30. 10. 2017, RNDr.
- Mgr. DĚDKOVÁ, LUCIE: Sekvenční injekční chromatografie – testování moderních chromatografických kolon pro rychlé a efektivní separace (Sequential injection chromatography – testing of modern chromatographic columns for fast and effective separations), 24. 10. 2017, PharmDr.
- Mgr. DOLÁKOVÁ, ANDREA: Štúdium monovrstevných lipidových modelov ochorení kožnej bariéry (Study of monolayer lipid models of skin barrier diseases), 19. 12. 2017, PharmDr.
- Mgr. DRASTÍKOVÁ, MARKÉTA, Ph.D.: Využití separačních metod v klinickém výzkumu (Using of separation methods for clinical research), 30. 10. 2017, RNDr.
- Mgr. ĎURIŠOVÁ, MARKÉTA: Studium role nukleosidových transportéru v intestinální absorpci s využitím *in vitro* transportního modelu založeném na buněčné linii Caco-2 (Study of the role of nucleoside transporters in intestinal absorption with the use of *in vitro* transport method based on the Caco-2 cell line), 22. 9. 2017, PharmDr.
- Mgr. FARKAŠOVSKÝ, MAREK: Alkaloidy *Narcissus pseudonarcissus* L. cv. Dutch Master a ich cholinesterázová a prolyloligopeptidázová inhibiční aktivita (Alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master and their cholinesterase and prolyl oligopeptidase inhibitory activity), 21. 9. 2017, PharmDr.
- Mgr. FEKETE, SOŇA, Ph.D.: The effect on bone metabolism of selected substances affecting the central nervous system, 10. 2. 2017, RNDr.
- Mgr. FIŠEROVÁ, KATEŘINA: Vliv albendazolu na proliferaci buněk *in vitro* (Influence of albendazole on cell proliferation *in vitro*), 10. 2. 2017, RNDr.
- Mgr. HERBOLT, DANIEL: Vývoj nové spektrofotometrické metodiky pro screening chelatace iontů zinku (Development of a novel spectrophotometric method for zinc ions chelation screening), 22. 9. 2017, PharmDr.
- Mgr. HESSLER, FILIP, Ph.D.: Využití couplingových reakcí k syntéze potenciálně biologicky aktivních látek (Use of coupling reactions in the synthesis of potentially biologically active compounds), 24. 2. 2017, PharmDr.
- Mgr. HOFMANOVÁ, TEREZA: Léková pochybení u psychiatricky nemocných pacientů (Dosage errors in psychiatrically diagnosed patients), 02. 1. 2017, PharmDr.
- Mgr. HOLZNEROVÁ, ANEŽKA: Testování a optimalizace on-line SPE HPLC podmínek pro stanovení mykotoxinu patulinu v jablečných nápojích (On-line SPE HPLC method optimization for determination of patulin mycotoxin in apple drinks), 30. 10. 2017, RNDr.

- Mgr. HROCH, LUKÁŠ, Ph.D.: Inhibitors of mitochondrial enzymes as potential therapeutics for Alzheimer's disease, 09. 11. 2017, PharmDr.
- Mgr. JAKUBÍKOVÁ, HANA: Liberace terbinafinu z polyesterů větvených kyselinou polyakrylovou (The release of terbinafine from polyesters branched with polyacrylic acid), 3. 5. 2017, PharmDr.
- Mgr. JANĎOUREK, ONDŘEJ, Ph.D.: Deriváty pyrazinu jako potenciální antituberkulotika – příprava a studium biologických vlastností (Derivatives of pyrazine as potential antituberculars – preparation and study of biological properties), 6. 3. 2017, PharmDr.
- Mgr. JANOUŠEK, MARTIN: Využití zlatného katalyzátoru při syntéze substituovaných pyridinů (The synthesis of substituted pyridines employing gold(I) catalyst), 24. 2. 2017, PharmDr.
- Mgr. JANSOVÁ, HANA, Ph.D.: Studium možnosti farmakologické ochrany srdečních buněk před oxidačním stresem a antracyklinovými cytostatiky (Study of potential pharmacological protection of cardiac cells against oxidative stress and antiradical anticancer drugs), 21. 3. 2017, PharmDr.
- Mgr. JEDLIČKOVÁ, ADÉLA: *In vitro* hodnocení fotodynamické aktivity derivátů tetrapyridoporphyrinu pro léčbu solidních nádorů (*In vitro* evaluation of photodynamic activity of tetrapyridoporphyrine derivatives for treatment of solid tumours), 10. 2. 2017, RNDr.
- Mgr. JEŘÁBEK, JAKUB: Design and synthesis of hybrid compounds based on tacrin/resveratrol derivatives, 09. 11. 2017, PharmDr.
- Mgr. JEŘÁBKOVÁ, JANA: Výzkum nových liganů FXR receptoru (Study of novel FXR ligands), 22. 9. 2017, PharmDr.
- Mgr. KATRNOŠKOVÁ, SIMONA: Studium cytotoxicity potenciálních antituberkulotik s využitím vybraných metod na jaterní a ledvinné buněčné linii (Study of cytotoxicity of potential antituberculars using selected methods on liver and kidney cell line), 17. 2. 2017, PharmDr.
- Mgr. KOMRSKOVÁ, JITKA: Hledání a testování nových inhibitorů vybraného mykobakteriálního enzymu (Identification of new potent inhibitors of selected mycobacterial enzyme), 25. 9. 2017, RNDr.
- Mgr. KONDĚLKOVÁ, KATEŘINA, Ph.D.: Vliv Goeckermanovy terapie na vybrané parametry imunity u pacientů s psoriázou (The effect of Goeckerman therapy on selected immune markers in patients with psoriasis), 10. 2. 2017, RNDr.
- Mgr. KOŠŤÁKOVÁ, ŠÁRKA: Stanovení aktivity a exprese vybraných isoform glutathion-*S*-transferasy v *in vivo* modelu glutamátem navozené obezity (Assessment of activity and expression of selected isoforms of glutathione *S*-transferase in the *in vivo* model of glutamate-induced obesity), 10. 2. 2017, RNDr.
- Mgr. KRATOCHVÍL, JIŘÍ, Ph.D.: Syntéza specificky substituovaných heterocyklů katalytickými reakcemi (Synthesis of specifically substituted heterocycles via catalytic reactions), 24. 2. 2017, PharmDr.
- Mgr. KRŽÍŽOVÁ, KATEŘINA: Vývoj a validace HPLC metody pro stanovení antokyanů v kanadských borůvkách (HPLC method development and validation for analysis of anthocyanins in highbush blueberries), 24. 2. 2017, PharmDr.
- Mgr. KUBEŠ, JAN, Ph.D.: Transportní mechanismy sekundárních metabolitů přes membrány rostlinných buněk (Transport mechanisms of secondary metabolites across membranes of plant cells), 16. 1. 2017, PharmDr.
- Mgr. LOKVENCOVÁ, KATEŘINA: Farmakokinetika ivermektinu v trusu ovce domácí (The pharmacokinetics of ivermectin in the feces of *Ovis ammon*), 25. 9. 2017, PharmDr.
- Mgr. MARTAN, DAVID: Influence of TNF- α on hENaC subunits expression, 25. 9. 2017, PharmDr.
- Mgr. MIKUŠEK, JIŘÍ, Ph.D.: Syntéza a využití vybraných dusíkatých heterocyklů (Synthesis and utilization of selected nitrogen heterocycles), 24. 2. 2017, PharmDr.
- Mgr. MÍSAŘ, JAKUB: Interakce fenylpropionových kyselin se železem (Interaction of phenylpropionic acids with iron), 16. 1. 2017, PharmDr.
- Mgr. MOTLOVÁ, TEREZA: Studium vlivu kluzných látek na průběh lisování tabletoviny s mikrokrystalickou celulosou (The evaluation of the influence of lubricants on the compaction process of tableting mixtures with microcrystalline cellulose), 3. 5. 2017, PharmDr.
- Mgr. NOVÁKOVÁ, DANA: Studium plazmatické vazebnosti radiofarmak značených ^{18}F z hlediska mezidruhového srovnání (Study of interspecies differences in plasma protein binding of ^{18}F -labeled radiopharmaceuticals), 17. 2. 2017, PharmDr.
- Mgr. OPÁLKA, LUKÁŠ, Ph.D.: Syntéza lidských ω -*O*-acylceramidů a hodnocení jejich vlivu na bariérové vlastnosti kožních lipidových membrán (Synthesis of human ω -*O*-acylceramides and evaluation of their effects on barrier properties of skin lipid membranes), 24. 2. 2017, PharmDr.

- Mgr. PAŠKOVÁ, BARBORA: Studium antimykotické aktivity nově syntetizovaných sloučenin (The study of antimycotic activity of newly synthesized substances), 17. 02. 2017, PharmDr.
- Mgr. PÁSZTÓ, LENKA: Biologická aktivita makromycet – D (Biological activity of macromycetes – D), 30. 5. 2017, PharmDr.
- Mgr. PAVLÍK, FRANTIŠEK: Metabolismus anthelmintik v rostlinách (Metabolism of anthelmintics in plants), 10. 2. 2017, PharmDr.
- Mgr. PECHOVÁ, MARTINA: Stanovení vybraných fenolických látek v ovoci (Determination of selected phenolic compounds in fruit), 30. 10. 2017, RNDr.
- Mgr. PETLÁNOVÁ, TEREZA: Studium interakce nově syntetizovaných sloučenin s bakteriálním agens (Study of the interaction of newly synthesized compounds with bacterial agents), 17. 2. 2017, PharmDr.
- Mgr. PILAŘOVÁ, VERONIKA, Ph.D.: Vývoj a optimalizace kroku úpravy vzorku pro rychlé chromatografické analýzy (Development and optimization of sample preparation step for fast chromatographic analysis), 9. 10. 2017, PharmDr.
- Mgr. PILKOVÁ, ALENA: Identifikace a analýza terapie užívané těhotnými ženami (Identification and analysis of therapy used by pregnant women), 7. 4. 2017, PharmDr.
- Mgr. PIMKOVÁ, KRISTÝNA, Ph.D.: Proteomická analýza vybraných onkohematologických onemocnění (Proteomic analysis of selected oncohematological diseases), 10. 2. 2017, RNDr.
- Mgr. PIPOTOVÁ, HELENA: Vliv průběhu těhotenství na vznik alergií u dětí – porovnání studií z let 2005 a 2011 (The influence of course of pregnancy on the risk of allergies in children – studies comparison from the year 2005 and from the year 2011), 22. 9. 2017, PharmDr.
- Mgr. POLÁKOVÁ, TEREZIE: Asociace utilizace nutričních substrátů a prediktorů morbidity a mortality u pacientů s CHOPN (Association of nutrition substrate utilization and predictors of morbidity and mortality in patients with COPD), 17. 2. 2017, PharmDr.
- Mgr. POLONIOVÁ, VERONIKA: Epilepsie v dětské populaci v okrese Bruntál – farmakoterapeutické postupy a zkušenosti v léčbě (Epilepsy in children in the Bruntál district – experience of pharmaceutical treatment), 22. 9. 2017, PharmDr.
- Mgr. POPOVSKÁ, LENKA: Optimalizace postupu izolace fosforylovaných peptidů ze směsi metodou afinitní chromatografie na oxidech kovů pro analýzu hmotnostní spektrometrií (Optimization of procedure for isolation of phosphorylated peptides from a peptide mixture by metal oxide affinity chromatography for mass spectrometry analysis), 30. 10. 2017, RNDr.
- Mgr. POSPĚCHOVÁ, LUCIE: Neuroprotective and antioxidant effects of a series of coumarins in *in vitro* Alzheimer's disease models, 22. 9. 2017, PharmDr.
- Mgr. RUDECKÁ, KATEŘINA: Formulace a (trans)dermální podání imiquimodu (Formulation and (trans)dermal application of imiquimod), 26. 10. 2017, PharmDr.
- Mgr. RŮŽIČKOVÁ, MICHAELA: Vyhledání referenčních genů pro relativní kvantifikaci mRNA z *Haemonchus contortus* (Reference gene selection for mRNA quantification in *Haemonchus contortus*), 10. 2. 2017, PharmDr.
- Mgr. SEMELKOVÁ, LUCIA, Ph.D.: Příprava derivátů pyrazinu jako potenciálních antituberkulotik: Studium vztahů mezi chemickou strukturou a biologickou aktivitou (Preparation of pyrazinamide derivatives as potential antituberculotics: Study of structure activity relationships), 9. 11. 2017, PharmDr.
- Mgr. SCHIMMEROVÁ, ANETA: Příprava nesymetrického azafthalocyaninu pro značení DNA sond zvyšujících citlivost molekulárně-biologických metod (Synthesis of low-symmetry azaphthalocyanine for the labeling of DNA probes increasing the susceptibility of the molecular-biological methods), 9. 11. 2017, PharmDr.
- Mgr. SLEZÁČKOVÁ, JANA: Vliv teploty sušení na vlastnosti sprejově sušené laktosy (The effect of the drying temperature on the properties of spray-dried lactose), 26. 10. 2017, PharmDr.
- Mgr. SKOŘEPOVÁ, ZUZANA: Hodnocení vlastností granulátů a tablet připravených ze škrobů (Evaluation of the properties of granules and tablets prepared from starch), 3. 5. 2017, PharmDr.
- Mgr. SMUTNÝ, TOMÁŠ, Ph.D.: Novel approaches for development of *in vitro* liver cell models (Nové přístupy ve vývoji *in vitro* jaterních buněčných modelů), 22. 9. 2017, PharmDr.
- Mgr. STACHOVÁ, HANA: Vývoj HPLC metody pro stanovení umělých barviv ve vzorcích zeleného piva (HPLC method development for artificial colorants determination in green beer samples), 30. 10. 2017, RNDr.
- Mgr. STUDENÁ, HANA: Problematika obsahu těžkých kovů v rostlinných drogách: Sambuci nigrae fructus (The problems of content of heavy metals in herbal drugs: Sambuci nigrae fructus), 30. 10. 2017, RNDr.

- Mgr. ŠAFRATOVÁ, MARCELA, Ph.D.: Studium inhibičního (toxického) vlivu alkaloidů vybraných druhů rostlin z čeledi Amaryllidaceae na některé lidské enzymové systémy (*in vitro* studie) III (Study of inhibition (toxicity) activity of alkaloids from selected plant species of Amaryllidaceae family on human enzyme systems (*in vitro* study) III), 16. 1. 2017, PharmDr.
- Mgr. ŠEBL, RENĚ: Syntéza substituovaných pyrazino[2,3-*b*]pyrazinů jako prekurzorů azaftalocyaninů (Synthesis of pyrazino[2,3-*b*]pyrazines – azaphthalocyanine precursors), 6. 3. 2017, PharmDr.
- Mgr. ŠENITKOVÁ, IVA, Ph.D.: Strukturální a funkční analýza faktorů virulence mikroba *Francisella tularensis* (Structural and functional analysis of *Francisella tularensis* virulence factors), 16. 6. 2017, RNDr.
- Mgr. ŠESTÁK, VÍT, Ph.D.: Analytické a bioanalytické hodnocení nových protinádorových léčiv (Analytical and bioanalytical assessment of novel anticancer drugs), 9. 10. 2017, PharmDr.
- Mgr. ŠILAROVÁ, MICHAELA: Permeabilita a mikrostruktura modelových lipidových membrán stratum corneum: srovnání nehydroxylovaných a (*R*)- a (*S*)- α -hydroxylovaných ceramidů (The permeability and microstructure of model stratum corneum lipid membranes: comparison of non-hydroxylated and (*R*)- and (*S*)- α -hydroxylated ceramides), 31. 10. 2017, PharmDr.
- Mgr. ŠKOLOVÁ, BARBORA, Ph.D.: Syntéza a studium analogů ceramidů (Synthesis and study of ceramide analogues), 24. 2. 2017, PharmDr.
- Mgr. ŠTURCOVÁ, KLÁRA: Analýza farmakoterapie u pacientů ve zdravotnickém zařízení následné péče I (Analysis of the pharmacotherapy in patients in aftercare health facility I), 29. 3. 2017, PharmDr.
- Mgr. ŠTURMOVÁ, ZUZANA: Studium přímo lisovatelných tabletovin s granulovanou α -laktosou monohydrátem a mazadly (The study of directly compressible tableting materials with granulated α -lactose monohydrate and lubricants), 19. 12. 2017, PharmDr.
- Mgr. ŠUMPELOVÁ, KATEŘINA: Účinek kvercetinů a jeho vybraných metabolitů na izolovaných aortálních kroužcích potkana (The effect of quercetin and its selected metabolites on isolated aortal rings of rat), 22. 9. 2017, PharmDr.
- Mgr. ŠVIDRNOCHOVÁ, MICHAELA: Vliv derivátů benzoxazindionu na vybrané mykobakteriální enzymy (Influence of benzoxazinedione derivatives on selected mycobacterial enzymes), 10. 2. 2017, PharmDr.
- Mgr. TAMBOROVÁ, BARBORA: Assessment of chelation of cupric ions with flavones by use of hematoxylin method, 16. 1. 2017, PharmDr.
- Mgr. TRHLÍKOVÁ, ANNA: Hodnocení reologických a adhezivních vlastností polotuhých excipientů (Evaluation of rheological and adhesive properties of semisolid excipients), 3. 5. 2017, PharmDr.
- Mgr. UHLÍŘOVÁ, ŠTĚPÁNKA: Příprava fluorescenčních senzorů odvozených od azaftalocyaninů se zvýšenou selektivitou pro vybrané kationty kovů (Syntheses of azaphthalocyanine fluorescence sensors with the improved selectivity towards desired metal cations), 9. 11. 2017, PharmDr.
- Mgr. URBANOVÁ, MARTINA: Využití disperzní extrakce na tuhou fázi pro analýzu vybraných obsahových látek zázvorovníku lékařského (Dispersive solid-phase extraction for the analysis of chosen substances in *Zingiber officinale*), 24. 2. 2017, PharmDr.
- Mgr. VAŇÁSKOVÁ, BARBORA, Ph.D.: Deriváty pyrazinkarboxylové kyseliny jako potenciální antituberkulotika – příprava a studium biologických vlastností (Derivatives of pyrazinecarboxylic acid as potential antituberculars – synthesis and biological evaluation), 6. 3. 2017, PharmDr.
- Mgr. VAVREČKOVÁ, MAGDA: Syntéza potenciálně fotodynamicky aktivních derivátů tetrapyrído-porfyrazinů (Synthesis of tetrapyrroloporphyrazines with potential photodynamic activity), 6. 3. 2017, PharmDr.
- Mgr. VEREŠOVÁ, ERIKA: Účinek vybraných seskviterpénů na antioxidantní enzymy v diferencované buněčné linii Caco-2 (The impact of selected sesquiterpenes on the activity of antioxidant enzymes in the differentiated Caco-2 cell line), 10. 2. 2017, PharmDr.
- Mgr. VYHLÍDALOVÁ, BARBORA: Studium přímo lisovatelných tabletovin s aglomerovanou α -laktosou monohydrátem a mazadly (The study of directly compressible tableting materials with agglomerated α -lactose monohydrate and lubricants), 26. 10. 2017, PharmDr.
- Mgr. ZAPPE, LUKÁŠ: Role of disulphide bonds in hA_{2A} subtype adenosine receptor, 25. 9. 2017, PharmDr.

PUBLICATIONS OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ, CHARLES UNIVERSITY IN THE YEAR 2018

ORIGINAL PAPERS AND REVIEWS

- ANDRŠ, M., POSPÍŠILOVÁ, M., SEIFRTOVÁ, M., HAVELEK, R., TICHÝ, A., VEJRYCHOVÁ, K., POLEDNÍKOVÁ, M., GÓRECKI, L., JUN, D., KORÁBEČNÝ, J., ŘEZÁČOVÁ, M.: Purin-6-one and pyrrolo[2,3-*d*]pyrimidin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity. *Future Medicinal Chemistry*, 10 (17), 2018, 2029–2038.
- APPOLOVÁ, L., VELJOVIČ, E., MURATOVIĆ, S., KARLÍČKOVÁ, J., MACÁKOVÁ, K., ZAVRŠNIK, D., SASO, L., DURIC, K., MLADĚNKA, P.: 9-(4'-Dimethylaminophenyl)-2,6,7-trihydroxyxanthene-3-one is a potentially novel antiplatelet drug which antagonizes the effect of thromboxane A₂. *Medicinal Chemistry*, 14 (2), 2018, 200–209.
- BALANSIN RIGON, R., KAESSMEYER, S., WOLFF, C., HAUSMANN, C., ZHANG, N., SOCHOROVÁ, M., KOVÁČIK, A., HAAG, R., VÁVROVÁ, K., ULRICH, M., SCHÄFER-KORTING, M., ZOSCHKE, C.: Ultrastructural and molecular analysis of ribose-induced glycated reconstructed human skin. *International Journal of Molecular Sciences*, 19 (11), 2018, art. 3521.
- BAUDISCHOVÁ, L., STRÁŽNICKÁ, J., POKLADNÍKOVÁ, J., JAHODÁŘ, L.: The quality of information on the internet relating to top-selling dietary supplements in the Czech Republic. *International Journal of Clinical Pharmacy*, 40 (1), 2018, 183–189.
- BERÁNEK, M., FIALA, Z., KREMLÁČEK, J., ANDRÝS, C., KREJSEK, J., HAMÁKOVÁ, K., PALIČKA, V., BORSKÁ, L.: Serum levels of aryl hydrocarbon receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. *Folia Biologica*, 64 (3), 2018, 97–102.
- BERLEC, A., ŠKRLEC, K., KOJAN, J., OLENIC, M., ŠTRUKELJ, B.: Single plasmid systems for inducible dual protein expression and for CRISPR-Cas9/CRISPRi gene regulation in lactic acid bacterium *Lactococcus lactis*. *Scientific Reports*, 8 (January), 2018, art. 1009.
- BOHDÁLKOVÁ, L., BOHDÁLEK, P., BRÍZOVÁ, E., PACHEROVÁ, P., KUBĚNA, A.: Atmospheric metal pollution records in the Kovářská Bog (Czech Republic) as an indicator of anthropogenic activities over the last three millennia. *Science of the Total Environment*, 633 2018, 857–874.
- BORISOV, S., POMMER, R., ŠVEC, J., PETERS, S., NOVÁKOVÁ, V., KLIMANT, I.: New red-emitting Schiff base chelates: Promising dyes for sensing and imaging of temperature and oxygen via phosphorescence decay time. *Journal of Materials Chemistry C*, 6 (33), 2018, 8999–9009.
- BOUZ, G., AL HASAWI, N.: The zebrafish model of tuberculosis – No lungs needed. *Critical Reviews in Microbiology*, 44 (6), 2018, 779–792.
- BRABCOVÁ, I., HAJDUCHOVÁ, H., TÓTHOVÁ, V., BÁRTLOVÁ, S., FILKA, J., DOSEDĚL, M., MALÝ, J., VLČEK, J.: Analysis of selected cases of falls of hospitalized patients. *Journal of Nursing, Social Studies, Public Health and Rehabilitation*, 9 (3–4), 2018, 121–128.
- BRABCOVÁ, I., HAJDUCHOVÁ, H., TÓTHOVÁ, V., BÁRTLOVÁ, S., FILKA, J., DOSEDĚL, M., MALÝ, J., VLČEK, J.: Selected risk factors of falls in hospitalized patients: A case-control study. *Neuroendocrinology Letters*, 39 (7), 2018, 481–488.
- BREITEROVÁ, K., LOČÁREK, M., KOHELOVÁ, E., TALÁČKOVÁ, M., HULCOVÁ, D., OPLETAL, L., CAHLÍKOVÁ, L.: Daffodils as potential crops of biologically-active compounds: Assessment of 40 ornamental taxa for their alkaloid profile and cholinesterases inhibition activity. *Natural Product Communications*, 13 (4), 2018, 419–422.
- CARAZO FERNÁNDEZ, A. J., DUŠEK, J., HOLAS, O., ŠKODA, J., HYRŠOVÁ, L., SMUTNÝ, T., SOUKUP, T., DOSEDĚL, M., PÁVEK, P.: Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. *Frontiers in Pharmacology*, 9, 2018, art. 993.
- CATAPANO, M. C., KARLÍČKOVÁ, J., TVRDÝ, V., SHARMA, S., PRASAD, A., SASO, L., CHILLAR, A., KUNEŠ, J., POUR, M., PARMAR, V., MLADĚNKA, P.: Mono and dihydroxy coumarin derivatives: Copper chelation and reduction ability. *Journal of Trace Elements in Medicine and Biology*, 46, 2018, 88–95.

- CATAPANO, M. C., TVRDÝ, V., KARLÍČKOVÁ, J., MERCOLINI, L., MLADĚNKA, P.: A simple, cheap but reliable method for evaluation of zinc chelating properties. *Bioorganic Chemistry*, 77, 2018, 287–292.
- CSANÁDI, M., KALÓ, Z., PRINS, CH. P. J., GRÉLINGER, E., MENCZELNÉ KISS, A., FRICKE, F., FUKSA, L., TESAR, T., MANOVA, M., LORENZOVICI, L., VOKÓ, Z., GARRISON, L. P.: The implications of external price referencing on pharmaceutical list prices in Europe. *Health Policy and Technology*, 7 (3), 2018, 243–250.
- ČEČKOVÁ, M., ŘEZNÍČEK, J., DEUTSCH, B., FROMM, M., ŠTAUD, F.: Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate). *PLoS One*, 13 (8), 2018, art. e0202706.
- ČEPA, A., RÁLIŠ, J., KRÁL, V., PAŮROVÁ, M., KUČKA, J., HUMAJOVÁ, J., LÁZNÍČEK, M., LEBEDA, O.: *In vitro* evaluation of the monoclonal antibody Cu-64-IgG M75 against human carbonic anhydrase IX and its *in vivo* imaging. *Applied Radiation and Isotopes*, 133, 2018, 9–13.
- ČERVENÝ, L., PTÁČKOVÁ, Z., ČEČKOVÁ, M., KARAHODA, R., KARBANOVÁ, S., JIRÁSKOVÁ, L., GREENWOOD, S. L., GLAZIER, J. D., ŠTAUD, F.: Equilibrative nucleoside transporter 1 (ENT1, SLC29A1) facilitates transfer of the antiretroviral drug abacavir across the placenta. *Drug Metabolism and Disposition*, 46 (11), 2018, 1817–1826.
- ČERVENÝ, L., PTÁČKOVÁ, Z., ĎURIŠOVÁ, M., ŠTAUD, F.: Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats. *Reproductive Toxicology*, 79, 2018, 57–65.
- DEMUTH, J., KUČERA, R., KOPECKÝ, K., HAVLÍNOVÁ, Z., LIBRA, A., NOVÁKOVÁ, V., MILETÍN, M., ZIMČÍK, P.: Efficient synthesis of a wide-range absorbing azaphthalocyanine dark quencher and its application to dual-labeled oligonucleotide probes for quantitative real-time polymerase chain reactions. *Chemistry – A European Journal*, 24 (38), 2018, 9658–9666.
- DISPAS, A., MARINI, R., DESFONTAINE, V., VEUTHEY, J., KOTONI, D., LOSACCO, L., CLARKE, A., GALEA, C., MANGELINGS, D., JOCHER, B., REGALADO, E., PLACHKÁ, K., NOVÁKOVÁ, L., WUYTS, B., FRANÇOIS, I., GRAY, M., AUBIN, A., TARAFDER, A., CAZES, M., DESVIGNES, C., VILLEMET, L., SARRUT, M., RAIMBAULT, A., LEMASSON, E., LESELLIER, E., WEST, C., LEEK, T., WONG, M., DAI, L., ZHANG, K., PERRENOUD, A. G., BRUNELLI, C., HENNIG, P., BERTIN, S., MAUGE, F., Da COSTA, N., FARRELL, W. P., HILL, M., DESPHANDE, N., GRANGRADE, M., SADA-PHULE, S., YADAV, R., RANE, S., SHRINGARE, S., IGUINIZ, M., HEINISCH, S., LEFEVRE, J., CORBEL, E., ROQUES, N., VANDER HEYDEN, Y., GUILLARME, D., HUBERT, P.: First inter-laboratory study of a supercritical fluid chromatography method for the determination of pharmaceutical impurities. *Journal of Pharmaceutical and Biomedical Analysis*, 161, 2018, 414–424.
- DOVRTĚLOVÁ, G., ZENDULKA, O., NOSKOVÁ, K., JUŘICA, J., PES, O., DUŠEK, J., CARAZO FERNÁNDEZ, A. J., ZAPLETALOVÁ, I., HLAVÁČOVÁ, N., PÁVEK, P.: Effect of endocannabinoid oleamide on rat and human liver cytochrome P450 enzymes in *in vitro* and *in vivo* models. *Drug Metabolism and Disposition*, 46 (6), 2018, 913–923.
- DUINTJER TEBBENS, E. J., AZAR, M., FRIEDMANN, E., LANZENDÖRFER, M., PÁVEK, P.: Mathematical models in the description of pregnane X receptor (PXR)-regulated cytochrome P450 enzyme induction. *International Journal of Molecular Sciences*, 19 (6), 2018, art. 1785.
- DUŠEK, T., ÖRHALMI, J., SOTONA, O., KUJOVSKÁ KRČMOVÁ, L., JAVORSKÁ, L., DOLEJŠ, J., PÁRAL, J.: Neopterin, kynurenine and tryptophan as new biomarkers for early detection of rectal anastomotic leakage. *Videosurgery and Other Miniinvasive Techniques*, 13 (1), 2018, 44–52.
- FIBIGR, J., MAJEROVÁ, M., KOČOVÁ VLČKOVÁ, H., SOLICH, P., ŠATÍNSKÝ, D.: A validated UHPLC method for the determination of caffeoylquinic and di-caffeoylquinic acids in green coffee extracts using an RP-Amide fused-core column. *Journal of Pharmaceutical and Biomedical Analysis*, 151, 2018, 291–300.
- FIBIGR, J., ŠATÍNSKÝ, D., SOLICH, P.: Current trends in the analysis and quality control of food supplements based on plant extracts. *Analytica Chimica Acta*, 1036, 2018, 1–15.
- GONZÁLEZ, N., GRÜNHUT, M., HORSTKOTTE ŠRÁMKOVÁ, I., LISTA, A., HORSTKOTTE, B., SOLICH, P., SKLENÁŘOVÁ, H., ACEBAL, C.: Flow-batch analysis of clenbuterol based on analyte extraction on molecularly imprinted polymers coupled to an in-system chromogenic reaction. Application to human urine and milk substitute samples. *Talanta*, 178, 2018, 934–942.
- HABARTOVÁ, K., HAVELEK, R., SEIFRTOVÁ, M., KRÁLOVEC, K., CAHLÍKOVÁ, L., CHLEBEK, J., ČERMÁKOVÁ, E., MAZÁNKOVÁ, N., MAŘÍKOVÁ, J., KUNES, J., NOVÁKOVÁ, L., ŘEZÁČOVÁ, M.:

- Scoulerine affects microtubule structure, inhibits proliferation, arrests cell cycle and thus culminates in the apoptotic death of cancer cells. *Scientific Reports*, 8, 2018, art. 4829.
- HÁJEK, R., LÍSA, M., KHALIKOVA, M., JIRÁSKO, R., CÍFKOVÁ, E., ŠTUDENT, V., VRÁNA, D., OPÁLKA, L., VÁVROVÁ, K., MATZENAUER, M., MELICHAR, B., HOLČAPEK, M.: HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues. *Analytical and Bioanalytical Chemistry*, 410 (25), 2018, 6585–6594.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., CHVOJKA, J., ERBEN, J., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: A comparison study of nanofiber, microfiber, and new composite nano/microfiber polymers used as sorbents for on-line solid phase extraction in chromatography system. *Analytica Chimica Acta*, 1023, 2018, 44–52.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., CHVOJKA, J., SOLICH, P., ŠATÍNSKÝ, D.: An on-line coupling of nanofibrous extraction with column-switching high performance liquid chromatography – A case study on the determination of bisphenol A in environmental water samples. *Talanta*, 178, 2018, 141–146.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., CHVOJKA, J., ŠVEC, F., SOLICH, P., ŠATÍNSKÝ, D.: Nanofiber polymers as novel sorbents for on-line solid phase extraction in chromatographic system: A comparison with monolithic reversed phase C18 sorbent. *Analytica Chimica Acta*, 1018, 2018, 26–34.
- HÁKOVÁ, M., RAABOVÁ, H., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., CHOCHOLOUŠ, P., CHVOJKA, J., ŠATÍNSKÝ, D.: Testing of nylon 6 nanofibers with different surface densities as sorbents for solid phase extraction and their selectivity comparison with commercial sorbent. *Talanta*, 18, 2018, 326–332.
- HANUŠOVÁ, V., SKÁLOVÁ, L., KRÁLOVÁ, V., MATOUŠKOVÁ, P.: The effect of flubendazole on adhesion and migration in SW480 and SW620 colon cancer cells. *Anti-Cancer Agents in Medicinal Chemistry*, 18 (6), 2018, 837–846.
- HEPNAROVÁ, V., KORÁBEČNÝ, J., MATOUŠKOVÁ, L., JOŠT, P., MŮČKOVÁ, L., HRABINOVÁ, M., VYKOUKALOVÁ, N., KERHARTOVÁ, M., KUČERA, T., DOLEŽAL, R., NEPOVIMOVÁ, E., ŠPILOVSKÁ, K., MEZEIOVÁ, E., PHAM, N. L., JUN, D., ŠTAUD, F., KAPING, D., KUČA, K., SOUKUP, O.: The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease. *European Journal of Medicinal Chemistry*, 150, 2018, 292–306.
- HORKÝ, P., VORÁČOVÁ, M., KONEČNÁ, K., SEDLÁK, D., BARTŮNĚK, P., VACEK, J., KUNEŠ, J., POUR, M.: Nontoxic combretafuranone analogues with high *in vitro* antibacterial activity. *European Journal of Medicinal Chemistry*, 143, 2018, 843–853.
- HORSTKOTTE ŠRÁMKOVÁ, I., HORSTKOTTE, B., FIKAROVÁ, K., SKLENÁŘOVÁ, H., SOLICH, P.: Direct-immersion single-drop microextraction and in-drop stirring microextraction for the determination of nanomolar concentrations of lead using automated Lab-In-Syringe technique. *Talanta*, 184, 2018, 162–172.
- HORSTKOTTE, B., LÓPEZ de LOS MOZOS ATOCHERO, N., SOLICH, P.: Lab-In-Syringe automation of stirring-assisted room-temperature headspace extraction coupled online to gas chromatography with flame ionization detection for determination of benzene, toluene, ethylbenzene, and xylenes in surface waters. *Journal of Chromatography A*, 1555, 2018, 1–9.
- HORSTKOTTE, B., MIRÓ, M., SOLICH, P.: Where are modern flow techniques heading to? *Analytical and Bioanalytical Chemistry*, 410 (25), 2018, 6361–6370.
- HORVÁTOVÁ, A., UTAIPAN, T., OTTO, A., ZHANG, Y., GAN-SCHREIER, H., PÁVEK, P., PATHIL, A., STREMMEL, W., CHAMULITRAT, W.: Ursodeoxycholylyl-lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages. *European Journal of Pharmacology*, 825, 2018, 63–74.
- HRČKOVÁ, G., MAČÁK KUBAŠKOVÁ, T., BENADA, O., KOFROŇOVÁ, O., TŮMOVÁ, L., BIEDERMANN, D.: Differential effects of the flavonolignans silybin, silychristin and 2,3-dehydrosilybin on *Mesocostoides vogae* larvae (Cestoda) under hypoxic and aerobic *in vitro* conditions. *Molecules*, 23 (11), 2018, art. 2999.
- HRUŠKOVÁ, K., POTUČKOVÁ, E., OPÁLKA, L., HERGESELOVÁ, T., HAŠKOVÁ, P., KOVAŘÍKOVÁ, P., ŠIMŮNEK, T., VÁVROVÁ, K.: Structure-activity relationships of nitro-substituted aroylhydrazone iron chelators with antioxidant and antiproliferative activities. *Chemical Research in Toxicology*, 31 (6), 2018, 435–446.
- HUBČÍK, L., GALLIKOVÁ, D., PULLMANNOVÁ, P., LACINOVÁ, E., SULOVÁ, Z., HANULOVÁ, M., FUNARI, S. S., DEVÍNSKY, F., UHRÍKOVÁ, D.: DNA-DOPE-gemini surfactants complexes at low surface

- charge density: From structure to transfection efficiency. *General Physiology and Biophysics*, 37 (1), 2018, 57–69.
- HULCOVÁ, D., BREITEROVÁ, K., SIATKA, T., KLÍMOVÁ, K., DAVANI, L., ŠAFRATOVÁ, M., HOŠTÁLKOVÁ, A., De SIMONE, A., ANDRISANO, V., CAHLÍKOVÁ, L.: Amaryllidaceae alkaloids as potential glycogen synthase kinase-3 β inhibitors. *Molecules*, 23 (4), 2018, art. 719.
- HURYCHOVÁ, H., KUENTZ, M., ŠKLUBALOVÁ, Z.: Fractal aspects of static and dynamic flow properties of pharmaceutical excipients. *Journal of Pharmaceutical Innovation*, 13 (1), 2018, 15–26.
- HURYCHOVÁ, H., ONDREJČEK, P., ŠKLUBALOVÁ, Z., VRANÍKOVÁ, B., SVĚRÁK, T.: The influence of stevia on the flow, shear and compression behavior of sorbitol, a pharmaceutical excipient for direct compression. *Pharmaceutical Development and Technology*, 23 (2), 2018, 125–131.
- INOTAI, A., CSANÁDI, M., PETROVA, G., DIMITROVA, M., BOCHENEK, T., TESAŘ, T., YORK, K., FUKSA, L., KOSTYUK, A., LORENZOVICI, L., OMELYANOVSKIY, V., EGYED, K., KALÓ, Z.: Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: A survey of experts. *BioMed Research International*, 18, 2018, art. 9597362.
- JANSOVÁ, H., KUBEŠ, J., REIMEROVÁ, P., ŠTĚRBOVÁ, P., ROH, J., ŠIMŮNEK, T.: 2,6-Dihydroxybenzaldehyde analogues of the iron chelator salicylaldehyde isonicotinoyl hydrazone: Increased hydrolytic stability and cytoprotective activity against oxidative stress. *Chemical Research in Toxicology*, 31 (11), 2018, 1151–1163.
- JIRÁSKOVÁ, L., ČERVENÝ, L., KARBANOVÁ, S., PTÁČKOVÁ, Z., ŠTAUD, F.: Expression of concentrative nucleoside transporters (SLC28A) in the human placenta: Effects of gestation age and prototype differentiation-affecting agents. *Molecular Pharmaceutics*, 15 (7), 2018, 2732–2741.
- JIRKOVSKÝ, E., JIRKOVSKÁ, A., BUREŠ, J., CHLÁDEK, J., LENČOVÁ, O., STARIAT, J., POKORNÁ, Z., KARBANOVICH, G., ROH, J., BRÁZDOVÁ, P., ŠIMŮNEK, T., KOVAŘÍKOVÁ, P., ŠTĚRBA, M.: Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart. *Journal of Pharmacology and Experimental Therapeutics*, 364 (3), 2018, 433–446.
- JOSKOVÁ, V., PATKOVÁ, A., HAVEL, E., NAJPAVEROVÁ, S., URAMOVÁ, D., KOVAŘÍK, M., ZADÁK, Z., HRONEK, M.: Critical evaluation of muscle mass loss as a prognostic marker of morbidity in critically ill patients and methods for its determination. *Journal of Rehabilitation Medicine*, 50 (8), 2018, 696–704.
- KAMEKIS, A., BERTSIAS, A., MOSCHANDREAS, J., PETELOS, E., PAPADAKAKI, M., TSIANTOU, V., SARIDAKI, A., SYMVOULAKIS, E. K., SOULIOTIS, K., PAPADAKIS, N., FARESJÖ, T., FARESJÖ, A., MARTINEZ, L., AGIUS, D., UNCU, Y., ŞENGEZER, T., SAMOUTIS, G., VLČEK, J., ABASAEED ELHAG, A., MERKOURIS, B., LIONIS, C.: Patients' intention to consume prescribed and non-prescribed medicines: A study based on the theory of planned behaviour in selected European countries. *Journal of Clinical Pharmacy and Therapeutics*, 43 (1), 2018, 26–35.
- KAREŠOVÁ, I., ŠIMKO, J., FEKETE, S., ZIMČÍKOVÁ, E., MALÁKOVÁ, J., ŽIVNÁ, H., PAVLÍKOVÁ, L., PALÍČKA, V.: The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolism. *European Journal of Pharmacology*, 824, 2018, 115–119.
- KAŠPAROVÁ, M., PILAŘOVÁ, P., TŮMOVÁ, L., SIATKA, T.: Effect of precursor and phytohormones on podophyllotoxin production in *Juniperus virginiana* suspension cultures. *Natural Product Communications*, 13 (11), 2018, 1527–1529.
- KHALIKOVA, M., LESELLIER, E., CHAPUZET, E., ŠATÍNSKÝ, D., WEST, C.: Development and validation of ultra-high performance supercritical fluid chromatography method for quantitative determination of nine sunscreens in cosmetic samples. *Analytica Chimica Acta*, 1034, 2018, 184–194.
- KNEBEL, C., NEEB, J., ZAHN, E., SCHMIDT, F., CARAZO FERNÁNDEZ, A. J., HOLAS, O., PÁVEK, P., PÜSCHEL, G., ZANGER, U., SÜSSMUTH, R., LAMPEN, A., MARX-STOELTING, P., BRAEUNING, A.: Unexpected effects of propiconazole, tebuconazole, and their mixture on the receptors CAR and PXR in human liver cells. *Toxicological Sciences*, 163 (1), 2018, 170–181.
- KOČOVÁ VLČKOVÁ, H., PILAŘOVÁ, V., SVOBODOVÁ, P., PLÍŠEK, J., ŠVEC, F., NOVÁKOVÁ, L.: Current state of bioanalytical chromatography in clinical analysis. *The Analyst*, 143 (6), 2018, 1305–1325.
- KOMERSOVÁ, A., LOCHAŘ, V., MYSLÍKOVÁ, K., MUŽÍKOVÁ, J., BARTOŠ, M.: The effect of co-processed dry binder with microcrystalline cellulose on release of verapamil hydrochloride from hydrophilic matrix tablets. *Acta Poloniae Pharmaceutica*, 75 (5), 2018, 1223–1231.

- KOVÁČIK, A., PULLMANNOVÁ, P., MAIXNER, J., VÁVROVÁ, K.: Effects of ceramide and dihydroceramide stereochemistry at C-3 on the phase behavior and permeability of skin lipid membranes. *Langmuir*, 34 (1), 2018, 521–529.
- KOVÁČIK, A., VOGEL, A., ADLER, J., PULLMANNOVÁ, P., VÁVROVÁ, K., HUSTER, D.: Probing the role of ceramide hydroxylation in skin barrier lipid models by H-2 solid-state NMR spectroscopy and X-ray powder diffraction. *Biochimica et Biophysica Acta – Biomembranes*, 1860 (5), 2018, 1162–1170.
- KRÁLOVÁ, V., HANUŠOVÁ, V., CALTOVÁ, K., ŠPAČEK, P., HOCHMALOVÁ, M., SKÁLOVÁ, L., RUDOLF, E.: Flubendazole and mebendazole impair migration and epithelial to mesenchymal transition in oral cell lines. *Chemico-Biological Interactions*, 293, 2018, 124–132.
- KRÁTKÝ, M., ŠTĚPÁNKOVÁ, Š., VORČÁKOVÁ, K., VINŠOVÁ, J.: Investigation of salicylanilide and 4-chlorophenol-based *N*-monosubstituted carbamates as potential inhibitors of acetyl- and butyrylcholinesterase. *Bioorganic Chemistry*, 80, 2018, 668–673.
- KRIJTT, M., JIRKOVSKÁ, A., KABÍČKOVÁ, T., MELENOVSKÝ, V., PETRÁK, J., VYORAL, D.: Detection and quantitation of iron in ferritin, transferrin and labile iron pool (LIP) in cardiomyocytes using Fe-55 and storage phosphorimaging. *Biochimica et Biophysica Acta – General Subjects*, 1862 (12), 2018, 2895–2901.
- KUBEŠ, J., SKALICKÝ, M., HEJNÁK, V., TŮMOVÁ, L., MARTIN, J., MARTINKOVÁ, J.: The first genistin absorption screening into vacuoles of *Trifolium pratense* L. *Plant Soil and Environment*, 64 (6), 2018, 290–296.
- KUBEŠ, R., SALAJ, P., HROMÁDKA, R., VČELÁK, J., KUBĚNA, A. A., FRYDRYCHOVÁ, M., MARGERSKÝ, Š., BURIAN, M., OŠTĀDAL, M., VACULÍK, J.: Range of motion after total knee arthroplasty in hemophilic arthropathy. *BMC Musculoskeletal Disorders*, 19, 2018, art. 162.
- KUČEROVÁ-CHLUPÁČOVÁ, M., DOSEDĚL, M., KUNEŠ, J., ŠOLTĚSOVÁ-PRNOVÁ, M., MÁJEKOVÁ, M., ŠTEFEK, M.: Chalcones and their pyrazine analogs: Synthesis, inhibition of aldose reductase, antioxidant activity, and molecular docking study. *Monatshefte für Chemie – Chemical Monthly*, 149 (5), 2018, 921–929.
- KUDLÁČEK, K., NESMĚRÁK, K., ŠTÍCHA, M., KOZLÍK, P., BABICA, J.: Degradation of ouabain in 80-year-old injection solution studied by HILIC-MS. *Monatshefte für Chemie – Chemical Monthly*, 149 (9), 2018, 1555–1560.
- LEBEDEVA (YABLOKOVA), I. A., IVANOVA, S. S., NOVÁKOVÁ, V., ZHABANOV, Y. A., STUZHIN, P. A.: Perfluorinated porphyrazines. 3. Synthesis, spectral-luminescence and electrochemical properties of perfluorinated octaphenylporphyrazinatozinc(II). *Journal of Fluorine Chemistry*, 214, 2018, 86–93.
- LENČO, J., VAJRYCHOVÁ, M., PIMKOVÁ, K., PROKŠOVÁ, M., BENKOVÁ, M., KLIMENTOVÁ, J., TAMBOR, V., SOUKUP, O.: Conventional-flow liquid chromatography-mass spectrometry for exploratory bottom-up proteomic analyses. *Analytical Chemistry*, 90 (8), 2018, 5381–5389.
- LHOTSKÁ, I., GAJDOŠOVÁ, B., SOLICH, P., ŠATÍNSKÝ, D.: Molecularly imprinted vs. reversed-phase extraction for the determination of zearalenone: A method development and critical comparison of sample clean-up efficiency achieved in an on-line coupled SPE chromatography system. *Analytical and Bioanalytical Chemistry*, 410 (14), 2018, 3265–3273.
- LHOTSKÁ, I., SOLICH, P., ŠATÍNSKÝ, D.: A comparative study of advanced stationary phases for fast liquid chromatography separation of synthetic food colorants. *Molecules*, 23 (12), 2018, art. 3335.
- LI, M., VOKŘÁL, I., EVERS, B., De GRAAF, I., De JAGER, M., GROOTHUIS, G.: Human and rat precision-cut intestinal slices as *ex vivo* models to study bile acid uptake by the apical sodium-dependent bile acid transporter. *European Journal of Pharmaceutical Sciences*, 121, 2018, 65–73.
- LIEBOLD, M., SHARIKOW, E., SEIKEL, E., TROMBACH, L., HARMS, K., ZIMČÍK, P., NOVÁKOVÁ, V., TONNER, R., SUNDERMEYER, J.: An experimental and computational study on isomerically pure, soluble azaphthalocyanines and their complexes and boron azasubphthalocyanines of a varying number of aza units. *Organic and Biomolecular Chemistry*, 16 (35), 2018, 6586–6599.
- LNĚNIČKOVÁ, K., SKÁLOVÁ, L., RAISOVÁ STUHLÍKOVÁ, L., SZOTÁKOVÁ, B., MATOUŠKOVÁ, P.: Induction of xenobiotic-metabolizing enzymes in hepatocytes by beta-naphthoflavone: Time-dependent changes in activities, protein and mRNA levels. *Acta Pharmaceutica*, 68 (1), 2018, 75–85.
- LNĚNIČKOVÁ, K., SVOBODOVÁ, H., SKÁLOVÁ, L., AMBROŽ, M., NOVÁK, F., MATOUŠKOVÁ, P.: The impact of sesquiterpenes β -caryophyllene oxide and *trans*-nerolidol on xenobiotic-metabolizing enzymes in mice *in vivo*. *Xenobiotica*, 48 (11), 2018, 1089–1097.

- MACHÁČEK, M., CARTER, K. A., KOSTELANSKÝ, F., MIRANDA, D., SEFFOUH, A., ORTEGA, J., ŠIMŮNEK, T., ZIMČÍK, P., LOVELL, J. F.: Binding of an amphiphilic phthalocyanine to pre-formed liposomes confers light-triggered cargo release. *Journal of Materials Chemistry B*, 6 (44), 2018, 7298–7305.
- MAREK, J., JOSKOVÁ, V., DOLEŽAL, R., SOUKUP, O., BENKOVÁ, M., FUČÍKOVÁ, A., MALIŇÁK, D., BOŠTÍKOVÁ, V., KUČA, K.: Synthesis, antimicrobial effect and surface properties of hydroxymethyl-substituted pyridinium salts. *Letters in Drug Design & Discovery*, 15 (8), 2018, 828–842.
- MAREK, J., MALIŇÁK, D., DOLEŽAL, R., SOUKUP, O., BENKOVÁ, M., NACHTIGAL, P., VÁVRA, P., KUČA, K.: Novel series of quaternary ammonium surfactants based on 2,3-dihydro-[1,4]dioxino[2,3-*b*]pyridin-7-ol ring: Synthesis, analysis and antimicrobial evaluation. *Letters in Organic Chemistry*, 15 (1), 2018, 3–9.
- MATOUŠKOVÁ, P., HANOUSKOVÁ, B., SKÁLOVÁ, L.: MicroRNAs as potential regulators of glutathione peroxidases expression and their role in obesity and related pathologies. *International Journal of Molecular Sciences*, 19 (4), 2018, art. 1199.
- MATOUŠKOVÁ, P., LECOVÁ, L., LAING, R., DIMUNOVÁ, D., VOGEL, H., RAISOVÁ STUHLÍKOVÁ, L., NGUYEN, T. L., KELLEROVÁ, P., VOKŘÁL, I., LAMKA, J., SZOTÁKOVÁ, B., VÁRADY, M., SKÁLOVÁ, L.: UDP-glycosyltransferase family in *Haemonchus contortus*: Phylogenetic analysis, constitutive expression, sex-differences and resistance-related differences. *International Journal for Parasitology: Drugs and Drug Resistance*, 8 (3), 2018, 420–429.
- MAULDIN, E., CRUMRINE, D., CASAL, M., JEONG, S., OPÁLKA, L., VÁVROVÁ, K., UCHIDA, Y., PARK, K., CRAIGLOW, B., CHOATE, K., SHIN, K., LEE, Y., GROVE, G., WAKEFIELD, J., KHNYKIN, D., ELIAS, P.: Cellular and metabolic basis for the ichthyotic phenotype in NIPAL4 (ichthyin)-deficient canines. *American Journal of Pathology*, 188 (6), 2018, 1419–1429.
- MIHALČÍKOVÁ, L., BOONJOB, W., SKLENÁŘOVÁ, H.: Automated sequential injection method for determination of caffeine in coffee drinks. *Food Analytical Methods*, 11 (1), 2018, 111–118.
- MILETÍN, M., ZIMČÍK, P., NOVÁKOVÁ, V.: Photodynamic properties of aza-analogues of phthalocyanines. *Photochemical and Photobiological Sciences*, 17 (11), 2018, 1749–1766.
- MLADĚNKA, P., APPLOVÁ, L., PATOČKA, J., COSTA, V., REMIAO, F., POUROVÁ, J., MLADĚNKA, A., KARLÍČKOVÁ, J., JAHODÁŘ, L., VOPRŠALOVÁ, M., VARNER, K., ŠTĚRBA, M.: Comprehensive review of cardiovascular toxicity of drugs and related agents. *Medicinal Research Reviews*, 38 (4), 2018, 1332–1403.
- MORENO-GONZÁLEZ, D., KRULIŠOVÁ, M., GÁMIZ-GRACIA, L., GARCÍA-CAMPAÑA, A. M.: Determination of tetracyclines in human urine samples by capillary electrophoresis in combination with field amplified sample injection. *Electrophoresis*, 39 (4), 2018, 608–615.
- MURÍN, R., ABDALLA, M., MURÍNOVÁ, N., HATOK, J., DOBROTA, D.: The metabolism of 5-methylcytosine residues in DNA. *Physiological Research*, 67 (3), 2018, 383–389.
- MUSIL, F., POKLADNÍKOVÁ, J., PAVELEK, Z., WANG, B., GUAN, X., VALIŠ, M.: Acupuncture in migraine prophylaxis in Czech patients: an open-label randomized controlled trial. *Neuropsychiatric Disease and Treatment*, 14, 2018, 1221–1228.
- MUŽÍKOVÁ, J., KOMERSOVÁ, A., LOCHAŘ, V., VILDOVÁ, L., VOŠOUSTOVÁ, B., BARTOŠ, M.: Comparative evaluation of the use of dry binders in a physical mixture or as a coprocessed dry binder in matrix tablets with extended drug release. *Acta Pharmaceutica*, 68 (3), 2018, 295–311.
- NARCISO MEIRELLES, L., SILVA CAMPOS, T., RODRIGUEZ, Z., HERNANDEZ, R., ŠVEC, F., ZAJÍČKOVÁ, Z.: “Single-pot” approach towards the preparation of alkyl and polyfluoroalkyl organo-silica monolithic capillaries for reversed-phase liquid chromatography. *Journal of Separation Science*, 41 (19), 2018, 3669–3676.
- NAVRÁTILOVÁ, L., APPLOVÁ, L., HORKÝ, P., MLADĚNKA, P., PÁVEK, P., TREJTNAR, F.: Interaction of soy isoflavones and their main metabolites with hOATP2B1 transporter. *Naunyn-Schmiedeberg's Archives of Pharmacology*, 391 (10), 2018, 1063–1071.
- NAVRÁTILOVÁ, L., RAMOS MANDÍKOVÁ, J., PÁVEK, P., MLADĚNKA, P., TREJTNAR, F.: Honey flavonoids inhibit hOATP2B1 and hOATP1A2 transporters and hOATP-mediated rosuvastatin cell uptake *in vitro*. *Xenobiotica*, 48 (7), 2018, 745–755.
- NAWROT, D., KOLENIČ, M., KUNEŠ, J., KOSTELANSKÝ, F., MILETÍN, M., NOVÁKOVÁ, V., ZIMČÍK, P.: Transalkylation of alkyl aryl sulfides with alkylating agents. *Tetrahedron*, 74 (5), 2018, 594–599.

- NOVÁKOVÁ, L., PAVLÍK, J., CHRENKOVÁ, L., MARTINEC, O., ČERVENÝ, L.: Current antiviral drugs and their analysis in biological materials – Part I: Antivirals against respiratory and herpes viruses. *Journal of Pharmaceutical and Biomedical Analysis*, 147, 2018, 400–416.
- NOVÁKOVÁ, L., PAVLÍK, J., CHRENKOVÁ, L., MARTINEC, O., ČERVENÝ, L.: Current antiviral drugs and their analysis in biological materials – Part II: Antivirals against hepatitis and HIV viruses. *Journal of Pharmaceutical and Biomedical Analysis*, 147, 2018, 378–399.
- NOVÁKOVÁ, V., DONZELLO, M., ERCOLANI, C., ZIMČÍK, P., STUZHIN, P.: Tetrapyrazinoporphyrazines and their metal derivatives. Part II: Electronic structure, electrochemical, spectral, photophysical and other application related properties. *Coordination Chemistry Reviews*, 361, 2018, 1–73.
- NOVOTNÁ, E., BŮKŮM, N., HOFMAN, J., FLAXOVÁ, M., KOUKLÍKOVÁ, E., LOUVAROVÁ, D., WSÓL, V.: Aldo-keto reductase 1C3 (AKR1C3): A missing piece of the puzzle in the dinaciclib interaction profile. *Archives of Toxicology*, 92 (9), 2018, 2845–2857.
- NOVOTNÁ, E., BŮKŮM, N., HOFMAN, J., FLAXOVÁ, M., KOUKLÍKOVÁ, E., LOUVAROVÁ, D., WSÓL, V.: Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment. *Biochemical Pharmacology*, 156, 2018, 22–31.
- PATKOVÁ, A., JOSKOVÁ, V., HAVEL, E., NAJPAVEROVÁ, S., URAMOVÁ, D., KOVAŘÍK, M., ZADÁK, Z., HRONEK, M.: Prognostic value of respiratory quotients in severe polytrauma patients with nutritional support. *Nutrition*, 49, 2018, 90–95.
- PĚNČÍK, A., CASANOVA-SÁEZ, R., PILAŘOVÁ, V., ŽUKAUSKAITE, A., PINTO, R., MICOL, J. L., LJUNG, K., NOVÁK, O.: Ultra-rapid auxin metabolite profiling for high-throughput mutant screening in *Arabidopsis*. *Journal of Experimental Botany*, 69 (10), 2018, 2569–2579.
- PILAŘOVÁ, V., PLACHKÁ, K., CHRENKOVÁ, L., NAJMANOVÁ, I., MLADĚNKA, P., ŠVEC, F., NOVÁK, O., NOVÁKOVÁ, L.: Simultaneous determination of quercetin and its metabolites in rat plasma by using ultra-high performance liquid chromatography tandem mass spectrometry. *Talanta*, 185, 2018, 71–79.
- PILKA, R., NEUBERT, D., STEJSKAL, D., KREJČÍ, G., ŠVESTÁK, M., MAREK, R., ADAM, T., SOBKOVÁ, K., ONDROVÁ, D., HAMBÁLEK, J., MADĚRKA, M., SOLICHOVÁ, D., KUJOVSKÁ KRČMOVÁ, L., JAVORSKÁ, L., MELICHAR, B.: Serum concentrations of TFF3, S100-A11 and AIF-1 in association with systemic inflammatory response, disease stage and nodal involvement in endometrial cancer. *Pteridines*, 29 (1), 2018, 6–12.
- PLACHKÁ, K., ŠVEC, F., NOVÁKOVÁ, L.: Ultra-high performance supercritical fluid chromatography in impurity control: Searching for generic screening approach. *Analytica Chimica Acta*, 1039, 2018, 149–161.
- POKLADNÍKOVÁ, J., MAREŠOVÁ, P., DOLEJŠ, J., PARK, A., WANG, B., GUAN, X., MUSIL, F.: Economic analysis of acupuncture for migraine prophylaxis. *Neuropsychiatric Disease and Treatment*, 14, 2018, 3053–3061.
- POKLADNÍKOVÁ, J., SELKE-KRULICHOVÁ, I.: The use of complementary and alternative medicine by the general population in the Czech Republic: A follow-up study. *Complementary Medicine Research*, 25 (3), 2018, 159–166.
- PORCU, E., COSSU, M., RASSU, G., GIUNCHEDI, P., CERRI, G., POUROVÁ, J., NAJMANOVÁ, I., MIGKOS, T., PILAŘOVÁ, V., NOVÁKOVÁ, L., MLADĚNKA, P., GAVINI, E.: Aqueous injection of quercetin: An approach for confirmation of its direct *in vivo* cardiovascular effects. *International Journal of Pharmaceutics*, 541 (1–2), 2018, 224–233.
- POSPÍŠILOVÁ, Š., MICHNOVÁ, H., KAUEROVÁ, T., PAUK, K., KOLLÁR, P., VINŠOVÁ, J., IMRAMOVSKÝ, A., ČÍŽEK, A., JAMPÍLEK, J.: *In vitro* activity of salicylamide derivatives against vancomycin-resistant enterococci. *Bioorganic and Medicinal Chemistry Letters*, 28 (12), 2018, 2184–2188.
- POUROVÁ, J., NAJMANOVÁ, I., VOPRŠALOVÁ, M., MIGKOS, T., PILAŘOVÁ, V., APPLOVÁ, L., NOVÁKOVÁ, L., MLADĚNKA, P.: Two flavonoid metabolites, 3,4-dihydroxyphenylacetic acid and 4-methylcatechol, relax arteries *ex vivo* and decrease blood pressure *in vivo*. *Vascular Pharmacology*, 111, 2018, 36–43.
- RAISOVÁ STUHLÍKOVÁ, L., KRÁLOVÁ, V., LNĚNIČKOVÁ, K., ZÁRYBNICKÝ, T., MATOUŠKOVÁ, P., HANUŠOVÁ, V., AMBROŽ, M., ŠUBRT, Z., SKÁLOVÁ, L.: The metabolism of flubendazole in human liver and cancer cell lines. *Drug Testing and Analysis*, 10 (7), 2018, 1139–1146.
- RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P., VOKŘÁL, I., LAMKA, J., SZOTÁKOVÁ, B., SEČKAŘOVÁ, A., DIMUNOVÁ, D., NGUYEN, T. L., VÁRADY, M., SKÁLOVÁ, L.: Metabolism of alben-dazole, ricobendazole and flubendazole in *Haemonchus contortus* adults: Sex differences, resistance-related

- differences and the identification of new metabolites. *International Journal for Parasitology: Drugs and Drug Resistance*, 8 (1), 2018, 50–58.
- RAISOVÁ STUHLÍKOVÁ, L., SKÁLOVÁ, L., SZOTÁKOVÁ, B., SYSLOVÁ, E., VOKŘÁL, I., VANĚK, T., PODLIPNÁ, R.: Biotransformation of flubendazole and fenbendazole and their effects in the ribwort plantain (*Plantago lanceolata*). *Ecotoxicology and Environmental Safety*, 147, 2018, 681–687.
- REID, J., PRYDDERCH, H., ŠPULÁK, M., SHIMIZU, S., WALKER, A., GATHERGOOD, N.: Green profiling of aprotic versus protic ionic liquids: Synthesis and microbial toxicity of analogous structures. *Sustainable Chemistry and Pharmacy*, 7, 2018, 17–26.
- RIASOVÁ, P., DOUBKOVÁ, D., PINCOVÁ, L., JUNG, O., POLÁŠEK, M., JÁČ, P.: Development of micellar electrokinetic chromatography method for the determination of three defined impurities in indomethacin. *Electrophoresis*, 39 (20), 2018, 2550–2557.
- SCHRÖTEROVÁ, L., JEŽKOVÁ, A., RUDOLF, E., CALTOVÁ, K., KRÁLOVÁ, V., HANUŠOVÁ, V.: Inositol hexaphosphate limits the migration and the invasiveness of colorectal carcinoma cells *in vitro*. *International Journal of Oncology*, 53 (4), 2018, 1625–1632.
- SIATKA, T.: Production of anthocyanins in callus cultures of *Angelica archangelica*. *Natural Product Communications*, 13 (12), 2018, 1645–1648.
- SKALICKÝ, M., KUBEŠ, J., HEJNÁK, V., TŮMOVÁ, L., MARTINKOVÁ, J., MARTIN, J., HNILÍČKOVÁ, H.: Isoflavones production and possible mechanism of their exudation in *Genista tinctoria* L. suspension culture after treatment with vanadium compounds. *Molecules*, 23 (7), 2018, art. 1619.
- SKARKOVÁ, V., KRÁLOVÁ, V., KRBAL, L., MATOUŠKOVÁ, P., SOUKUP, J., RUDOLF, E.: Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells. *Experimental Cell Research*, 369 (2), 2018, 295–303.
- SKLENÁŘOVÁ, H., BÍLKOVÁ, A., PECHOVÁ, M., CHOCHOLOUŠ, P.: Determination of major phenolic compounds in apples: Part I – Optimization of high-performance liquid chromatography separation with diode array detection. *Journal of Separation Science*, 41 (15), 2018, 3042–3050.
- SMUTNÝ, T., HARJUMÄKI, R., KANNINEN, L., YLIPERTTULA, M., PÁVEK, P., LOU, Y.: A feasibility study of the toxic responses of human induced pluripotent stem cell-derived hepatocytes to phytochemicals. *Toxicology in Vitro*, 52, 2018, 94–105.
- SOUKUP, O., KORÁBEČNÝ, J., MALIŇÁK, D., NEPOVIMOVÁ, E., PHAM, N., MUSÍLEK, K., HRABINOVÁ, M., HEPNAROVÁ, V., DOLEŽAL, R., PÁVEK, P., JOŠT, P., KOBRLOVÁ, T., JANOČKOVÁ, J., GÓRECKI, L., PSOTKA, M., NGUYEN, T. D., BOX, K., OUTHWAITE, B., ČEČKOVÁ, M., ŠORF, A., JUN, D., KUČA, K.: *In vitro* and *in silico* evaluation of non-quaternary reactivators of AChE as antidotes of organophosphorus poisoning – A new hope or a blind alley? *Medicinal Chemistry*, 14 (3), 2018, 281–292.
- SOUKUP, T., BARVÍK, I., NEKVINDOVÁ, J., VELETA, T., KUBĚNA, A., DUINTJER TEBBENS, E. J., PÁVEK, P., DOSEDĚL, M.: Are haplotypes in a single methotrexate pathway more predictive for response in rheumatoid arthritis than in different pathways? *Pharmacogenomics*, 19 (5), 2018, 379–381.
- STOJKOVÁ, P., ŠPIDLOVÁ, P., LENČO, J., ŘEHULKOVÁ, H., KRÁTKÁ, L., STULÍK, J.: HU protein is involved in intracellular growth and full virulence of *Francisella tularensis*. *Virulence*, 9 (1), 2018, 754–770.
- ŠAFRATOVÁ, M., HOŠTÁLKOVÁ, A., HULCOVÁ, D., BREITEROVÁ, K., HRABCOVÁ, V., MACHADO, M., FONTINHA, D., PRUDENCIO, M., KUNEŠ, J., CHLEBEK, J., JUN, D., HRABINOVÁ, M., NOVÁKOVÁ, L., HAVELK, R., SEIFRTOVÁ, M., OPLETAL, L., CAHLÍKOVÁ, L.: Alkaloids from *Narcissus poeticus* cv. Pink Parasol of various structural types and their biological activity. *Archives of Pharmacal Research*, 41 (2), 2018, 208–218.
- ŠIROKÁ, J., ČEČKOVÁ, M., URBÁNEK, L., KRYŠTOF, V., GUCKÝ, T., HOFMAN, J., STRNAD, M., ŠTAUD, F.: LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. *Journal of Chromatography B*, 1089, 2018, 24–32.
- ŠORF, A., HOFMAN, J., KUČERA, R., ŠTAUD, F., ČEČKOVÁ, M.: Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms *in vitro*. *Biochemical Pharmacology*, 154, 2018, 10–17.
- ŠTAUD, F., KARAHODA, R.: Trophoblast: The central unit of fetal growth, protection and programming. *International Journal of Biochemistry and Cell Biology*, 105, 2018, 35–40.
- TSACHAKI, M., MLADENOVIC, N., ŠTAMBERGOVÁ, H., BIRK, J., ODERMATT, A.: Hexose-6-phosphate dehydrogenase controls cancer cell proliferation and migration through pleiotropic effects on the unfolded-protein response, calcium homeostasis, and redox balance. *The FASEB Journal*, 32 (5), 2018, 2690–2705.

- TŮMOVÁ, L., HENDRYCHOVÁ, H., VOKURKOVÁ, D.: Immunostimulant activity of *Bergenia* extracts. *Pharmacognosy Magazine*, 14 (56), 2018, 328–332.
- TVRDÝ, V., CATAPANO, M. C., RAWLIK, T., KARLÍČKOVÁ, J., BIEDERMANN, D., KŘEN, V., MLADĚNKA, P., VALENTOVÁ, K.: Interaction of isolated silymarin flavonolignans with iron and copper. *Journal of Inorganic Biochemistry*, 189, 2018, 115–123.
- VAŇKOVÁ, B., MALÁ, K., KUBĚNA, A., MALÝ, J., DUSILOVÁ SULKOVÁ, S.: Immunosuppressive therapy related adherence, beliefs and self-management in kidney transplant outpatients. *Patient Preference and Adherence*, 12, 2018, 2605–2613.
- VITVEROVÁ, B., BLAŽÍČKOVÁ, K., NAJMANOVÁ, I., VICEN, M., HYŠPLER, R., DOLEŽELOVÁ, E., NĚMEČKOVÁ, I., DUINTJER TEBBENS, E. J., BERNABÉU, C., PERICACHO, M., NACHTIGAL, P.: Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. *Atherosclerosis*, 271, 2018, 15–25.
- VODÁČKOVÁ, P., VRÁŇKOVÁ, B., SVAČINOVÁ, P., FRANC, A., ELBL, J., MUSELÍK, J., KUBALÁK, R., SOLNÝ, T.: Evaluation and comparison of three types of spray dried coprocessed excipient Avicel® for direct compression. *BioMed Research International*, 18, 2018, art. 2739428.
- VOSÁTKA, R., KRÁTKÝ, M., ŠVARCOVÁ, M., JANOUŠEK, J., STOLAŘÍKOVÁ, J., MADACKI, J., HUSZÁR, S., MIKUŠOVÁ, K., KORDULÁKOVÁ, J., TREJTAR, F., VINŠOVÁ, J.: New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. *European Journal of Medicinal Chemistry*, 151, 2018, 824–835.
- VOSÁTKA, R., KRÁTKÝ, M., VINŠOVÁ, J.: Triclosan and its derivatives as antimycobacterial active agents. *European Journal of Pharmaceutical Sciences*, 114, 2018, 318–331.
- ZAHÁLKA, L., KLOVRZOVÁ, S., MATYSOVÁ, L., ŠKLUBALOVÁ, Z., SOLICH, P.: Furosemide ethanol-free oral solutions for paediatric use: Formulation, HPLC method and stability study. *European Journal of Hospital Pharmacy: Science and Practice*, 25 (3), 2018, 144–149.
- ZÁRYBNICKÝ, T., BOUŠOVÁ, I., AMBROŽ, M., SKÁLOVÁ, L.: Hepatotoxicity of monoterpenes and sesquiterpenes. *Archives of Toxicology*, 92 (1), 2018, 1–13.
- ZÁRYBNICKÝ, T., MATOUŠKOVÁ, P., LANCOŠOVÁ, B., ŠUBRT, Z., SKÁLOVÁ, L., BOUŠOVÁ, I.: Inter-individual variability in acute toxicity of *R*-pulegone and *R*-menthofuran in human liver slices and their influence on miRNA expression changes in comparison to acetaminophen. *International Journal of Molecular Sciences*, 19 (6), 2018, art. 1805.
- ZITKO, J., DOLEŽAL, M.: Old drugs and new targets as an outlook for the treatment of tuberculosis. *Current Medicinal Chemistry*, 25 (38), 2018, 5142–5167.
- ZITKO, J., JANDŮREK, O., PATEROVÁ, P., NAVRÁTILOVÁ, L., KUNEŠ, J., VINŠOVÁ, J., DOLEŽAL, M.: Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold. *MedChemComm*, 9 (4), 2018, 685–696.
- ZITKO, J., MINDLOVÁ, A., VALÁŠEK, O., JANDŮREK, O., PATEROVÁ, P., JANOUŠEK, J., KONEČNÁ, K., DOLEŽAL, M.: Design, synthesis and evaluation of *N*-pyrazinylbenzamides as potential antimycobacterial agents. *Molecules*, 23 (9), 2018, art. 2390.

ARTICLES IN JOURNALS WITHOUT IMPACT FACTOR AND PROCEEDINGS

- ARNDT, T., DOHNAL, F., BABICA, J.: Lékárna, lékárnici a léky v ghettu Terezín. (Pharmacy, pharmacists and drugs in the Terezín ghetto). *Česká a slovenská farmacie*, 67 (3), 2018, 116–129.
- DOHNAL, F.: První kroky Československé republiky v oblasti vojenského zdravotnictví (The first steps of the Czechoslovak Republic in the field of military health care). In *Medicína, farmácia a veterinárna medicína v období vzniku Československej republiky*. Bratislava, Stímul, 2018, 122–127. ISBN 978-80-8127-218-9.
- DOHNAL, F., KLEIN, L.: Dvojí výročí Vojenského lékařského výzkumného a doškolovacího ústavu Jana Evangelisty Purkyně v Hradci Králové (The double anniversary of the J. E. Purkinje Military Medical Research and Training Institute in Hradec Králové). *Vojenské zdravotnické listy*, 87 (4), 2018, 184–191.
- DOSEDĚL, M., MALÝ, J., VOSÁTKA, J., MIKOLÁŠEK, P., BRABCOVÁ, I., HAJDUCHOVÁ, H., BARTLOVÁ, S., TÓTHOVÁ, V., VLČEK, J.: Zapojení klinického farmaceuta do managementu pádů u polymorbidního geriatrického pacienta s opakovanými pády v anamnéze (Clinical pharmacist involvement in fall

- management in a polymorbid geriatric patient with a history of recurrent falls). *Česká a slovenská farmacie*, 67 (5–6), 2018, 205–211.
- FIALOVÁ, D.: Specifické rysy racionální geriatrické farmakoterapie: Role klinických farmaceutů v individualizované léčbě ve stáří (Specific features of rational geriatric pharmacotherapy: The role of clinical pharmacists in individualized drug treatment in older age). *Vnitřní lékařství*, 64 (11), 2018, 1028–1037.
- KOLÁŘ, J., KOSTŘIBA, J., KOTLÁŘOVÁ, J., AMBRUS, T., SMEJKALOVÁ, L.: Wastage of medicines and its financial impact on the healthcare system in the Czech Republic. *Česká a slovenská farmacie*, 67 (5–6), 2018, 192–199.
- KOLDA, J.: Zárůdky zdravotnických knihoven českých milosrdných bratří v 18. století (The beginnings of health libraries of the Czech Brothers Hospitallers in the 18th century). *Česká a slovenská farmacie*, 67 (5–6), 2018, 216–220.
- MALÝ, J., MALÁ, K., HORKÝ, P.: XX. symposium klinické farmacie René Macha (XX. Symposium on Clinical Pharmacy René Mach). Hradec Králové, Faculty of Pharmacy, 2018, 89 pp. ISBN 978-80-906644-2-5.
- PAVLUŠOVÁ, M., KLIMEŠ, J., ŠPINAR, J., ZEMAN, K., JARKOVSKÝ, J., BENEŠOVÁ, K., MIKLÍK, R., POHLUDKOVÁ, L., FELŠOČI, M., VESELÁ, V., BLAHOVCOVÁ, M., DOSTÁL, F., VONKA, R., PÁRENICA, J.: Chronické srdeční selhání – dopad onemocnění na pacienty a zdravotní systém v České republice: retrospektivní analýza typu cost-of-illness (Chronic heart failure – Impact of the condition on patients and the healthcare system in the Czech Republic: A retrospective cost-of-illness analysis). *Cor et Vasa*, 60 (3), 2018, e224–e233.
- VOSÁTKA, J., VAŇKOVÁ, B., DVOŘÁČKOVÁ, S., MALÝ, J.: Léčivé přípravky a doplňky stravy ovlivňující nežádoucí symptomy klimakteria (Medicinal products and dietary supplements affecting unfavorable symptoms of climacterium). *Praktické lékařství*, 14 (4), 2018, 162–169.

MONOGRAPHS AND TEXTBOOKS

- FIALOVÁ, D., KUMMER, I., DRŽAIČ, M., LEPPÉE, M.: Ageism in medication use in older patients. In *Contemporary Perspectives on Ageism*. Cham, Springer, 2018, pp. 213–240. ISBN 978-3-319-73819-2.
- GAJZDIOK, J., VRANÍKOVÁ, B., KOSTELANSKÁ, K., VETCHÝ, D., MUSELÍK, J., GONĚC, R.: Drug solubility and bioavailability improvement. Possible methods with emphasis on liquid systems formulation. München, GRIN Verlag, 2018, 176 pp. ISBN 978-3-668-81046-4.
- HAVLÍČKOVÁ, I., DOSTÁLOVÁ, Š., KATEROVÁ, Z.: English for Pharmacy and Medical Bioanalytics, 2nd ed. (reprint), Prague, Karolinum Press, 2018, 296 pp. ISBN 978-80-246-2797-7.
- JAHODÁŘ, L.: Rostliny způsobující otravy (Plants causing poisoning). Prague, Karolinum Press, 2018, 384 pp. ISBN 978-80-246-4050-1, ISBN 978-80-246-4190-4 (e-book, PDF).
- KLEMER, P.: Aplikovaná matematika (Applied mathematics), 3rd ed., Prague, Karolinum Press, 2018, 94 pp. ISBN 978-80-246-3863-8.
- KUNEŠOVÁ, K.: Latina pro farmaceuty. Učebnice pro posluchače oborů Farmacie a Zdravotnická bioanalytika (Latin for pharmacist. Textbook for students of pharmacy and medical bioanalytics), 4th ed. (2nd reprint), Prague, Karolinum Press, 2018, 196 pp. ISBN 978-80-246-2346-7.
- SKÁLOVÁ, L., BOUŠOVÁ, I., MACHALA, M., MATOUŠKOVÁ, P., PÁVEK, P., PODLIPNÁ, R., SOUČEK, P., SVOBODOVÁ, H., SZOTÁKOVÁ, B., TREJTNAR, F., VONDRÁČEK, J., WSÓL, V.: Metabolismus léčiv a jiných xenobiotik (Metabolism of drugs and other xenobiotics), 2nd modified and extended ed., Prague, Karolinum Press, 2018, 172 pp. ISBN 978-80-246-3762-4 (e-book, PDF).
- SVATOŠ, L.: Hospitalstiftung und Krankenhaus der Barmherzigen Brüder in Kukus 1696–1780 (The Hospital Foundation and Hospital of the Brothers Hospitallers of Saint John of God in Kuks 1696–1780). In *Germanische Provinz des Hospitalordens des Hl. Johannes von Gott bis 1780*. Cieszyn, Konwent Zakonu Bonifratrów, 2018, pp. 399–433. ISBN 978-83-932300-5-1.
- SVATOŠ, L.: Krankenprotokolle des Kukuser Krankenhauses des Ordens der Barmherzigen Brüder (1744–1780) (Medical Records of Patients of Hospital of the Brothers Hospitallers of Saint John of God in Kuks (1744–1780)). In *Germanische Provinz des Hospitalordens des Hl. Johannes von Gott bis 1780*. Cieszyn, Konwent Zakonu Bonifratrów, 2018, pp. 457–483. ISBN 978-83-932300-5-1.
- SVATOŠ, L., RUSEK, V.: Apothekekunde der Barmherzigen Brüder in der Frühen Neuzeit (The pharmacy practice of the Brothers Hospitallers of Saint John of God in the early modern period). In *Germanische Provinz*

des Hospitalordens des Hl. Johannes von Gott bis 1780. Cieszyn, Konwent Zakonu Bonifratrów, 2018, pp. 47–64. ISBN 978-83-932300-5-1.

ŠKLUBALOVÁ, Z., VRANÍKOVÁ, B.: Oční přípravky (Ocularia, ophthalmica) (Ophthalmic preparations (ocularia, ophthalmica), Praha, Maxdorf, 2018, 120 pp. ISBN 978-80-7345-572-9.

ŠPAČEK, J., KALOUSEK, I., JÍLEK, P., BAVOR, J., BENDOVIÁ, M., BOČKOVÁ, I., BOUDA, J., BUCHTA, V., HALADA, P., HOŘEJŠÍ, J., CHOVANEC, J., KALOUSEK, Š., KESTRÁNEK, J., KOPECKÝ, P., KOŠTÁL, M., KRÍŽ, J., KUDELA, M., LACO, J., LIEBICHOVÁ, I., ONDROVÁ, D., OTČENÁŠEK, M., PETERA, J., PILKA, R., POSPÍŠILOVÁ, B., ROB, L., ROBOVÁ, H., SALAVEC, M., SEDLÁKOVÁ, I., SIRÁK, I., SLÁMA, J., ŠTĚPÁN, J., TOŠNER, J., ŽEMLICKOVÁ, H.: Vybrané kapitoly z gynekologie (Selected chapters in gynecology), Praha, Mladá fronta, 2018, 676 pp. ISBN 978-80-204-4646-6.

CERTIFIED METHODOLOGY

BÍLKOVÁ, A., VÁVRA, R., HOLLÁ, M., SKLENÁŘOVÁ, H., CHOCHOLOUŠ, P., DVOŘÁKOVÁ, R., HORNA, A., EICHLEROVÁ, E.: Metodika stanovení hlavních fenolických sloučenin v genotypech jabloní s ohledem na různé podmínky skladování. (Methodology of determination of main phenolic compounds in genotypes of apples with regard to various storage conditions), Holovousy, Výzkumný a šlechtitelský ústav ovocnářský, 2018, 43 pp. ISBN 978-80-87030-68-4.

DEGREES

Lectures for the Professorship Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2018

doc. PharmDr. PETR ZIMČÍK, Ph.D.: Associate Professor, Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, Hradec Králové.

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 30. 8. 2017

Continuation: 10. 10. 2017

Title of Lecture: Fotodynamická terapie – Minulost, současnost, budoucnost (?) (Photodynamic therapy – Past, present, future (?)), 12. 12. 2017

Appointment: 05. 12. 2018

Habilitation Theses and Lectures for Associated Professor Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2018

PharmDr. JAROSLAV ROH, Ph.D.: Senior Lecturer, Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Hradec Králové.

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 7. 9. 2017

Continuation: 10. 10. 2017

Habilitation Thesis: Příprava a studium antituberkuloticky účinných látek ze skupiny dusíkatých heterocyklů (Preparation and study of antituberculous agents from the class of nitrogen heterocycles), defended 12. 12. 2017

Title of Lecture: Nové strukturální typy antituberkulotik v preklinické a klinické fázi vývoje (Novel structural types of antituberculous drugs in preclinical and clinical phases of development), 12. 12. 2017

Appointment: 1. 3. 2018

- Mgr. BUREŠ, JAN: Analytické a bioanalytické hodnocení nových potencionálních léčiv ze skupiny chelátorů železa (Analytical and bioanalytical evaluation of novel potential drugs from the group of iron chelators), 11. 5. 2018, Ph.D.
- Mgr. HULCOVÁ, DANIELA: Biologická aktivita alkaloidů *Narcissus pseudonarcissus* L. cv. Dutch Master (Amaryllidaceae) (Biological activity of alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master (Amaryllidaceae)), 25. 10. 2018, Ph.D.
- Ing. HURYCHOVÁ, HANA: Studium statických a dynamických sypných vlastností farmaceutických excipientů (Study of static and dynamic flow properties of pharmaceutical excipients), 13. 6. 2018, Ph.D.
- Mgr. HYRŠOVÁ, LUCIE: Nové aspekty funkce a regulace pregnanového X receptoru (New aspects of pregnane X receptor function and regulation), 6. 12. 2018, Ph.D.
- Mgr. LOCHMAN, LUKÁŠ: Studium rozpoznávacích částí senzoričkových azaftalocyaninů (Study of recognition moieties of sensoric azaphthalocyanines), 23. 1. 2018, Ph.D.
- Mgr. PATKOVÁ, ANNA: Aplikace nepřímé kalorimetrie u dvou různých inzulinorezistentních stavů – polytraumatu a gravidity (Indirect calorimetry application in two different insulin-resistant states – polytrauma and pregnancy), 26. 9. 2018, Ph.D.
- Mgr. ŘEZNÍČEK, JOSEF: Interakce antivirotik s lékovými transportéry; vliv na farmakokinetiku (Interactions of antiretrovirals with drug transporters; role in pharmacokinetics), 14. 9. 2018, Ph.D.
- Ing. STRÁNSKÁ, DENISA: Nanovláknenné membrány jako nosiče léčiv II (Nanofibrous membranes as drug delivery systems II), 20. 9. 2018, Ph.D.
- Mgr. VANĚČKOVÁ, NINA: Study of the inhibitory (toxic) effect of the alkaloids from chosen plants of Amaryllidaceae family on some human enzymatic systems (*in vitro* study) II, 25. 10. 2018, Ph.D.
- Mgr. ZEMČÍKOVÁ, LUCIE: Vliv přírodních látek na transport lékovými OATP transportéry (The effect of natural compounds on transport by OATP drug transporters), 16. 11. 2018, Ph.D.

Rigorous Theses to obtain the degree PharmDr. (Doctor of Pharmacy, graduates of the study programme Pharmacy) or RNDr. (Doctor of Natural Sciences, graduates of study programme Bioanalytical Laboratory Diagnostics in Medicine), Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2018

- Mgr. AMBROŽ, MARTIN, Ph.D. Seskviterpeny v protinádorové terapii (Sesquiterpenes in cancer therapy), 29. 5. 2018, PharmDr.
- Mgr. ANDRŠ, MARTIN, Ph.D.: Investigation of compounds affecting the neoplastic cell changes, 17. 5. 2018, PharmDr.
- Mgr. BABINSKÁ, AGÁTA: Využitie kapalinovej chromatografie vo farmaceutickej analýze III (Use of liquid chromatography in pharmaceutical analysis III), 22. 11. 2018, PharmDr.
- Mgr. BAĐUROVÁ, KRISTÝNA: Hodnocení obsahu fenolických látek v ovoci (Evaluation of phenolic compounds content in fruits), 15. 11. 2018, RNDr.
- Mgr. BAKOVÁ, IZABELA: Izolace alkaloidů druhu *Magnolia soulangeana* Soul.-Bod. a studium jejich biologické aktivity (Isolation of alkaloids of the species *Magnolia soulangeana* Soul.-Bod. and study of their biological activity), 28. 2. 2018, PharmDr.
- Mgr. BEIL, KAMIL: Hodnocení oxidace nutričních substrátů a energetického výdeje u polytraumatizovaných pacientů na nutriční podpoře (Evaluation of the nutritional substrates oxidation and energy expenditure in polytrauma patients on nutritional support), 15. 2. 2018, PharmDr.
- Mgr. BELKINA, TATIANA, Ph.D.: Non-prescribed antibiotic use in some developing countries and its association with drug resistance, 10. 4. 2018, PharmDr.
- Mgr. BĚREŠOVÁ, MICHAELA: Štúdium konsolidačného chovania laktosy a jej zmesi (Study of consolidation behaviour of lactose and its blends), 24. 4. 2018, PharmDr.
- Mgr. BLAŽÍČKOVÁ, KATEŘINA, Ph.D.: Vztah tkáňového a solubilního endoglinu k endotelové dysfunkci a možnosti jejich ovlivnění (Tissue and soluble endoglin relation to the endothelial dysfunction and possible treatment), 15. 2. 2018, PharmDr.
- Mgr. BLAŽKOVÁ, ANDREA: Modifikace kapilární stěny pro separační účely I (Modification of the capillary wall for the separation purpose I), 23. 3. 2018, PharmDr.

- Mgr. BOUNTALIS, KONSTANTINOS SPYRIDON: Soluble endoglin effects on endothelial dysfunction markers in mice, 14. 9. 2018, PharmDr.
- Mgr. BROKEŠOVÁ, KATEŘINA: Deriváty aminobenzoových kyselin jako potenciální antimikrobní látky (Derivatives of aminobenzoic acids as potential antimicrobial agents), 9. 11. 2018, PharmDr.
- Mgr. BULVOVÁ, LEONTINA: Alkaloidy *Papaver rhoeas* L. (Papaveraceae) a jejich biologická aktivita vztážená k Alzheimerově chorobě I (Alkaloids of *Papaver rhoeas* L. (Papaveraceae) and their biological activity related to Alzheimer's disease I), 28. 2. 2018, PharmDr.
- Mgr. BUREŠ, JAN, Ph.D.: Analytické a bioanalytické hodnocení nových potencionálních léčiv ze skupiny chelátorů železa (Analytical and bioanalytical evaluation of novel potential drugs from the group of iron chelators), 15. 11. 2018, PharmDr.
- Mgr. BURKERTOVÁ, ALICE: Alkaloidy čeledi Amaryllidaceae: Isolace, strukturální identifikace, biologická aktivita. I (Alkaloids of Amaryllidaceae family: Isolation, structural identification, biological activity. I), 28. 2. 2018, PharmDr.
- Mgr. ČAKURDOVÁ, MARTA: Alkaloidy *Papaver rhoeas* L. (Papaveraceae) a jejich biologická aktivita vztážená k Alzheimerově chorobě II (Alkaloids of *Papaver rhoeas* L. (Papaveraceae) and their biological activity related to Alzheimer's disease II), 27. 6. 2018, PharmDr.
- Mgr. ČERMÁKOVÁ, MARTINA: Western blot analýza vybraných molekul oxidačního stresu v aortě apoE/LDLR deficientního myšičího modelu (Western blot analysis of selected oxidative stress markers in aorta of apoE/LDLR deficient mice), 27. 6. 2018, RNDr.
- Mgr. DOSTÁLOVÁ, ELIŠKA: Studium sypných a konsolidačních vlastností velikostních frakcí bezvodé laktosy (Study of bulk and consolidation properties of size fractions of anhydrous lactose), 24. 10. 2018, PharmDr.
- Mgr. DOUBKOVÁ, DAGMAR: Vývoj kapilární elektroforetické metody pro stanovení vybraných lékopisných nečistot indometacinu (Development of capillary electrophoresis method for the determination of three pharmacopoeial impurities in indomethacin), 22. 11. 2018, PharmDr.
- Mgr. DYMÁKOVÁ, ANDREA: Effect of synthetic magnolol derivatives on activity of nuclear receptors PPAR γ and RXR α , 06. 02. 2018, PharmDr.
- Mgr. DZÁMOVÁ, PAVLÍNA: Hodnocení sypných a konsolidačních vlastností magnesiumu aluminometasilikátu (Evaluation of flow and consolidation properties of magnesium aluminometasilicate), 29. 5. 2018, PharmDr.
- Mgr. EISNER, TOMÁŠ: Synthesis of novel cardioprotectants and metabolites of potent anticancer drug Bp4eT, 9. 11. 2018, PharmDr.
- Mgr. ERBENOVÁ, KATEŘINA: Studium interakce antiretrovirotika maraviroku s lékovými transportéry ABCB1 a ABCG2 (Study on interaction potential of maraviroc with drug transporters ABCB1 and ABCG2), 15. 2. 2018, PharmDr.
- Mgr. FOUISOVÁ, DOMINIKA: Studium přímo lisovatelných tabletovin a tablet s retardační složkou obsahující polyvinyl-acetát a povidone (A study of directly compressible tableting materials and tablets with the retarding component containing polyvinyl acetate and povidone), 17. 4. 2018, PharmDr.
- Mgr. GAJDOŠOVÁ, VANESA: Analýza liekových problémov ("drug-related problems") v zdravotníckom zariadení IV (Analysis of drug-related problems in a healthcare facility IV), 21. 6. 2018, PharmDr.
- Mgr. GORBUNOVÁ, EVA: Porovnání chelatace iontů mědi benzoovými kyselinami (Comparison of copper ion chelation by benzoic acids), 12. 9. 2018, PharmDr.
- Mgr. GOROVÁ, BARBORA: Železo-chelatační vlastnosti extraktů plodů z různých variet bezu černého (Iron-chelating properties of fruit extracts of various elderberries), 14. 9. 2018, PharmDr.
- Mgr. GULÁŠ, ONDREJ: Testovanie separačného potenciálu stacionárnych fáz na báze porézného grafitového uhlíku (Evaluation of separation potential of stationary phases based on porous graphitic carbon), 22. 11. 2018, PharmDr.
- Mgr. HADRAVSKÁ, PAVLÍNA: Metabolomic analysis of bile acids in various biological samples, 14. 09. 2018, PharmDr.
- Mgr. HALVOVÁ, PETRA, Ph.D.: Terapeutické monitorování léčiv v klinické praxi a výzkumu – Nové možnosti TDM cyklosporinu A a jeho metabolitů po transplantaci ledvin (Therapeutic drug monitoring in clinical practice and research – new possibilities of TDM of cyclosporine A and its metabolites after renal transplantation), 2. 10. 2018, PharmDr.
- Mgr. HARTINGER, JAN, Ph.D.: Molekulární podstata etiologie toxického působení fluoropyrimidinů se zaměřením na palmární-plantární erythrodysesthesii a použití potenciálních antidotů (Molecular basis of fluo-

- ropyrimidine toxic effect etiology with focus on palmar-plantar erythrodysesthesia and potential antidote use), 15. 2. 2018, PharmDr.
- Mgr. HIRŠOVÁ, PETRA, Ph.D.: Effect of epigallocatechin gallate on bile production, 15. 2. 2018, PharmDr.
- Mgr. HLADKÝ, PAVEL: Formulace a (trans)dermální podání imiquimodu (Formulation and (trans)dermal delivery of imiquimod), 24. 10. 2018, PharmDr.
- Mgr. HOMOLA, PAVEL: Studium vybraných chelátorů železa pro prevenci oxidačního stresu u buněčné linie PC12 (Study of selected iron chelators for oxidative stress prevention in PC12 cell line), 27. 6. 2018, PharmDr.
- Mgr. HRUŠKOVÁ, MAGDA: Alkaloidy dřeva druhu *Liriodendron tulipifera* L. a jejich aktivita vůči lidským cholinesterasám (Alkaloids from the wood of the species *Liriodendron tulipifera* L. and their activity against human cholinesterases), 8. 6. 2018, PharmDr.
- Mgr. JANČAROVÁ, ALENA: Sulfonované azaftalocyaniny – syntéza a hodnocení jejich fotodynamické aktivity (Sulfonated azaphthalocyanines – synthesis and evaluation of their photodynamic activity), 8. 11. 2018, PharmDr.
- Mgr. JANETKOVÁ, MONIKA: Využití HPLC v chirálních separacích III (The employment of HPLC in the field of chiral separations III), 23. 3. 2018, PharmDr.
- Mgr. JANÍČEK, TOMÁŠ: Účinek vybraných seskviterpenů na antioxidační enzymy u buněčné linie Caco-2 (The effect of selected sesquiterpenes on antioxidant enzymes in Caco-2 cell line), 6. 2. 2018, PharmDr.
- Mgr. JELENKOVÁ, KLÁRA: Vliv monepantelu na expresi vybraných enzymů u vlasovky slezové (Effect of monepantel on the expression of selected enzymes in *Haemonchus contortus*), 6. 2. 2018, PharmDr.
- Mgr. JIŘÍČKOVÁ, NINA: Nesilikagelové materiály v analýze léčiv III (Non-silica based materials in drug analysis III), 15. 11. 2018, PharmDr.
- Mgr. JON, VOJTĚCH: Syntéza a studium 1-*O*-acylceramidů (Synthesis and study of 1-*O*-acylceramides), 28. 2. 2018, PharmDr.
- Mgr. JUHÁS, MARTIN: Definition of the carbohydrate binding capacities of the novel enterotoxin LT-IIc, 8. 11. 2018, PharmDr.
- Mgr. KALÁBOVÁ, DIANA: Děkani farmaceutické fakulty UK v Hradci Králové (Deans of Charles University, Faculty of Pharmacy in Hradec Králové), 15. 3. 2018, PharmDr.
- Mgr. KASALOVÁ, EVA, Ph.D.: Moderní separační techniky pro analýzu biologického materiálu v klinickém výzkumu (Modern separation techniques for the analysis of biological material in clinical research), 28. 6. 2018, RNDr.
- Mgr. KERHARTOVÁ, MARKÉTA: Syntéza nových hybridních molekul M1 agonisty s inhibitory acetylcholinesterasy (Synthesis of novel hybrid molecules combining an M1 agonist and acetylcholinesterase inhibitors), 11. 1. 2018, PharmDr.
- Mgr. KLAUČOVÁ, MARTINA: Použití Amesovho testu v štúdiu genotoxicity novo vyvíjaných látok (Ames test in the drug development), 12. 9. 2018, PharmDr.
- Mgr. KLÍMOVÁ, KAMILA: Alkaloidy rostlin čeledi Amaryllidaceae a jejich biologická aktivita I (Alkaloids of the family Amaryllidaceae and their biological activity I), 27. 6. 2018, PharmDr.
- Mgr. KLINEROVÁ, JANA: Extrakce zinku z vodných roztoků pomocí extrakce na tuhou fázi v sekvenční injekční analýze (Extraction of zinc from water solutions using solid phase extraction in sequential injection analysis), 28. 6. 2018, RNDr.
- Mgr. KOLENIČ, MAREK: Studie transalkylace u aromatických *tert*-butylsulfidů (Study of transalkylation of *tert*-butylsulfides), 8. 11. 2018, PharmDr.
- Mgr. KOLLÁROVÁ, NIKOLA: Detection of Sap2 in the secretome of *Candida albicans* cell wall and secretory mutants, 15. 2. 2018, PharmDr.
- Mgr. KÖSZEGY, ERIK: Liberácia kyseliny listovej z mikrovlákién na báze kyseliny hyaluronovej (Liberation of folic acid from microfibers based on hyaluronic acid), 29. 5. 2018, PharmDr.
- Mgr. KOUKLÍKOVÁ, ETELA: Studium vlivu inhibitorů cyklin-dependenčních kinas na expresi vybraných AKR a CBR enzymů v lidských buněčných liniích (Study of the effect of cyclin-dependent kinase inhibitors on the expression of selected AKR and CBR enzymes in human cell lines), 14. 9. 2018, RNDr.
- Mgr. KOVÁČIK, ANDREJ, Ph.D.: Studium vlivu hydroxylace ceramidů na permeabilitu a mikrostrukturu modelových lipidových membrán (Study of effect of ceramide hydroxylation on permeability and microstructure of model lipid membranes), 28. 2. 2018, PharmDr.
- Mgr. KOVÁŘOVÁ, BARBORA: Reporter gene studies for nanoparticle mediated DNA and siRNA delivery, 27. 6. 2018, PharmDr.

- Mgr. KOVÁŘOVÁ, LENKA: Asociace fázového úhlu s parametry energetického metabolismu u pacientů s CHOPN (Association of phase angle with parameters of energy metabolism in patients with COPD), 14. 9. 2018, PharmDr.
- Mgr. KREJČAROVÁ, JANA: Western blot analýza vybraných molekul zánětu v aortě apoE/LDLR deficientního myšího modelu (Western blot analysis of selected inflammatory markers in aorta of apoE/LDLR deficient mice), 15. 2. 2018, PharmDr.
- Mgr. KRIVOŠOVÁ, MICHAELA: Hodnotenie potenciálne nevhodných liečiv a liekových postupov v starobe I (Evaluation of potentially inappropriate drugs and drug procedures in the old age I), 21. 6. 2018, PharmDr.
- Mgr. KROULÍKOVÁ, PAVLA: Testování inhibiční aktivity nových protinádorových léčiv vůči vybraným izoformám cytochromu P450 (Study of inhibition activity of new antitumor drugs against chosen isoforms of cytochromes P450), 15. 2. 2018, PharmDr.
- Mgr. KUNOVSKÁ, KLÁRA: Hodnocení antioxidantní aktivity přírodních látek (Evaluation of antioxidant activity of natural compounds), 23. 3. 2018, PharmDr.
- Mgr. KVĚTOŇ, MARTIN: Screening systémových amyloidóz v materiálu endoskopických biopsií (Screening for systemic amyloidoses in endoscopic biopsy samples), 14. 9. 2018, RNDr.
- Mgr. LALINSKÁ, ANEŽKA: Studium interakcí antiretroviálního léčiva tenofoviru a jeho proléčiva tenofoviru disoproxil fumarátu s placentárními nukleosidovými transportéry (Study of interactions of antiviral drug tenofovir and its prodrug tenofovir disoproxil fumarate with placental nucleoside transporters), 14. 9. 2018, PharmDr.
- Mgr. LÁZNIČKA, LUKÁŠ: Hodnocení viskozity celulosových základů pro magistraliter přípravu (Evaluation of viscosity of the cellulosis bases for extemporaneous preparation), 29. 5. 2018, PharmDr.
- Mgr. LEHEČKOVÁ, ZDEŇKA: Effects of exotic plant extracts on proliferation and migration of normal human dermal fibroblasts, 12. 9. 2018, PharmDr.
- Mgr. LEŠKOVÁ, PATRÍCIA: Štúdium lisovateľnosti a vlastností tableť zo zmesného suchého spojiva s manitolom pre tablety dispergovateľné v ústach (A study of the compressibility and the properties of tablets from the coprocessed dry binder with mannitol for oral disintegrating tablets), 24. 10. 2018, PharmDr.
- Mgr. LNĚNIČKOVÁ, KATEŘINA, Ph.D.: Modulace biotransformačních a antioxidantních enzymů vybranými přírodními látkami (Modulation of biotransformation and antioxidant enzymes by selected natural compounds), 29. 5. 2018, PharmDr.
- Mgr. LOCHMAN, LUKÁŠ, Ph.D.: Studium rozpoznávacích částí senzoričkých azafthalocyaninů (Study of recognition moieties of sensoric azaphthalocyanines), 17. 5. 2018, PharmDr.
- Mgr. MACHÁČEK, MILOSLAV, Ph.D.: Studium nových fotosenzitizérů ze skupiny ftalocyaninů a azafthalocyaninů pro fotodynamickou léčbu nádorových onemocnění (Study of novel phthalocyanine and azaphthalocyanine photosensitizers for the photodynamic therapy of cancer), 6. 2. 2018, RNDr.
- Mgr. MALINOVÁ, TEREZA: Využití kapalinové chromatografie ve farmaceutické analýze IV (Use of liquid chromatography in pharmaceutical analysis IV), 15. 11. 2018, PharmDr.
- Mgr. MATĚJKOVÁ, LENKA: Vliv nanočástic na proteom rostlin (Effect of nanoparticles on plant proteome), 6. 2. 2018, PharmDr.
- Mgr. MĚRKOVÁ, VERONIKA: Co²⁺ loaded block copolymer micelles: Preparation and their uptake into macrophages, 6. 2. 2018, PharmDr.
- Mgr. MILTOVÁ, LUCIE: Synthesis of new organic compounds containing chalcogens, 17. 5. 2018, PharmDr.
- Mgr. MOCO VÁ, KLÁRA: Stanovení stechiometrie komplexů 7,8-dihydroxykumarinů s mědí (Determination of the stoichiometry of the copper complexes with 7,8-dihydroxycoumarins), 14. 9. 2018, PharmDr.
- Mgr. MORAVČÍK, ŠTEFAN: Využití laktónů v syntéze acylceramidů (Use of lactones in acylceramide synthesis), 9. 11. 2018, PharmDr.
- Mgr. NAJMANOVÁ, IVETA, Ph.D.: Vliv polyfenolických látek na hladký cévní sval (The effect of polyphenolic substances on vascular smooth muscle), 15. 2. 2018, PharmDr.
- Mgr. NGUYEN THI, THU HA: Studium přímo lisovatelných tableťovin a tableť se směsným suchým pojivem obsahujícím laktosu, povidon a krosopovidon (A study of directly compressible tableting materials and tablets with the coprocessed dry binder containing lactose, povidone and krosopovidone), 17. 4. 2018, PharmDr.
- Mgr. NOVÁK, FILIP: HPLC-high resolution mass spectrometry analysis of *in vitro* and *in vivo* metabolism of scoparone, 14. 9. 2018, PharmDr.
- Mgr. NOVOTNÁ, MARTA: Semipreparativní separace biokonjugátů azafthalocyaninů (Semipreparative separation of bioconjugates of azaphthalocyanines), 23. 3. 2018, PharmDr.

- Mgr. NOVÝSEDLÁKOVÁ, ALENA: Účinky vybraných izoflavonoidů *in vitro* na izolované aorte potkana (The *in vitro* effects of selected isoflavonoids on isolated rat aorta), 15. 2. 2018, PharmDr.
- Mgr. OBERTOVIÁ, NIKOLA: Inhalačné podanie liečiv v terapii obštrukčných chorôb pľúc (Use of inhaled drugs in obstructive pulmonary diseases), 21. 6. 2018, PharmDr.
- Mgr. OBRDLÍK, DANIEL: Syntéza ceramidu NS pomocí Grubbsovy metateze (Synthesis of ceramide NS using Grubbs metathesis), 28. 2. 2018, PharmDr.
- Mgr. OHÁŇKOVÁ, ALENA: Hodnocení stability gestodenu s využitím HPLC (Evaluation of stability of gestodene using HPLC), 15. 11. 2018, PharmDr.
- Mgr. ONDRÁŠIKOVÁ, MICHAELA: Zdravý životný štýl záujemcov o zdravú výživu (Healthy lifestyle of people interested in healthy diet), 21. 6. 2018, PharmDr.
- Mgr. PAKÁNOVÁ, ALICA: Sekundární metabolity rostlinných kultur *in vitro* II (Secondary metabolites of plant cultures *in vitro* II), 27. 6. 2018, PharmDr.
- Mgr. PAEOVÁ, ROMANA: Miniaturized and fast method for solubility and level of supersaturation determinations of drug nanocrystals, 24. 4. 2018, PharmDr.
- Mgr. PATARÁKOVÁ, PAULA: Vplyv prenylovaných flavonoidov na biotransformačné enzýmy *in vitro* (Effect of prenylated flavonoids on biotransformation enzymes *in vitro*), 6. 2. 2018, PharmDr.
- Mgr. PLŠKOVÁ, MARTINA: Systémová zánětlivá odpověď organismu na klostridiovou infekci (The systemic inflammatory response of the organism to *Clostridium difficile* infection), 6. 2. 2018, RNDr.
- Mgr. PODHORSKÁ, GABRIELA: Effects of simple sugar consumption on cognitive functions in female rats, 6. 2. 2018, PharmDr.
- Mgr. POLEDNÍKOVÁ, MICHAELA: Syntéza a biologické hodnocení purinových inhibitorů fosfatidylinositol-3-kinas a příbuzných proteinkinas I (Synthesis and biological evaluation of purine inhibitors of phosphatidylinositol 3-kinases and related protein kinases I), 11. 1. 2018, PharmDr.
- Mgr. PRAŽIENKOVÁ, NIKOLA: Vliv domácího prostředí na vznik alergií u dětí (The effect of household characteristics on the allergies in children), 15. 2. 2018, PharmDr.
- Mgr. PRCHAL, LUKÁŠ, Ph.D.: Anthelmintic and other xenobiotic biotransformation in helminths and its contribution to resistance development, 29. 5. 2018, PharmDr.
- Mgr. PŘEDOTA, VÁCLAV: Analýza magistraliter receptů v lékárně nemocnice České Budějovice (The analysis of extemporaneously compounded prescriptions in the pharmacy of the Hospital České Budějovice), 21. 6. 2018, PharmDr.
- Mgr. PŮLKRÁBKOVÁ, MARTINA: Hodnocení fotodynamické aktivity derivátů tetrapyrido-porphyrzinu pro léčbu nádorových onemocnění (Evaluation of photodynamic activity of tetrapyridoporphyrzine derivatives for treatment of tumorous diseases), 27. 6. 2018, PharmDr.
- Mgr. PUZYREVSKÁ, JANA: Biologická aktivita obsahových látek rostlin XXXIV. Alkaloidy nati *Glaucium flavum* CRANTZ a jejich vliv na lidské cholinesterasy (Biological activity of plant metabolites XXXIV. Alkaloids from the herb of *Glaucium flavum* CRANTZ and their impact on human cholinesterases), 28. 2. 2018, PharmDr.
- Mgr. ŘEHOUNKOVÁ, MICHAELA: Genetické markery pro sledování posttransplantačního chimerismu (Genetic markers for monitoring post-transplant chimerism), 14. 9. 2018, RNDr.
- Mgr. REPEEOVÁ, BEÁTA: Studium vlivu antiretrovirálních léčiv na transmembránový transport tenofoviru disoproxil fumarátu přes monovrstvu MDCKII-ABCB1 buněk (Study of effects of antiretroviral drugs on transmembrane transport of tenofovir disoproxil fumarate across MDCKII-ABCB1 cell monolayer), 15. 2. 2018, PharmDr.
- Mgr. ŘEZNÍČEK, JOSEF, Ph.D.: Interakce antivirotik s lékovými transportéry; vliv na farmakokinetiku (Interactions of antiretrovirals with drug transporters; role in pharmacokinetics), 13. 11. 2018, PharmDr.
- Mgr. RÖSLEROVÁ, ELIŠKA: Analýza vzdělávání farmaceutů v České republice po dosažení odborné způsobilosti (Analysis of education of pharmacists in the Czech Republic after graduation), 21. 6. 2018, PharmDr.
- Mgr. RŮŽIČKA, ŠTĚPÁN: Vývoj HPLC metody pro stanovení vybraných karotenoidů v ovoci (HPLC method development for carotenoids determination in fruits), 04. 05. 2018, PharmDr.
- Mgr. RÝDLOVÁ, KATEŘINA: Alkaloidy *Narcissus* 'Dutch Master' (Amaryllidaceae) a jejich biologická aktivita III (Alkaloids of *Narcissus* 'Dutch Master' (Amaryllidaceae) and their biological activity III), 28. 2. 2018, PharmDr.

- Mgr. SAGANDYKOVA, AIGUL: The effect of lipid signaling pathway interference on sorafenib cytotoxic efficacy and function of efflux transporters in mouse hepatocellular carcinoma cells, 14. 9. 2018, PharmDr.
- Mgr. ŠAMAJOVÁ, MARIANNA: Vstup baktérie *Mycobacterium bovis* BCG do B lymfocytů (Entry of bacteria *Mycobacterium bovis* BCG into B lymphocytes), 12. 9. 2018, PharmDr.
- Mgr. SEDLÁKOVÁ, JANA: Synthesis of phosphoramidate prodrugs "ProTides" as novel potential therapeutic agents for the treatment of congenital disorders of glycosylation and mitochondrial DNA depletion syndrome, 9. 11. 2018, PharmDr.
- Mgr. ŠIŠMOVÁ, PETRA: The impaired change in plasma long-chain acylcarnitine level as a marker of insulin resistance, 15. 2. 2018, PharmDr.
- Mgr. ŠOFRANKOVÁ, ALEXANDRA: Fraktální aspekty sypného a konsolidačného chovania mikrokryštalickej celulózy (Fractal aspects of flow and consolidation behaviour of microcrystalline cellulose), 24. 4. 2018, PharmDr.
- Mgr. SOUKUPOVÁ, ANDREA: Hodnocení potenciálních léčiv Alzheimerovy choroby jakožto inhibitorů prolyliloligopeptidasy (Evaluation of potential Alzheimer's disease drugs as prolyliloligopeptidase inhibitors), 14. 9. 2018, PharmDr.
- Mgr. ŠPATENKOVÁ, NIKOLA: Vplyv onkomarkeru CA 19-9 na prognózu pacientov s karcinómom pankreasu (Influence of oncomarker CA 19-9 in prognosis of patients with pancreatic cancer), 15. 2. 2018, PharmDr.
- Mgr. STEHLÍKOVÁ, TEREZA: Časné změny exprese eNOS a ICAM-1 v aortě myši po podávání vysokotukové diety (Early changes in eNOS and ICAM-1 expression in mice aorta after administration of high fat diet), 15. 2. 2018, PharmDr.
- Mgr. STRAKA, ONDŘEJ: Syntéza substituovaných arylguanidinů jako potenciálních léčiv XIII (Synthesis of substituted arylguanidines as potential drugs XIII), 9. 11. 2018, PharmDr.
- Mgr. STUPKOVÁ, EVA: Výrobní program lékárny U Černého orla na Malé Straně (Products of Black Eagle Pharmacy at Malá Strana district of Prague), 15. 3. 2018, PharmDr.
- Mgr. SVOBODA, PAVEL, Ph.D.: Matricové efekty v LC-MS analýze: Vznik, hodnocení a jejich odstranění (Matrix effects in LC-MS analysis: Occurrence, evaluation, and their elimination), 23. 3. 2018, PharmDr.
- Mgr. SVOBODOVÁ, MAGDALÉNA: Microglia control adenosine A_{2A}-receptor mediated astrogliosis, 15. 2. 2018, PharmDr.
- Mgr. SWIERCZKOVÁ, IVA: Časné změny exprese tkáňového endoglinu a VCAM-1 v aortě myši po podávání vysokotukové diety (Early changes in tissue endoglin and VCAM-1 expression in mice aorta after administration of high fat diet), 6. 2. 2018, RNDr.
- Mgr. TEPLÁ, LENKA: HILIC separace acikloviru a jeho degradačního produktu II (HILIC separation of acyclovir and its degradation product II), 4. 5. 2018, PharmDr.
- Mgr. TIRALA, PETR: Formulace a (trans)dermální podání lipozómů s obsahem imiquimodu (Formulation and (trans)dermal delivery of liposomes containing imiquimod), 24. 10. 2018, PharmDr.
- Mgr. TOMANOVÁ, PAVLA: Fyzikálně chemické vlastnosti léčiv (Physico-chemical properties of drugs), 8. 11. 2018, PharmDr.
- Mgr. TOUŠKOVÁ, TEREZA, Ph.D.: Kvalitativní a kvantitativní aspekty adherence v léčbě osteoporózy (Qualitative and quantitative aspects of adherence to osteoporosis treatment), 10. 4. 2018, PharmDr.
- Mgr. TRNČÁKOVÁ, VERONIKA: Modulační účinek humulenu, karyofylenu a karyofylenoxidu na vybrané biotransformační enzymy v lidských jaterních buňkách (Modulatory effect of humulene, caryophyllene and caryophyllene oxide on selected biotransformation enzymes in human liver cells), 14. 9. 2018, RNDr.
- Mgr. TUČKOVÁ, TEREZA: Základní charakterizace lidských enzymů DHRS7B a DHRS7C (Basic characterization of human enzymes DHRS7B and DHRS7C), 27. 6. 2018, PharmDr.
- Mgr. TURŇOVÁ, IVANA: Stanovení mastných kyselin v lidských tkáních (Determination of fatty acids in human tissues), 28. 6. 2018, RNDr.
- Mgr. UHER, MARTIN: Pulsní léčba glukokortikoidy a změny exprese mikroRNA u pacientů se systémovými autoimunitními onemocněními (MicroRNA expression in glucocorticoid-treated patients with systemic autoimmune diseases), 14. 9. 2018, RNDr.
- Mgr. VÁCHOVÁ, LENKA, Ph.D.: Syntéza a studium fotofyzikálních a fotochemických vlastností ftalocyaninů a azafthalocyaninů (Synthesis and study of photophysical and photochemical properties of phthalocyanines and azaphthalocyanines), 17. 5. 2018, PharmDr.
- Mgr. VALER, VOJTĚCH: Syntéza derivátů azafthalocyaninů s fenolickou skupinou jako fluorescenčních senzorů pro pH (Synthesis of phenol-substituted azaphthalocyanines as fluorescent pH sensors), 17. 5. 2018, PharmDr.

- Mgr. VANÍČEK, JIŘÍ: Účinky chmele na růst podmíněně patogenních bakterií (The effect of hop on the growth of facultative pathogenic bacteria), 12. 9. 2018, PharmDr.
- Mgr. VAREJČKOVÁ, MICHALA, Ph.D.: Sledování vlivu statinů a solubilního endoglinu na markery endotelové dysfunkce u vybraných buněčných linií a kultur (Monitoring the effect of statins and soluble endoglin on markers of endothelial dysfunction in selected cell line and culture), 15. 2. 2018, PharmDr.
- Mgr. VEJRYCHOVÁ, KATEŘINA: Syntéza a biologické hodnocení purinových inhibitorů fosfatidylinositol-3-kinas a příbuzných proteinkinas II (Synthesis and biological evaluation of purine inhibitors of phosphatidylinositol 3-kinases and related protein kinases II), 11. 1. 2018, PharmDr.
- Mgr. VODIČKOVÁ, KAROLÍNA: Tuhé disperze s aciklovirem plastifikované methylsalicylátém (Aciclovir loaded solid dispersions plasticized with methyl salicylate), 24. 4. 2018, PharmDr.
- Mgr. VONDRUŠKOVÁ, HANA: Hodnocení společně zpracovaných pomocných látek určených pro formulaci orálně dispergovatelných tablet (Evaluation of co-processed excipients intended for orodispersible tablets formulation), 24. 10. 2018, PharmDr.
- Mgr. VYKOUKALOVÁ, NIKOL: Predikce průchodu takrin-BQCA derivátů přes hematoencefalickou bariéru (Prediction of tacrine-BQCA derivatives across blood-brain-barrier), 15. 2. 2018, PharmDr.
- Mgr. ZAHÁLKA, LUKÁŠ, Ph.D.: Stability studies of oral liquid preparations using HPLC, 15. 11. 2018, PharmDr.
- Mgr. ZAHRADNÍKOVÁ, TEREZA: Solubilizace, purifikace a příprava rekonstitučního systému pro lidský enzym 17 β -hydroxysteroiddehydrogenasu typu 3 (Solubilisation, purification and reconstitution of human 17 β -hydroxysteroid dehydrogenase type 3), 27. 6. 2018, PharmDr.
- Mgr. ZAJDLOVÁ, MARTINA: Působení *trans*-nerolidolu a valencenu na ovariální nádorové buňky (The effect of *trans*-nerolidol and valencene in ovarian cancer cells), 6. 2. 2018, PharmDr.
- Mgr. ŽÁK, ONDŘEJ: Sloučeniny kombinující fragment pyrazinamidu a *p*-aminosalicylové kyseliny jako potenciální antituberkulotika II (Compounds combining pyrazinamide and *p*-aminosalicylic acid fragments as potential antituberculars II), 8. 11. 2018, PharmDr.
- Mgr. ŽÁKOVÁ, KATEŘINA: Působení alfa-humulenu a karyofylenoxidu na ovariální nádorové buňky (The effect of alpha-humulene and carophyllene oxide in ovarian cancer cells), 6. 2. 2018, PharmDr.
- Mgr. ZEMANOVÁ, KAMILA: Interakce fenylpropionových kyselin s mědí (Interaction of phenylpropionic acids with copper), 28. 2. 2018, PharmDr.
- Mgr. ŽIŽKOVÁ, KLÁRA: Automatizace toxikologických testů (Automation of toxicology tests), 15. 11. 2018, RNDr.
- Mgr. ZUBÁŇOVÁ, VERONIKA: Vplyv anestézie na mieru oxidatívneho poškodenia DNA (The influence of anesthesia on the degree of DNA oxidative damage). 14. 9. 2018, RNDr.

PUBLICATIONS OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ, CHARLES UNIVERSITY IN THE YEAR 2019

ORIGINAL PAPERS AND REVIEWS

- ADAMCOVÁ, M., BAKA, T., DOLEŽELOVÁ, E., AZIRIOVÁ, S., KRAJČÍROVIČOVÁ, K., KAREŠOVÁ, I., STANKO, P., REPOVÁ, K., ŠIMKO, F.: Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model. *Journal of Physiology and Pharmacology*, 70 (1), 2019, 71–77.
- AMBROŽ, M., LNĚNIČKOVÁ, K., MATOUŠKOVÁ, P., SKÁLOVÁ, L., BOUŠOVÁ, I.: Antiproliferative effects of hop-derived prenylflavonoids and their influence on the efficacy of oxaliplatin, 5-fluorouracil and irinotecan in human colorectal cells. *Nutrients*, 11 (4), 2019, art. 879.
- AMBROŽ, M., ŠMATOVÁ, M., ŠADIBOLOVÁ, M., POSPÍŠILOVÁ, E., HADRAVSKÁ, P., KAŠPAROVÁ, M., HANUŠOVÁ, V., KRÁLOVÁ, V., SKÁLOVÁ, L.: Sesquiterpenes α -humulene and β -caryophyllene oxide

- enhance the efficacy of 5-fluorouracil and oxaliplatin in colon cancer cells. *Acta Pharmaceutica*, 69 (1), 2019, 121–128.
- APPOVÁ, L., KARLÍČKOVÁ, J., WARNCKE, P., MACÁKOVÁ, K., HRUBŠA, M., MACHÁČEK, M., TVRDÝ, V., FISCHER, D., MLADĚNKA, P.: 4-Methylcatechol, a flavonoid metabolite with potent anti-platelet effects. *Molecular Nutrition and Food Research*, 63 (20), 2019, art. 1900261.
- ARISTORENA, M., GALLARDO-VARA, E., VICEN, M., De LAS CASAS-ENGEL, M., OJEDA-FERNANDEZ, L., NIETO, C., BLANCO, F. J., VALBUENA-DIEZ, A. C., BOTELLA, L. M., NACHTIGAL, P., CORBI, A. L., COLMENARES, M., BERNABEU, C.: MMP-12, secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells. *International Journal of Molecular Sciences*, 20 (12), 2019, art. 3107.
- BERÁNEK, M., MÁLKOVÁ, A., FIALA, Z., KREMLÁČEK, J., HAMÁKOVÁ, K., ŽALOUĐKOVÁ, L., BORSKÝ, P., ADAMUS, T., PALÍČKA, V., BORSKÁ, L.: Goeckerman therapy of psoriasis: Genotoxicity, dietary micronutrients, homocysteine, and MTHFR gene polymorphisms. *International Journal of Molecular Sciences*, 20 (8), 2019, art. 1908.
- BERKA, P., STRÁNSKÁ, D., SEMECKÝ, V., BERKA, K., DOLEŽAL, P.: *In vitro* testing of flash-frozen sublingual membranes for storage and reproducible permeability studies of macromolecular drugs from solution or nanofiber mats. *International Journal of Pharmaceutics*, 572, 2019, art. 118711.
- BOUZ, G., SEMELKOVÁ, L., JANĎOUREK, O., KONEČNÁ, K., PATEROVÁ, P., ZEMČÍKOVÁ, L., KUBÍČEK, V., KUNES, J., DOLEŽAL, M., ZITKO, J.: Derivatives of 3-aminopyrazine-2-carboxamides: Synthesis, antimicrobial evaluation, and *in vitro* cytotoxicity. *Molecules*, 24 (7), 2019, art. 1212.
- BRŮŽA, Z., KRATOCHVÍL, J., HARVEY, J. N., RULÍŠEK, L., NOVÁKOVÁ, L., MAŘÍKOVÁ, J., KUNES, J., KOČOVSKÝ, P., POUR, M.: A new insight into the stereoelectronic control of the Pd-0-catalyzed allylic substitution: Application for the synthesis of multisubstituted pyran-2-ones via an unusual 1,3-transposition. *Chemistry – A European Journal*, 25 (34), 2019, 8053–8060.
- BUKUM, N., NOVOTNÁ, E., MORELL, A., HOFMAN, J., WSÓL, V.: Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. *Chemico-Biological Interactions*, 302, 2019, 101–107.
- CAHLÍKOVÁ, L., VANĚČKOVÁ, N., ŠAFRATOVÁ, M., BREITEROVÁ, K., BLUNDEN, G., HULCOVÁ, D., OPLETAL, L.: The genus *Nerine* Herb. (Amaryllidaceae): Ethnobotany, phytochemistry, and biological activity. *Molecules*, 24 (23), 2019, art. 4238.
- CARAZO FERNÁNDEZ, A., MLADĚNKA, P., PÁVEK, P.: Marine ligands of the pregnane X receptor (PXR): An overview. *Marine Drugs*, 17 (10), 2019, art. 554.
- CATAPANO, M. C., PROTTI, M., FONTANA, T., MANDRIOLI, R., MLADĚNKA, P., MERCOLINI, L.: An original HPLC method with coulometric detection to monitor hydroxyl radical generation via Fenton chemistry. *Molecules*, 24 (17), 2019, art. 3066.
- CONNORS, J. M., GREGOR, S., CRANDALL, D., NETUKA, I., MEHRA, M. R.: Low-intensity anti-coagulation using vitamin K antagonists and factor X activity: A validation analysis of the MAGENTUM-1 study. *The Journal of Heart and Lung Transplantation*, 38 (6), 2019, 668–669.
- ČEPA, A., RÁLIŠ, J., MAREŠOVÁ, L., KLEINOVÁ, M., SEIFERT, D., SIEGLOVÁ, I., KRÁL, V., POLÁŠEK, M., PAŮROVÁ, M., LÁZNÍČEK, M., LEBEDA, O.: Radiolabeling of the antibody IgG M75 for epitope of human carbonic anhydrase IX by Cu-61 and Cu-64 and its biological testing. *Applied Radiation and Isotopes*, 143, 2019, 87–97.
- ČURÍKOVÁ-KINDLOVÁ, B. A., DIAT, O., ŠTĚPÁNEK, F., VÁVROVÁ, K., ZBYTOVSKÁ, J.: Probing the interactions among sphingosine and phytosphingosine ceramides with non- and alpha-hydroxylated acyl chains in skin lipid model membranes. *International Journal of Pharmaceutics*, 563, 2019, 384–394.
- D'ATRI, V., NOVÁKOVÁ, L., FEKETE, S., STOLL, D., LAUBER, M., BECK, A., GUILLARME, D.: Orthogonal middle-up approaches for characterization of the glycan heterogeneity of etanercept by hydrophilic interaction chromatography coupled to high-resolution mass spectrometry. *Analytical Chemistry*, 91 (1), 2019, 873–880.
- DOLEŽAL, R., HOUDKOVÁ, I., KALÁSZ, H., ANDRÝS, R., NOVÁK, M., MALTSEVSKAYA, N. V., KARÁSKOVÁ, N., KOLÁŘ, K., NOVOTNÁ, E., KUČA, K., ŽĎÁROVÁ KARASOVÁ, J.: Determination of hypericin in *Hypericum perforatum* (St. John's Wort) using classical C18 and pentafluorophenyl stationary phases: Contribution of Pi-Pi interactions to high-performance liquid chromatography (HPLC). *Analytical Letters*, 52 (11), 2019, 1788–1812.

- DOLEŽELOVÁ, E., IGREJA e SÁ, I. C., PRAŠNICKÁ, A., HROCH, M., HYŠPLER, R., TICHÁ, A., LAŠTŮVKOVÁ, H., CERMANOVÁ, J., PERICACHO, M., VÍŠEK, J., LÁŠTICOVÁ, M., MIČUDA, S., NACHTIGAL, P.: High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. *Life Sciences*, 232, 2019, art. 116643.
- DUINTJER TEBBENS, E. J., MATONOHA, C., MATTHIOS, A., PAPÁČEK, Š.: On parameter estimation in an *in vitro* compartmental model for drug-induced enzyme production in pharmacotherapy. *Applications of Mathematics*, 64 (2), 2019, 253–277.
- DUŠEK, J., ŠKODA, J., HOLAS, O., HORVÁTOVÁ, A., SMUTNÝ, T., LINHARTOVÁ, L., HIRŠOVÁ, P., KUČERA, O., MIČUDA, S., BRAEUNING, A., PÁVEK, P.: Stilbene compound *trans*-3,4,5,4'-tetramethoxystilbene, a potential anticancer drug, regulates constitutive androstane receptor (Car) target genes, but does not possess proliferative activity in mouse liver. *Toxicology Letters*, 313, 2019, 1–10.
- DVOŘÁČKOVÁ, E., PÁVEK, P., KOVÁČOVÁ, B., RYCHLÍČKOVÁ, J., SUCHOPÁR, O., HOJNÝ, M., DUINTJER TEBBENS, E. J., VLČEK, J.: Is computer-assisted aminoglycoside dosing managed by a pharmacist a safety tool of pharmacotherapy? *Physiological Research*, 68 (Suppl. 1), 2019, S87–S96.
- DVOŘÁČKOVÁ, E., RYCHLÍČKOVÁ, J., PÁVEK, P., HOJNÝ, M., VLČEK, J.: Analysis and management of drug related problems on a nephrology ward from a pharmacist's point of view. *Pharmazie*, 74 (10), 2019, 625–629.
- FÁBRYOVÁ, T., CHEEL, J., KUBÁČ, D., HROUZEK, P., VU, D. L., TŮMOVÁ, L., KOPECKÝ, J.: Purification of lutein from the green microalgae *Chlorella vulgaris* by integrated use of a new extraction protocol and a multi-injection high performance counter-current chromatography (HPLCC). *Algal Research*, 41, 2019, art. 101574.
- FIALOVÁ, D., BRKIĆ, J., LAFFON, B., REISSIGOVÁ, J., GREŠÁKOVÁ, S., DOGAN, S., DORO, P., TASIĆ, L., MARINKOVIĆ, V., VALDIGLESIAS, V., COSTA, S., KOSTŘIBA, J.: Applicability of EU(7)-PIM criteria in cross-national studies in European countries. *Therapeutic Advances in Drug Safety*, 10, 2019, art. 2042098619854010.
- FIALOVÁ, D., LAFFON, B., MARINKOVIĆ, V., TASIĆ, L., DORO, P., SÓOS, G., MOTA, J., DOGAN, S., BRKIĆ, J., TEIXEIRA, J. P., VALDIGLESIAS, V., COSTA, S.: Medication use in older patients and age-blind approach: Narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies). *European Journal of Clinical Pharmacology*, 75 (4), 2019, 451–466.
- FIKAROVÁ, K., COCOVI-SOLBERG, D. J., ROSENDE, M., HORSTKOTTE, B., SKLENÁŘOVÁ, H., MIRÓ, M.: A flow-based platform hyphenated to on-line liquid chromatography for automatic leaching tests of chemical additives from microplastics into seawater. *Journal of Chromatography A*, 1602, 2019, 160–167.
- FIKAROVÁ, K., HORSTKOTTE, B., SKLENÁŘOVÁ, H., ŠVEC, F., SOLICH, P.: Automated continuous-flow in-syringe dispersive liquid-liquid microextraction of mono-nitrophenols from large sample volumes using a novel approach to multivariate spectral analysis. *Talanta*, 202, 2019, 11–20.
- HAISEL, D., CYRUSOVÁ, T., VANĚK, T., PODLIPNÁ, R.: The effect of nanoparticles on the photosynthetic pigments in cadmium-zinc interactions. *Environmental Science and Pollution Research*, 26 (4), 2019, 4147–4151.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., CHVOJKA, J., ERBEN, J., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: Polycaprolactone nanofibers functionalized with a dopamine coating for on-line solid phase extraction of bisphenols, betablockers, nonsteroidal drugs, and phenolic acids. *Microchimica Acta*, 186 (11), 2019, art. 710.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: Electrospun nanofiber polymers as extraction phases in analytical chemistry – The advances of the last decade. *Trends in Analytical Chemistry*, 110, 2019, 81–96.
- HANOUSKOVÁ, B., NEPRAŠOVÁ, B., SKÁLOVÁ, L., MALETÍNSKÁ, L., ZEMANOVÁ, K., AMBROŽ, M., MATOUŠKOVÁ, P.: High-fructose drinks affect microRNAs expression differently in lean and obese mice. *Journal of Nutritional Biochemistry*, 68, 2019, 42–50.
- HANOUSKOVÁ, B., SKÁLA, M., BRYNYCHOVÁ, V., ZÁRYBNICKÝ, T., SKARKOVÁ, V., KAZIMÍROVÁ, P., VERNEROVÁ, A., SOUČEK, P., SKÁLOVÁ, L., PUDIL, R., MATOUŠKOVÁ, P.: Imatinib-induced changes in the expression profile of microRNA in the plasma and heart of mice – A comparison with doxorubicin. *Biomedicine & Pharmacotherapy*, 115, 2019, art. 108883.

- HAUSMANN, C., ZOSCHKE, C., WOLFF, C., DARVIN, M. E., SOCHOROVÁ, M., KOVÁČIK, A., WANJIKU, B., SCHUMACHER, F., TIGGES, J., KLEUSER, B., LADEMANN, J., FRITSCHKE, E., VÁVROVÁ, K., MA, N., SCHÄFER-KORTING, M.: Fibroblast origin shapes tissue homeostasis, epidermal differentiation, and drug uptake. *Scientific Reports*, 9, 2019, art. 2913.
- HOFMAN, J., ŠORF, A., VAGIANNIS, D., SUCHÁ, S., KAMMERER, S., KÜPPER, J., CHEN, S., GUO, L., ČEČKOVÁ, M., ŠTAUD, F.: Brivanib exhibits potential for pharmacokinetic drug-drug interactions and the modulation of multidrug resistance through the inhibition of human ABCG2 drug efflux transporter and CYP450 biotransformation enzymes. *Molecular Pharmaceutics*, 16 (11), 2019, 4436–4450.
- HOFMAN, J., ŠORF, A., VAGIANNIS, D., SUCHÁ, S., NOVOTNÁ, E., KAMMERER, S., KÜPPER, J., ČEČKOVÁ, M., ŠTAUD, F.: Interactions of alectinib with human ATP-binding cassette drug efflux transporters and cytochrome P450 biotransformation enzymes: Effect on pharmacokinetic multidrug resistance. *Drug Metabolism and Disposition*, 47 (7), 2019, 699–709.
- HORSTKOTTE ŠRÁMKOVÁ, I., CARBONELL-ROZAS, L., HORSTKOTTE, B., HÁKOVÁ, M., ERBEN, J., CHVOJKA, J., ŠVEC, F., SOLICH, P., GARCÍA-CAMPAÑA, A. M., ŠATÍNSKÝ, D.: Screening of extraction properties of nanofibers in a sequential injection analysis system using a 3D printed device. *Talanta*, 197, 2019, 517–521.
- HOŠTÁLKOVÁ, A., MAŘÍKOVÁ, J., OPLETAL, L., KORÁBEČNÝ, J., HULCOVÁ, D., KUNEŠ, J., NOVÁKOVÁ, L., PÉREZ, D. I., JUN, D., KUČERA, T., ANDRISANO, V., SIATKA, T., CAHLÍKOVÁ, L.: Isoquinoline alkaloids from *Berberis vulgaris* as potential lead compounds for the treatment of Alzheimer's disease. *Journal of Natural Products*, 82 (2), 2019, 239–248.
- HULCOVÁ, D., MAŘÍKOVÁ, J., KORÁBEČNÝ, J., HOŠTÁLKOVÁ, A., JUN, D., KUNEŠ, J., CHLEBEK, J., OPLETAL, L., De SIMONE, A., NOVÁKOVÁ, L., ANDRISANO, V., RŮŽIČKA, A., CAHLÍKOVÁ, L.: Amarylidaceae alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease. *Phytochemistry*, 165, 2019, art. 112055.
- HYRŠOVÁ, L., VANDUCHOVÁ, A., DUŠEK, J., SMUTNÝ, T., CARAZO FERNÁNDEZ, A., MAREŠOVÁ, V., TREJTNAR, F., BÁRTA, P., ANZENBACHER, P., DVOŘÁK, Z., PÁVEK, P.: *Trans*-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. *Toxicology Letters*, 300, 2019, 81–91.
- CHALUPOVÁ, K., KORÁBEČNÝ, J., BARTOLINI, M., MONTI, B., LAMBA, D., CALIANDRO, R., PESARESI, A., BRAZZOLOTTA, X., GASTELLIER, A., NACHON, F., PEJCHAL, J., JAROŠOVÁ, M., HEPNAROVÁ, V., JUN, D., HRABINOVÁ, M., DOLEŽAL, R., ŽDÁROVÁ KARASOVÁ, J., MŽIK, M., KRIŠTOFIKOVÁ, Z., MISÍK, J., MÚČKOVÁ, E., JOŠT, P., SOUKUP, O., BENKOVÁ, M., SETNIČKA, V., HABARTOVÁ, L., CHVOJKOVÁ, M., KLETEČKOVÁ, L., VALEŠ, K., MEZEIOVÁ, E., ULIASSI, E., VALIŠ, M., NEPOVIMOVÁ, E., BOLOGNESI, M. L., KUČA, K.: Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. *European Journal of Medicinal Chemistry*, 168, 2019, 491–514.
- CHLÁDKOVÁ, G., KUNOVSKÁ, K., CHOCHOLOUŠ, P., POLÁŠEK, M., SKLENÁŘOVÁ, H.: Automatic screening of antioxidants based on the evaluation of kinetics of suppression of chemiluminescence in a luminol-hydrogen peroxide system using a sequential injection analysis setup with a flow-batch detection cell. *Analytical Methods*, 11 (19), 2019, 2531–2536.
- CHLEBEK, J., KORÁBEČNÝ, J., DOLEŽAL, R., ŠTĚPÁNKOVÁ, Š., PÉREZ, D. I., HOŠTÁLKOVÁ, A., OPLETAL, L., CAHLÍKOVÁ, L., MACÁKOVÁ, K., KUČERA, T., HRABINOVÁ, M., JUN, D.: *In vitro* and *in silico* acetylcholinesterase inhibitory activity of thalicttricavine and canadine and their predicted penetration across the blood-brain barrier. *Molecules*, 24 (7), 2019, art. 1340.
- CHOCHOLOUŠ, P., ŠATÍNSKÝ, D., SOLICH, P.: New generation of sequential injection chromatography: Great enhancement of capabilities of separation using flow analysis. *Talanta*, 204, 2019, 272–277.
- JANOUŠEK, J., BÁRTA, P., NOVÝ, Z., ŽILKOVÁ, K., TREJTNAR, F.: Antiangiogenic human monoclonal antibody ramucirumab radiolabelling: *In vitro* evaluation on VEGFR2-positive cell lines. *Anticancer Research*, 39 (2), 2019, 735–744.
- JANSOVÁ, H., ŠIMŮNEK, T.: Cardioprotective potential of iron chelators and prochelators. *Current Medicinal Chemistry*, 26 (2), 2019, 288–301.
- JIRÁSKOVÁ, L., RYŠKA, A., DUINTJER TEBBENS, E. J., HORNÝCHOVÁ, H., ČEČKA, F., ŠTAUD, F., ČERVENÝ, L.: Are ENT1/ENT1, NOTCH3, and miR-21 reliable prognostic biomarkers in patients with

- resected pancreatic adenocarcinoma treated with adjuvant gemcitabine monotherapy? *Cancers*, 11 (11), 2019, art. 1621.
- JOSKOVÁ, V., PATKOVÁ, A., HAVEL, E., NAJPAVEROVÁ, S., URAMOVÁ, D., KOVAŘÍK, M., ZADÁK, Z., HRONEK, M.: The bioimpedance spectroscopy as useful tool for measuring the fluid excess and fluid management in severe polytrauma patients. *Physiological Research*, 68 (2), 2019, 255–264.
- JOUROVÁ, L., ANZENBACHER, P., MATUŠKOVÁ, Z., VEČEŘA, R., STROJIL, J., KOLÁŘ, M., NOBILIS, M., HERMANOVÁ, P., HUDCOVIC, T., KOZÁKOVÁ, H., KVERKA, M., ANZENBACHEROVÁ, E.: Gut microbiota metabolizes nabumetone *in vitro*: Consequences for its bioavailability *in vivo* in the rodents with altered gut microbiome. *Xenobiotica*, 49 (11), 2019, 1296–1302.
- JUVONEN, R. O., NOVÁK, F., EMMANOUILIDOU, E., AURIOLA, S., TIMONEN, J., HEIKKINEN, A. T., KÜBLBECK, J., FINEL, M., RAUNIO, H.: Metabolism of scoparone in experimental animals and humans. *Planta Medica*, 85 (6), 2019, 453–464.
- KAPITANOV, I. V., JORDAN, A., KARPICHEV, Y., ŠPULÁK, M., PEREZ, L., KELLETT, A., KUEMMERER, K., GATHERGOOD, N.: Synthesis, self-assembly, bacterial and fungal toxicity, and preliminary biodegradation studies of a series of L-phenylalanine-derived surface-active ionic liquids. *Green Chemistry*, 21 (7), 2019, 1777–1794.
- KARABANOVICH, G., DUŠEK, J., SAVKOVÁ, K., PAVLIŠ, O., PÁVKOVÁ, I., KORÁBEČNÝ, J., KUČERA, T., KOČOVÁ VLČKOVÁ, H., HUSZÁR, S., KONYARIKOVÁ, Z., KONEČNÁ, K., JANĎOUREK, O., STOLARÍKOVÁ, J., KORDULÁKOVÁ, J., VÁVROVÁ, K., PÁVEK, P., KLIMEŠOVÁ, V., HRABÁLEK, A., MIKUŠOVÁ, K., ROH, J.: Development of 3,5-dinitrophenyl-containing 1,2,4-triazoles and their trifluoromethyl analogues as highly efficient antitubercular agents inhibiting decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase. *Journal of Medicinal Chemistry*, 62 (17), 2019, 8115–8139.
- KARAHODA, R., ČEČKOVÁ, M., ŠTAUD, F.: The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta. *Toxicology and Applied Pharmacology*, 368, 2019, 18–25.
- KARBANOVÁ, S., ČERVENÝ, L., JIRÁSKOVÁ, L., KARAHODA, R., ČEČKOVÁ, M., PTÁČKOVÁ, Z., ŠTAUD, F.: Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. *Biochemical Pharmacology*, 163, 2019, 60–70.
- KARLÍKOVÁ, M., ČERMÁKOVÁ, V., DEMUTH, J., VALER, V., MILETÍN, M., NOVÁKOVÁ, V., ZIMČÍK, P.: Magnesium tetrapyrazinoporphyrazines: Tuning of the pK_a of red-fluorescent pH indicators. *Dalton Transactions*, 48 (18), 2019, 6162–6173.
- KELLEROVÁ, P., MATOUŠKOVÁ, P., LAMKA, J., VOKŘÁL, I., SZOTÁKOVÁ, B., ZAJÍČKOVÁ, M., PASÁK, M., SKÁLOVÁ, L.: Ivermectin-induced changes in the expression of cytochromes P450 and efflux transporters in *Haemonchus contortus* female and male adults. *Veterinary Parasitology*, 273 (September), 2019, 24–31.
- KOČIŠČÁKOVÁ, L., SENIPEK, M. I., ZIMČÍK, P., NOVÁKOVÁ, V.: Non-peripherally alkylamino-substituted phthalocyanines: Synthesis, spectral, photophysical and acid-base properties. *Journal of Porphyrins and Phthalocyanines*, 23 (4–5), 2019, 427–436.
- KOHELOVÁ, E., PEŘINOVÁ, R., MAAFI, N., KORÁBEČNÝ, J., HULCOVÁ, D., MAŘÍKOVÁ, J., KUČERA, T., MARTÍNEZ GONZÁLEZ, L., HRABINOVÁ, M., VORČÁKOVÁ, K., NOVÁKOVÁ, L., De SIMONE, A., HAVELEK, R., CAHLÍKOVÁ, L.: Derivatives of the β-crinane Amaryllidaceae alkaloid haemanthamine as multi-target directed ligands for Alzheimer's disease. *Molecules*, 24 (7), 2019, art. 1307.
- KOHLVÁ, M., GOMES AMORIM, C., ARAÚJO, A., SANTOS-SILVA, A., SOLICH, P., CONCEICAO, B. S. M. MONTENEGRO, M.: The biocompatibility and bioactivity of hemodialysis membranes: Their impact in end-stage renal disease. *Journal of Artificial Organs*, 22 (1), 2019, 14–28.
- KOLLÁR, J., MACHÁČEK, M., JANČÁROVÁ, A., KUBÁT, P., KUČERA, R., MILETÍN, M., NOVÁKOVÁ, V., ZIMČÍK, P.: Effect of bovine serum albumin on the photodynamic activity of sulfonated tetrapyrazinoporphyrazine. *Dyes and Pigments*, 162, 2019, 358–366.
- KONEČNÁ, K., KLIMENTOVÁ, J., BENADA, O., NĚMEČKOVÁ, I., JANĎOUREK, O., JÍLEK, P., VEJSOVÁ, M.: A comparative analysis of protein virulence factors released via extracellular vesicles in two *Candida albicans* strains cultivated in a nutrient-limited medium. *Microbial Pathogenesis*, 136, 2019, art. 103666.
- KOPEČNÁ, M., KOVÁČIK, A., KUČERA, O., MACHÁČEK, M., SOCHOROVÁ, M., AUDRLICKÁ, P., VÁVROVÁ, K.: Fluorescent penetration enhancers reveal complex interactions among the enhancer, drug, solvent, and skin. *Molecular Pharmaceutics*, 16 (2), 2019, 886–897.

- KOPEČNÁ, M., MACHÁČEK, M., NOVÁČKOVÁ, A., PARASKEVOPOULOS, G., ROH, J., VÁVROVÁ, K.: Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers. *Scientific Reports*, 9, 2019, art. 14617.
- KOZIOLEK, M., ALCARO, S., AUGUSTIJNS, P., BASIT, A. W., GRIMM, M., HENS, B., HOAD, C. L., JEDAMZIK, P., MADLA, C. M., MALIEPAARD, M., MARCIANI, L., MARUCA, A., PARROTT, N., PÁVEK, P., PORTER, C. J. H., REPPAS, C., Van RIET-NALES, D., RUBBENS, J., STATELOVA, M., TREVASKIS, N. L., VALENTOVÁ, K., VERTZONI, M., ČEPO, D. V., CORSETTI, M.: The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. *European Journal of Pharmaceutical Sciences*, 134, 2019, 31–59.
- KOŽÁK, J., RABIŠKOVÁ, M., LAMPRECHT, A.: Silk fibroin as a novel alcohol-resistant excipient for sustained-release tablet formulation. *AAPS PharmSciTech*, 20 (7), 2019, art. 279.
- KRÁTKÝ, M., JANDOUREK, O., BARANYAI, Z., NOVOTNÁ, E., STOLAŘÍKOVÁ, J., BŐSZE, S., VINŠOVÁ, J.: Phenolic *N*-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds. *European Journal of Medicinal Chemistry*, 181, 2019, art. 111578.
- KRÁTKÝ, M., ŠTĚPÁNKOVÁ, Š., HOUNGBEDJI, N., VOSÁTKA, R., VORČÁKOVÁ, K., VINŠOVÁ, J.: 2-Hydroxy-*N*-phenylbenzamides and their esters inhibit acetylcholinesterase and butyrylcholinesterase. *Bio-molecules*, 9 (11), 2019, art. 698.
- KUBEŠ, J., SKALICKÝ, M., TŮMOVÁ, L., MARTIN, J., HEJNÁK, V., MARTINKOVÁ, J.: Vanadium elicitation of *Trifolium pratense* L. cell culture and possible pathways of produced isoflavones transport across the plasma membrane. *Plant Cell Reports*, 38 (5), 2019, 657–671.
- KUBÍČEK, V., SKÁLOVÁ, L., SKARKA, A., KRÁLOVÁ, V., HOLUBOVÁ, J., ŠTĚPÁNKOVÁ, J., ŠUBRT, Z., SZOTÁKOVÁ, B.: Carbonyl reduction of flubendazole in the human liver: Strict stereospecificity, sex difference, low risk of drug interactions. *Frontiers in Pharmacology*, 10, 2019, art. 600.
- KUČEROVÁ, K., KUJOVSKÁ KRČMOVÁ, L., MIKANOVÁ, Z., MATYSOVÁ, L., MELICHAR, B., ŠVEC, F.: Determination of urinary retinol and creatinine as an early sensitive marker of renal dysfunction. *Journal of Chromatography A*, 1607, 2019, art. 460390.
- KUČEROVÁ, K., REISKÁ, V., ŠVEC, F., KUJOVSKÁ KRČMOVÁ, L., MATYSOVÁ, L.: Fast determination of omeprazole in extemporaneous suspensions used in paediatrics and stability studies. *Analytical Methods*, 11 (4), 2019, 517–523.
- KUCHAŘOVÁ, M., HRONEK, M., RYBÁKOVÁ, K., ZADÁK, Z., ŠTĚTINA, R., JOSKOVÁ, V., PATKOVÁ, A.: Comet assay and its use for evaluating oxidative DNA damage in some pathological states. *Physiological Research*, 68 (1), 2019, 1–15.
- LHOTSKÁ, I., KHOLOVÁ, A., MACHYŇÁKOVÁ, A., HROBOŇOVÁ, K., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: Preparation of citrinin-selective molecularly imprinted polymer and its use for on-line solid-phase extraction coupled to liquid chromatography. *Analytical and Bioanalytical Chemistry*, 411 (11), 2019, 2395–2404.
- LOCHMAN, L., MACHÁČEK, M., MILETÍN, M., UHLÍŘOVÁ, Š., LANG, K., KIRAKCI, K., ZIMČÍK, P., NOVÁKOVÁ, V.: Red-emitting fluorescence sensors for metal cations: The role of counteranions and sensing of SCN⁻ in biological materials. *ACS Sensors*, 4 (6), 2019, 1552–1559.
- MACÁKOVÁ, K., AFONSO OLIVEIRA, R., SASO, L., MLADĚNKA, P.: The influence of alkaloids on oxidative stress and related signaling pathways. *Free Radical Biology & Medicine*, 134, 2019, 429–444.
- MACÁKOVÁ, K., CATAPANO, M. C., TVRDÝ, V., KLIMKOVÁ, K., KARLÍČKOVÁ, J., MLADĚNKA, P.: Hematoxylin assay of cupric chelation can give false positive results. *Journal of Trace Elements in Medicine and Biology*, 52, 2019, 29–36.
- MALÝ, J., DOSEDĚL, M., VOSÁTKA, J., MALÁ, K., KUBĚNA, A., BRABCOVÁ, I., HAJDUCHOVÁ, H., BARTLOVÁ, S., TÓTHOVÁ, V., VLČEK, J.: Pharmacotherapy as major risk factor of falls – analysis of 12 months experience in hospitals in South Bohemia. *Journal of Applied Biomedicine*, 17 (1), 2019, 53–60.
- MALÝ, J., DVOŘÁČKOVÁ, S., ZIMČÍKOVÁ, E., KUBĚNA, A., KOLÁŘ, J., VLČEK, J., PENKA, M., MALÁ, K.: Patterns in anticoagulant utilization in the Czech Republic during 2007–2017. *Journal of Thrombosis and Thrombolysis*, 47 (2), 2019, 305–311.
- MALÝ, J., ZIMČÍKOVÁ, E., BABICA, J., KUBĚNA, A., KOSTŘIBA, J., MALÁ, K.: Representative sample survey on factors determining the Czech physicians' awareness of generic drugs and substitution. *BMC Health Services Research*, 19 (1), 2019, art. 777.

- MALÝ, O., ZAJAK, J., HYŠPLER, R., TUREK, Z., ASTAPENKO, D., JUN, D., VÁŇOVÁ, N., KOHOUT, A., RADOCHOVÁ, V., KOTEK, J., PÁRAL, J.: Inhalation of molecular hydrogen prevents ischemia-reperfusion liver damage during major liver resection. *Annals of Translational Medicine*, 7 (23), 2019, art. 774.
- MARKS, N. D., WINTER, A. D., GU, H. Y., MAITLAND, K., GILLAN, V., AMBROŽ, M., MARTINELLI, A., LAING, R., MacLELLAN, R., TOWNE, J., ROBERTS, B., HANKS, E., DEVANEY, E., BRITTON, C.: Profiling microRNAs through development of the parasitic nematode *Haemonchus* identifies nematode-specific miRNAs that suppress larval development. *Scientific Reports*, 9 (November), 2019, art. 17594.
- MARTINEC, O., HULIČIAK, M., ŠTAUD, F., ČEČKA, F., VOKŘÁL, I., ČERVENÝ, L.: Anti-HIV and anti-hepatitis C virus drugs inhibit P-glycoprotein efflux activity in Caco-2 cells and precision-cut rat and human intestinal slices. *Antimicrobial Agents and Chemotherapy*, 63 (11), 2019, art. e00910-19.
- MARTIŠKA, J., ŠNEJDROVÁ, E., DRASTÍK, M., MATYSOVÁ, L., DITTRICH, M., LOSKOT, J., JÍLEK, P.: Terbinafine-loaded branched PLGA-based cationic nanoparticles with modifiable properties. *Pharmaceutical Development and Technology*, 24 (10), 2019, 1308–1316.
- MIGKOS, T., APPLOVÁ, L., HORKÝ, P., TVRDÝ, V., KARLÍČKOVÁ, J., MACÁKOVÁ, K., HRUBŠA, M., CATAPANO, M. C., TOMANEK, M., POUR, M., MLADĚNKA, P.: The influence of microbial isoflavonoid specific metabolites on platelets and transition metals iron and copper. *Phytomedicine*, 62, 2019, art. 152974.
- MICHALÍKOVÁ, K., DOMINGUEZ-VEGA, E., SOMSEN, G. W., HASELBERG, R.: Middle-up characterization of the monoclonal antibody infliximab by capillary zone electrophoresis-mass spectrometry. *LC-GC Europe*, 32 (3), 2019, 130–137.
- MLADĚNKA, A., MLADĚNKA, P., ŠIMETKA, O., KLÁT, J.: Intra-operative and postoperative complications depend on operating approach and body mass index in patients with malignant uterus body neoplasm. *European Journal of Gynaecological Oncology*, 40 (4), 2019, 593–598.
- MOHOS, V., PÁNOVICS, A., FLISZÁR-NYÚL, E., SCHILLI, G., HETÉNYI, C., MLADĚNKA, P., NEEDS, P. W., KROON, P. A., PETHŐ, G., POÓR, M.: Inhibitory effects of quercetin and its human and microbial metabolites on xanthine oxidase enzyme. *International Journal of Molecular Sciences*, 20 (11), 2019, art. 2681.
- MONTEIRO, S., PARASKEVOPOULOS, G., IMRAMOVSKÝ, A.: Synthesis of 13,14-dehydro-prostaglandins synthetic analogues: A review. *ChemistrySelect*, 4 (38), 2019, 11247–11255.
- MUŽÍKOVÁ, J., NOVOTNÁ, A., BARTOŠ, M.: A study of the combination of microcrystalline cellulose and mannitol in a co-processed dry binder and in a physical mixture for the use in orally disintegrating tablets. *Acta Poloniae Pharmaceutica*, 76 (2), 2019, 355–365.
- NESMĚRÁK, K., KUDLÁČEK, K., ŠTÍCHA, M., KOZLÍK, P., BABICA, J.: HPLC-MS/MS analysis of degradation products of neosalvarsan in 76-year-old injection preparation. *Monatshefte für Chemie – Chemical Monthly*, 150 (9), 2019, 1611–1615.
- NGUYEN, T. L., KURZ, T., PRESTON, S., BRUECKMANN, H., LUNGERICH, B., HERATH, H. M. P. D., KOEHLER, A. V., WANG, T., SKÁLOVÁ, L., JABBAR, A., GASSER, R. B.: Phenotypic screening of the ‘Kurz-box’ of chemicals identifies two compounds (BLK127 and HBK4) with anthelmintic activity *in vitro* against parasitic larval stages of *Haemonchus contortus*. *Parasites & Vectors*, 12), 2019, art. 191.
- NOVÁKOVÁ, L., SEJKOROVÁ, M., SMOLKOVÁ, K., PLACHKÁ, K., ŠVEC, F.: The benefits of ultra-high-performance supercritical fluid chromatography in determination of lipophilic vitamins in dietary supplements. *Chromatographia*, 82 (1), 2019, 477–487.
- NOVOSVĚTSKÁ, L., CHOCHOLOUŠ, P., ŠVEC, F., SKLENÁŘOVÁ, H.: Fully automated method based on on-line molecularly imprinted polymer solid-phase extraction for determination of lovastatin in dietary supplements containing red yeast rice. *Analytical and Bioanalytical Chemistry*, 411 (6), 2019, 1219–1228.
- PAVLÍKOVÁ PŘECECHTĚLOVÁ, J., MLÁDEK, A., ZAPLETAL, V., HRITZ, J.: Quantum chemical calculations of NMR chemical shifts in phosphorylated intrinsically disordered proteins. *Journal of Chemical Theory and Computation*, 15 (10), 2019, 5642–5658.
- PILAŘOVÁ, V., AL HAMIMI, S., CUNICO, L. P., NOVÁKOVÁ, L., TURNER, C.: Extending the design space in solvent extraction – from supercritical fluids to pressurized liquids using carbon dioxide, ethanol, ethyl lactate, and water in a wide range of proportions. *Green Chemistry*, 21 (19), 2019, 5427–5436.
- PILAŘOVÁ, V., PLACHKÁ, K., KHALIKOVA, M., ŠVEC, F., NOVÁKOVÁ, L.: Recent developments in supercritical fluid chromatography-mass spectrometry: Is it a viable option for analysis of complex samples? *Trends in Analytical Chemistry*, 112, 2019, 212–225.

- POKLADNÍKOVÁ, J., ŠTEFANČÍKOVÁ, M., HAVIGER, J., BISHOP, F. L., WANG, B., GUAN, X., MUSIL, F.: Effect of expectation on short- and long-term treatment response to Acupuncture in migraine patients. *European Journal of Integrative Medicine*, 26, 2019, 31–36.
- POKORNÁ, Z., JIRKOVSKÝ, E., HLAVÁČKOVÁ, M., JANSOVÁ, H., JIRKOVSKÁ, A., LENČOVÁ-POPELOVÁ, O., BRÁZDOVÁ, P., KUBEŠ, J., SOTÁKOVÁ-KAŠPAROVÁ, D., MAZUROVÁ, Y., ADAMCOVÁ, M., VOSTATKOVÁ, L., HOLZEROVÁ, K., KOLÁŘ, F., ŠIMŮNEK, T., ŠTĚRBA, M.: *In vitro* and *in vivo* investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. *Clinical Science*, 133 (16), 2019, 1827–1844.
- POUROVÁ, J., APPLOVÁ, L., MACÁKOVÁ, K., VOPRŠALOVÁ, M., MIGKOS, T., BENTANACHS, R., BIEDERMANN, D., PETRÁSKOVÁ, L., TVRDÝ, V., HRUBŠA, M., KARLÍČKOVÁ, J., KRĚN, V., VALENTOVÁ, K., MLADĚNKA, P.: The effect of silymarin flavonolignans and their sulfated conjugates on platelet aggregation and blood vessels *ex vivo*. *Nutrients*, 11 (10), 2019, art. 2286.
- PRASŇNICKÁ, A., LAŠTŮVKOVÁ, H., ALAEI FARADONBEH, F., CERMANOVÁ, J., HROCH, M., MOKRÝ, J., DOLEŽELOVÁ, E., PÁVEK, P., ŽÍŽALOVÁ, K., VÍTEK, L., NACHTIGAL, P., MIČUDA, S.: Iron overload reduces synthesis and elimination of bile acids in rat liver. *Scientific Reports*, 9, 2019, art. 9780.
- PROKOP, J., LNĚNIČKOVÁ, K., CIBIČEK, N., KOSINA, P., TOMÁNKOVÁ, V., JOUROVÁ, L., LÁNÍČKOVÁ, T., SKÁLOVÁ, L., SZOTÁKOVÁ, B., ANZENBACHER, P., ZAPLETALOVÁ, I., RÁCOVÁ, Z., ANZENBACHEROVÁ, E., ULRICHOVÁ, J.: Effect of bilberry extract (*Vaccinium myrtillus* L.) on drug-metabolizing enzymes in rats. *Food and Chemical Toxicology*, 129, 2019, 382–390.
- PULLMANNOVÁ, P., ERMAKOVA, E., KOVÁČIK, A., OPÁLKA, L., MAIXNER, J., ZBYTOVSKÁ, J., KUČERKA, N., VÁVROVÁ, K.: Long and very long lamellar phases in model stratum corneum lipid membranes. *Journal of Lipid Research*, 60 (5), 2019, 963–971.
- RAISOVÁ STUHLÍKOVÁ, L., JAKUBEC, P., LANGHANSOVÁ, L., PODLIPNÁ, R., NAVRÁTILOVÁ, M., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: The uptake, effects and biotransformation of monepantel in meadow plants used as a livestock feed. *Chemosphere*, 237, 2019, art. 124434.
- REIMEROVÁ, P., JIRKOVSKÁ, A., BAVLOVIČ PISKÁČKOVÁ, H., KARABANOVICH, G., ROH, J., ŠIMŮNEK, T., ŠTĚRBOVÁ, P.: UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. *Scientific Reports*, 9, 2019, art. 4524.
- REIMEROVÁ, P., STARIAT, J., BAVLOVIČ PISKÁČKOVÁ, H., JANSOVÁ, H., ROH, J., KALINOWSKI, D. S., MACHÁČEK, M., ŠIMŮNEK, T., RICHARDSON, D. R., ŠTĚRBOVÁ, P.: Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: A case example of DpC, an anti-cancer drug that entered clinical trials. *Analytical and Bioanalytical Chemistry*, 411 (11), 2019, 2383–2394.
- RIBEIRO, L. F., MASINI, J. C., ŠVEC, F.: Use of thiol functionalities for the preparation of porous monolithic structures and modulation of their surface chemistry: A review. *Trends in Analytical Chemistry*, 118, 2019, 606–624.
- SEDLÁČEK, J., HERMANNOVÁ, M., MRÁZEK, J., BUFFA, R., LIŠKOVÁ, P., ŠATÍNSKÝ, D., VELEBNÝ, V.: Insight into the distribution of amino groups along the chain of chemically deacetylated hyaluronan. *Carbohydrate Polymers*, 225, 2019, art. 115156.
- SIATKA, T.: Effects of growth regulators on production of anthocyanins in callus cultures of *Angelica archangelica*. *Natural Product Communications*, 14 (6), 2019, art. 4.
- SKÁLA, M., HANOUSKOVÁ, B., SKÁLOVÁ, L., MATOUŠKOVÁ, P.: MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity. *Archives of Toxicology*, 93 (1), 2019, 1–9.
- SMUTNÝ, T., BARVÍK, I., VELETA, T., PÁVEK, P., SOUKUP, T.: Genetic predispositions of glucocorticoid resistance and therapeutic outcomes in polymyalgia rheumatica and giant cell arteritis. *Journal of Clinical Medicine*, 8 (5), 2019, art. 582.
- SOCHOROVÁ, M., AUDRLICKÁ, P., ČERVENÁ, M., KOVÁČIK, A., KOPEČNÁ, M., OPÁLKA, L., PULLMANNOVÁ, P., VÁVROVÁ, K.: Permeability and microstructure of cholesterol-depleted skin lipid membranes and human stratum corneum. *Journal of Colloid and Interface Science*, 535, 2019, 227–238.
- STEPANIĆ, V., MATIJAŠIĆ, M., HORVAT, T., VERBANAC, D., KUČEROVÁ-CHLUPÁČOVÁ, M., SASO, L., ŽARKOVIĆ, N.: Antioxidant activities of alkyl substituted pyrazine derivatives of chalcones *in vitro* and *in silico* study. *Antioxidants*, 8 (4), 2019, art. 90.

- STRÁNSKÁ, D., BERKA, P., DOLEŽAL, P.: Validace výroby jednodávkových medikovaných nanovlákných přípravků produkovaných elektrospinningem. [Validation of production of single-dose medicated nanofiber matrices manufactured by electrospinning.] *Chemické listy*, 113 (5), 2019, 337–342.
- SVACINOVÁ, P., VRANÍKOVÁ, B., DOMINIK, M., ELBL, J., PAVLOKOVÁ, S., KUBALÁK, R., KOPECKÁ, P., FRANC, A.: Comprehensive study of co-processed excipients F-Melts®: Flow, viscoelastic and compacts properties. *Powder Technology*, 355, 2019, 675–687.
- SYSLOVÁ, E., LANDA, P., NAVRÁTILOVÁ, M., RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P., SKÁLOVÁ, L., SZOTÁKOVÁ, B., VANĚK, T., PODLIPNÁ, R.: Ivermectin biotransformation and impact on transcriptome in *Arabidopsis thaliana*. *Chemosphere*, 234, 2019, 528–535.
- SYSLOVÁ, E., LANDA, P., RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P., SKÁLOVÁ, L., SZOTÁKOVÁ, B., NAVRÁTILOVÁ, M., VANĚK, T., PODLIPNÁ, R.: Metabolism of the anthelmintic drug fenbendazole in *Arabidopsis thaliana* and its effect on transcriptome and proteome. *Chemosphere*, 218, 2019, 662–669.
- ŠADIBOLOVÁ, M., ZÁRYBNICKÝ, T., SMUTNÝ, T., PÁVEK, P., ŠUBRT, Z., MATOUŠKOVÁ, P., SKÁLOVÁ, L., BOUŠOVÁ, I.: Sesquiterpenes are agonists of the pregnane X receptor but do not induce the expression of phase I drug-metabolizing enzymes in the human liver. *International Journal of Molecular Sciences*, 20 (18), 2019, art. 4562.
- ŠATÍNSKÝ, D., SOBEK, V., LHOŠKÁ, I., SOLICH, P.: Micro-extraction by packed sorbent coupled on-line to a column-switching chromatography system – A case study on the determination of three beta-blockers in human urine. *Microchemical Journal*, 147, 2019, 60–66.
- ŠIMKO, J., KAREŠOVÁ, I., KREMLÁČEK, J., ZIMČÍKOVÁ, E., HORÁČEK, J., FEKETE, S., MALÁKOVÁ, J., ŽIVNÁ, H., PALÍČKA, V.: The effect of gabapentin and pregabalin on bone turnover and bone strength: A prospective study in Wistar rats. *Pharmacological Reports*, 71 (6), 2019, 1213–1218.
- ŠÍŠKA, B., ŠNEJDROVÁ, E., MACHAČ, I., DOLEČEK, P., MARTIŠKA, J.: Contribution to the rheological testing of pharmaceutical semisolids. *Pharmaceutical Development and Technology*, 24 (1), 2019, 80–88.
- ŠORF, A., NOVOTNÁ, E., HOFMAN, J., MORELL, A., ŠTAUD, F., WSÓL, V., ČEČKOVÁ, M.: Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. *Biochemical Pharmacology*, 163, 2019, 290–298.
- ŠPIČÁKOVÁ, A., BAZGIER, V., SKÁLOVÁ, L., OTYEPKA, M., ANZENBACHER, P.: β -caryophyllene oxide and *trans*-nerolidol affect enzyme activity of CYP3A4 – *In Vitro* and *in silico* studies. *Physiological Research*, 68 (Suppl. 1), 2019, S51–S58.
- ŠVEC, F.: Which chromatographia papers have influenced my favorite field: Monolithic columns. *Chromatographia*, 82 (1), 2019, 5–6.
- ŽUPOVÁ, L., ČEČKOVÁ, M., AMBRUS, C., ŠORF, A., PTÁČKOVÁ, Z., GÁBORIK, Z., ŠTAUD, F.: Interactions between maraviroc and the ABCB1, ABCG2, and ABCC2 transporters: An important role in transplacental pharmacokinetics. *Drug Metabolism and Disposition*, 47 (9), 2019, 954–960.
- UDE, Z., KAVANAGH, K., TWAMLEY, B., POUR, M., GATHERGOOD, N., KELLETT, A., MARMION, C. J.: A new class of prophylactic metallo-antibiotic possessing potent anti-cancer and anti-microbial properties. *Dalton Transactions*, 48 (24), 2019, 8578–8593.
- VÁLEK, T., KOSTELNÍK, A., VÁLKOVÁ, P., POHANKA, M.: Indoxyl acetate as a substrate for analysis of lipase activity. *International Journal of Analytical Chemistry*, 2019, art. 8538340.
- VALÍŠ, M., HERMAN, D., VÁŇOVÁ, N., MASOPUST, J., VYŠATA, O., HORT, J., PAVELEK, Z., KLÍMOVÁ, B., KUČA, K., MISÍK, J., ŽDÁROVÁ KARASOVÁ, J.: The concentration of memantine in the cerebrospinal fluid of Alzheimer's disease patients and its consequence to oxidative stress biomarkers. *Frontiers in Pharmacology*, 10, 2019, art. 943.
- VICEN, M., VITVEROVÁ, B., HAVELEK, R., BLAŽÍČKOVÁ, K., MACHÁČEK, M., RATHOUSKÁ, J., NAJMANOVÁ, I., DOLEŽELOVÁ, E., PRAŠNICKÁ, A., STERNAK, M., BERNABEU, C., NACHTIGAL, P.: Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction *in vivo* and *in vitro*. *The FASEB Journal*, 33 (5), 2019, 6099–6114.
- VOKŘÁL, I., ŠADIBOLOVÁ, M., PODLIPNÁ, R., LAMKA, J., PRCHAL, L., SOBOTOVÁ, D., LOKVENCOVÁ, K., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: Ivermectin environmental impact: Excretion profile in sheep and phytotoxic effect in *Sinapis alba*. *Ecotoxicology and Environmental Safety*, 169, 2019, 944–949.

- Von GERICHTEN, J., LAMPRECHT, D., OPÁLKA, L., SOULARD, D., MARSCHING, C., PILZ, R., SENCIO, V., HERZER, S., GALY, B., NORDSTRÖM, V., HOPF, C., GRÖNE, H., TROTTEIN, F., SANDHOFF, R.: Bacterial immunogenic α -galactosylceramide identified in the murine large intestine: Dependency on diet and inflammation. *Journal of Lipid Research*, 60 (11), 2019, 1892–1904.
- VYTRŠALOVÁ, M., HENDRYCHOVÁ, T., TOUŠKOVÁ, T., ZIMČÍKOVÁ, E., VLČEK, J., NEVORÁNEK, L., SVOBODA, M., HEJDUK, K., BRAT, K., PLUTINSKÝ, M., NOVOTNÁ, B., MUSILOVÁ, P., ČERNOHORSKÝ, M., KOBLÍŽEK, V.: Breathing out completely before inhalation: The most problematic step in application technique in patients with non-mild chronic obstructive pulmonary disease. *Frontiers in Pharmacology*, 10, 2019, art. 241.
- ZÁRYBNICKÝ, T., MATOUŠKOVÁ, P., AMBROŽ, M., ŠUBRT, Z., SKÁLOVÁ, L., BOUŠOVÁ, I.: The selection and validation of reference genes for mRNA and microRNA expression studies in human liver slices using RT-qPCR. *Genes*, 10 (10), 2019, art. 763.
- ZEMANOVÁ, L., NAVRÁTILOVÁ, H., ANDRÝS, R., ŠPERKOVÁ, K., ANDREJS, J., KOZÁKOVÁ, K., MEIER, M., MÖLLER, G., NOVOTNÁ, E., ŠAFR, M., ADAMSKI, J., WSÓL, V.: Initial characterization of human DHRS1 (SDR19C1), a member of the short chain dehydrogenase/reductase superfamily. *Journal of Steroid Biochemistry and Molecular Biology*, 185, 2019, 80–89.

ARTICLES IN JOURNALS WITHOUT IMPACT FACTOR AND PROCEEDINGS

- HAJDUCHOVÁ, H., BRABCOVÁ, I., TÓTHOVÁ, V., BÁRTLOVÁ, S., DOSEDĚL, M., MALÝ, J., VLČEK, J.: Applying the intervention programme in clinical practice. *Journal of Nursing, Social Studies, Public Health and Rehabilitation*, 10 (1–2), 2019, 14–20.
- HAJDUCHOVÁ, H., BRABCOVÁ, I., TÓTHOVÁ, V., BÁRTLOVÁ, S., DOSEDĚL, M., MALÝ, J., VLČEK, J.: Factors associated with falls in hospitals: Outcomes for nursing care. *Kontakt*, 21 (2), 2019, 114–120.
- HOLICKÁ, L., DOČEKALOVÁ, Š., ŠTICHHAUER, R., ROZSÍVAL, P., EIMER, L., ROZSÍVALOVÁ, P.: Tragická záměna – Poleptání kyselinou mravenčí. (Formic acid burns – Two cases of terrible medication administration error). *Pediatric pro praxi*, 20 (2), 2019, 114–117.
- KARLÍČKOVÁ, J.: Potenciální léčebné využití kanabidiolu (CBD) z konopí setého. (Potential therapeutic use of cannabidiol (CBD) from *Cannabis sativa*). *Praktické lékárenství*, 15 (4), 2019, 227–230.
- MACHÁČEK, M., KOLLÁR, J., HALAŠKOVÁ, M., STEKLÁ, M., MAKHSEED, S., ŠIMŮNEK, T., ZIMČÍK, P.: Influence of cationic, anionic or non-charged substituents on photodynamic activity of water-soluble zinc (aza)phthalocyanines. In 17th International Photodynamic Association World Congress. Bellingham: Society of Photo-Optical Instrumentation Engineers, 2019, art. 11070_9M. ISBN 978-1-5106-2833-5.
- MALÁ, K., PATKOVÁ, A., ŠOLÍNOVÁ, J., Da COSTA, F. A.: Měření tepové frekvence v lékárnách jako nástroj pro zvyšování povědomí o fibrilaci síní v České republice – pilotní projekt. (Pulse check as a tool to raise awareness of atrial fibrillation in pharmacies in the Czech Republic – a pilot project). *Česká a slovenská farmacie*, 68 (5), 2019, 198–203.
- MALÝ, J., MALÁ, K., HORKÝ, P., DOMECKÝ, P.: XXI. symposium klinické farmacie René Macha (XXI. Symposium on Clinical Pharmacy René Mach). Hradec Králové, Farmaceutická fakulta UK, 2019, 85 pp. ISBN 978-80-906644-5-6.
- MALÝ, J., VALKO, A., DOSEDĚL, M.: Farmakoterapie jako rizikový faktor pádu pohledem klinického farmaceuta. (Pharmacotherapy as a risk factor of fall from the clinical pharmacist's perspective). *Geriatric a gerontologie*, 8 (4), 2019, 164–167.
- SVATOŠ, L.: Století dějin farmacie v samostatném státu 1918–2018. (A century of history of pharmacy in the independent Czechoslovakia and Czech Republic 1918–2018). *Dějiny věd a techniky (History of Science and Technology)*, 52 (1), 2019, 34–42.
- ŠPAČEK, J., BUCHTA, V., LEŠKO, D., KESTŘÁNEK, J., JÍLEK, P.: Současné možnosti managementu vulvovaginálního dyskomfortu (Current opinion of management of vulvovaginal discomfort). *Acta Medicinæ*, 8 (5–7), 2019, 20–26.
- VAŇKOVÁ, B., MALÁ, K., DUSILOVÁ SULKOVÁ, S., MALÝ, J.: Přehled poznatků o účinnosti intervencí na podporu adherence k léčbě u pacientů po orgánových transplantacích (Review analyzing the effectiveness of interventions to promote medication adherence in patients after solid organ transplantation). *Klinická farmakologie a farmacie*, 33 (1), 2019, 4–11.

- VLČEK, J., BÁRTLOVÁ, S., BRABCOVÁ, I., DOSEDĚL, M., HAJDUCHOVÁ, H., KUBĚNA, A., MALÝ, J., TÓTHOVÁ, V., VOSÁTKA, J.: Minimalizace rizik a teorie tří pilířů u léčiv zvyšujících riziko pádů (Risk minimization and three pillar theory for drugs that increase the risk of falls). *Klinická farmakologie a farmacie*, 33 (4), 2019, 30–34.
- VOSÁTKA, J., MALÝ, J., DOSEDĚL, M.: Riziko pádu u pacientů užívajících léčiva ovlivňující centrální nervový systém pohledem klinického farmaceuta (The risk of falls in patients using drugs affecting central nervous system from the perspective of a clinical pharmacist). *Praktické lékařství*, 15 (4), 2019, 218–222.

MONOGRAPHS AND TEXTBOOKS

- DOHNAL, F., DUINTJER TEBBENS, E. J., ROH, J., CAHLÍKOVÁ, L., SKLENÁŘOVÁ, H., SOLICH, P., NACHTIGAL, P., BOUŠOVÁ, I., DRŠATA, J., HRDINA, R., LÁZNÍČEK, M., SIATKA, T., DOLEŽAL, M., ŠKLUBALOVÁ, Z., VLČEK, J., MALÝ, J., MALÁ, K., ROZSÍVALOVÁ, P., FIALOVÁ, D., BEZOUŠKA, J., KATEROVÁ, Z., HANDLOVÁ, Š., OPLETAL, L., CHLEBKOVÁ, A., VALÁŠKOVÁ, L., RUDIŠAR, L.: Sborník k 50. výročí založení Farmaceutické fakulty Univerzity Karlovy v Hradci Králové. (The 50th Anniversary of the Faculty of Pharmacy of the Charles University in Hradec Králové). Hradec Králové, Farmaceutická fakulta UK, 2019, 176 pp. ISBN 978-80-906644-3-2.
- HARTL, J., DOLEŽAL, M., MILETÍN, M., OPLETALOVÁ, V., ZIMČÍK, P.: Farmaceutická chemie IV (Pharmaceutical Chemistry IV), 3rd ed., Prague, Karolinum Press, 2019, 166 pp. ISBN 978-80-246-4264-2.
- MUŽÍKOVÁ, J., HOLAS, O., ONDREJČEK, P., SVAČINOVÁ, P., ŠNEJDROVÁ, E.: Speciální praktická cvičení z farmaceutické technologie (Special Practical Exercises from Pharmaceutical Technology), 1st ed., Prague, Karolinum Press, 2019. ISBN 978-80-246-4275-8 (e-book, PDF).
- SCRIBA, G. K. E., JÁČ, P.: Cyclodextrins as chiral selectors in capillary electrophoresis enantioseparations. In *Chiral Separations: Methods and Protocols*. New York, Humana, 2019, 339–356. ISBN 978-1-4939-9437-3.
- WAISSER, K., NOVOTNÁ, E.: Názvosloví organických sloučenin (Nomenclature of organic compounds), 2nd ed. (reprint), Prague, Karolinum Press, 2019, 160 pp., ISBN 978-80-246-3418-0.

UTILITY MODEL AND CERTIFIED METHODOLOGY

- BÍLKOVÁ, A., ŠIŠKA, F., HOLLÁ, M., SKLENÁŘOVÁ, H.: Sušený jablečný produkt (Dried apple product). Praha: Úřad průmyslového vlastnictví, 2019, Utility model No. CZ33395(U1).
- HOLLÁ, M., SKLENÁŘOVÁ, H., CHOCHOLOUŠ, P., ADAMCOVÁ, A., KOŠKOVÁ, S., ŠMÍDOVÁ, B., BÍLKOVÁ, A., NEKVINDOVÁ, V., SURAN, P.: Metodika pro kvalitativní hodnocení ovoce a zpracovatelských produktů z hlediska obsahu látek prospěšných pro zdraví člověka (Methodology for the qualitative assessment of fruit and processing products in terms of the content of substances beneficial to human health). Hradec Králové: Farmaceutická fakulta UK, 2019, 55 pp. ISBN 978-80-906644-4-9.

DEGREES

Lectures for the Professorship Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2019

doc. PharmDr. KAMIL MUSÍLEK, Ph.D.: Associate Professor, Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 9. 11. 2017

Continuation: 12. 12. 2018

Title of Lecture: Reaktivátory cholinesteras a perspektiva jejich využití při intoxikacích organofosforovými sloučeninami (Cholinesterase reactivators and the perspective of their use in intoxications with organophosphorus compounds), 12. 6. 2018

Appointment: 23. 5. 2019

doc. PharmDr. LUCIE NOVÁKOVÁ, Ph.D.: Associate Professor, Department of Analytical Chemistry, Faculty of Pharmacy, Hradec Králové
Discipline: Analytical Chemistry, MŠMT 24 295/2007-30/1
Inauguration: 5. 11. 2018
Continuation: 11. 12. 2018
Title of Lecture: Moderní superkritická fluidní chromatografie (Modern supercritical fluid chromatography), 12. 3. 2019
Appointment: 28. 11. 2019

Habilitation Theses and Lectures for Associated Professor Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2019

PharmDr. LUCIE CHOCHOLOUŠOVÁ HAVLÍKOVÁ, Ph.D.: Senior Lecturer, Department of Analytical Chemistry, Faculty of Pharmacy, Hradec Králové
Discipline: Analytical Chemistry, MŠMT 24 295/2007-30/1
Inauguration: 23. 8. 2018
Continuation: 9. 10. 2018
Habilitation Thesis: Stabilita léčivých látek z pohledu analytické chemie (Stability of drug substances from the perspective of analytical chemistry), defended 11. 12. 2018
Title of Lecture: Moderní přístupy v problematice sledování nečistot léčivých látek (Modern approaches in the field of monitoring impurities of active substances), 11. 12. 2018
Appointment: 1. 3. 2019

RNDr. LUCIE ZEMANOVÁ, Ph.D.: Senior Lecturer, Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové
Discipline: Biochemistry, MŠMT 24 295/2007-30/1
Inauguration: 6. 9. 2018
Continuation: 9. 10. 2018
Habilitation Thesis: Význam enzymů z nadrodin AKR a SDR u člověka (The importance of enzymes from the superfamilies AKR and SDR in humans), defended 11. 12. 2018
Title of Lecture: Lidské membránové enzymy a jejich role v organismu (Human membrane enzymes and their roles in the body), 11. 12. 2018
Appointment: 1. 3. 2019

Ing. PETRA MATOUŠKOVÁ, Ph.D.: Scientific/Academic Worker, Department of Biochemical Sciences, Faculty of Pharmacy, Hradec Králové
Discipline: Biochemistry, MŠMT 24 295/2007-30/1
Inauguration: 7. 9. 2018
Continuation: 9. 10. 2018
Habilitation Thesis: Stanovení genové exprese (Determination of gene expression), defended 11. 12. 2018
Title of Lecture: Nekódující RNA – diagnostické markery budoucnosti? (Non-coding RNA – diagnostic markers of the future?), 11. 12. 2018
Appointment: 1. 3. 2019

PharmDr. MARTIN KRÁTKÝ, Ph.D.: Senior Lecturer, Department of Organic and Bioorganic Chemistry, Faculty of Pharmacy, Hradec Králové
Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1
Inauguration: 11. 8. 2018
Continuation: 12. 11. 2018
Habilitation Thesis: Vztahy mezi strukturou a aktivitou malých antimikrobně aktivních molekul a tuftsinových nosičů (Relationships between structure and activity of small antimicrobial active molecules and tuftsin carriers), defended 12. 3. 2019

Title of Lecture: Peptidové nosiče pro malé antimykobakteriální sloučeniny (Peptide carriers for small antimycobacterial compounds), 12. 3. 2019

Appointment: 1. 7. 2019

PharmDr. LUKÁŠ ČERVENÝ, Ph.D.: Senior Lecturer, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hradec Králové

Discipline: Human and Veterinary Pharmacology, MŠMT 24 295/2007-30/1

Inauguration: 29. 10. 2018

Continuation: 11. 12. 2018

Habilitation Thesis: Role transportních mechanismů v materno-fetálním přestupu antiretrovirotik (The role of transport mechanisms in maternal-fetal transfer of antiretrovirotics), defended 12. 3. 2019

Title of Lecture: Farmakokinetické lékové interakce antiretrovirálních léčiv; mechanismy vzniku, rizika a výhody (Pharmacokinetic drug interactions of antiretroviral drugs; mechanisms of origin, risks and benefits), 12. 3. 2019

Appointment: 1. 7. 2019

PharmDr. DANIELA FIALOVÁ, Ph.D.: Senior Lecturer, Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Hradec Králové

Discipline: Clinical and Social Pharmacy, MŠMT 29 593/2011-M3

Inauguration: 12. 11. 2018

Continuation: 11. 12. 2018

Habilitation Thesis: Hodnocení racionality geriatrické farmakoterapie v mezinárodním kontextu (Evaluation of the rationality of geriatric pharmacotherapy in an international context), defended 12. 3. 2019

Title of Lecture: Specifika geriatrické farmakoterapie a výhledy budoucího výzkumu v klinické farmacii v geriatricii (Specifics of geriatric pharmacotherapy and future research perspectives in clinical pharmacy in geriatrics), 12. 3. 2019

Appointment: 1. 7. 2019

Ing. PAVEL BOBÁL, CSc.: Senior Lecturer, Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 18. 12. 2018

Continuation: 12. 3. 2019

Habilitation Thesis: Syntetické přístupy k přípravě biologicky aktivních heterocyklů a jejich isosterů (Synthetic approaches to the preparation of biologically active heterocycles and their isosteres), defended 10. 6. 2019

Title of Lecture: Inhibitory histondeacetylasy: molekulární architektura a protinádorová aktivita (Histone deacetylase inhibitors: Molecular architecture and antitumor activity), 10. 6. 2019

Appointment: 1.10. 2019

PharmDr. JOSEF MALÝ, Ph.D.: Senior Lecturer, Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Hradec Králové

Discipline: Clinical and Social Pharmacy, MŠMT 29 593/2011-M3

Inauguration: 15. 1. 2019

Continuation: 12. 3. 2019

Habilitation Thesis: Možnosti rozvoje kultury bezpečí ve farmakoterapii (Possibilities of developing a culture of safety in pharmacotherapy), defended 11. 6. 2019

Title of Lecture: Současný stav a perspektivy farmaceutické péče v České republice (Current status and perspectives of pharmaceutical care in the Czech Republic), 11. 6. 2019

Appointment: 1. 10. 2019

PharmDr. PETR CHOCHOLOUŠ, Ph.D.: Senior Lecturer, Department of Analytical Chemistry, Faculty of Pharmacy, Hradec Králové

Discipline: Analytical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 25. 1. 2019

Continuation: 12. 3. 2019

Habilitation Thesis: Vývojové trendy v sekvenční injekční chromatografii (Trends in sequential injection analysis), defended 10. 6. 2019

Title of Lecture: Stacionární fáze pro separace v průtokových metodách (Stationary phases for separations in flow methods), 10. 6. 2019

Appointment: 1. 10. 2019

Ing. KATEŘINA MACÁKOVÁ, Ph.D.: Scientific/Academic Worker, Department of Pharmaceutical Botany, Faculty of Pharmacy, Hradec Králové

Discipline: Pharmacognosy, NAU-518/2018-9

Inauguration: 7. 2. 2019

Continuation: 4. 3. 2019

Habilitation Thesis: Přírodní látky potenciálně využitelné v prevenci a léčbě některých chronických onemocnění (Natural substances potentially usable in the prevention and treatment of some chronic diseases), defended 11. 6. 2019

Title of Lecture: Biologické účinky flavonoidů a jejich potenciální využití v terapii (Biological effects of flavonoids and their potential use in therapy), 11. 6. 2019

Appointment: 1. 10. 2019

PharmDr. JAN ZITKO, Ph.D.: Senior Lecturer, Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, Hradec Králové

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 11. 2. 2019

Continuation: 12. 3. 2019

Habilitation Thesis: Návrh, příprava a hodnocení derivátů pyrazinamidu jako potenciálních antimykobakteriálních sloučenin (Design, preparation and evaluation of pyrazinamide derivatives as potential antimycobacterial compounds), defended 10. 6. 2019

Title of Lecture: Počítačem podporovaný návrh a vývoj léčiv – CADD (Computer Aided Drug Design and Development – CADD), 10.06.2019

Appointment: 1. 10. 2019

*Doctoral Dissertation Theses to obtain the Ph.D. Degree, Faculty of Pharmacy
in Hradec Králové (CZ), Charles University (CZ), 2019*

Mgr. APPLOVÁ, LENKA: Ovlivnění aktivace krevních destiček polyfenolickými látkami a jejich metabolity (The influence of polyphenolic compounds and their metabolites on platelet activation), 20. 9. 2019, Ph.D.

Mgr. BERKA, PAVEL: Biofarmaceutické aspekty makromolekulárních nosičů pro systémovou sublingvální aplikaci léčiv (Biopharmaceutical aspects of macromolecular carriers for systemic sublingual drug delivery), 30. 9. 2019, Ph.D.

Mgr. BREITEROVÁ, KATEŘINA: Alkaloidy rostlin čeledi Amaryllidaceae jako potenciální léčiva v terapii civilizačních onemocnění (Alkaloids of the Amaryllidaceae family as potential drugs in therapy of diseases of affluence), 26. 6. 2019, Ph.D.

Mgr. BRŮŽA, ZDENĚK: Syntéza a využití polysubstituovaných pyranonů (Synthesis and application of polysubstituted pyranones), 29. 8. 2019, Ph.D.

Mgr. ČEPA, ADAM: Modifikace fragmentů protilátek, jejich značení nekonvenčními pozitronovými zářiči a biologické testování pro diagnostiku PET (Modification of antibody fragments and their radiolabeling by unconventional positron emitters and biological testing for PET diagnostics), 1. 2. 2019, Ph.D.

Mgr. DUŠEK, JAN: Development of novel constitutive androstane receptor (CAR) ligands, 20. 9. 2019, Ph.D.

Mgr. DVOŘÁČKOVÁ, ELIŠKA: Analýza lékových problémů na oddělení z pohledu farmaceuta (Analysis of drug problems at hospital department from the pharmacist's point of view), 25. 9. 2019, Ph.D.

Mgr. FIBIGR, JAKUB: Využití HPLC techniky v analýze doplňků stravy na bázi rostlinných extraktů (Application of HPLC technique in analysis of food supplements based on plant extracts), 19. 2. 2019, Ph.D.

- Mgr. HORKÝ, PAVEL: Nové deriváty přírodních látek s biologickým účinkem (Synthesis and biological activity of novel natural product derivatives), 14. 6. 2019, Ph.D.
- Mgr. JANOUŠEK, JIŘÍ: Studium vlastností radioaktivně značených monoklonálních protilátek pro zobrazování v onkologii (The study of properties of radiolabelled monoclonal antibodies for imaging in oncology), 20. 9. 2019, Ph.D.
- Mgr. JAVORSKÁ LENKA: Vývoj bioanalytických metod pro stanovení diagnostických markerů a léčiv s využitím chromatografických technik (Development of bioanalytical methods for the determination of diagnostic markers and drugs using chromatographic techniques), 23. 9. 2019, Ph.D.
- Mgr. JOSKOVÁ, VĚRA: Klinická aplikace metody bioimpedanční spektroskopie u polytraumatizovaných pacientů a těhotných žen (The clinical application of bioimpedance spectroscopy in polytrauma patients and in pregnant women), 4. 2. 2019, Ph.D.
- Mgr. KOPEČNÁ, MONIKA: Syntéza a studium akceleračních transdermálních permeací léčiv (Synthesis and evaluation of transdermal drug permeation enhancers), 29. 8. 2019, Ph.D.
- Mgr. LHOTSKÁ, IVONA: Využití moderních chromatografických technik v analýze cizorodých a kontaminujících látek v potravinách (Modern chromatographic techniques in food contamination analysis), 19. 2. 2019, Ph.D.
- Mgr. TOMÁŠ NEJEDLÝ: Vývoj HPLC metod pro analytické hodnocení léčivých přípravků a modelové studie přírodní degradace reziduí léčiv (Development of HPLC methods for analytical evaluation of drug products and model studies of natural degradation of drug residues), 26. 6. 2019, Ph.D.
- Mgr. NĚMEČEK, JAN: Syntéza substituovaných dusíkatých heterocyklů jako potenciálních antituberkulotik (Synthesis of substituted nitrogen heterocycles as potential antitubercular agents), 14. 6. 2019, Ph.D.
- Mgr. NOVOSVĚTSKÁ, LUCIE: Sequential injection analysis capability in automation of analytical processes, 26. 6. 2019, Ph.D.
- Mgr. SOCHOROVÁ, MICHAELA: Studium bariérových lipidů v kůži a kožních modelech (Study of barrier lipids in the skin and skin models), 29. 8. 2019, Ph.D.
- Mgr. SYSLOVÁ, ELIŠKA: Anthelmintika v rostlinách – příjem, biotransformace a transkripční odpověď (Anthelmintics in plants – uptake, biotransformation and transcriptional response), 13. 12. 2019, Ph.D.
- Mgr. ŠORF, ALEŠ: Studium interakcí nových protinádorových léčiv s lékovými transportéry (A study of interactions of novel anticancer drugs with drug transporters), 12. 12. 2019, Ph.D.
- Mgr. VITVEROVÁ, BARBORA: Solubilní endoglin a jeho role v patogenezi endotelové dysfunkce (Soluble endoglin role in the pathogenesis of endothelial dysfunction), 18. 10. 2019, Ph.D.
- Mgr. VOSÁTKA, RUDOLF: Design a syntéza nových potenciálně antibakteriálně účinných sloučenin (Design and synthesis of new potentially antibacterial active compounds), 27. 5. 2019, Ph.D.

Rigorous Theses to obtain the degree PharmDr. (Doctor of Pharmacy, graduates of the study programme Pharmacy) or RNDr. (Doctor of Natural Sciences, graduates of study programme Bioanalytical Laboratory Diagnostics in Medicine), Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2019

- Mgr. APPLOVÁ, LENKA, Ph.D.: Ovlivnění aktivace krevních destiček polyfenolickými látkami a jejich metabolismu (The influence of polyphenolic compounds and their metabolites on platelet activation), 19. 12. 2019, PharmDr.
- Mgr. BALCIAROVÁ, ANDREA: Formulácia a testovanie nanočastíc z vetvených polyesterov s rifampicínom (Formulation and testing of rifampicin-loaded branched polyesters nanoparticles), 28. 3. 2019, PharmDr.
- Mgr. BĀROVÁ, KAROLÍNA: GC analýza léčiv s využitím iontové kapaliny jako stacionární fáze I (GC analysis of drugs with utilization of ionic liquid as a stationary phase I), 5. 6. 2019, PharmDr.
- Mgr. BAUDISCHOVÁ, LENKA: Kvalita poskytovaných informací u nejprodávanějších doplňků stravy v České republice na internetu (The quality of information on top selling dietary supplements on the internet in the Czech Republic), 22. 1. 2019, PharmDr.
- Mgr. BAŽANTOVÁ, MICHAELA: Exercise as medicine. Growth hormone response to high-intensity interval training, 15. 2. 2019, PharmDr.
- Mgr. BERDYCH, MARTIN: Zavedení nového analytického systému do rutinní biochemické laboratoře (Implementation of new analytical system into a routine biochemical laboratory), 6. 5. 2019, RNDr.

- Mgr. BIELESZOVÁ, DOMINIKA: Studium liberace terbinafinu z PLGA nanočástic (Terbinafine release from PLGA-based nanoparticles), 30. 9. 2019, PharmDr.
- Mgr. BÍMOVÁ, DANIELA: Studium směsného suchého pojiva s mannitem, laktosou, dextrousou a krospondonem pro tablety dispergovatelné v ústech (A study of the coprocessed dry binder with mannitol, lactose, dextrose and croscopovidone for orally disintegrating tablets), 17. 10. 2019, PharmDr.
- Mgr. BLÁŠKOVÁ, DOMINIKA: Postoje a znalosti o očkování proti HPV I (Attitudes and beliefs on HPV infection and vaccination), 5. 6. 2019, PharmDr.
- Mgr. BRADOVÁ, HANA: Farmakoterapie diabetu mellitu sledovaná v diabetologické poradně (Pharmacotherapy of diabetes mellitus followed up in diabetes clinic), 11. 2. 2019, PharmDr.
- Mgr. BREITEROVÁ, KATEŘINA, Ph.D.: Alkaloidy rostlin čeledi Amaryllidaceae jako potenciální léčiva v terapii civilizačních onemocnění (Alkaloids of the Amaryllidaceae family as potential drugs in therapy of diseases of affluence), 12. 8. 2019, PharmDr.
- Mgr. BRŮŽA, ZBYNĚK, Ph.D.: Syntéza a využití polysubstituovaných pyranonů (Synthesis and application of polysubstituted pyranones), 9. 12. 2019, PharmDr.
- Mgr. CARAZO FERNÁNDEZ, ALEJANDRO, Ph.D.: Nuclear receptors – new ligands study and importance of the genetic variability, 10. 10. 2019, PharmDr.
- Mgr. CICHÝ, JAKUB: Faktory ovlivňující purifikaci a stabilitu biokonjugátů azaftalocyaninů (Factors which affect the purification and stability of azaftalocyanines bioconjugates), 5. 6. 2019, PharmDr.
- Mgr. ČEČKOVÁ, PATRÍCIA: Studium interakcí léčiv s transportéry z rodiny OATP za využití střevních tkáňových řezů (Study of drug interactions with OATP family transporters using intestinal tissue slices), 26. 9. 2019, PharmDr.
- Mgr. ČEPA, ADAM, Ph.D.: Modifikace fragmentů protilátek, jejich značení nekonvenčními pozitronovými zářiči a biologické testování pro diagnostiku PET (Modification of antibody fragments and their radiolabeling by unconventional positron emitters and biological testing for PET diagnostics), 27. 3. 2019, PharmDr.
- Mgr. ČERMÁKOVÁ, VERONIKA: Ovlivnění pKa rozpoznávací části azaftalocyaninových sensorů (Modulation of pKa of the recognition moiety of azaftalocyanine sensors), 12. 11. 2019, PharmDr.
- Mgr. ČERVINKOVÁ, TEREZA: Beneficial effects of 11β-HSD1 inhibition on cognitive performance in a mouse model of Alzheimer's disease, 21. 9. 2018, PharmDr.
- Mgr. ČIKOVSKÁ, NATÁLIA: Analýza činnosti Liekového informačního centra II (Drug Information Centre service analysis II), 22. 1. 2019, PharmDr.
- Mgr. DOUDĚROVÁ, ANETA: Radiosensibilizace linie buněk nemalobuněčného karcinomu plic pomocí inhibitoru autofagie Lys05 (Radiosensitization of non-small cell lung cancer cell line using autophagy inhibitor Lys05), 17. 6. 2019, RNDr.
- Mgr. DUGASOVÁ, LUCIA: Vplyv doxorubicínu na vybrané myšacie mikroRNA (Effect of doxorubicin on selected mice microRNAs), 26. 9. 2019, RNDr.
- Mgr. DUCHAČOVÁ, KATEŘINA: Vliv glutamátom navozené obezity na detoxikační enzymy obsahující glutathion (Influence of glutamate-induced obesity on detoxification enzymes contains glutathione), 13. 2. 2019, PharmDr.
- Mgr. FABRIKOVÁ, DANIELA, Ph.D.: Molekulární mechanizmy patogeneze mikroba *Francisella tularensis* (Molecular mechanisms of *Francisella tularensis* pathogenesis), 15. 3. 2019, RNDr.
- Mgr. FIBIGR, JAKUB, Ph.D.: Využití HPLC techniky v analýze doplňků stravy na bázi rostlinných extraktů (Application of HPLC technique in analysis of food supplements based on plant extracts), 7. 11. 2019, PharmDr.
- Mgr. FLANDERKOVÁ, MICHAELA: Reologické vlastnosti gelů na hojení ran (Rheological properties of the scar treatment gels), 30. 9. 2019, PharmDr.
- Mgr. FLAXOVÁ, MICHAELA: Studium rezistence v nádorové terapii – vliv inhibitorů protein kinas na aktivitu vybraných lidských reduktas II (Study of resistance in cancer therapy – protein kinase inhibitors influence on activity of selected human reductases II), 17. 6. 2019, PharmDr.
- Mgr. GAJDOŠ, JAKUB: Radioaktivní značení ramucirumabu s následnou studií jeho internalizace *in vitro* (Radiolabeling of ramucirumab followed with the study of its internalization *in vitro*), 17. 6. 2019, RNDr.
- Mgr. GAJDOŠOVÁ, BARBORA: Vývoj on-line SPE-HPLC metody pro stanovení zearalenonu ve vzorcích piva (On-line SPE-HPLC method development for determination of zearalenone in beers), 6. 5. 2019, RNDr.
- Mgr. GÓRECKI, LUKÁŠ, Ph.D.: Development of novel cholinesterase modulators (Development of novel cholinesterase modulators), 10. 10. 2019, PharmDr.

- Mgr. HANULÍKOVÁ, MARKÉTA: Vliv anthelmintik na aktivitu vybraných biotransformačních enzymů u rostlin (Effect of anthelmintics on activity of selected biotransformation enzymes in plants), 15. 2. 2019, PharmDr.
- Mgr. HANUŠČINOVÁ, LUCIA: Schopnost chelátorů mezi interagovat so železom a zinkom (Ability of copper chelators to interact with iron and zinc), 8. 2. 2019, PharmDr.
- Mgr. HARIKOVÁ, MICHAELA: Deriváty amidoximů jako syntetické intermediáty a potenciální léčiva (Amidoxime derivatives as synthetic intermediates and potential drugs), 12. 11. 2019, PharmDr.
- Mgr. HAVLÍKOVÁ, NATÁLIE: Vliv velikosti částic na lisovatelnost laktosy (The effect of particle size on lactose compressibility), 21. 11. 2019, PharmDr.
- Mgr. HEGLASOVÁ, SILVIA: Vplyv imatinibu na vybrané myšacie mikroRNA (Effect of imatinib on selected mice microRNAs), 26. 9. 2019, RNDr.
- Mgr. HERMANOVÁ, KATEŘINA: Studium interakcí enzymu DHRS7 s proteiny metodou pull-down (Study of protein-protein interaction of DHRS7 enzyme by pull-down assay), 17. 6. 2019, PharmDr.
- Mgr. HOČELOVÁ, ZUZANA: Analýza spotřeby antikoagulancií v České republice v letech 2007–2016 (Analysis of anticoagulant utilization in the Czech Republic in the period from 2007 to 2016), 5. 6. 2019, PharmDr.
- Mgr. HOCHMALOVÁ, MARTINA: Vplyv flubendazolu a mebendazolu na epitelialne-mezenchymálnu tranzíciu (The effect of flubendazole and mebendazole on epithelial-mesenchymal transition), 13. 2. 2019, PharmDr.
- Mgr. HOMOLKOVÁ, LUDMILA: Deriváty Amaryllidaceae alkaloidu haemanthaminy jako potenciální léčiva (Derivatives of Amaryllidaceae alkaloid haemanthamine as potential drugs), 3. 12. 2019, PharmDr.
- Mgr. HONSÁRKOVÁ, TEREZA: Bazotesty a lymfocytární transformační testy s vazbou na lékové intolerance (Bazotests and lymphocyte transformation tests linked to drug intolerance), 17. 6. 2019, RNDr.
- Mgr. HORÁČKOVÁ, MARKÉTA: Vasorelaxační účinky vybraných metabolitů kvercetinů na izolované aortě potkana (Vasorelaxant activity of selected metabolites of quercetine on isolated rat aorta), 14. 2. 2019, PharmDr.
- Mgr. HORÁKOVÁ, KAROLÍNA: Kvalita života studentů farmacie (Pharmacy students' quality of life), 22. 1. 2019, PharmDr.
- Mgr. HORKÝ, PAVEL, Ph.D.: Nové deriváty přírodních látek s biologickým účinkem (Synthesis and biological activity of novel natural product derivatives), 9. 12. 2019, PharmDr.
- Mgr. HOUNGBEDJI, NETO-HONORIUS: Syntéza a hodnocení potenciálních inhibitorů cholinesteráz (Synthesis and evaluation of potential cholinesterases inhibitors), 9. 12. 2019, PharmDr.
- Mgr. HULCOVÁ, DANIELA, Ph.D.: Biologická aktivita alkaloidů *Narcissus pseudonarcissus* L. cv. Dutch Master (Amaryllidaceae) (Biological activity of alkaloids from *Narcissus pseudonarcissus* L. cv. Dutch Master (Amaryllidaceae)), 29. 1. 2019, PharmDr.
- Mgr. HYRŠOVÁ, LUCIE, Ph.D.: Nové aspekty funkce a regulace pregnanového X receptoru (New aspects of pregnane X receptor function and regulation), 22. 1. 2019, PharmDr.
- Mgr. CHALUPOVÁ, KATEŘINA: Historický vývoj lékárenství na Velkomeziříčsku a v městě Třebíč (The history of pharmacy in the region of Velké Meziříčí and in Třebíč), 5. 6. 2019, PharmDr.
- Mgr. CHLUPÁČOVÁ, ADÉLA: Biofilmy a lidské tělo (Biofilms and human body), 5. 6. 2019, PharmDr.
- Mgr. CHREŇOVÁ, KATEŘINA: Vliv methylviologenu na produkci sekundárních metabolitů v *in vitro* kultuře *Hypericum perforatum* (The effect of methylviologen on secondary metabolites production in *in vitro* culture of *Hypericum perforatum*), 29. 1. 2019, PharmDr.
- Mgr. Ing. BARANOVÁ, IVANA, Ph.D.: Epigenetická regulace adhezivních molekul v vysoké stadium ovarian carcinoma, 8. 11. 2019, RNDr.
- Mgr. JANÁKOVÁ, GABRIELA: Biodegradabilní pevné disperze k aplikaci na sliznici (Biodegradable solid dispersions for application to mucous membranes), 9. 5. 2019, PharmDr.
- Mgr. JANOUSEK, JIŘÍ, Ph.D.: Studium vlastností radioaktivně značených monoklonálních protilátek pro zobrazování v onkologii (The study of properties of radiolabelled monoclonal antibodies for imaging in oncology), 10. 10. 2019, PharmDr.
- Mgr. JOSKOVÁ, VĚRA, Ph.D.: Klinická aplikace metody bioimpedance spektroskopie u polytraumatizovaných pacientů a těhotných žen (The clinical application of bioimpedance spectroscopy in polytrauma patients and in pregnant women), 5. 6. 2019, PharmDr.
- Mgr. JUNKOVÁ, MARTINA: Vliv vybraných seskviterpenů na antioxidační enzymy u buněčné linie HT-29 (The impact of selected sesquiterpenes on antioxidant enzymes in HT-29 cell line), 26. 9. 2019, PharmDr.

- Mgr. KALMANOVÁ, LENKA: Vplyv dlhodobého pôsobenia solubilného endoglinu na markery endotelovej dysfunkcie v myšacej aorte (Soluble endoglin effects on endothelial dysfunction markers in mouse aorta), 26. 9. 2019, PharmDr.
- Mgr. KAMAN, PETR: Vliv biologické ochrany rostlin na produkci sekundárních metabolitů *Papaver somniferum* III (Influence of plant biological protection on production of secondary metabolites of *Papaver somniferum* III), 28. 3. 2019, PharmDr.
- Mgr. KAMARÝTOVÁ, MARTINA: Studium lisovateľnosti a vlastností tablet ze směsného suchého pojiva s mannitolom a sodnou solí kroskarmelosu pro tablety dispergovateľné v ústech (A study of compressibility and properties of tablets from coprocessed dry binder with mannitol and croscarmellose sodium for orodispersible tablets), 28. 3. 2019, PharmDr.
- Mgr. KAŠPAROVÁ, MICHAELA: Synthesis of epitestosterone and 4-hydroxyestrone glucuronides using recombinant human UDP-glucuronosyltransferases, 13. 2. 2019, PharmDr.
- Mgr. KLIMKOVÁ, KATEŘINA: Stanovení stechiometrie komplexů dehydrosilybinu A s mědí (Determination of the stoichiometry of the copper complexes with dehydrosilybine A), 26. 9. 2019, PharmDr.
- Mgr. KOČÍ, ZUZANA, Ph.D.: Mesenchymal stromal cells and biological scaffolds for neural tissue regeneration, 19. 4. 2019, PharmDr.
- Mgr. KOLÁČKOVÁ, PAVLA: Neoadjuvantní terapie u pacientů s karcinomem jícnu a její vliv na funkci ledvin (Neoadjuvant therapies in patients with oesophageal carcinoma and the effect of therapy on renal function), 8. 2. 2019, PharmDr.
- Mgr. KOLČÁRKOVÁ, LUCIE: Oxadiazoly jako potenciální léčiva II (Oxadiazoles as potential drugs II), 8. 1. 2019, PharmDr.
- Mgr. KOPECKÁ, IVA: Chromatografické hodnocení amiodaronu a jeho aktivního metabolitu (Chromatographic evaluation of amiodarone and its active metabolite), 7. 11. 2019, PharmDr.
- Mgr. KOPEČNÁ, MONIKA, Ph.D.: Syntéza a studium akceleračtů transdermální permeace léčiv (Synthesis and evaluation of transdermal drug permeation enhancers), 9. 12. 2019, PharmDr.
- Mgr. KOŠČÁKOVÁ, MÁRIA: Vplyv spinálnej anestézie na mieru poškodenia DNA (The influence of spinal anesthesia on the degree of DNA damage), 25. 9. 2019, PharmDr.
- Mgr. KOVALÍKOVÁ, ZUZANA: Vplyv derivátov pyrazínu na tvorbu sekundárných metabolitov v rastlinných kultúrach *in vitro* (The effect of pyrazine derivatives on secondary metabolites in *in vitro* cultures), 29. 1. 2019, PharmDr.
- Mgr. KRAUZOVÁ, BARBORA: Spouštěcí mechanismy vulvovaginálního diskomfortu (Triggers of vulvovaginal discomfort), 5. 6. 2019, PharmDr.
- Mgr. KREJČIOVÁ, MARKÉTA: Sledování základních parametrů farmakokinetiky inhibitorů acetylcholinesterasy užívaných v terapii Alzheimerovy choroby (Monitoring of basic pharmacokinetic parameters of acetylcholinesterase inhibitors used in the treatment of Alzheimer's disease), 14. 11. 2019, PharmDr.
- Mgr. KREJZOVÁ, ANDREA: Vliv albendazolu na aktivitu vybraných enzymů u tasemnice *Hymenolepis diminuta* (Effect of albendazole on the activity of selected enzymes in tapeworm *Hymenolepis diminuta*), 11. 2. 2019, PharmDr.
- Mgr. KRCHOVÁ, LUCIE: LC-MS analýza 1. fáze biotransformace K1277, potenciálního léčiva Alzheimerovy nemoci (LC-MS analysis of phase one biotransformation of K1277, a potential drug against Alzheimer's disease), 14. 2. 2019, PharmDr.
- Mgr. KRÍVKOVÁ, MARIE: Modifikace parametrů nanočástic z polyesterů alifatických hydroxykyselin (Modification of parameters of nanoparticles prepared from aliphatic hydroxyacids polyesters), 9. 5. 2019, PharmDr.
- Mgr. KRŽÍŽ, JAKUB: Měď-chelatační potenciál chelátorů železa ze skupiny aroylhydrazonů (Copper chelating potential of iron chelators from the group of aroylhydrazones), 26. 9. 2019, PharmDr.
- Mgr. LACMANOVÁ, TEREZA: Využití superkritické fluidní chromatografie v analýze přírodních látek (Application of supercritical fluid chromatography in analysis of natural compounds), 14. 11. 2019, PharmDr.
- Mgr. LACH, FRANTIŠEK: *In vitro* saturačné štúdie 99mTc-HYNIC-ramucirumabu na PC-3 bunkách (*In vitro* saturation study of 99mTc-HYNIC-ramucirumab on PC-3 cell line), 8. 2. 2019, PharmDr.
- Mgr. LANCOŠOVÁ, BIBIÁNA: Toxicita pulegónu a mentofuránu a ich vplyv na expresiu miRNA v ľudských pečenečných rezoch (Toxicity of pulegone and menthofuran and their effect on miRNA expression in human liver slices), 26. 9. 2019, PharmDr.
- Mgr. LANGEROVÁ, MARTINA: Nové polyamidoaminodendrimery s ethylendiaminovým jádrom a aminoskupinami na periférii: Syntéza a potenciální využití při (trans)dermálním přenosu léčiv (Novel amino-dec-

- orated polyamidoamine dendrimers with ethylenediamine core: Synthesis and potential application in (trans) dermal drug delivery), 5. 2. 2019, PharmDr.
- Mgr. LEJNAROVÁ, MICHAELA: Porovnání dvou způsobů hodnocení matricových efektů při LC-MS/MS analýze (Comparison of two types of matrix effect evaluation for LC-MS/MS analysis), 14. 11. 2019, PharmDr.
- Mgr. LEPŠOVÁ, NIKOL: Analýza hospodaření lékáren Královéhradeckého kraje (Analysis of pharmacy economy in the Hradec Králové region), 22. 1. 2019, PharmDr.
- Mgr. LHOTSKÁ, IVONA, Ph.D.: Využití moderních chromatografických technik v analýze cizorodých a kontaminujících látek v potravinách (Modern chromatographic techniques in food contamination analysis), 7. 11. 2019, PharmDr.
- Mgr. LIČKOVÁ, ANETA: Analýza dispenzační péče poskytované lékárnami v Hradci Králové (Analysis of the dispensing care provided by pharmacies in Hradec Králové), 5. 6. 2019, PharmDr.
- Mgr. LINHARTOVÁ, LENKA: Molekulární podstata lékových interakcí – interakce konstitutivního androstanového receptoru s vybranými stilbenoidy (Molecular mechanisms of interactions – interactions of constitutive androstane receptor with selected stilbene compounds), 26. 9. 2019, PharmDr.
- Mgr. LOJDOVÁ, KATEŘINA: Inhibitory lidského enzymu AKR1C3 rostlinného původu (Inhibitors of human enzyme AKR1C3 of plant origin), 17. 6. 2019, PharmDr.
- Mgr. LUDÍNOVÁ, KRISTÝNA: Delineating pain and fear engrams in the prefrontal cortex, 11. 2. 2019, PharmDr.
- Mgr. LUKAČIKOVÁ, KAROLÍNA: Vliv mebendazolu na aktivitu vybraných enzymů u tasemnice *Hymenolepis diminuta* (Effect of mebendazole on the activity of selected enzymes in tapeworm *Hymenolepis diminuta*), 11. 2. 2019, PharmDr.
- Mgr. LUKAČIŠINOVÁ, ANNA, Ph.D.: Evaluation of rationality and risks of pharmacotherapy in older patients in long-term care facilities, 22. 1. 2019, PharmDr.
- Mgr. MACHALOVÁ, VANDA: Interakce vybraných anti-HCV léčiv s placentárním OCTN2 transportním proteinem (Interaction of selected anti-HCV drugs with placental OCTN2 transport protein), 08. 2. 2019, PharmDr.
- Mgr. MACHAN, MATĚJ: Syntéza azafthalocyaninových zhášeců fluorescence vhodných pro vazbu doprostřed oligonukleotidového řetězce (Synthesis of azaphthalocyanine quenchers of fluorescence for intrastrand binding to oligonucleotides), 12. 11. 2019, PharmDr.
- Mgr. MAJOROVÁ, MICHAELA: Využití HPLC v analýze nutraceutik s obsahem chlorogenových kyselin (HPLC in nutraceuticals analysis of chlorogenic acids), 1. 3. 2019, PharmDr.
- Mgr. MALČÍKOVÁ, BARBORA: Metody diagnostiky lokálního stágu u karcinomu prsu (Methods for diagnosing the local staging of breast cancer), 26. 9. 2019, RNDr.
- Mgr. MÁLKOVÁ, KATEŘINA: HPLC hodnocení L-tryptofanu a jeho metabolitů v biologickém materiálu (HPLC evaluation of L-tryptophan and its metabolites in biological material), 14. 11. 2019, PharmDr.
- Mgr. MANÍŠOVÁ, MICHAELA: Farmakovigilance: Vývoj lékové regulace a přehled platné legislativy (Pharmacovigilance: Drug regulation development and legislation overview), 6. 3. 2019, PharmDr.
- Mgr. MAREŠOVÁ, VERONIKA: Lékové interakce derivátů resveratrolu s nukleárním receptorem PXR (Interactions of resveratrol derivatives with PXR receptor), 26. 9. 2019, PharmDr.
- Mgr. MARKOVÁ, ELIŠKA: Study of the effect of novel antiretroviral drugs on carnitine transport in the placenta, 25. 9. 2019, PharmDr.
- Mgr. MARTINKOVÁ, MARTINA: Deriváty pyrazinamidu jako potenciální antimikrobní látky (Pyrazinamide derivatives as potential antimicrobial compounds), 8. 1. 2019, PharmDr.
- Mgr. MATIAŠKOVÁ, ZUZANA: Role vybraných ABC a SLC transportérů v přestupu maraviroku přes buněčné membrány: vliv na transport v placentě (Role of selected ABC and SLC transporters in transmembrane permeability of maraviroc: effect on transport in placenta), 25. 9. 2019, PharmDr.
- Mgr. MATOUŠKOVÁ, LENKA: Farmakologické hodnocení potenciálních léčiv Alzheimerovy choroby (Pharmacological evaluation of potential drugs for Alzheimer's disease treatment), 11. 2. 2019, PharmDr.
- Mgr. MAZURKOVÁ, VERONIKA: Vliv vybraných seskviterpenů na aktivitu karbonylreduktasy 1 *in vitro* (Effect of selected sesquiterpenes on carbonyl reductase 1 activity *in vitro*), 26. 9. 2019, PharmDr.
- Mgr. MEDVIĎOVÁ, SIMONA: Formulácia a testovanie nanočastic z vetvených polyesterov s siRNA (Formulation and testing of siRNA-loaded branched polyesters nanoparticles), 28. 3. 2019, PharmDr.
- Mgr. MIHALIČOKOVÁ, DAJANA: *In vitro* assays for investigating nucleic acid delivery, 17. 6. 2019, PharmDr.

- Mgr. MIKULCOVÁ, JITKA: Analýza marketingových strategií lékáren (Analysis of marketing strategies of pharmacies), 5. 6. 2019, PharmDr.
- Mgr. MINDLOVÁ, ALŽBĚTA: Deriváty pyrazinu jako potenciální léčiva V (Pyrazine derivatives as potential drugs V), 8. 1. 2019, PharmDr.
- Mgr. MLÁDKOVÁ, ZUZANA: Vliv parazita na aktivitu biotransformačních a antioxidačních enzymů ve střevě hostitele (Effect of parasite on activity of biotransformation and antioxidant enzymes in host intestine), 13. 2. 2019, PharmDr.
- Mgr. MRÁZKOVÁ, ANETA: Studium vlivu metody měření na statický synpý úhel volně synpých pomocných látek (The study of influence of the measurement method on static angle of repose of free-flowable excipients), 17. 10. 2019, PharmDr.
- Mgr. MŽIK, MARTIN, Ph.D.: Bioanalytické hodnocení nových inhibitorů acetylcholinesteráz (Bioanalytical evaluation of new acetylcholinesterase inhibitors), 8. 11. 2019, RNDr.
- Mgr. NEJEDLÝ, TOMÁŠ, Ph.D.: Vývoj HPLC metod pro analytické hodnocení léčivých přípravků a modelové studie přírodní degradace reziduí léčiv (Development of HPLC methods for analytical evaluation of drug products and model studies of natural degradation of drug residues), 7. 11. 2019, PharmDr.
- Mgr. NEMCOVÁ, LUCIA: Štúdium lisovateľnosti liquisolid práškov s premenným zastúpením obalovacieho materiálu (Compressibility evaluation of liquisolid powders containing varying amount of coating material), 9. 5. 2019, PharmDr.
- Mgr. NEMČIKOVÁ, LENKA: Propargyltacríny – inhibitory acetylcholinesterázy s anti-MAO aktivitou (Propargyltacrine – acetylcholinesterase inhibitors with anti-MAO activity), 8. 1. 2019, PharmDr.
- Mgr. NĚMEČEK, JAN, Ph.D.: Syntéza substituovaných dusíkatých heterocyklů jako potenciálních antituberkulotik (Synthesis of substituted nitrogen heterocycles as potential antitubercular agents), 9. 12. 2019, PharmDr.
- Mgr. NOVOSVĚTSKÁ, LUCIE, Ph.D.: Sequential injection analysis capability in automation of analytical processes, 7. 11. 2019, PharmDr.
- Mgr. NOVOTNÁ, ANDREA: Studium tabletovin a tablet s kombinací mikrokrystalické celulosy a mannitolu pro tablety dispergovatelné v ústech (A study of tableting materials and tablets with the combination of microcrystalline cellulose and mannitol for orally disintegrating tablets), 17. 10. 2019, PharmDr.
- Mgr. OČOVSKÁ, ZUZANA: Analýza liekových problémov potenciálne vedúcich k hospitalizácii u geriatrických pacientov (The analysis of drug-related problems potentially leading to hospitalization among geriatric patients), 5. 6. 2019, PharmDr.
- Mgr. PASÁK, MICHAEL: Změny v expresi vybraných enzymů metabolizujících léčiva u parazita po kontaktu se subletálními dávkami léčiv (The changes in expression of selected drug-metabolizing enzymes in parasites after exposition to sublethal doses of drugs), 26. 9. 2019, RNDr.
- Mgr. PATKOVÁ, ANNA, Ph.D.: Aplikace nepřímé kalorimetrie u dvou různých inzulinorezistentních stavů – polytraumatu a gravidity (Indirect calorimetry application in two different insulin-resistant states – polytrauma and pregnancy), 22. 1. 2019, PharmDr.
- Mgr. PAVLÍKOVÁ, VERONIKA: Postoje k liečbe a znalosti o hormonálnej antikoncepcii u študentov posledného ročníka farmácie (Attitudes towards treatment and knowledge of hormonal contraceptives among final year pharmacy students), 22. 1. 2019, PharmDr.
- Mgr. PEKAŘOVÁ, KATEŘINA: Kationické povrchově aktivní látky a hodnocení jejich vlastností (Cationic surface active compounds and evaluation of its properties), 12. 11. 2019, PharmDr.
- Mgr. PEŠKOVÁ, KLÁRA: Vliv vybraných prenylflavonoidů na účinek cytostatik v nádorových buňkách (The impact of selected prenylflavonoids on the effect of anticancer therapy in cancer cell lines), 15. 2. 2019, PharmDr.
- Mgr. POHANOVÁ, LUCIE: Chelatace železnatých iontů deriváty xanthen-3-onu (Chelation of ferrous ions by derivatives of xanthene-3-one), 25. 9. 2019, PharmDr.
- Mgr. POKORNÁ, TEREZA: Biodegradabilní polymerní systémy s terbinafinem k topické aplikaci (Terbinafine-loaded biodegradable polymeric systems for topical administration), 5. 2. 2019, PharmDr.
- Mgr. POSPÍŠILOVÁ, MARKÉTA: Hodnocení svalové výdrže u skupin osob s rozdílným stupněm fyzické aktivity (Evaluation of muscle endurance among groups with varying degrees of physical activity), 22. 1. 2019, PharmDr.
- Mgr. PROCHÁZKOVÁ, MARTINA: Analýza terapie u pacientů s juvenilní idiopatickou artritidou (Analysis of the therapy in patients with juvenile idiopathic arthritis), 22. 1. 2019, PharmDr.

- Mgr. PULKRÁBKOVÁ, LENKA: Porovnání schopnosti takrin-fenothiazinových derivátů inhibovat cholinestéru (A comparison of tacrine-phenothiazine derivatives in the efficacy of cholinesterase inhibition), 15. 2. 2019, RNDr.
- Mgr. PUSKÁSOVÁ, DOMINIKA: Alkaloidy čeledi Amaryllidaceae a ich biologická aktivita I (Alkaloids of the family Amaryllidaceae and their biological activity I), 3. 12. 2019, PharmDr.
- Mgr. RAJTMAJEROVÁ, IVETA: Studium účinků vybraných fenolických látek *in vitro* na izolované cévě potkana (The *in vitro* effects of selected phenolic substances on isolated rat vessels), 26. 9. 2019, PharmDr.
- Mgr. ROHOVÁ, MARIE: Podávání cytostatik a extravazace (Administration of cytostatic drugs and extravasation), 25. 9. 2019, PharmDr.
- Mgr. RUDIŠAROVÁ, SIMONA: Účinek metabolitu quercetinu na izolovaných potkaních arteriích (The effect of quercetin metabolite on the rat isolated arteries), 8. 2. 2019, PharmDr.
- Mgr. RUMLEROVÁ, LENKA: Vliv rýžového extraktu na lisovatelnost a mechanické vlastnosti tablet z mikrokryсталické celulózy (The effect of rice extract on the compressibility and mechanical properties of microcrystalline cellulose tablets), 21. 11. 2019, PharmDr.
- Mgr. ŘEPOVÁ, VERONIKA: Alterations in gene expression of hepatobiliary transporters as potential mechanisms for drug-induced cholestasis by amoxicillin and clavulanic acid, 14. 2. 2019, PharmDr.
- Mgr. SCHEJBALOVÁ, KATEŘINA: Stanovení farmakologických vlastností potencionálních léčiv Alzheimerovy choroby (Determination of pharmacological properties of potential drugs for the treatment of Alzheimer's disease), 11. 2. 2019, PharmDr.
- Mgr. SCHICKEROVÁ, JULIE: Alkaloidy *Narcissus pseudonarcissus* cv. Dutch Master: Isolace, strukturální identifikace, příprava analog, biologická aktivita (Alkaloids of *Narcissus pseudonarcissus* cv. Dutch Master: Isolation, structural identification, preparation of analogues, biological activity), 28. 3. 2019, PharmDr.
- Mgr. SLATINSKÝ, LUKÁŠ: Interakce vybraných protinádorových látek ze skupiny inhibitorů MAPK/ERK signální kaskády s ABC lékovými transportéry (Interactions of selected anticancer drugs of the MAPK/ERK signaling pathway inhibitors group with the ABC drug transporters), 11. 2. 2019, PharmDr.
- Mgr. SLAVÍČKOVÁ, ZLATA: Jaterní řezy – modelový systém pro studium vlivu seskviterpenů na detoxikační enzymy (Liver slices – model system for studying the effect of sesquiterpenes on detoxifying enzymes), 13. 2. 2019, PharmDr.
- Mgr. SOCHOROVÁ, MICHAELA, Ph.D.: Studium bariérových lipidů v kůži a kožních modelech (Study of barrier lipids in the skin and skin models), 9. 12. 2019, PharmDr.
- Mgr. SOUCHOVÁ, PAVLÍNA: Příprava sprejově sušené laktózy z vodných roztoků o vysoké koncentraci (Preparation of spray-dried lactose from high concentrated aqueous solutions), 21. 11. 2019, PharmDr.
- Mgr. SUCHÝ, MIROSLAV: Měření disociačních konstant potenciálních antituberkulotik (Measurement of dissociation constants of potential antituberculotics), 12. 11. 2019, PharmDr.
- Mgr. SVOBODOVÁ, MARKÉTA: Stanovení obsahu betakarotenu v odrůdách višni pomocí HPLC (Determination of beta-carotene content in sour cherries by HPLC), 5. 6. 2019, PharmDr.
- Mgr. SYCHRA, PAVEL: Pětičlenné dusíkaté heterocykly jako potenciální antituberkulotika (Five-members *N*-heterocycles as potential antituberculotics), 9. 12. 2019, PharmDr.
- Mgr. SZANYIOVÁ, ALEXANDRA: Příprava biodegradovatelných nanočástic pro dodání hydrofilních makromolekulárních léčiv (Preparation of biodegradable nanoparticles for hydrophilic macromolecular drugs delivery), 17. 10. 2019, PharmDr.
- Mgr. ŠACHOVÁ, IVANA: Preparation of strategy for studying interaction of human constitutive adrostone receptor with steroid receptor coactivator-1, 26. 9. 2019, PharmDr.
- Mgr. ŠANTOROVÁ, ANNA: Phylogenetic and taxonomic characterization of new haloarchaea related to *Natronomonas*, 8. 2. 2019, PharmDr.
- Mgr. ŠINALOVÁ, LUCIA: Testovanie cytotoxicity potenciálnych liečiv na bunkových líniiach spoločne s meraním ich priechodu cez hematoencefalickú bariéru pomocou metódy PAMPA (Testing of the cytotoxicity of potential drugs in the cell lines together with the measurement of their passage through the blood brain barrier by the PAMPA method), 14. 2. 2019, PharmDr.
- Mgr. ŠMÍDLOVÁ, MONIKA: Vliv vybraných cytostatik určených pro terapii leukémie na aktivitu lidských enzymů redukujících karbonylovou skupinu (Effect of selected cytostatics for the treatment of leukemia on the activity of human carbonyl reducing enzymes), 17. 6. 2019, RNDr.
- Mgr. ŠPAČEK, PETR: Stanovení markerů epitelialně mezenchymální tranzice (EMT) u buněk *in vitro* (Detection of epithelial-mesenchymal transition markers (EMT) in cells *in vitro*), 15. 2. 2019, PharmDr.

- Mgr. ŠPERKOVÁ, KRISTÝNA: Příprava lidského DHRS1 enzymu a jeho základní charakterizace (Preparation of human DHRS1 enzyme and its basic characterization), 17. 6. 2019, PharmDr.
- Mgr. ŠTĚPÁNKOVÁ, JANA: Charakterizace redukce flubendazolu u člověka *in vitro* (Characterization of flubendazole reduction in human *in vitro*), 13. 2. 2019, PharmDr.
- Mgr. ŠVĚDOVÁ, MONIKA: Využívání vakcíny proti MenB a počty hlášených případů tohoto onemocnění (MenB vaccine uptake and number of reported cases with MenB infection), 22. 1. 2019, PharmDr.
- Mgr. TALÁČKOVÁ, MARKÉTA: Vliv nespecifických faktorů na účinnost akupunktury u pacientů s migrénou (An effect of non-specific factors on acupuncture effectiveness in patients with migraine), 22. 1. 2019, PharmDr.
- Mgr. TANKOVÁ, SABINA: Alkaloidy rodu *Narcissus* a ich biologická aktivita (Alkaloids of the genus *Narcissus* and their biological activity), 3. 12. 2019, PharmDr.
- Mgr. TLÁSKALOVÁ, ANNA: LC-HRMS analýza vybraných antihypertenziv v biologickém materiálu jako průkaz compliance (LC-HRMS analysis of selected antihypertensive drugs in biological material for compliance assessment), 7. 11. 2019, PharmDr.
- Mgr. URBANOVÁ, JOHANA: Transportní studie *in vitro* na 2D a 3D buněčné úrovni (Transport studies *in vitro* on 2D and 3D cellular level), 14. 2. 2019, PharmDr.
- Mgr. VACHUDOVÁ, ELIŠKA: Identifikace a analýza terapie užívané těhotnými ženami II (Identification and analysis of therapy used by pregnant women II), 5. 6. 2019, PharmDr.
- Mgr. VALENA, TOMÁŠ: Real world data and health-economics aspects of treatment of respiratory diseases in the Czech Republic, 5. 6. 2019, PharmDr.
- Mgr. VÁŇOVÁ, NELA, Ph.D.: Sledování biomarkerů oxidačního stresu HPLC metodami (Determination of oxidative stress biomarkers by HPLC), 10. 10. 2019, PharmDr.
- Mgr. VELIČKOVÁ, ZUZANA: Hodnocení intervencí klinického farmaceuta na oddělení nemocnice (Evaluation of clinical pharmacists interventions in the hospital), 22. 1. 2019, PharmDr.
- Mgr. VILDOVÁ, LUCIE: Studium přímo lisovatelných tabletovin a matricových tablet s polyvinylalkoholem (A study of directly compressible tableting materials and matrix tablets with polyvinyl alcohol), 28. 3. 2019, PharmDr.
- Mgr. VÍTKOVÁ, MARTINA: *In vitro* stanovení měď-chelatačních vlastností čistých látek izolovaných ze silymarinu (*In vitro* assessment of copper-chelating properties of isolated pure compounds from silymarine), 3. 12. 2019, PharmDr.
- Mgr. VÍTOVCOVÁ, BARBORA: Vliv flubendazolu na účinek paklitaxelu v prvních nádorových buňkách (The effect of flubendazole on the efficacy of paclitaxel in breast cancer cells), 13. 2. 2019, PharmDr.
- Mgr. VLACHOVÁ, VERONIKA: Vliv methylviologenu na produkci sekundárních látek v *in vitro* kultuře *Fagopyrum esculentum*, odrůda Bambi (The effect of methylviologen on secondary metabolites production in *in vitro* culture of *Fagopyrum esculentum*, variety Bambi), 28. 3. 2019, PharmDr.
- Mgr. VOPLAKALOVÁ, SABINA: Hodnocení svalové síly u skupin osob s rozdílným stupněm fyzické aktivity (Evaluation of muscle strength among groups with varying degrees of physical activity), 15. 2. 2019, PharmDr.
- Mgr. VORÁČOVÁ, MANUELA: Synthesis of natural product analogues as potential antitumour agents, 19. 9. 2019, PharmDr.
- Mgr. VOSÁTKA, RUDOLF, Ph.D.: Design a syntéza nových potenciálně antibakteriálně účinných sloučenin (Design and synthesis of new potentially antibacterial active compounds), 19. 09. 2019, PharmDr.
- Mgr. ZÁLEŠÁKOVÁ, HELENA: *In vitro* metody pro predikci penetrace látek přes HEB (*In vitro* methods for the prediction of blood brain barrier penetration), 25. 9. 2019, PharmDr.
- Mgr. ZAYAKOVÁ, KRISTÝNA: A potential neuroprotective action of ghrelin on dopaminergic neurons transplanted into the 6-hydroxydopamine lesioned rat, 25. 9. 2019, PharmDr.
- Mgr. ZDENĚK, PAVEL: Hemonchóza ovce domácí jako modelová parazitóza – výsledky její parazitologické kontroly v experimentální studii (Haemonchosis as a model parasitosis in sheep – the results of its control during experimental study), 26. 9. 2019, PharmDr.
- Mgr. ZEMČÍKOVÁ, LUCIE, Ph.D.: Vliv přírodních látek na transport lékovými OATP transportéry (The effect of natural compounds on transport by OATP drug transporters), 4. 1. 2019, PharmDr.
- Mgr. ZUBATÁ, KAROLÍNA: Oxidative stress biomarkers of the erythrocyte in the newborn – a follow-up study, 14. 2. 2019, PharmDr.

Mgr. ŽECOVÁ, JANA: Zlúčeniny kombinujúce fragment pyrazinamidu a 4-aminobenzoovej kyseliny ako potenciálne antituberkulotika (Compounds combining pyrazinamide and 4-aminobenzoic acid fragments as potential antituberculars), 8. 1. 2019, PharmDr.

PUBLICATIONS OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ, CHARLES UNIVERSITY IN THE YEAR 2020

ORIGINAL PAPERS AND REVIEWS

- ABAD, C., KARAHODA, R., KASTNER, P., PORTILLO, R., HORÁČKOVÁ, H., KUČERA, R., NACHTIGAL, P., ŠTAUD, F.: Profiling of tryptophan metabolic pathways in the rat fetoplacental unit during gestation. *International Journal of Molecular Sciences*, 21 (20), 2020, art. 7578.
- AL MAMUN, A., MAŘÍKOVÁ, J., HULCOVÁ, D., JANOUŠEK, J., ŠAFRATOVÁ, M., NOVÁKOVÁ, L., KUČERA, T., HRABINOVÁ, M., KUNEŠ, J., KORÁBEČNÝ, J., CAHLÍKOVÁ, L.: Amaryllidaceae alkaloids of belladine-type from *Narcissus pseudonarcissus* cv. Carlton as new selective inhibitors of butyrylcholinesterase. *Biomolecules*, 10 (5), 2020, art. 800.
- AL SHAMMARI, L., AL MAMUN, A., KOUTOVÁ, D., MAJOROŠOVÁ, M., HULCOVÁ, D., ŠAFRATOVÁ, M., BREITEROVÁ, K., MAŘÍKOVÁ, J., HAVELEK, R., CAHLÍKOVÁ, L.: Alkaloid profiling of *Hippeastrum* cultivars by GC-MS, isolation of Amaryllidaceae alkaloids and evaluation of their cytotoxicity. *Records of Natural Products*, 14 (2), 2020, 154–159.
- ALVES da COSTA, F., MALÁ-LÁDOVÁ, K., LEE, V., TOUS, S., PAPASTERGIOU, J., GRIFFITHS, D., CHAUMAIS, M., HERSBERGER, K. E., VIOLA, R., PAULINO, E., LOBBAN, T., NEUBECK, L., FREEDMAN, B., ANTONIOU, S.: Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: An international cross-sectional study. *Journal of Thrombosis and Thrombolysis*, 49 (4), 2020, 606–617.
- AMBROŹKIEWICZ, W., KUČEROVÁ-CHLUPÁČOVÁ, M., JANĎOUREK, O., KONEČNÁ, K., PATEROVÁ, P., BÁRTA, P., VINŠOVÁ, J., DOLEŽAL, M., ZITKO, J.: 5-Alkylamino-*N*-phenylpyrazine-2-carboxamides: Design, preparation, and antimycobacterial evaluation. *Molecules*, 25 (7), 2020, art. 1561.
- APARICIO-MURIANA, M. M., LHOTSKÁ, I., GARCÍA-CAMPAÑA, A. M., LARA, F. J.: A first approach using micellar electrokinetic capillary chromatography for the determination of fipronil and fipronil-sulfone in eggs. *Electrophoresis*, 41 (3–4), 2020, 202–208.
- AUSTIN, P. D., JOSKOVÁ, V., PATKOVÁ, A., ELIA, M.: Contribution of intravenous medication to water and sodium intake in upper and lower gastrointestinal surgical patients. *Nutrition*, 78, 2020, art. 110808.
- AYDOGAN, C., RIGANO, F., KUJOVSKÁ KRČMOVÁ, L., CHUNG, D. S., MACKA, M., MONDELLO, L.: Miniaturized LC in molecular omics. *Analytical Chemistry*, 92 (17), 2020, 11485–11497.
- BARTOUŠKOVÁ, M., HROUZKOVÁ, M., ČVRTLÍK, F., PETROVÁ, P., RUŠAROVÁ, N., KUČEROVÁ, K., VERNEROVÁ, A., MELICHAR, B., ŠTUDENTOVÁ, H.: Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: A case report. *Pteridines*, 31 (1), 2020, 151–157.
- BEEGUM, S., SHEENA MARY, Y., SHYMA MARY, Y., THOMAS, R., ARMAKOVIĆ, S., ARMAKOVIĆ, S. J., ZITKO, J., DOLEŽAL, M., Van ALSENOY, C.: Exploring the detailed spectroscopic characteristics, chemical and biological activity of two cyanopyrazine-2-carboxamide derivatives using experimental and theoretical tools. *Spectrochimica Acta – Part A: Molecular and Biomolecular Spectroscopy*, 224, 2020, art. 117414.
- BERKA, P., BERKA, K., DOLEŽAL, P.: Dextrany jako permeační markery a nosiče pro orální trans mukosální podání léčiv. (Dextrans as permeation markers and carriers for oral transmucosal drug delivery). *Chemické listy*, 114 (8), 2020, 552–558.
- BERNHAEUEROVÁ, V., REZELJ, V. V., VIGNUZZI, M.: Modelling degradation and replication kinetics of the Zika virus *in vitro* infection. *Viruses*, 12 (5), 2020, art. 547.

- BÍLKOVÁ, A., BAĐUROVÁ, K., SVOBODOVÁ, P., VÁVRA, R., JAKUBEC, P., CHOCHOLOUŠ, P., ŠVEC, F., SKLENÁŘOVÁ, H.: Content of major phenolic compounds in apples: Benefits of ultra-low oxygen conditions in long-term storage. *Journal of Food Composition and Analysis*, 92, 2020, art. 103587.
- BINNEFELD, M., FRITZ, S., BALZER, V., SKALICKÁ, V., WITZIGMANN, D., KAUCZOR, H., FRICKER, G., SALOMON, J. J.: Physicochemical and biopharmaceutical characterization of novel matrix-liposomes. *European Journal of Pharmaceutics and Biopharmaceutics*, 153, 2020, 158–167.
- BORSKÝ, P., CHMELÁŘOVÁ, M., FIALA, Z., PALIČKA, V., BERÁNEK, M., KREMLÁČEK, J., ANDRÝS, C., HAMÁKOVÁ, K., MÁLKOVÁ, A., BORSKÁ, L.: Variation of selected genotoxic and epigenetic markers due to therapeutic exposure to PAHs and ultraviolet radiation. *Bratislavské lekárske listy / Bratislava Medical Journal*, 121 (8), 2020, 558–564.
- BOUZ, G., JUHÁS, M., PAUSAS OTERO, L., PAREDES de la RED, C., JANĎOUREK, O., KONEČNÁ, K., PATEROVÁ, P., KUBÍČEK, V., JANOUŠEK, J., DOLEŽAL, M., ZITKO, J.: Substituted *N*-(pyrazin-2-yl)benzenesulfonamides; synthesis, anti-infective evaluation, cytotoxicity, and *in silico* studies. *Molecules*, 25 (1), 2020, art. 138.
- BRAEUNING, A., PÁVEK, P.: β -Catenin signaling, the constitutive androstane receptor and their mutual interactions. *Archives of Toxicology*, 94 (12), 2020, 3983–3991.
- BREITEROVÁ, K., KOUTOVÁ, D., MAŘÍKOVÁ, J., HAVELEK, R., KUNEŠ, J., MAJOROŠOVÁ, M., OPLETAL, L., HOŠŤÁLKOVÁ, A., JENČO, J., ŘEZÁČOVÁ, M., CAHLÍKOVÁ, L.: Amaryllidaceae alkaloids of different structural types from *Narcissus* L. cv. Professor Einstein and their cytotoxic activity. *Plants*, 9 (2), 2020, art. 137.
- CAHLÍKOVÁ, L., BREITEROVÁ, K., OPLETAL, L.: Chemistry and biological activity of alkaloids from the genus *Lycoris* (Amaryllidaceae). *Molecules*, 25 (20), 2020, art. 4797.
- CAHLÍKOVÁ, L., ŠAFRATOVÁ, M., HOŠŤÁLKOVÁ, A., CHLEBEK, J., HULCOVÁ, D., BREITEROVÁ, K., OPLETAL, L.: Pharmacognosy and its role in the system of profile disciplines in pharmacy. *Natural Product Communications*, 15 (9), 2020, 1–7.
- De VOS, J., DAMS, M., BROECKHOVEN, K., DESMET, G., HORSTKOTTE, B., EELTINK, S.: Prototyping of a microfluidic modulator chip and its application in heart-cut strong-cation-exchange-reversed-phase liquid chromatography coupled to nano-electrospray mass spectrometry for targeted proteomics. *Analytical Chemistry*, 92 (3), 2020, 2388–2392.
- DEMUTH, J., MILETÍN, M., KUČERA, R., RŮŽIČKA, A., HAVLÍNOVÁ, Z., LIBRA, A., NOVÁKOVÁ, V., ZIMČÍK, P.: Self-assembly of azaphthalocyanine-oligodeoxynucleotide conjugates into J-dimers: Towards biomolecular logic gates. *Organic Chemistry Frontiers*, 7 (3), 2020, 445–456.
- DEMUTH, J., MILETÍN, M., MACHAN, M., KÁNTOR, M., ZIMČÍK, P., NOVÁKOVÁ, V.: Synthesis and J-dimer formation of tetrapyrazinoporphyrazines with different functional groups for potential biomolecular probe applications. *ChemPlusChem*, 85 (3), 2020, 527–537.
- DOLEŽIL, D., MARKOVÁ, J., KLIMEŠ, J., POČÍKOVÁ, Z., DOSTÁL, F., ŠTĚPÁNOVÁ, R., SVOBODNÍK, A.: An investigation into the prevalence of migraine and its prophylactic treatment patterns in the Czech Republic: An observational study. *Journal of Pain Research*, 13, 2020, 2895–2906.
- DOOKUN, E., WALASZCZYK, A., REDGRAVE, R., PALMOWSKI, P., TUAL-CHALOT, S., SUWANA, A., CHAPMAN, J., JIRKOVSKÝ, E., DONASTORG SOSA, L., GILL, E., YAUSEP, O. E., SANTIN, Y., MIALET-PEREZ, J., OWENS, W. A., GRIEVE, D., SPYRIDOPOULOS, I., TAGGART, M., ARTHUR, H. M., PASSOS, J. F., RICHARDSON, G. D.: Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. *Aging Cell*, 19 (10), 2020, art. e13249.
- DUINTJER TEBBENS, E. J., MEURANT, G.: On the residual norms, the Ritz values and the harmonic Ritz values that can be generated by restarted GMRES. *Numerical Algorithms*, 84 (4), 2020, 1329–1352.
- ELPELT, A., IVANOV, D., NOVÁČKOVÁ, A., KOVÁČIK, A., SOCHOROVÁ, M., SAEIDPOUR, S., TEUTLOFF, C., LOHAN, S. B., LADEMANN, J., VÁVROVÁ, K., HEDTRICH, S., MEINKE, M. C.: Investigation of TEMPO partitioning in different skin models as measured by EPR spectroscopy – Insight into the stratum corneum. *Journal of Magnetic Resonance*, 310, 2020, art. 106637.
- ENGBERG, O., KOVÁČIK, A., PULLMANNOVÁ, P., JUHAŠČIK, M., OPÁLKA, L., HUSTER, D., VÁVROVÁ, K.: The sphingosine and acyl chains of ceramide [NS] show very different structure and dynamics that challenge our understanding of the skin barrier. *Angewandte Chemie – International Edition*, 59 (40), 2020, 17383–17387.

- FÁBRYOVÁ, T., TŮMOVÁ, L., CORREIA da SILVA, D., PEREIRA, D. M., ANDRADE, P. B., VALENTAO, P., HROUZEK, P., KOPECKÝ, J., CHEEL, J.: Isolation of astaxanthin monoesters from the microalgae *Haematococcus pluvialis* by high performance countercurrent chromatography (HPCCC) combined with high performance liquid chromatography (HPLC). *Algal Research*, 49, 2020, art. 101947.
- FLISZÁR-NYÚL, E., MOHOS, V., CSEPREGI, R., MLADĚNKA, P., POÓR, M.: Inhibitory effects of polyphenols and their colonic metabolites on CYP2D6 enzyme using two different substrates. *Biomedicine & Pharmacotherapy*, 131, 2020, art. 110732.
- GENDRISCH, F., NOVÁČKOVÁ, A., SOCHOROVÁ, M., HAARHAUS, B., VÁVROVÁ, K., SCHEMPP, C. M., WÖLFLE, U.: *Gentiana lutea* extract modulates ceramide synthesis in primary and psoriasis-like keratinocytes. *Molecules*, 25 (8), 2020, art. 1832.
- GODYŇ, J., GUCWA, D., KOBRLOVÁ, T., NOVÁK, M., SOUKUP, O., MALAWSKA, B., BAJDA, M.: Novel application of capillary electrophoresis with a liposome coated capillary for prediction of blood-brain barrier permeability. *Talanta*, 217, 2020, art. 121023.
- GRAMEC SKLEDAR, D., TVRDÝ, V., KENDA, M., ZEGA, A., POUR, M., HORKÝ, P., MLADĚNKA, P., SOLLNER DOLENC, M., PETERLIN MAŠIČ, L.: Applicability of the OECD 455 *in-vitro* assay for determination of hERA agonistic activity of isoflavonoids. *Toxicology and Applied Pharmacology*, 386, 2020, art. 114831.
- GRANITZER, S., ELLINGER, I., KHAN, R., GELLES, K., WIDHALM, R., HENGSTSCHLÄGER, M., ZEISLER, H., DESOYE, G., ŤUPOVÁ, L., ČEČKOVÁ, M., SALZER, H., GUNDACKER, C.: *In vitro* function and *in situ* localization of Multidrug Resistance-associated Protein (MRP)I (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. *Archives of Toxicology*, 94 (11), 2020, 3799–3817.
- GROOTEN, Y., RIASOVÁ, P., SALSINHA, I., MANGELINGS, D., VANDER HEYDEN, Y.: Stationary-phase optimized selectivity in supercritical fluid chromatography using a customized Phase Optimized Liquid Chromatography kit: comparison of different prediction approaches. *Analytical and Bioanalytical Chemistry*, 412 (24), 2020, 6553–6565.
- HÁKOVÁ, M., CHOCHOLOUŠ, P., VALACHOVIČ, A., ERBEN, J., CHVOJKA, J., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: On-line polydopamine coating as a new way to functionalize polypropylene fiber sorbent for solid phase extraction. *Talanta*, 219, 2020, art. 121189.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., ŠVEC, F., SOLICH, P., ERBEN, J., CHVOJKA, J., ŠATÍNSKÝ, D.: Novel nanofibrous sorbents for the extraction and determination of resveratrol in wine. *Talanta*, 206, 2020, art. 120181.
- HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., ŠVEC, F., SOLICH, P., ŠATÍNSKÝ, D.: Nanofibers as advanced sorbents for on-line solid phase extraction in liquid chromatography: A tutorial. *Analytica Chimica Acta*, 1121, 2020, 83–96.
- HALLINGSTRÖM, M., ZEDNÍKOVÁ, P., TAMBOR, V., BARMAN, M., VAJRYCHOVÁ, M., LENČO, J., VIKLUND, F., TANCREDE, L., RABE, H., JONSSON, D., KACHIKIS, A., NILSSON, S., KACEROVSKÝ, M., ADAMS WALDORF, K. M., JACOBSSON, B.: Mid-trimester amniotic fluid proteome's association with spontaneous preterm delivery and gestational duration. *PLoS One*, 15 (5), 2020, art. e0232553.
- HERMAN, D., DLABKOVÁ, A., ČECHOVÁ, L., VÁŇOVÁ, N., MISÍK, J., JUN, D., ŽĎÁROVÁ KARASOVÁ, J.: Simple validated method of LC-MS/MS determination of BZ agent in rat plasma samples. *Drug Testing and Analysis*, 12 (4), 2020, 431–438.
- HORSTKOTTE ŠRÁMKOVÁ, I., HORSTKOTTE, B., ERBEN, J., CHVOJKA, J., ŠVEC, F., SOLICH, P., ŠATÍNSKÝ, D.: 3D-printed magnetic stirring cages for semidispersive extraction of bisphenols from water using polymer micro- and nanofibers. *Analytical Chemistry*, 92 (5), 2020, 3964–3971.
- HORSTKOTTE, B., SOLICH, P.: The automation technique Lab-In-Syringe: A practical guide. *Molecules*, 25 (7), 2020, art. 1612.
- HUSAIN, A., GANESAN, A., MACHÁČEK, M., ČERVENÝ, L., KUBÁT, P., GHAZAL, B., ZIMČÍK, P., MAKHSEED, S.: Dually directional glycosylated phthalocyanines as extracellular red-emitting fluorescent probes. *Dalton Transactions*, 49 (28), 2020, 9605–9617.
- CHALUPA, R., BABICA, J., NESMĚRÁK, K.: Farmaceuti, chemie a Přírodovědecká fakulta Univerzity Karlovy (Pharmacists, chemistry and Faculty of Science of Charles University). *Chemické listy*, 114 (10), 2020, 635–643.

- CHALUPA, R., BABICA, J., NESMĚRÁK, K.: Historie výuky farmacie na Přírodovědecké fakultě Univerzity Karlovy v letech 1920–1950 (History of teaching of pharmacy at the Faculty of Science of the Charles University in 1920–1950). *Chemické listy*, 114 (9), 2020, 578–585.
- CHIARELLO, D. I., ABAD, C., ROJAS, D., TOLEDO, F., VÁZQUEZ, C. M., MATE, A., SOBREVIA, L., MARÍN, R.: Oxidative stress: Normal pregnancy versus preeclampsia. *Biochimica et Biophysica Acta – Molecular Basis of Disease*, 1866 (2), 2020, art. 165354.
- IGREJA e SÁ, I. C., TRIPSKÁ, K., HROCH, M., HYŠPLER, R., TICHÁ, A., LAŠTŮVKOVÁ, H., SCHREIBEROVÁ, J., DOLEŽELOVÁ, E., EISSAZADEH, S., VITVEROVÁ, B., NAJMANOVÁ, I., VAŠINOVÁ, M., PERICACHO, M., MIČUDA, S., NACHTIGAL, P.: Soluble endoglin as a potential biomarker of nonalcoholic steatohepatitis (NASH) development, participating in aggravation of NASH-related changes in mouse liver. *International Journal of Molecular Sciences*, 21 (23), 2020, art. 9021.
- JÁČ, P., BUBÁKOVÁ, Z., MORENO GONZÁLEZ, D., KOVÁČOVÁ, G., ŠPULÁK, M., POLÁŠEK, M.: Stability study of α -bromophenylacetic acid: Does it represent an appropriate model analyte for chiral separations? *Electrophoresis*, 41 (18–19), 2020, 1557–1563.
- JAKUBEC, P., DOUŠA, M., NOVÁKOVÁ, L.: Supercritical fluid chromatography in chiral separations: Evaluation of equivalency of polysaccharide stationary phases. *Journal of Separation Science*, 43 (13), 2020, 2675–2689.
- JAMES, S. L., CASTLE, C. D., DINGELS, Z. V., FOX, J. T., HAMILTON, E. B., LIU, Z., ROBERTS, N. L. S., SYLTE, D. O., BERTOLACCI, G. J., CUNNINGHAM, M., HENRY, N. J., LEGRAND, K. E., BHAGAVATHULA, A.: Estimating global injuries morbidity and mortality: Methods and data used in the Global Burden of Disease 2017 study. *Injury Prevention*, 26 (Supp 1), 2020, 125–153.
- JENČO, J., KUJOVSKÁ KRČMOVÁ, L., SOBOTKA, L., BLAHA, V., SOLICH, P., ŠVEC, F.: Development of novel liquid chromatography method for clinical monitoring of vitamin B₁ metabolites and B₆ status in the whole blood. *Talanta*, 211, 2020, art. 120702.
- JEVTIĆ, M., LÖWA, A., NOVÁČKOVÁ, A., KOVÁČIK, A., KAESSMEYER, S., ERDMANN, G., VÁVROVÁ, K., HEDTRICH, S.: Impact of intercellular crosstalk between epidermal keratinocytes and dermal fibroblasts on skin homeostasis. *Biochimica et Biophysica Acta – Molecular Cell Research*, 1867 (8), 2020, art. 118722.
- JUHÁS, M., KUČEROVÁ, L., HORÁČEK, O., JANĎOUREK, O., KUBÍČEK, V., KONEČNÁ, K., KUČERA, R., BÁRTA, P., JANOUŠEK, J., PATEROVÁ, P., KUNEŠ, J., DOLEŽAL, M., ZITKO, J.: *N*-Pyrazinoyl substituted amino acids as potential antimycobacterial agents – The synthesis and biological evaluation of enantiomers. *Molecules*, 25 (7), 2020, art. 1518.
- JUHÁS, M., ZITKO, J.: Molecular interactions of pyrazine-based compounds to proteins. *Journal of Medicinal Chemistry*, 63 (17), 2020, 8901–8916.
- KAPKOWSKI, M., LUDYNIA, M., RUDNICKA, M., DZIDA, M., ZORĘBSKI, E., MUSIAŁ, M., DOLEŽAL, M., POLAŃSKI, J.: Enhancing the CO₂ capturing ability in leaf via xenobiotic auxin uptake. *Science of the Total Environment*, 745, 2020, art. 141032.
- KARAHODA, R., ABAD, C., HORÁČKOVÁ, H., KASTNER, P., ZAUGG, J., ČERVENÝ, L., KUČERA, R., ALBRECHT, C., ŠTAUD, F.: Dynamics of tryptophan metabolic pathways in human placenta and placental-derived cells: Effect of gestation age and trophoblast differentiation. *Frontiers in Cell and Developmental Biology*, 8, 2020, art. 574034.
- KARAHODA, R., HORÁČKOVÁ, H., KASTNER, P., MATTHIOS, A., ČERVENÝ, L., KUČERA, R., KACEROVSKÝ, M., DUINTJER TEBBENS, E. J., BONNIN, A., ABAD, C., ŠTAUD, F.: Serotonin homeostasis in the materno-foetal interface at term: Role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta. *Acta Physiologica*, 229 (4), 2020, art. e13478.
- KARBANOVA, S., ŠORF, A., JIRÁSKOVÁ, L., LALINSKÁ, A., PTÁČKOVÁ, Z., ŠTAUD, F., ČERVENÝ, L.: *S*-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is not a selective inhibitor of equilibrative nucleoside transporters but also blocks efflux activity of breast cancer resistance protein. *Pharmaceutical Research*, 37 (3), 2020, art. 58.
- KELLEROVÁ, P., NAVRÁTILOVÁ, M., NGUYEN, T. L., DIMUNOVÁ, D., RAISOVÁ STUHLÍKOVÁ, L., ŠTĚRBOVÁ, K., SKÁLOVÁ, L., MATOUŠKOVÁ, P.: UDP-glycosyltransferases and albendazole metabolism in the juvenile stages of *Haemonchus contortus*. *Frontiers in Physiology*, 11, 2020, art. 594116.

- KELLEROVÁ, P., RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P., ŠTĚRBOVÁ, K., LAMKA, J., NAVRÁTILOVÁ, M., VOKŘÁL, I., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: Sub-lethal doses of albendazole induce drug metabolizing enzymes and increase albendazole deactivation in *Haemonchus contortus* adults. *Veterinary Research*, 51 (1), 2020, art. 94.
- KHOLOVÁ, A., LHOTSKÁ, I., UHROVÁ, A., ŠPÁNIK, I., MACHYŇÁKOVÁ, A., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: Determination of ochratoxin A and ochratoxin B in archived Tokaj wines (Vintage 1959–2017) using on-line solid phase extraction coupled to liquid chromatography. *Toxins*, 12 (12), 2020, art. 739.
- KOHLOVÁ, M., GOMES AMORIM, C., DA NOVA ARAÚJO, A., SANTOS-SILVA, A., SOLICH, P., MONTENEGRO, M. C. B. S. M.: *In vitro* assessment of polyethylene glycol and polyvinylpyrrolidone as hydrophilic additives on bioseparation by polysulfone membranes. *Journal of Materials Science*, 55 (3), 2020, 1292–1307.
- KOHLOVÁ, M., ROCHA, S., GOMES AMORIM, C., DE NOVA ARAÚJO, A., SANTOS-SILVA, A., SOLICH, P., MONTENEGRO, M. C. B. S. M.: Doping polysulfone membrane with alpha-tocopherol and alpha-lipoic acid for suppressing oxidative stress induced by hemodialysis treatment. *Macromolecular Bioscience*, 20 (7), 2020, art. 2000046.
- KOLLÁR, J., MACHÁČEK, M., HALAŠKOVÁ, M., LENČO, J., KUČERA, R., DEMUTH, J., ROHLÍČKOVÁ, M., HASOŇOVÁ, K., MILETÍN, M., NOVÁKOVÁ, V., ZIMČÍK, P.: Cationic versus anionic phthalocyanines for photodynamic therapy: What a difference the charge makes. *Journal of Medicinal Chemistry*, 63 (14), 2020, 7616–7632.
- KOLLÁROVÁ-BRÁZDOVÁ, P., JIRKOVSKÁ, A., KARABANOVICH, G., POKORNÁ, Z., BAVLOVIČ-PISKÁČKOVÁ, H., JIRKOVSKÝ, E., KUBEŠ, J., LENČOVÁ-POPELOVÁ, O., MAZUROVÁ, Y., ADAMCOVÁ, M., SKALICKÁ, V., ŠTĚRBOVÁ-KOVAŘÍKOVÁ, P., ROH, J., ŠIMŮNEK, T., ŠTĚRBA, M.: Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase II β interaction as a prerequisite for effective protection against anthracycline cardiotoxicity. *Journal of Pharmacology and Experimental Therapeutics*, 373 (3), 2020, 402–415.
- KOUTOVÁ, D., KULHAVÁ, M., HAVELEK, R., MAJOROŠOVÁ, M., KRÁLOVEC, K., HABARTOVÁ, K., HOŠŤÁLKOVÁ, A., OPLETAL, L., CAHLÍKOVÁ, L., ŘEZÁČOVÁ, M.: Bersavine: A novel bisbenzylisoquinoline alkaloid with cytotoxic, antiproliferative and apoptosis-inducing effects on human leukemic cells. *Molecules*, 25 (4), 2020, art. 964.
- KOUTOVÁ, D., MAAFI, N., HAVELEK, R., OPLETAL, L., BLUNDEN, G., ŘEZÁČOVÁ, M., CAHLÍKOVÁ, L.: Chemical and biological aspects of montanine-type alkaloids isolated from plants of the Amaryllidaceae family. *Molecules*, 25 (10), 2020, art. 2337.
- KOVÁČIK, A., KOPEČNÁ, M., VÁVROVÁ, K.: Permeation enhancers in transdermal drug delivery: Benefits and limitations. *Expert Opinion on Drug Delivery*, 17 (2), 2020, 145–156.
- KOVÁČIK, A., PULLMANNOVÁ, P., PAVLÍKOVÁ, L., MAIXNER, J., VÁVROVÁ, K.: Behavior of 1-deoxy-, 3-deoxy- and *N*-methyl-ceramides in skin barrier lipid models. *Scientific Reports*, 10 (1), 2020, art. 3832.
- KOVAŘÍK, M., NAJPAVEROVÁ, S., KOBLÍŽEK, V., ZADÁK, Z., HRONEK, M.: Association of resting energy expenditure and nutritional substrate oxidation with COPD stage and prediction indexes. *Respiratory Medicine*, 174 (November), 2020, art. 106174.
- KRÁTKÝ, M., BARANYAI, Z., ŠTĚPÁNKOVÁ, Š., SVRČKOVÁ, K., ŠVARCOVÁ, M., STOLAŘÍKOVÁ, J., HORVÁTH, L., BŐSZE, S., VINŠOVÁ, J.: *N*-Alkyl-2-[4-(trifluoromethyl)benzoyl]hydrazine-1-carboxamides and their analogues: Synthesis and multitarget biological activity. *Molecules*, 25 (10), 2020, art. 2268.
- KRÁTKÝ, M., JAKLOVÁ, K., ŠTĚPÁNKOVÁ, Š., SVRČKOVÁ, K., PFLÉGR, V., VINŠOVÁ, J.: *N*-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide analogues: Novel acetyl- and butyrylcholinesterase inhibitors. *Current Topics in Medicinal Chemistry*, 20 (23), 2020, 2094–2105.
- KRÁTKÝ, M., KONEČNÁ, K., JANOUŠEK, J., BRABLÍKOVÁ, M., JANĎOUREK, O., TREJTNAR, F., STOLAŘÍKOVÁ, J., VINŠOVÁ, J.: 4-Aminobenzoic acid derivatives: Converting folate precursor to antimicrobial and cytotoxic agents. *Biomolecules*, 10 (1), 2020, art. 9.
- KRÁTKÝ, M., ŠTĚPÁNKOVÁ, Š., BRABLÍKOVÁ, M., SVRČKOVÁ, K., ŠVARCOVÁ, M., VINŠOVÁ, J.: Novel iodinated hydrazide-hydrazones and their analogues as acetyl- and butyrylcholinesterase inhibitors. *Current Topics in Medicinal Chemistry*, 20 (23), 2020, 2106–2117.
- KUBAČKOVÁ, J., ZBYTOVSKÁ, J., HOLAS, O.: Nanomaterials for direct and indirect immunomodulation: A review of applications. *European Journal of Pharmaceutical Sciences*, 142 (January), 2020, art. 105139.

- KUČEROVÁ-CHLUPÁČOVÁ, M., HALÁKOVÁ, D., MÁJEKOVÁ, M., TREML, J., ŠTEFEK, M., ŠOLTÉSOVÁ PRNOVÁ, M.: (4-Oxo-2-thioxothiazolidin-3-yl)acetic acids as potent and selective aldose reductase inhibitors. *Chemico-Biological Interactions*, 332, 2020, art. 109286.
- KUCHAROVÁ, M., ASTAPENKO, D., ZUBÁNOVÁ, V., KOŠČÁKOVÁ, M., ŠTĚTINA, R., ZADÁK, Z., HRONEK, M.: Does neuraxial anesthesia as general anesthesia damage DNA? A pilot study in patients undergoing orthopedic traumatological surgery. *International Journal of Molecular Sciences*, 21 (1), 2020, art. 84.
- KUJOVSKÁ KRČMOVÁ, L., MELICHAR, B., ŠVEC, F.: Chromatographic methods development for clinical practice: Requirements and limitations. *Clinical Chemistry and Laboratory Medicine*, 58 (11), 2020, 1785–1793.
- LENČO, J., KHALIKOVA, M., ŠVEC, F.: Dissolving peptides in 0.1% formic acid brings risk of artificial formylation. *Journal of Proteome Research*, 19 (3), 2020, 993–999.
- LNĚNIČKOVÁ, K., ŠADIBOLOVÁ, M., MATOUŠKOVÁ, P., SZOTÁKOVÁ, B., SKÁLOVÁ, L., BOUŠOVÁ, I.: The modulation of phase II drug-metabolizing enzymes in proliferating and differentiated CaCo-2 cells by hop-derived prenylflavonoids. *Nutrients*, 12 (7), 2020, art. 2138.
- LOCHAŘ, V., KOMERSOVÁ, A., MATZICK, K., SLEZÁKOVÁ, B., BARTOŠ, M., MUŽÍKOVÁ, J., HADDOUCHI, S.: The effect of alcohol on ionizing and non-ionizing drug release from hydrophilic, lipophilic and dual matrix tablets. *Saudi Pharmaceutical Journal*, 28 (2), 2020, 187–195.
- MALÝ, J., DOSEDĚL, M., KUBĚNA, A., MALÁ-LÁDOVÁ, K., VOSÁTKA, J., BRABCOVÁ, I., HAJDUCHOVÁ, H., BÁRTOLOVÁ, S., TÓTHOVÁ, V., VLČEK, J.: Analysis of the fall-related risk of pharmacotherapy in Czech hospitals: A case control study. *Journal of Evaluation in Clinical Practice*, 26 (3), 2020, 973–982.
- MARÍN, R., CHIARELLO, D. I., ABAD, C., ROJAS, D., TOLEDO, F., SOBREVIA, L.: Oxidative stress and mitochondrial dysfunction in early-onset and late-onset preeclampsia. *Biochimica et Biophysica Acta – Molecular Basis of Disease*, 1866 (12), 2020, art. 165961.
- MARKOVÁ, I., KONÍČKOVÁ, R., VAŇKOVÁ, K., LENÍČEK, M., KOLÁŘ, M., STRNAD, H., HRADILOVÁ, M., ŠÁCHOVÁ, J., RASL, J., KLÍMOVÁ, Z., VOMASTEK, T., NĚMEČKOVÁ, I., NACHTIGAL, P., VÍTEK, L.: Anti-angiogenic effects of the blue-green alga *Arthrospira platensis* on pancreatic cancer. *Journal of Cellular and Molecular Medicine*, 24 (4), 2020, 2402–2415.
- MAŘÍKOVÁ, J., RITOMSKÁ, A., KORÁBEČNÝ, J., PEŘINOVÁ, R., AL MAMUN, A., KUČERA, T., KOHELOVÁ, E., HULCOVÁ, D., KOBRLOVÁ, T., KUNEŠ, J., NOVÁKOVÁ, L., CAHLÍKOVÁ, L.: Aromatic esters of the crinine Amaryllidaceae alkaloid ambelline as selective inhibitors of butyrylcholinesterase. *Journal of Natural Products*, 83 (5), 2020, 1359–1367.
- MATOUŠ, P., KADANÍK, M., TIMORACKÝ, M., KUNEŠ, J., MAŘÍKOVÁ, J., RŮŽIČKA, A., KOČOVSKÝ, P., POUR, M.: Nucleophile-assisted cyclization of beta-propargylamino acrylic compounds catalyzed by gold(I): A rapid construction of multisubstituted tetrahydropyridines and their fused derivatives. *Organic Chemistry Frontiers*, 7 (21), 2020, 3356–3367.
- MIGKOS, T., POUROVÁ, J., VOPRŠALOVÁ, M., AUGER, C., SCHINI-KERTH, V., MLADĚNKA, P.: Biochanin A, the most potent of 16 isoflavones, induces relaxation of the coronary artery through the calcium channel and cGMP-dependent pathway. *Planta Medica*, 86 (10), 2020, 708–716.
- MILIA, E., USAI, M., SZOTÁKOVÁ, B., ELSTNEROVÁ, M., KRÁLOVÁ, V., D'HALLEWIN, G., SPISSU, Y., BARBERIS, A., MARCHETTI, M., BORTONE, A., CAMPANELLA, V., MASTANDREA, G., LANGHANSOVÁ, L., EICK, S.: The pharmaceutical ability of *Pistacia lentiscus* L. leaves essential oil against periodontal bacteria and *Candida* sp. and its anti-inflammatory potential. *Antibiotics*, 9 (6), 2020, art. 281.
- MLADĚNKA, P., KARLÍČKOVÁ, J., HRUBŠA, M., VELJOVIĆ, E., MURATOVIĆ, S., CARAZO, A., MALI, A. S., ŠPIRTOVIĆ-HALILOVIĆ, S., SASO, L., POUR, M., DURIĆ, K.: Interaction of 2,6,7-trihydroxyxanthene-3-ones with iron and copper biological effect of the most active derivative on breast cancer cells and erythrocytes. *Applied Sciences*, 10 (14), 2020, art. 4846.
- MOHOS, V., FLISZÁR-NYÚL, E., LEMLI, B., ZSIDÓ, B. Z., HETÉNYI, C., MLADĚNKA, P., HORKÝ, P., POUR, M., POÓR, M.: Testing the pharmacokinetic interactions of 24 colonic flavonoid metabolites with human serum albumin and cytochrome P450 enzymes. *Biomolecules*, 10 (3), 2020, art. 409.
- MONTESDEOCA-ESPONDA, S., TORRES-PADRÓN, M. E., NOVÁK, M., KRCHOVÁ, L., SOSA-FERRERA, Z., SANTANA-RODRÍGUEZ, J. J.: Occurrence of benzotriazole UV stabilizers in coastal fishes. *Journal of Environmental Management*, 269 (September), 2020, art. 110805.

- MORELL, A., ČERMÁKOVÁ, L., NOVOTNÁ, E., LAŠTOVIČKOVÁ, L., HADDAD, M., HADDAD, A., PORTILLO, R., WSÓL, V.: Bruton's tyrosine kinase inhibitors ibrutinib and acalabrutinib counteract anthracycline resistance in cancer cells expressing AKR1C3. *Cancers*, 12 (12), 2020, art. 3731.
- MORENO GONZÁLEZ, D., JÁČ, P., ŠVEC, F., NOVÁKOVÁ, L.: Determination of Sudan dyes in chili products by micellar electrokinetic chromatography-MS/MS using a volatile surfactant. *Food Chemistry*, 310, 2020, art. 125963.
- NAJMANOVÁ, I., POUROVÁ, J., MLADĚNKA, P.: A mixture of phenolic metabolites of quercetin can decrease elevated blood pressure of spontaneously hypertensive rats even in low doses. *Nutrients*, 12 (1), 2020, art. 213.
- NAJMANOVÁ, I., VOPRŠALOVÁ, M., SASO, L., MLADĚNKA, P.: The pharmacokinetics of flavanones. *Critical Reviews in Food Science and Nutrition*, 60 (18), 2020, 3155–3171.
- NAJPAVEROVÁ, S., KOVAŘÍK, M., KACEROVSKÝ, M., ZADÁK, Z., HRONEK, M.: The relationship of nutritional energy and macronutrient intake with pregnancy outcomes in Czech pregnant women. *Nutrients*, 12 (4), 2020, art. 1152.
- NAVRÁTILOVÁ, M., RAISOVÁ STUHLÍKOVÁ, L., MOŤKOVÁ, K., SZOTÁKOVÁ, B., SKÁLOVÁ, L., LANGHANSOVÁ, L., PODLIPNÁ, R.: The uptake of ivermectin and its effects in roots, leaves and seeds of soybean (*Glycine max*). *Molecules*, 25 (16), 2020, art. 3655.
- NAVRÁTILOVÁ, M., RAISOVÁ STUHLÍKOVÁ, L., SKÁLOVÁ, L., SZOTÁKOVÁ, B., LANGHANSOVÁ, L., PODLIPNÁ, R.: Pharmaceuticals in environment: The effect of ivermectin on ribwort plantain (*Plantago lanceolata* L.). *Environmental Science and Pollution Research*, 27 (25), 2020, 31202–31210.
- NESMĚRÁK, K., KUDLÁČEK, K., KOZLÍK, P., ŠTÍCHA, M., VAŠÍČKOVÁ, P., BABICA, J.: Dlouhodobá stabilita alkaloidů v pevných lékových formách (Long-term stability of alkaloids in solid dosage forms). *Chemické listy*, 114 (1), 2020, 52–57.
- NOVÁKOVÁ, M., FÁBRYOVÁ, T., VOKURKOVÁ, D., DOLEČKOVÁ, I., KOPECKÝ, J., HROUZEK, P., TŮMOVÁ, L., CHEEL, J.: Separation of the glycosylated carotenoid myxoxanthophyll from *Synechocystis salina* by HPLC and evaluation of its antioxidant, tyrosinase inhibitory and immune-stimulating properties. *Separations*, 7 (4), 2020, art. 73.
- NOVOTNÁ, E., MORELL, A., BŮKŮM, N., HOFMAN, J., DANIELISOVÁ, P., WSÓL, V.: Interactions of antileukemic drugs with daunorubicin reductases: Could reductases affect the clinical efficacy of daunorubicin chemoregimens? *Archives of Toxicology*, 94 (9), 2020, 3059–3068.
- OPÁLKA, L., KOVÁČIK, A., PULLMANNOVÁ, P., MAIXNER, J., VÁVROVÁ, K.: Effects of omega-*O*-acylceramide structures and concentrations in healthy and diseased skin barrier lipid membrane models. *Journal of Lipid Research*, 61 (2), 2020, 219–228.
- PERINOVÁ, R., MAAFI, N., KORÁBEČNÝ, J., KOHELOVÁ, E., De SIMONE, A., AL MAMUN, A., HULCOVÁ, D., MARKOVÁ, J., KUČERA, T., JUN, D., ŠAFRATOVÁ, M., MAŘÍKOVÁ, J., ANDRISANO, V., JENČO, J., KUNEŠ, J., MARTINEZ, A., NOVÁKOVÁ, L., CAHLÍKOVÁ, L.: Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their *in vitro* and *in silico* biological activity connected to Alzheimer's disease. *Bioorganic Chemistry*, 100, 2020, art. 103928.
- PILAŘOVÁ, V., KOČOVÁ VLČKOVÁ, H., JUNG, O., PROTTI, M., BUCHTA, V., MERCOLINI, L., ŠVEC, F., NOVÁKOVÁ, L.: Unambiguous determination of farnesol and tyrosol in vaginal fluid using fast and sensitive UHPLC-MS/MS method. *Analytical and Bioanalytical Chemistry*, 412 (24), 2020, 6529–6541.
- PLACHKÁ, K., KHALIKOVA, M., BABIČOVÁ, B., MACHOVÁ, Z., ROUBÍČKOVÁ, L., ŠVEC, F., NOVÁKOVÁ, L.: Ultra-high performance supercritical fluid chromatography in impurity control II: Method validation. *Analytica Chimica Acta*, 1117, 2020, 48–59.
- POKLADNÍKOVÁ, J., TELEC, I.: Provision of complementary and alternative medicine: Compliance with the health professional requirements. *Health Policy*, 124 (3), 2020, 311–316.
- PROKŠOVÁ, M., ŘEHULKOVÁ, H., ŘEHULKA, P., LAYS, C., LENČO, J., STULÍK, J.: Using proteomics to identify host cell interaction partners for VgrG and IgJ. *Scientific Reports*, 10 (1), 2020, art. 14612.
- RAABOVÁ, H., HÁKOVÁ, M., CHOCHOLOUŠOVÁ HAVLÍKOVÁ, L., ERBEN, J., CHVOJKA, J., SOLICH, P., ŠVEC, F., ŠATÍNSKÝ, D.: Poly- ϵ -caprolactone nanofibrous polymers: A simple alternative to restricted access media for extraction of small molecules from biological matrixes. *Analytical Chemistry*, 92 (10), 2020, 6801–6805.
- RAISOVÁ STUHLÍKOVÁ, L., NAVRÁTILOVÁ, M., LANGHANSOVÁ, L., MOŤKOVÁ, K., PODLIPNÁ, R., SZOTÁKOVÁ, B., SKÁLOVÁ, L.: The identification of metabolites and effects of albendazole in alfalfa (*Medicago sativa*). *International Journal of Molecular Sciences*, 21 (16), 2020, art. 5943.

- SEDLÁČEK, J., HERMANNOVÁ, M., ŠATÍNSKÝ, D., VELEBNÝ, V.: Current analytical methods for the characterization of *N*-deacetylated hyaluronan: A critical review. *Carbohydrate Polymers*, 249, 2020, art. 116720.
- SEPANLOU, S. G., SAFIRI, S., BISIGNANO, C., IKUTA, K. S., MERAT, S., SABERIFIROOZI, M., POUSTCHI, H., TSOI, D., COLOMBARA, D. V., BHAGAVATHULA, A., NAGHAVI, M., MALEKZADEH, R.: The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterology & Hepatology*, 5 (3), 2020, 245–266.
- SILVA TAVARES, T., HOFMAN, J., LEKEŠOVÁ, A., ŽELAZKOVÁ, J., WSÓL, V.: Olaparib synergizes the anticancer activity of daunorubicin via interaction with AKR1C3. *Cancers*, 12 (11), 2020, art. 3127.
- SKVORTSOV, I. A., ZIMČÍK, P., STUZHIN, P. A., NOVÁKOVÁ, V.: pH-Sensitive subphthalocyanines and subazaphthalocyanines. *Dalton Transactions*, 49 (32), 2020, 11090–11098.
- SMUTNÝ, T., DUŠEK, J., HYRŠOVÁ, L., NEKVINDOVÁ, J., HORVÁTOVÁ, A., MIČUDA, S., GERBAL-CHALOIN, S., PÁVEK, P.: The 3'-untranslated region contributes to the pregnane X receptor (PXR) expression down-regulation by PXR ligands and up-regulation by glucocorticoids. *Acta Pharmaceutica Sinica B*, 10 (1), 2020, 136–152.
- SOUKUP, T., HLOCH, K., DOSEDĚL, M., DUINTJER TEBBENS, E. J., NEKVINDOVÁ, J., ŠEMBERA, Š., VELETA, T., PÁVEK, P., BARVÍK, I.: The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis. *Pharmacogenomics*, 21 (11), 2020, 735–749.
- STEWART, D., PAUDYAL, V., CADOGAN, C., HAZEN, A., OKUYAN, B., LUTTERS, M., HENMAN, M., FIALOVÁ, D.: A survey of the European Society of Clinical Pharmacy members' research involvement, and associated enablers and barriers. *International Journal of Clinical Pharmacy*, 42 (4), 2020, 1073–1087.
- STUDENÁ, Š., DOLEŽELOVÁ, E., CERMANOVÁ, J., PRAŠNICKÁ, A., SPRINGER, D., MIČUDA, S., CHLÁDEK, J.: Evaluation of neutrophil gelatinase-associated lipocalin as a predictor of glomerular filtration rate and amikacin clearance during early rat endotoxemia: Comparison with traditional endogenous and exogenous biomarkers. *European Journal of Drug Metabolism and Pharmacokinetics*, 45 (1), 2020, 71–80.
- ŠKODA, J., DUŠEK, J., DRASTÍK, M., ŠTEFELA, A., DOHNALOVÁ, K., CHALUPSKÝ, K., SMUTNÝ, T., MIČUDA, S., GERBAL-CHALOIN, S., PÁVEK, P.: Diazepam promotes translocation of human constitutive androstane receptor (CAR) via direct interaction with the ligand-binding domain. *Cells*, 9 (12), 2020, art. 2532.
- ŠNEJDROVÁ, E., PODZIMEK, Š., MARTIŠKA, J., HOLAS, O., DITTRICH, M.: Branched PLGA derivatives with tailored drug delivery properties. *Acta Pharmaceutica*, 70 (1), 2020, 63–75.
- ŠORF, A., SUCHÁ, S., MORELL, A., NOVOTNÁ, E., ŠTAUD, F., ZAVŘELOVÁ, A., VÍŠEK, B., WSÓL, V., ČEČKOVÁ, M.: Targeting pharmacokinetic drug resistance in acute myeloid leukemia cells with CDK4/6 inhibitors. *Cancers*, 12 (6), 2020, art. 1596.
- ŠTEFELA, A., KAŠPAR, M., DRASTÍK, M., HOLAS, O., HROCH, M., SMUTNÝ, T., ŠKODA, J., HUTNÍKOVÁ, M., PANDEY, A. V., MIČUDA, S., KUDOVÁ, E., PÁVEK, P.: 3β-Isoobeticolic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism. *Journal of Steroid Biochemistry and Molecular Biology*, 202, 2020, art. 105702.
- ŠVEC, F.: Moje srdeční záležitost: monolity (My love affair: monoliths). *Chemické listy*, 114 (11), 2020, 718–728.
- TRPĚLKOVÁ, Ž., HURYCHOVÁ, H., KUENTZ, M., VRANÍKOVÁ, B., ŠKLUBALOVÁ, Z.: Introduction of the energy to break an avalanche as a promising parameter for powder flowability prediction. *Powder Technology*, 375, 2020, 33–41.
- TRPĚLKOVÁ, Ž., HURYCHOVÁ, H., ONDREJČEK, P., SVĚRÁK, T., KUENTZ, M., ŠKLUBALOVÁ, Z.: Predicting the angle of internal friction from simple dynamic consolidation using lactose grades as model. *Journal of Pharmaceutical Innovation*, 15 (3), 2020, 380–391.
- TSACHAKI, M., STRAUSS, P., DUNKEL, A., NAVRÁTILOVÁ, H., MLADENOVIC, N., ODERMATT, A.: Impact of 17β-HSD12, the 3-ketoacyl-CoA reductase of long-chain fatty acid synthesis, on breast cancer cell proliferation and migration. *Cellular and Molecular Life Sciences*, 77 (6), 2020, 1153–1175.
- ŽUPOVÁ, L., HIRSCHMUGL, B., SUCHÁ, S., PILAŘOVÁ, V., SZÉKELY, V., BAKOS, É., NOVÁKOVÁ, L., ÖZVEGY-LACZKA, C., WADSACK, C., ČEČKOVÁ, M.: Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. *Biomedicine & Pharmacotherapy*, 129, 2020, art. 110506.

- VAGIANNIS, D., NOVOTNÁ, E., SKARKA, A., KAMMERER, S., KÜPPER, J., CHEN, S., GUO, L., ŠTAUD, F., HOFMAN, J.: Entrectinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme. *Cancers*, 12 (4), 2020, art. 813.
- VAGIANNIS, D., ZHANG, Y., NOVOTNÁ, E., MORELL GARCIA, A., HOFMAN, J.: Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. *Biochemical Pharmacology*, 178, 2020, art. 114061.
- VAJRYCHOVÁ, M., STRÁNÍK, J., PIMKOVÁ, K., BARMAN, M., KUKLA, R., ZEDNÍKOVÁ, P., BOLEHOVSKÁ, R., PLÍŠKOVÁ, L., HORNÝCHOVÁ, H., ANDRÝS, C., TAMBOR, V., LENČO, J., JACOBSSON, B., KACEROVSKÝ, M.: Comprehensive proteomic investigation of infectious and inflammatory changes in late preterm prelabour rupture of membranes. *Scientific Reports*, 10 (1), 2020, art. 17696.
- VITVEROVÁ, B., NAJMANOVÁ, I., VICEN, M., TRIPSKÁ, K., IGREJA e SÁ, I. C., HYŠPLER, R., PERICACHO, M., NACHTIGAL, P.: Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts. *PLoS One*, 15 (5), 2020, art. e0233725.
- VRANÍKOVÁ, B., NIEDERQUELL, A., DITZINGER, F., ŠKLUBALOVÁ, Z., KUENTZ, M.: Mechanistic aspects of drug loading in liquisolid systems with hydrophilic lipid-based mixtures. *International Journal of Pharmaceutics*, 578, 2020, art. 119099.
- VRANÍKOVÁ, B., NIEDERQUELL, A., ŠKLUBALOVÁ, Z., KUENTZ, M.: Relevance of the theoretical critical pore radius in mesoporous silica for fast crystallizing drugs. *International Journal of Pharmaceutics*, 591, 2020, art. 120019.
- ZAJÍČKOVÁ, M., NGUYEN, T. L., SKÁLOVÁ, L., RAISOVÁ STUHLÍKOVÁ, L., MATOUŠKOVÁ, P.: Anthelmintics in the future: Current trends in the discovery and development of new drugs against gastrointestinal nematodes. *Drug Discovery Today*, 25 (2), 2020, 430–437.
- ZAJÍČKOVÁ, Z., NOVÁKOVÁ, L., ŠVEC, F.: Monolithic poly(styrene-co-divinylbenzene) columns for supercritical fluid chromatography-mass spectrometry analysis of polypeptide. *Analytical Chemistry*, 92 (17), 2020, 11525–11529.
- ZÁRYBNICKÝ, T., MATOUŠKOVÁ, P., SKÁLOVÁ, L., BOUŠOVÁ, I.: The hepatotoxicity of alantolactone and germacrone: Their influence on cholesterol and lipid metabolism in differentiated HepaRG Cells. *Nutrients*, 12 (6), 2020, art. 1720.
- ZUBROVÁ, J., POKLADNÍKOVÁ, J., DRAESSLER, J.: The use of dietary supplements by patients in the pre-operative period in the Czech Republic. *International Journal of Clinical Pharmacy*, 42 (5), 2020, 1304–1310.

ARTICLES IN JOURNALS WITHOUT IMPACT FACTOR AND PROCEEDINGS

- BRABCOVÁ, I., HAJDUCHOVÁ, H., TÓTHOVÁ, V., BÁRTLOVÁ, S., DOSEDĚL, M., MALÝ, J., KUBĚNA, A., VLČEK, J., BOTÍKOVÁ, A.: The efficiency of the patient fall prevention programme in selected medical institutions. *Kontakt*, 22 (2), 2020, 79–84.
- BRABCOVÁ, I., HAJDUCHOVÁ, H., TÓTHOVÁ, V., BÁRTLOVÁ, S., HOLÝ, J., DOSEDĚL, M., MALÝ, J., VLČEK, J., PAPP, K.: Vybrané rizikové faktory pádů pacientů v nemocnici: nízký BMI, hypotenze, zvýšená tepová frekvence, hypoglykemie, anemie. [Selected risk factors of patients' falls in hospitals: low BMI, hypotension, increased heart rate, hypoglycaemia, anaemia.] *Praktický lékař*, 100 (1), 2020, 23–28.
- DOMECKÝ, P., HAUSCHKE, L., ČERNÝ, V., MALÝ, J.: Audit antibiotické profylaxe v chirurgii (Audit of antibiotic prophylaxis in surgery). *Anesteziologie a intenzivní medicína*, 31 (4), 2020, 152–156.
- FIALOVÁ, D., HALAČOVÁ, M., BRKIČ, J., GREŠÁKOVÁ, S., KUMMER, I., TOPINKOVÁ, E., JURAŠKOVÁ, B.: Klinická farmacie v geriatrici a 20 let klinických a výzkumných zkušeností s hodnocením racionality geriatrické preskripce v České republice a v evropských zemích (Clinical pharmacy in geriatrics and 20 years of clinical and scientific experience with the evaluation of rationality of geriatric drug prescribing in the Czech republic and European countries). *Klinická farmakologie a farmacie*, 34 (3), 2020, 122–129.
- FIALOVÁ, D., PŘÍHODOVÁ, V., BRKIČ, J., KUMMER, I., GREŠÁKOVÁ, S., LUKAČIŠINOVÁ, A., TOPINKOVÁ, E.: Hodnocení geriatrických interakcí lék-nemoc u seniorů v dlouhodobé ošetrovatelské péči v České republice (Evaluation of geriatric drug-disease interactions in seniors in long-term care in the Czech Republic). *Klinická farmakologie a farmacie*, 34 (3), 2020, 99–107.
- HERMAN, D., DLABKOVÁ, A., VÁNOVÁ, N., PRCHAL, L., VAJRYCHOVÁ, M., DOLEŽAL, R., BZONEK, P., JUN, D.: OPCW biomedical proficiency test v laboratoři analytické chemie Katedry toxikologie a vojenské

- farmacie (OPCW biomedical proficiency test in the laboratory of analytical chemistry at the Department of Toxicology and Military Pharmacy). *Military Medical Science Letters – Vojenské zdravotnické listy*, 89 (3), 2020, 126–141.
- KOLÁŘ, J.: Mezinárodní a národní kampaně v oblasti zdraví II (International and national health campaigns II). *Farmaceutický obzor*, 89 (7–9), 2020, 173–179.
- KOLÁŘ, J.: Mezinárodní kampaně v oblasti zdraví (International health campaigns). *Farmaceutický obzor*, 89 (4–5), 2020, 93–97.
- KOLÁŘ, J., GREGA, D., ŠUTOROVÁ, M., AMBRUS, T.: Vývoj vybraných požiadaviek na zriaďovanie verejných lekární na Slovensku (Development of selected requirements for the establishment of community pharmacies in Slovakia). *Praktické lékárnictvo*, 10 (3), 2020, 87–89.
- KOLDA, J.: Zdravotní péče u pražských benedikteinek v 17. a 18. století (Health care at the St. George Monastery at the Prague Castle in the 17th a 18th century). *Časopis lékařů českých*, 159 (5), 2020, 206–210.
- KOVÁČIK, A., PARASKEVOPOULOS, G., VRANÍKOVÁ, B.: Přípravky pro péči o zuby a dutinu ústní (Preparations for care of teeth and oral cavity). *Praktické lékárenství*, 16 (4), 2020, 243–246.
- KOVÁČIK, A., VRANÍKOVÁ, B.: Transdermální léčivé přípravky dostupné v České republice a základní principy jejich aplikace (Transdermal medical preparations available in Czech Republic and basic principles of their application). *Praktické lékárenství*, 16 (2), 2020, 97–99.
- KUKLA, R., MAZUROVÁ, J., KŘOVÁKOVÁ, I., SLEHOVÁ, E., SLEHA, R., ROZKOT, M., OPLETAL, L.: *In vitro* antimicrobial activity of natural substances convenient for use in animal breeding instead of antibiotics. *Military Medical Science Letters – Vojenské zdravotnické listy*, 89 (1), 2020, 2–13.
- MACHO, O., DEMKOVÁ, K., GABRIŠOVÁ, L., ČIERNY, M., MUŽÍKOVÁ, J., GALBAVÁ, P., NIŽNANSKÁ, Ž., BLAŠKO, J., PECIAR, P., FEKETE, R., PECIAR, M.: Analysis of static angle of repose with respect to powder material properties. *Acta Polytechnica*, 60 (1), 2020, 73–80.
- MALÝ, J.: Lékové problémy v teorii a příkladech v podmínkách České republiky (Drug-related problems in theory and practice in the Czech Republic). *Klinická farmakologie a farmacie*, 34 (3), 2020, 116–121.
- MALÝ, J., HORKÝ, P., DOMECKÝ, P., STRÍBRNÁ, L.: XXII. symposium klinické farmacie René Macha (XXII. Symposium on Clinical Pharmacy René Mach). Hradec Králové, Farmaceutická fakulta UK, 2020, 85 pp. ISBN 978-80-906644-6-3.
- ROZSÍVALOVÁ, P., ŠTICHHAUER, R., HOLICKÁ, L., ROZSÍVAL, P., KOPECKÁ, M., SKÁLOVÁ, S., MALÝ, J.: Metamizol v léčbě bolesti u pediatrické populace (Metamizol in paediatric pain management). *Pediatric pro praxi*, 21 (5), 2020, 323–329.
- SHARMA, R., CHHABRA, M., VIDYASAGAR, K., RASHID, M., FIALOVÁ, D., BHAGAVATHULA, A.: Potentially inappropriate medication use in older hospitalized patients with type 2 diabetes: A cross-sectional study. *Pharmacy*, 8 (4), 2020, art. 219.
- TESAŘ, O., MĚRKOVÁ, V., DOSEDĚL, M., MALÝ, J.: Potrava jako důležitá součást maximalizace účinku a minimalizace rizik farmakoterapie – absorpce a gastrointestinální tolerance (Food as an important part of maximizing the effect and minimizing the risks of pharmacotherapy – absorption and gastrointestinal tolerance). *Klinická farmakologie a farmacie*, 34 (3), 2020, 108–115.
- TÓTHOVÁ, V., BÁRTLOVÁ, S., BRABCOVÁ, I., HAJDUCHOVÁ, H., DOSEDĚL, M., MALÝ, J., VLČEK, J.: Knowledge of nurses in relation to the treatment of medicinal products. *Kontakt*, 22 (4), 2020, 214–221.
- VRANÍKOVÁ, B., KOVÁČIK, A., SVAČINOVÁ, P.: Zdravotnické prostředky pro stomické pacienty I.: 1D systémy, 2D systémy a adhezivní technologie (Medical devices for ostomy patients I.: One-piece systems, two-piece systems and adhesive technology). *Praktické lékárenství*, 16 (3), 2020, 150–153.
- VRANÍKOVÁ, B., KOVÁČIK, A., SVAČINOVÁ, P.: Zdravotnické prostředky pro stomické pacienty II.: Doplnkové prostředky v péči o stomie (Medical devices for ostomy patients II.: Supplementary devices in ostomy care). *Praktické lékárenství*, 16 (4), 2020, 221–225.

MONOGRAPHS AND TEXTBOOKS

- ARNDT, T.: Lékárny s Davidovou hvězdou v čase šoa (Pharmacies with the Star of David during the Shoah). Prague, Academia, 2020, 464 pp. ISBN 978-80-200-3049-8.
- KORÁBEČNÝ, J., SOUKUP, O., VALIŠ, M., BABKOVÁ, K., BENEK, O., DLABKOVÁ, A., DOLEŽAL, R., DRTINOVÁ, L., GÓRECKI, L., HEPNAROVÁ, V., HONEGR, J., HROCH, L., CHA-

- LUPOVÁ, K., KUBIŠOVÁ, J., KUČA, K., LINKOVÁ, H., MAREK, J., MAREŠOVÁ, P., MASOPUST, J., MEZEIOVÁ, E., MISÍK, J., MOHELSKÁ, H., MUSÍLEK, K., NEPOVÍMOVÁ, E., PATOČKA, J., ZEMEK, F., ŽDÁROVÁ KARASOVÁ, J.: Alzheimerova nemoc (Alzheimer's disease). Prague, Maxdorf, 2020, 198 pp. ISBN 978-80-7345-643-6.
- KOŠTÁLOVÁ, B., DUSILOVÁ SULKOVÁ, S., GUŇKA, I., MALÁ-LÁDOVÁ, K., MALÝ, J., MATYSKOVÁ KUBIŠOVÁ, M., ŠAFRÁNEK, R.: Světem léků po transplantaci (The world of drugs after transplantation). Prague, Tigris, 2020, 103 pp. ISBN 978-80-87323-16-8.
- MEURANT, G., DUINTJER TEBBENS, E. J.: Krylov methods for nonsymmetric linear systems: From theory to computations. Cham, Springer, 2020, 686 pp. ISBN 978-3-030-55250-3.
- ŠKLUBALOVÁ, Z., ZBYTOVSKÁ, J., MUŽÍKOVÁ, J., HOLAS, O., KOVÁČIK, A., PARASKEVOPOULOS, G., SVAČINOVÁ, P., ŠNEJDROVÁ, E., VRANÍKOVÁ, B.: Základní praktická cvičení z farmaceutické technologie (Basic practical exercises from pharmaceutical technology). Prague, Karolinum Press, 2020. 136 pp. ISBN 978-80-246-4561-2.
- ŠKLUBALOVÁ, Z., ZBYTOVSKÁ, J., MUŽÍKOVÁ, J., HOLAS, O., KOVÁČIK, A., PARASKEVOPOULOS, G., SVAČINOVÁ, P., ŠNEJDROVÁ, E., VRANÍKOVÁ, B.: Základní praktická cvičení z farmaceutické technologie (Basic practical exercises from pharmaceutical technology). Prague, Karolinum Press, 2020. 136 pp. ISBN 978-80-246-4582-7 (e-book, PDF).
- VÁGNEROVÁ, T., TOPINKOVÁ, E., MICHÁLKOVÁ, H., FIALOVÁ, D., KUŠNIARIKOVÁ, I., MÁDLOVÁ, P.: Výživa v geriatрии a gerontologii (Nutrition in geriatrics and gerontology). Prague, Karolinum Press, 2020, 198 pp. ISBN 978-80-246-4620-6.

DEGREES

Lectures for the Professorship Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2020

doc. Ing. LUCIE CAHLÍKOVÁ, Ph.D.: Associate Professor, Department of Pharmaceutical Botany, Faculty of Pharmacy, Hradec Králové

Discipline: Pharmacognosy, NAU-518/2018-9

Inauguration: 1. 3. 2019

Continuation: 12. 3. 2019

Title of lecture: Alkaloidy čeledi Amaryllidaceae a jejich deriváty jako potenciální léčiva (Alkaloids of Amaryllidaceae family and their derivatives as potential drugs), 11.06.2019

Appointment: 17. 6. 2020

doc. PharmDr. KAREL ŠMEJKAL, Ph.D.: Associate Professor, Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno

Discipline: Pharmacognosy, NAU-518/2018-9

Inauguration: 10. 9. 2019

Continuation: 8. 10. 2019

Title of lecture: Pokrok a trendy ve využití přírodních látek jako potenciálních léčiv – prenylované fenolické sloučeniny (Progress and trends in the use of natural substances as potential drugs), 10. 12. 2019

Appointment: 15. 12. 2020

doc. PharmDr. FRANTIŠEK TREJTAR, CSc.: Associate Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hradec Králové

Discipline: Human and veterinary pharmacology, MŠMT 24 295/2007-30/1

Inauguration: 8. 11. 2019

Continuation: 10. 12. 2019

Title of lecture: Mechanismy ledvinné eliminace léčiv a možnosti jejich preklinické predikce (Mechanisms of renal elimination of drugs and the possibility of their preclinical prediction), 10. 3. 2020

Appointment: 15. 12. 2020

doc. PharmDr. PŘEMYSL MLADĚNKA, Ph.D.: Associate Professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hradec Králové

Discipline: Human and veterinary pharmacology, MŠMT 24 295/2007-30/1

Inauguration: 15. 1. 2020

Continuation: 10. 3. 2020

Title of lecture: Flavonoidy a kardiovaskulární systém: od parentních látek k metabolitům (Flavonoids and cardiovascular system: from parent to metabolites), 9. 6. 2020

Appointment: 15. 12. 2020

Habilitation Theses and Lectures for Associated Professor Appointments, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2020

Mgr. et Mgr. RAFAEL DOLEŽAL, Ph.D.: Senior Lecturer, Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové and Research and Development Worker, Biomedical Research Centre, University Hospital Hradec Králové, Hradec Králové

Discipline: Pharmaceutical Chemistry, MŠMT 24 295/2007-30/1

Inauguration: 11. 6. 2019

Continuation: 11. 6. 2019

Habilitation Thesis: Počítačové metody návrhu a analýzy vybraných bioaktivních látek určených pro léčbu (Computer methods of design and analysis of selected bioactive substances intended for treatment), defended 8. 10. 2019

Title of Lecture: Výzkum a vývoj léčiv neurodegenerativních onemocnění s využitím počítačových technologií (Research and development of drugs for neurodegenerative diseases using computer technologies), 8. 10. 2019

Appointment: 1. 1. 2020

PharmDr. JITKA MUŽÍKOVÁ, Ph.D.: Senior Lecturer, Department of Pharmaceutical Technology, Faculty of Pharmacy, Hradec Králové

Discipline: Pharmaceutical Technology, NAU-518/2018-9

Inauguration: 20. 8. 2019

Continuation: 8. 10. 2019

Habilitation Thesis: Suchá pojiva v přímo lisovaných tabletách (Dry binders in directly pressed tablets), defended 10. 12. 2019

Title of Lecture: Přímé lisování tablet s využitím koprocetovaných pomocných látek (Direct pressing of tablets using co-processed excipients), 10. 12. 2019

Appointment: 1. 3. 2020

PharmDr. TOMÁŠ SIATKA, Ph.D.: Senior Lecturer, Department of Pharmacognosy, Faculty of Pharmacy, Hradec Králové

Discipline: Pharmacognosy, NAU-518/2018-9

Inauguration: 6. 9. 2019

Continuation: 8. 10. 2019

Habilitation Thesis: Přírodní látky – potenciální zdroje a biologická aktivita (Natural substances – potential resources and biological activity), defended 10. 12. 2019

Title of Lecture: Látky přírodního původu v léčbě nádorových onemocnění (Substances of natural origin in the treatment of cancer), 10. 12. 2019

Appointment: 1. 3. 2020

Doctoral Dissertation Theses to obtain the Ph.D. Degree, Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2020

MSc. BOUZ, GHADA BASEM: Derivatives of pyrazinecarboxylic acid as potential antimycobacterial active drugs, 5. 3. 2020, Ph.D.

- MSc. CATAPANO, MARIA CARMEN: Screening of novel chelators of microbiogenic metals, 19. 2. 2020, Ph.D.
- Mgr. DEMUTH, JIŘÍ: Studium azaftalocyaninů jako zhášeců fluorescence v oligodeoxynukleotidových sondách (Study of azaphthalocyanines as fluorescence quenchers in oligodeoxynucleotide probes), 2. 7. 2020, Ph.D.
- Mgr. FIKAROVÁ, KATEŘINA: Development of novel approaches to automated sample preparation for pharmaceutical and environmental analysis, 22. 9. 2020, Ph.D.
- Mgr. HÁKOVÁ, MARTINA: Využití nanovlákných sorbentů pro on-line extrakce v kapalinové chromatografii (Application of nanofibrous sorbents for on-line extraction in liquid chromatography), 14. 5. 2020, Ph.D.
- Mgr. JIRÁSKOVÁ, LUCIE: Interakce membránových transportérů s léčivými v placentě a duktálním adenokarcinomu pankreatu (Interactions of membrane transporters with drugs in the placenta and pancreatic ductal adenocarcinoma), 30. 6. 2020, Ph.D.
- Mgr. KARBANOVÁ, SÁRA: Studium interakcí antivirotik s vybranými placentárními transportéry (Study of interactions of antiviral drugs with selected placental transporters), 30. 6. 2020, Ph.D.
- Mgr. KOHLOVÁ, MICHAELA: Development of new types of biocompatible hemodialysis membranes for separation of biomolecules, 3. 9. 2020, Ph.D.
- Mgr. KOLLÁR, JAN: Syntéza anionických derivátů ftalocyaninů jako potenciálních fotodynamicky aktivních látek (Synthesis of anionic phthalocyanines as potential photodynamic active photosensitizers), 17. 9. 2020, Ph.D.
- Mgr. KUČEROVÁ, KATEŘINA: Využití technik HPLC a UHPLC-MS/MS pro klinický výzkum (Usage of HPLC and UHPLC-MS/MS techniques for clinical research), 3. 9. 2020, Ph.D.
- Mgr. MARTINEC, ONDŘEJ: Interakce antiretrovirálních léčiv s membránovými transportéry (Interactions of antiretroviral drugs with membrane transporters), 10. 12. 2020, Ph.D.
- Mgr. MARTIŠKA, JURAJ: Medikované polymerní systémy založené na větvených derivátech PLGA (Medicated polymer systems based on branched PLGA derivatives), 15. 9. 2020, Ph.D.
- Mgr. MATOUŠ, PETR: Cyklizační reakce 1,5-enynů katalyzované komplexy zlata (Gold-catalyzed cyclizations of 1,5-enynes), 23. 9. 2020, Ph.D.
- Mgr. PLACHKÁ, KATEŘINA: Vývoj nových metod ultra-vysokoúčinné superkritické fluidní chromatografie pro farmaceutické aplikace (The development of new methods of ultra-high performance supercritical fluid chromatography for pharmaceutical applications), 14. 5. 2020, Ph.D.
- Mgr. ŤUPOVÁ, LENKA: Interakce vybraných antiretrovirálních léčiv a metylmercuru s membránovými transportéry placenty (Interactions of selected antiretroviral drugs and methylmercury with placental membrane transporters), 29. 9. 2020, Ph.D.
- Mgr. VICEN, MATEJ: Membránový endoglin a jeho úloha v patogenéze endotelové dysfunkce v podmínkách *in vitro* (Membrane endoglin and its role in pathogenesis of endothelial dysfunction *in vitro*), 29. 9. 2020, Ph.D.
- Mgr. ZÁRYBNICKÝ, TOMÁŠ: Potential toxicity of terpenes and their effects in liver cells, 18. 6. 2020, Ph.D.
- PharmDr. ZUBROVÁ, JULIE: Rizika spojená s užíváním doplňků stravy (Risks associated with the dietary supplements use), 30. 9. 2020, Ph.D.

Rigorous Theses to obtain the degree PharmDr. (Doctor of Pharmacy, graduates of the study programme Pharmacy) or RNDr. (Doctor of Natural Sciences, graduates of study programme Bioanalytical Laboratory Diagnostics in Medicine), Faculty of Pharmacy in Hradec Králové (CZ), Charles University (CZ), 2020

- Mgr. BÁRTA, MICHAL: Příprava polymerních farmaceutických nanočástic: optimalizace procesu (Polymeric pharmaceutical nanoparticles preparation: a process optimization), 1. 10. 2020, PharmDr.
- Mgr. BAVOROVÁ, HANA, Ph.D.: Decelularizace a recelularizace tkání (Decellularization and recellularization of tissues), 17. 2. 2020, RNDr.
- Mgr. BENČOVÁ, SIMONA: Transcriptomic analysis of cutaneous inflammatory biomarkers in a mouse model of small fiber neuropathy, 24. 2. 2020, PharmDr.
- Mgr. BERKA, PAVEL, Ph.D.: Biofarmaceutické aspekty makromolekulárních nosičů pro systémovou sublingvální aplikaci léčiv (Biopharmaceutical aspects of macromolecular carriers for systemic sublingual drug delivery), 25. 6. 2020, PharmDr.
- Mgr. BIRKNEROVÁ, NATÁLIA: DNA methylation changes in oropharyngeal carcinoma, 19. 10. 2020, PharmDr.

- Mgr. BOSAKOVÁ, NIKOLA: Vplyv pulznej terapie glukokortikoidmi na EKG (The influence of pulse glucocorticoid therapy on ECG), 29. 9. 2020, PharmDr.
- Mgr. BOŽÍKOVÁ, MARTINA: Vplyv albendazolu na expresiu vybraných enzýmov *Haemonchus contortus* (Effect of albendazol on the expression of selected enzymes in *Haemonchus contortus*), 17. 2. 2020, PharmDr.
- Mgr. ČAPKOVÁ MAXOVÁ, ELIŠKA: Vývoj a validace UHPLC-MS/MS metody pro stanovení maraviroku v placentárních perfúziích (Development and validation of UHPLC-MS/MS method for determination of maraviroc in placental perfusion), 16. 7. 2020, PharmDr.
- Mgr. DANĚK, ALOIS: Využití HPLC v chirálních separacích IV (The use of HPLC in the field of chiral separations IV), 16. 7. 2020, PharmDr.
- Mgr. DAŇKOVÁ, VĚRA, Ph.D.: Identifikace nových faktorů virulence intracelulárního patogena *Francisella tularensis* (Identification of new virulence factors in intracellular pathogen *Francisella tularensis*), 21. 5. 2020, RNDr.
- Mgr. DEINGRUBEROVÁ, KRISTÝNA: Modulační účinek *cis*-nerolidolu, *trans*-nerolidolu a farnesolu na vybrané enzymy 1. fáze biotransformace v lidských jaterních řezech (Modulatory effect of *cis*-nerolidol, *trans*-nerolidol and farnesol on selected phase 1 drug-metabolizing enzymes in human liver slices), 17. 2. 2020, RNDr.
- Mgr. DEMUTH, JIŘÍ, Ph.D.: Studium azafthalocyaninů jako zhášeačů fluorescence v oligodeoxynukleotidových sondách (Study of azaphthalocyanines as fluorescence quenchers in oligodeoxynucleotide probes), 3. 8. 2020, PharmDr.
- Mgr. DIVIŠ, DANIEL: The role of miR-150 in the physiopathology of oligoarticular juvenile idiopathic arthritis, 21. 2. 2020, PharmDr.
- Mgr. DLOUHÁ, MICHAELA: Analýza poskytování konzultací zaměřených na lékové problémy lékárnami v České republice (Analysis of pharmacy counselling focused on drug related problems in the Czech Republic), 18. 2. 2020, PharmDr.
- Mgr. DOHNÁLKOVÁ, ESTER: Hepatocyte ROCK1 kinase activity incites liver inflammation in murine non-alcoholic fatty liver disease, 17. 2. 2020, PharmDr.
- Mgr. DOHNALOVÁ, KLÁRA: Studium inhibičního účinku antagonisty SPA70 na hPXR (Inhibitory effect of SPA70 on hPXR activation), 24. 2. 2020, PharmDr.
- Mgr. DOLINSKÁ, DAGMAR: Pokročilé metody testování antimikrobní aktivity (Advanced methods of antimicrobial activity screening), 24. 2. 2020, PharmDr.
- Mgr. DUCHOŇOVÁ, VERONIKA: Analýza lékových problémů v zařízeních pro seniory I (Analysis of the drug related problems in facilities for seniors I), 8. 9. 2020, PharmDr.
- Mgr. ĐURINOVÁ, ANNA: *In vitro* testovanie cytotoxicity a hematotoxicity vyvíjaných liečiv (*In vitro* testing of cytotoxicity and hematotoxicity of drugs in development), 29. 9. 2020, PharmDr.
- Mgr. DVOŘÁČKOVÁ, ELIŠKA, Ph.D.: Analýza lékových problémů na oddělení z pohledu farmaceuta (Analysis of drug problems at hospital department from the pharmacist's point of view), 18. 2. 2020, PharmDr.
- Mgr. DVOŘÁKOVÁ, PAVLÍNA: Průnik nanočástic sublingvální membránou 3 (Permeation of nanoparticles through sublingual membrane 3), 12. 6. 2020, PharmDr.
- Mgr. ELSTNEROVÁ, MARIE: Silice řečiku lentišku: *in vitro* stanovení cytotoxicity a protizánětlivé aktivity (*Pistacia lentiscus* essential oil: *in vitro* testing of cytotoxicity and anti-inflammatory activity), 9. 10. 2020, PharmDr.
- Mgr. FIKAROVÁ, KATEŘINA, Ph.D.: Development of novel approaches to automated sample preparation for pharmaceutical and environmental analysis, 18. 12. 2020, PharmDr.
- Mgr. FUFALOVÁ, VERONIKA: Postoje k liečbe a znalosti užívateľiek hormonálnej antikoncepcie (Attitudes towards treatment and knowledge of hormonal contraceptive users), 18. 2. 2020, PharmDr.
- Mgr. GARBE GDOVIN, DANIELA: Prospektivní průzkum respiračních infekcí u dětí předškolního věku a postojů rodičů k prevenci a samoléčbě (Prospective survey of respiratory infections in pre-school children and parents' attitude to prevention and self-treatment), 18. 2. 2020, PharmDr.
- Mgr. GIEROVÁ, LUCIE: Změny klidového energetického výdeje v průběhu gravidity (Changes in resting energy expenditure during pregnancy), 30. 06. 2020, PharmDr.
- Mgr. HÁKOVÁ, MARTINA, Ph.D.: Využití nanovláknenných sorbentů pro on-line extrakce v kapalinové chromatografii (Application of nanofibrous sorbents for on-line extraction in liquid chromatography), 16. 7. 2020, PharmDr.

- Mgr. HAVELKOVÁ, MICHAELA: Studium cytotoxicity vývojových bronchodilatancií *in vitro* (Study of cytotoxicity of newly prepared bronchodilators *in vitro*), 29. 9. 2020, PharmDr.
- Mgr. HAVRLANTOVÁ, ŠÁRKA: Optimization of separation conditions for HPCC of paclitaxel, 22. 1. 2020, PharmDr.
- Mgr. HEJKLÍKOVÁ, EVA: *In vitro* citlivost potenciálně patogenních hub izolovaných ve Fakultní nemocnici Hradec Králové k antimykotikům (*In vitro* susceptibility of potentially pathogenic fungi isolated in the University Hospital Hradec Králové to antifungal drugs), 29. 9. 2020, PharmDr.
- Mgr. HODINOVÁ, VERONIKA: Studium mechanismu vasodilatačního účinku 3,4-dihydroxyfenylacetové kyseliny a 4-methylcatecholu *ex vivo* (The *ex vivo* study of mechanism of vasodilatation effect of 3,4-dihydroxyphenylacetic acid and 4-methylcatechol), 24. 9. 2020, PharmDr.
- Mgr. HOLUBOVÁ, JANA: Metabolismus flubendazole v lidských jaterních subcelulárních frakcích (Metabolism of flubendazole in human liver subcellular fractions), 17. 2. 2020, PharmDr.
- Mgr. HORNOVÁ, ANETA: Studium transportu proteinových molekul přes buněčné membrány (Study of transport of protein molecules across cell membranes), 24. 9. 2020, PharmDr.
- Mgr. HRUBEŠOVÁ, IVANA: Analýza spotřeb antiosteoporotických léčiv (Analysis of antiosteoporotics consumption), 10. 6. 2020, PharmDr.
- Mgr. HUDÁKOVÁ, KRISTÍNA: *In vitro* evaluation of novel Toll-like receptor ligands I., 21. 2. 2020, PharmDr.
- Mgr. CHOJANOVÁ, ZUZANA: Study of the variations in the expression of different adhesion and cytoskeletal proteins of podocytes (E-cadherin, podocin, vimentin) due to bisphenol A, 21. 2. 2020, PharmDr.
- Mgr. CHYTKOVÁ, MARTINA: Hodnocení koprocesovaných pomocných látek s obsahem mannitolu nebo maltodextrinů (Evaluation of co-processed excipients containing mannitol or maltodextrins), 30. 9. 2020, PharmDr.
- Mgr. JAHODOVÁ, MICHAELA: *In vitro* a *ex vivo* studium lékových interakcí antiretrovirálních látek na střevních ATP-vázajících lékových transportérech (*In vitro* and *ex vivo* study of drug-drug interactions of antiretrovirals on intestinal ATP-binding drug transporters), 29. 09. 2020, PharmDr.
- Mgr. JANČÁLKOVÁ, PAVLA: Studium deplece cholesterolu v lidské kožní bariéře (Study of cholesterol depletion in human skin barrier), 18. 12. 2020, PharmDr.
- Mgr. JANOUTOVÁ, HANA: Studium sypného a konsolidačního chování farmaceutických volně sypných pomocných látek (Study of flow and consolidation behaviour of pharmaceutical free-flowable excipients), 1. 10. 2020, PharmDr.
- Mgr. JAVORSKÁ, LENKA, Ph.D.: Vývoj bioanalytických metod pro stanovení diagnostických markerů a léčiv s využitím chromatografických technik (Development of bioanalytical methods for the determination of diagnostic markers and drugs using chromatographic techniques), 9. 10. 2020, RNDr.
- Mgr. JIRÁSKOVÁ, LUCIE, Ph.D.: Interakce membránových transportérů s léčivem v placentě a dukálním adenokarcinomu pankreatu (Interactions of membrane transporters with drugs in the placenta and pancreatic ductal adenocarcinoma), 4. 9. 2020, RNDr.
- Mgr. JIROUŠKOVÁ, BARBORA: Vliv solubilního endoglinu na metabolismus žlučových kyselin v játrech u transgenických myší s vysokotukovou dietou (Effect of soluble endoglin on bile acids metabolism in the liver of high-fat diet-fed transgenic mice), 9. 10. 2020, PharmDr.
- Mgr. KARBANOVÁ, SÁRA, Ph.D.: Studium interakcí antivirotik s vybranými placentárními transportéry (Study of interactions of antiviral drugs with selected placental transporters), 26. 8. 2020, PharmDr.
- Mgr. KATIOVÁ, DIANA: Štúdium mechanismu vazorelaxačního účinku biochaninu A *ex vivo* na izolované aorte potkana (Mechanism of the vasorelaxant effect of biochanin A studied *ex vivo* on isolated rat aorta), 24. 9. 2020, PharmDr.
- Mgr. KOLLÁR, JAN, Ph.D.: Syntéza anionických derivátů ftalocyaninů jako potenciálních fotodynamicky aktivních látek (Synthesis of anionic phthalocyanines as potential photodynamic active photosensitizers), 16. 11. 2020, PharmDr.
- Mgr. KOMŮRKOVÁ, LENKA: Stacionární fáze na bázi iontových kapalin pro separaci nečistot ibuprofenu (Stationary phase based on ionic liquids for separation of ibuprofen impurities), 18. 12. 2020, PharmDr.
- Mgr. KORVASOVÁ, HANA: Energetický výdej a užití nutričních substrátů u kriticky nemocných pacientů (Energy expenditure and nutritional substrate utilization in critically ill patients), 30. 6. 2020, PharmDr.
- Mgr. KOŠKOVÁ, STANISLAVA: Hodnocení vybraných obsahových látek v ovoci metodou HPLC-DAD-CAD (Evaluation of selected substances in fruit by HPLC-DAD-CAD method), 10. 6. 2020, RNDr.

- Mgr. KREJČOVÁ, LADA: Alkaloidy *Nerine bowdenii* (Amaryllidaceae) a jejich biologická aktivita (Alkaloids from *Nerine bowdenii* (Amaryllidaceae) and their biological activity), 22. 12. 2020, PharmDr.
- Mgr. KROVOVÁ, TEREZA: Automatizace metody extrakce pevnou fází pro stanovení flavonoidů s využitím průtokového systému (Automation of solid phase extraction method for determination of flavonoids using a flow system), 10. 6. 2020, RNDr.
- Mgr. KRUBER, PETRA: Průběžné výsledky kontroly parazitostatu kozy bezoárové chované v oborním chovu Vřísek (Continuous results in control of bezoar goat parasitostatus bred in game enclosure Vřísek), 24. 9. 2020, PharmDr.
- Mgr. KUŘÍKOVÁ, BARBORA: Stanovení spektra mastných kyselin u pacientů podstupujících léčbu taxany (Determination of the fatty acids spectrum in patients undergoing treatment with taxanes), 17. 2. 2020, RNDr.
- Mgr. MACÁKOVÁ, ELIŠKA: Formulace lyofilizovaných tablet pro orální aplikaci peptidů (Formulation of freeze dried tablets for oromucosal administration of peptides), 30. 9. 2020, PharmDr.
- Mgr. MACHOVÁ, ZDENKA: Optimalizace a validace UHPSFC-UV metod pro kontrolu kvality agomelatinu a atorvastatinu v léčivé substanci a v tabletách (Optimization and validation of UHPSFC-UV methods for quality control of agomelatin and atorvastatin in drug substance and in tablets), 22. 1. 2020, PharmDr.
- Mgr. MATĚJKOVÁ, BARBORA: Sledování exprese adhezních molekul v aortě u myšičího modelu nealkoholické steatohepatitidy (Evaluation of cell adhesion molecules expression in mice aorta in animal model of non-alcoholic steatohepatitis), 17. 2. 2020, PharmDr.
- Mgr. MATOUŠ, PETR, Ph.D.: Cyklizační reakce 1,5-enynů katalyzované komplexy zlata (Gold-catalyzed cyclizations of 1,5-enynes), 18. 12. 2020, PharmDr.
- Mgr. MATOUŠOVÁ, KATEŘINA, Ph.D.: Využití technik HPLC a UHPLC-MS/MS pro klinický výzkum (Usage of HPLC and UHPLC-MS/MS techniques for clinical research), 18. 12. 2020, PharmDr.
- Mgr. MELICHAROVÁ, RŮŽENA: Detekce kovalentních komplexů proteinů s DNA s použitím fluorescenční mikroskopie (The detection of protein covalent complexes with DNA using fluorescent microscopy), 9. 10. 2020, PharmDr.
- Mgr. MIKLASOVÁ, MONIKA: Racionální farmakoterapie osteoartrózy ve stáří (Rational pharmacotherapy of osteoarthritis in older age), 29. 9. 2020, PharmDr.
- Mgr. MILAN, JAROSLAV: Vliv inhibice midostaurinu, vistusertibu a talazoparibu na aktivitu vybraných reduktas z nadrodiny AKR a SDR (The influence of midostaurin, vistusertib and talazoparib inhibition on the activity of selected reductases from AKR and SDR superfamilies), 30. 6. 2020, RNDr.
- Mgr. MIŠKOVČÍKOVÁ, ZUZANA: Stanovenie orgánovej toxicity BRAF inhibitorov *in vitro* (Determination of organ toxicity of BRAF inhibitors *in vitro*), 24. 9. 2020, PharmDr.
- Mgr. MLČOCHOVÁ, ALICE: Hodnocení vlivu roscovitinu a jeho derivátů na expresi lékových transportérů *in vitro* (Study of the effect of roscovitine and its derivatives on the expression of drugs transporters *in vitro*), 29. 9. 2020, PharmDr.
- Mgr. NEKOVÁ, LUCIE: Konstitutivní exprese UDP-glukosyltransferas vlasovky slezové (Constitutive expression of UDP-glucosyltransferases from *Haemonchus contortus*), 17. 2. 2020, PharmDr.
- Mgr. NOSKOVÁ, ANDREA: Bioimpedanční spektroskopická analýza kompozice těla v době gravidity (Bioimpedance spectroscopy analysis of body composition during pregnancy), 30. 6. 2020, PharmDr.
- Mgr. NOVÁKOVÁ, JANA: Zinek-chelatační aktivita vybraných nových chelátorů ze skupiny 4-acylpyrazol-5-onů (Zinc-chelating activity of selected novel chelators from 4-acylpyrazol-5-one group), 29. 9. 2020, PharmDr.
- Mgr. NOVOTNÁ, MONIKA: Stanovení hladin mastných kyselin v tkáních zdravých, náhle zemřelých a polymorbidních pacientů (The determination of fatty acid levels in the tissues of healthy, suddenly deceased persons and polymorbid patients), 30. 6. 2020, PharmDr.
- Mgr. NOWAK, TEREZA: Vliv inhibitorů cholinesteráz na monoaminergní systém a energetický metabolismus (Effect of cholinesterase inhibitors on monoaminergic system and energetic metabolism), 21. 2. 2020, PharmDr.
- Mgr. ORNSTOVÁ, EVA: Parametry hodnocení léčiv k terapii vzácných onemocnění (Parameters of drug assessment in the therapy of rare diseases), 29. 9. 2020, PharmDr.
- Mgr. PLACHKÁ, KATEŘINA, Ph.D.: Vývoj nových metod ultra-vysokoučinné superkritické fluidní chromatografie pro farmaceutické aplikace (The development of new methods of ultra-high performance supercritical fluid chromatography for pharmaceutical applications), 16. 7. 2020, PharmDr.
- Mgr. POLLÁKOVÁ, LENKA: Analýza nekardiálních nežiaducich javov pulznej terapie kortikoidmi (Analysis of non-cardiac adverse event of glucocorticoid pulse therapy), 29. 9. 2020, PharmDr.

- Mgr. POUŠKOVÁ, JITKA: Možnosti kapilární elektroforézy pro separaci boswellových kyselin (The capabilities of capillary electrophoresis in the separation of boswellic acids), 10. 6. 2020, RNDr.
- Mgr. PRAŠNICKÁ, ALENA, Ph.D.: Dispozice železa reguluje jaterní homeostázu cholesterolu a žlučových kyselin (The iron disposition regulates liver homeostasis of cholesterol and bile acids), 31. 1. 2020, PharmDr.
- Mgr. PRAŽÁKOVÁ, ANETA: Stanovení vybraných biomarkerů nefrotoxicity v moči a v plazmě (Determination of selected biomarkers of nephrotoxicity in urine and plasma), 29. 9. 2020, PharmDr.
- Mgr. PŘECECHTĚLOVÁ, MARTINA: Nedostupnost léčivých přípravků v České republice (Medicines shortages in the Czech Republic), 29. 9. 2020, PharmDr.
- Mgr. PŠENČÍKOVÁ, BARBORA: Vývoj HPLC metody pro hodnocení metabolitů tryptofanu (Development of HPLC method for evaluation of tryptophan metabolites), 18. 12. 2020, PharmDr.
- Mgr. RNDr. DUBÁNKOVÁ, MARIANNA: Medicinal plants used in the treatment of cardiovascular disorders in the Czech Republic – overview and consumption analysis in years 2015–2019, 22. 12. 2020, PharmDr.
- Mgr. RŮŽIČKOVÁ, KAROLÍNA: Hodnocení přípravy monovrstevných lipidových modelů kožní bariéry (Evaluation of preparation of monolayer lipid skin barrier models), 16. 1. 2020, PharmDr.
- Mgr. ŘEHÁKOVÁ, PAVLA: Spectrophotometric determination of chlorhexidine in mouthwash employing Lab-In-Syringe automated ion-pair extraction and back-extraction), 22. 1. 2020, PharmDr.
- Mgr. ŘÍHOVÁ, ANDREA: Postoje a znalosti o očkování proti HPV III (Attitudes and beliefs on HPV infection and vaccination III), 18. 2. 2020, PharmDr.
- Mgr. SEDLÁČKOVÁ, MARTINA: Studium topického podání cidofoviru *in vitro* (*In vitro* study of topical use of cidofovir), 18. 12. 2020, PharmDr.
- Mgr. SCHÖNGUT, MICHAL: Analytické hodnocení derivátů salicylaldehyd isonikotinoyl hydrazonu (Analytical evaluation of salicylaldehyde isonicotinoyl hydrazone derivatives), 18. 12. 2020, PharmDr.
- Mgr. STAŇKOVÁ, PETRA: Farmaceutické aplikace polyesterů jako nanonosičů léčiv (Pharmaceutical applications of polyesters as drug nanocarriers), 1. 10. 2020, PharmDr.
- Mgr. STRACHOŇOVÁ, ŠÁRKA: Studium regulace genové exprese nukleosidových transportérů v buněčné linii BeWo (Study of gene regulation of nucleoside transporters in BeWo cell line), 21. 2. 2020, PharmDr.
- Mgr. SUCHÁNEK, DAVID: Vyhrazené léčivé přípravky (Selected medicinal products), 18. 2. 2020, PharmDr.
- Mgr. SUK, ONDŘEJ: Hodnocení antimikrobní účinnosti nových látek typu kvarterních amoniových solí (Evaluation of antimicrobial effectiveness of new quaternary ammonium salt compounds), 29. 9. 2020, PharmDr.
- Mgr. SÝKOROVÁ, MARTINA: Štúdium vplyvu vybraných inhibitorov tyrozínkináz na mnohopočetnú liekovú rezistenciu sprostredkovanú ABC liekovými efluxnými transportérmí (Study on impact of selected tyrosine kinase inhibitors on multidrug resistance mediated by ABC drug efflux transporters), 24. 2. 2020, PharmDr.
- Mgr. SYSLOVÁ, ELIŠKA, Ph.D.: Anthelmintika v rostlinách – příjem, biotransformace a transkripční odpověď (Anthelmintics in plants – uptake, biotransformation and transcriptional response), 24. 1. 2020, PharmDr.
- Mgr. ŠIMÁNKOVÁ, LENKA: Studium vasodilatačních účinků vybraných flavonolignanů silymarinu *ex vivo* na izolované aortě potkana (Study of vasodilatory effects of selected silymarin flavonolignans *ex vivo* on isolated rats aorta), 24. 9. 2020, PharmDr.
- Mgr. ŠIMKOVÁ, MARIE: Změna tvorby žluče v důsledku nedostatku železa (Alternation of bile production due to iron depletion.), 24. 2. 2020, PharmDr.
- Mgr. ŠORF, ALEŠ, Ph.D.: Studium interakcí nových protinádorových léčiv s lékovými transportéry (A study of interactions of novel anticancer drugs with drug transporters), 12. 2. 2020, PharmDr.
- Mgr. ŠREJMA, ROBERT: Formulace nanočásticových polyesterových systémů pro průnik do buněk (Formulation of nanoparticles from aliphatic polyesters for cell penetration), 16. 1. 2020, PharmDr.
- Mgr. ŠTIBEARÍKOVÁ, ADRIÁNA: Faktory související s chronickým vulvovaginálním dyskomfortem – dotazníková studie na Slovensku (Factors related to chronic vulvovaginal discomfort – questionnaire study in Slovakia), 24. 2. 2020, PharmDr.
- Mgr. ŠTOČEK, JAKUB RADEK: Interactions of modified nucleobases studied by NMR spectroscopy, 18. 12. 2020, PharmDr.
- Mgr. ŠUBRTOVÁ, LINDA: Analýza lékových problémů ve zdravotnickém zařízení IV (Analysis of drug-related problems in a health facility IV), 18. 2. 2020, PharmDr.
- Mgr. ŠŮS, JAN: Synthesis of cardioprotective ion chelators derived from diethylenetriaminepentaacetic acid, 18. 12. 2020, PharmDr.

- Mgr. TALOVÁ, BARBORA: Hodnocení složení těla metodou bioimpedanční analýzy u zdravých dobrovolníků (Body composition determination by means of bioimpedance analysis in healthy volunteers), 17. 2. 2020, PharmDr.
- Mgr. TESAŘOVÁ, EVA: Regulace integrativní a komplementární medicíny (Regulation of integrative and complementary medicine), 18. 2. 2020, PharmDr.
- Mgr. TUSCHLOVÁ, DOMINIKA: Vplyv dlhodobého pôsobenia solubilného endoglinu na expresiu adhézných molekúl cievného endotelu (Effect of long-term exposure to soluble endoglin on the expression of adhesion molecules on endothelial cells), 9. 10. 2020, PharmDr.
- Mgr. VERONIKA DEMUTHOVÁ: Strukturální analýza přírodních látek pomocí NMR spektroskopie (Structural analysis of natural compounds employing NMR spectroscopy), 18. 12. 2020, PharmDr.
- Mgr. VIŠŇOVSKÝ, DANIEL: Hodnotenie tokových vlastností, lisovateľnosti a vlastností tabliet v zmesiach mikrokryštalickej celulózy a TRI-CAFOS® 200-7 (Evaluation of flow properties, compressibility and tablet properties of mixtures containing microcrystalline cellulose and TRI-CAFOS® 200-7), 30. 7. 2020, PharmDr.
- Mgr. VITVEROVÁ, BARBORA, Ph.D.: Solubilní endoglin a jeho role v patogenezi endotelové dysfunkce (Soluble endoglin role in the pathogenesis of endothelial dysfunction), 26. 8. 2020, PharmDr.
- Mgr. VODÍČKOVÁ, JANA: Nanovláknenné nosiče léčiv 1 (Nanofiber drug carriers 1), 16. 6. 2020, PharmDr.
- Mgr. VYSKOČILOVÁ, MARTINA: Morfológické zmeny v ledvinách u myši s vysokou expresií solubilného endoglinu (Morphological alterations in kidneys in mice with high soluble endoglin levels), 19. 10. 2020, RNDr.
- Mgr. ZÁBOJ, ZDENĚK: Studium lékových interakcí antivirotek na střevních transportérech (Study of drug-drug interactions of antiviral drugs on intestinal transporters), 24. 9. 2020, PharmDr.
- Mgr. ZÁRYBNICKÝ, TOMÁŠ, Ph.D.: Potential toxicity of terpenes and their effects in liver cells, 9. 7. 2020, PharmDr.
- Mgr. ZBOŘILOVÁ, ELIŠKA: *In vitro* screening nových, potenciálně antibakteriálně účinných sloučenin II (*In vitro* screening of novel potentially active antibacterial compounds II), 30. 6. 2020, RNDr.
- Mgr. ZELENÁ, MARKÉTA: Faktory doprovázející vulvovaginální dyskomfort (Factors accompanying vulvovaginal discomfort), 29. 9. 2020, PharmDr.
- Mgr. ZNAMÍNKOVÁ, JANA: Studium transportu lékovými transportéry na buněčných modelech (Study of transport mediated by drug transporters in model cell systems), 29. 9. 2020, PharmDr.
- Mgr. ŽÁKOVÁ, PETRA: Survivin, nový cíl signální cesty Hedgehog/GLI v lidských nádorových buňkách (Survivin, a novel target of the Hedgehog/GLI signaling pathway in human tumor cells), 17. 2. 2020, RNDr.
- Mgr. ŽÁRSKÁ, NIKOLA: Porovnání účinků smrtelné a maximální tolerované dávky standardních acetylcholinesterasových reaktivátorů (A comparison of lethal and maximum tolerated dose of standard acetylcholinesterase reactivators), 30. 6. 2020, RNDr.
- Mgr. ŽENÍŠKOVÁ, TEREZA: Nesilikagelové materiály v analýze léčiv IV (Non-silica based materials in drug analysis IV), 22. 1. 2020, PharmDr.

SOCIAL HAPPENINGS

50th ANNIVERSARY OF THE FACULTY OF PHARMACY IN HRADEC KRÁLOVÉ

In 2019, the Faculty of Pharmacy in Hradec Králové celebrated its 50th anniversary. It was established after the nine-year period (1960–1969), when only one pharmaceutical faculty in the then Czechoslovakia was in Bratislava (Slovakia). It became one of the faculties of Charles University, but was located in Hradec Králové, not in Prague.

Teaching initially took place in improvised conditions in sixteen places in the city. In 1972, the Faculty of Pharmacy acquired its first building. In the same year, the building of the garden of medicinal plants and objects intended for other purposes started. The faculty fulfilled all pedagogical and scientific activities, including rigorous and aspirant (equivalent of current doctoral studies) guidance, successfully defended research tasks, presented itself with professional publications and teaching texts. In 1980, the second permanent building of the faculty was opened. In spite of the adversity of the political climate, the first agreements on international cooperation were concluded in the 1980s.

The Velvet Revolution in 1989 meant a major social turning point in all areas of life and also new stage of development at the Faculty of Pharmacy. Both organizational structure and teaching programs were changed. Until 1989/1990, teaching took place in three study directions General Pharmacy, Clinical Pharmacy and Technological Pharmacy. In 1990, a five-year undifferentiated study course was introduced. Since the academic year 1994/1995, also foreign students have been studying at the faculty in English. In 2015, the campus of the Research and Teaching Centre of Charles University, where students of the Pharmaceutical and Medical Faculty are educated in the area at the University Hospital, was opened.

Today, the Faculty of Pharmacy of Charles University in Hradec Králové is an important, dynamically developing educational institution of European format. There are two Master study programmes (Pharmacy and Bioanalytical Laboratory Diagnostics in Medicine). The graduates that have acquired Magister (Mgr.) or Master (MS) degree or its equivalent in Pharmacy, Bioanalytical Laboratory Diagnostics in Medicine or of some related fields such as Medicine or Natural Sciences can apply for admission to postgraduate doctoral studies to obtain degree of Doctor (Ph.D). They may choose from nine fields approved by the Accreditation Committee of the Government of the Czech Republic.

Scientific research in pharmaceutical sciences and in the fields related to pharmacy is an integral part of the faculty activities. The scientific teams are engaged in all aspects of

the development and research of drugs from their chemical synthesis or isolation from natural materials, analytical assessment of their purity and composition, their formulation in suitable dosage forms, studying their effects and fate in the body and their rational use in practice. Academic staff of the faculty solve a number of important scientific grants and projects.

The faculty is also open to the public. They can study the specialization program Medicinal Plants or attend the University of the Third Age. Part of the faculty is the Garden of Medicinal Plants, which serves not only to students and research purposes, but is open to the public. The faculty can also boast of the Czech Pharmaceutical Museum. It is located in the Kuks Hospital near Dvůr Králové nad Labem, where one can visit two permanent exhibitions named The Magic of the Apothecary and From the Apothecary to the Factory.

The celebrations started as soon as in January 2019. 9th Postgraduate and 7th Postdoc Conference, dedicated to the 50th anniversary of the founding of the faculty, took place on 23 and 24 January 2019. The abstracts from the conference were published in the previous issue of *Folia Pharmaceutica Universitatis Carolinae*.

XLVIIIth Pharmaceutical Ball, organized by the Czech Pharmaceutical Students' Association, was held on 8 March 2019. It is a fancy event where pharmacy students and professors meet. In contrast to previous years, the ball took place in Petrof Gallery, modern cultural centre created from the reconstruction of an old production hall of a world-famous piano manufacturer Petrof Company.

On 27 May 2019, the Faculty of Pharmacy of Charles University in cooperation with the Faculty of Military Healthcare of the University of Defence organized student races in archery. Students of the University of the Third Age of Faculty of Pharmacy competed with students of the University of the Third Age of the Faculty of Transport Engineering, University of Pardubice. At the same time, there were races in the archery of undergraduate students of the Faculty of Pharmacy. The races took place according to the rules of the World Archery led by the renowned coach of archery František Ptáčník.

The Garden of Medicinal Plants with a greenhouse was opened to public on 8 and 9 June within the nationwide event Open Gardens Weekend.

Traditional Meeting of Seniors took place on 6 June 2019. Fifty-five seniors – former employees of the Faculty of Pharmacy in Hradec Králové – took part. Prof. PharmDr. Tomáš Šimůnek, Ph.D. (Dean), Prof. RNDr. Petr Solich, CSc. (Vice-Dean for Internal Affairs, European Projects and Strategic Development) and Ing. Lenka Vlčková (Registrar) represented the faculty management. Emeritus Professor MUDr. Jaroslav Dršata, CSc. screened and commented on the film with the poetic name “Journey to Prehistory” about the construction of the faculty and beginnings of teaching which he himself created from archival photographs. He met with great interest of the audience.

Staff of the Garden of Medicinal Plants together with Hradec Králové beekeepers organized an Educational Program Not Only About Medicinal and Melliferous Plants, intended for both schoolchildren and the general public, on 20 June 2019.

The 11th International Symposium Joint Meeting on Medicinal Chemistry was also held on the occasion of the 50th anniversary of the faculty. It was organized by the Faculty of Pharmacy (represented by Prof. RNDr. Jarmila Vinšová, CSc.) and the Section of the Synthetic Drugs of the Czech Pharmaceutical Association (represented by Prof. PharmDr. Martin Doležal, Ph.D.) under the auspices of the European Federation for Medicinal

Chemistry in cooperation with Guarant International, spol. s.r.o. and it took place in Prague on 27–30 June 2019.

On 16 September 2019, a ceremonial opening of the exhibition about the fifty-year history of the Faculty of Pharmacy in Hradec Králové took place in the historical part of Karolinum in Prague. Two days later, the same exhibition was opened during the ceremonial opening of the academic year 2019/2020 in the corridor of the faculty in Hradec Králové. Concurrently, the second exhibition devoted to the most important facts and events of all departments and other faculty workplaces was opened. After the opening word of the Dean Prof. PharmDr. Tomáš Šimůnek, Ph.D., the guests could taste white wine, made especially for the 50th anniversary of the faculty by the winery Hrdina & dcera. Prof. PharmDr. Alexander Hrabálek, CSc., the Mayor of Hradec Králové, and Prof. RNDr. Jaroslav Květina, DrSc., dr. h. c., one of the founders of the faculty and its first dean attended the event as well.

On Saturday, 19 October 2019, a rich programme was held on Open Day for Graduates and Friends in all parts of the faculty. Visitors could see the above-mentioned exhibitions. There was a great interest in visiting the new Campus building, where two departments are based. The Garden of Medicinal Plants offered guided tours that attracted a lot of people. Also, a new publication entitled “Almanac for the 50th Anniversary of the Faculty of Pharmacy, Charles University in Hradec Králové” enjoyed great attention. The Almanac is accessible on the website <https://www.faf.cuni.cz/Vyroci/Sbornik/> in PDF format, but only in Czech language. The Saturday programme was appropriately accompanied by films on the history and present days of the faculty that were screened in lecture hall A (“Retro Cinema”), lecture hall B (“Student Cinema”), and lecture hall C (“Contemporary Cinema”) and in the new Campus building. The Czech Pharmaceutical Museum in Kuks also provided guided tours.

In the afternoon, a meeting with faculty management and a discussion panel on “The History, Present and Future of Pharmaceutical Sciences, Practice and Education” were held.

Saturday celebrations were crowned by a social event held in the Petrof Gallery. Opening speeches by the Dean Prof. PharmDr. Tomáš Šimůnek, Ph.D. and Rector of the Charles University Prof. MUDr. Tomáš Zima, DrSc. were followed by a ceremony at which medals were awarded to leading personalities of the Faculty of Pharmacy. The programme was moderated by PharmDr. Jana Doleželová, a graduate of the faculty who won the beauty contest Miss Czech Republic 2004 and represented the Czech Republic at the Miss World 2004 competition. The ceremonial part of the evening ended with a concert by violin virtuoso Jaroslav Svěcený and a reception. The informal part of the event was accompanied by the DiJazzTiva faculty band.

On 15 November 2019, employees and students gathered to commemorate the 50th anniversary of the faculty and 30 years since the Velvet Revolution. The event was co-organized by the Czech Pharmaceutical Students’ Association. It was established in 1990 on the foundations of the Strike Committee that was formed on 19 November 1989. After an opening statement by the Dean, a former member of the Civic Forum, Assoc. Prof. RNDr. Petr Klemera, CSc. shared several memories from the first days after 17 November 1989. Events from thirty years ago were also remembered by Mgr. Libor Schwarz (Chairman) and other members of the then Strike Committee. Memories were completed with period

photographs and copies of texts from the civic periodical NAUZEJA, whose first issue was published on 10 December 1989.

Another part of the celebrations formed the XXIth Symposium of Clinical Pharmacy René Mach, traditionally held in Mikulov and named after the prematurely deceased PharmDr. René Mach, who was also a graduate of the faculty and a pioneer of pharmaceutical care and clinical pharmacy. The symposium took place on 22–23 November and its topic was Prevention and Treatment of Cardiovascular and Oncological Diseases.

The end of the year-round celebrations was a traditional concert that took place in the Municipal Music Hall on 12 December 2019. The program included Christmas and various other songs performed by the Magistri Flute Ensemble.

M. Doležal, V. Opletalová

INSTRUCTIONS FOR AUTHORS FOR FOLIA PHARMACEUTICA UNIVERSITATIS CAROLINAE

Manuscripts should be prepared on the A4 paper, in English, typed in Microsoft Word using Times New Roman font and spacing 1.5. It should be divided into the following sections:

Title – Times New Roman 14, left alignment, (SPECTROFOTOMETRIC DETERMINATION OF ...). Write the title in lowercase letters and then format it using Font – All Caps (Písmo – Všechna velká).

Names of Authors – Times New Roman 12, center alignment (GASPARIČ, J.,¹ MILENA ČERMÁKOVÁ, M.²). Write the names in lowercase letters and then format them using Font – All Caps (Písmo – Všechna velká).

Names of Institutions – Times New Roman 10, center alignment (¹ Department of....., Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic).

E-mail address – Times New Roman 10, center alignment (e-mail: gasparic@faf.cuni.cz.)

Text – Times New Roman 12, left alignment without indents, starting a new paragraph only by Enter. Bold and Italics may be used. Manuscripts of Original Papers should be divided into sections. Headings of the sections:

ABSTRACT – 12, left alignment

KEYWORDS – maximum 5 keywords, 12, left alignment (KEYWORDS: extraction – spectrophotometry)

INTRODUCTION – 12, left alignment

EXPERIMENTAL – 12, left alignment. This part may be further subdivided, *e.g.*

Chemistry

Materials and Methods

General procedure for the preparation of the studied compounds

(E)-1-(5-tert-butylpyrazin-2-yl)-3-(3-hydroxyphenyl)prop-2-en-1-one

Bioassays

Evaluation of antimycobacterial activity

Evaluation of photosynthesis-inhibiting activity

If it is not absolutely necessary, do not use more than three levels of headlines.

Figures must be submitted in black and white and in original size (not more than 12.5 × 18 cm), separately as a supplement. Indicate the placement of the figure in the text. Captions and notes are placed below (10, center alignment)

<KoukalFig2.jpg>

Fig. 1. Structures of the studied compounds

Tables are placed in the text. Values in the table are written in columns without frame. Title of the table (Table 1. Antifungal activities of the studied compounds.) (10, left alignment) is above the table. Notes are below the table. The layout of the table must be submitted separately.

Chemical structures and schemes should be drawn with a suitable drawing program and inserted into the text using wrapping style (Styl obtékání) in the line with text (“V textu”). Captions and notes are placed below (10, center alignment).

RESULTS AND DISCUSSION – 12, left alignment

Acknowledgements – 12 italic, left alignment, e.g.

This work was supported by Charles University (SVV-260-183).

References – 12, center alignment

References must be numbered continuously and indicated as an upper index in the text (.....cancer.^{1,2}). If there are more than 3 authors, use reduced format e.g. ŠPULÁK, M., POUROVÁ, J., VOPRŠÁLOVÁ, M. *et al.*: Eur. J. Med. Chem., 74, 2014, 65–72.

Journals

1. AGRAWAL, Y. K., PATEL, D. R.: Spectrophotometric determination of clioquinol. Indian J. Pharm. Sci., 47 (5), 1985, 207–209.

Books

1. NĚMCOVÁ, I., ČERMÁKOVÁ, L., GASPARIČ, J.: Spectrophotometric reactions. New York, Marcel Dekker Inc., 1996.
2. WINIWARTER, S., RIDDERSTRÖM, M., UNGELL, A.-L. *et al.*: Use of molecular descriptors for absorption, distribution, metabolism, and excretion predictions. In Comprehensive Medicinal Chemistry II., vol. 5., Testa, B., Van der Waterbeemd, H. (eds.), Amsterdam, Elsevier, 2007, pp. 531–544.

Theses

1. TRPĚLKOVÁ, Ž.: Studium procesu lisování pelet z mikrokrytalické celulosy (A study of the compaction process for the pellets made of microcrystalline cellulose). Diploma thesis, Faculty of Pharmacy in Hradec Králové, Charles University, 2016.
2. KATRNOŠKOVÁ, S.: Studium cytotoxicity potenciálních antituberkulotik s využitím vybraných metod na jaterní a ledvinné buněčné linii (Study of cytotoxicity of potential antituberculosics using selected methods on liver and kidney cell line). Rigorous Thesis. Faculty of Pharmacy in Hradec Králové, Charles University, 2017.

Patents

1. JAIN, K. P., EDAKI, D. U., MINHAS, H. S.: EP 2 516 369 B1, 31.10.2012.
2. VINSOVA, J., KRATKY, M., PARASKEVOPOULOS, G.: CZ 305738 B6, 24. 2. 2016.

Electronic sources

1. World Health Organization, Global Tuberculosis Report 2017 [online]. Available from: https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf.
2. EMA/HMPC/138386/2005, REV. 1 [online]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211079.pdf

3. SOÓS, S. A., JESZENŐI, N., DARVAS, K. *et al.*: BMC Complement. Alternat. Med. 15, 2015, Article 358. DOI: 10.1186/s12906-015-0890-2.

Manuscripts should be submitted in one hard copy and in electronic form (attachment to e-mail or on either CD or USB) to the Editor (Assoc. Prof. RNDr. Veronika Opletalová, Ph.D.) or Head of the Editorial Committee (PharmDr. Marta Kučerová, Ph. D.), Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic; e-mail: folia@faf.cuni.cz.